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“…Whenever I choose I can see before me her distorted features where she lay there in exceptional 
pain but otherwise obviously healthy without any temperature and without abdominal tenderness or 
muscular defence. I remember her gradual decay, her hopelessness when she in spite of the many 
journeys to the hospital never could get her health back between the attacks, her increasing 
nervousness and so the tottering gait, the ascending paralysis, the sloppy hands, the rigid facial 
expression, and finally the resignation when she after a final try had again been sent home from 
hospital without any other diagnosis than – only nervousness. Now she had not any attacks 
anymore, she just deteriorated and got more and more dependent on help from her surroundings. At 
last she stayed silent and immovable in her bed, tired of living and probably welcoming death when 
he one late afternoon came in disguise of a respiratory paralysis.” 
Einar Wallquist: from “Få mans land” (A land of few), 1939.  
Reprinted from Physiol. Res. 2006; 55 Suppl. 2: pp. 109–18. 
Porphyria in Sweden by Thunell S. et al. (1) with permission from the 
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Akutt intermitterende porfyri (AIP) er en sjelden autosomal dominant arvelig metabolsk sykdom 
med nedsatt funksjon på grunn av mutasjon i enzymet hydroksymetylbilan syntase (HMBS) i 
hemsyntesen. Dette kan gi opphopning av porfyrinforstadiene - aminolevulinsyre (ALA) og 
porfobilinogen (PBG) som kan gi akutte magesmerter, pareser, psykiske plager og fatigue samt økt 
risiko for nyresvikt og hepatocellulært carcinom (HCC). AIP anfall kan utløses av noen 
medikamenter, faste, infeksjoner og stress. 
Metabolske sykdommer som diabetes mellitus er assosiert med inflammasjon, og derfor 
undersøkte vi om det også var inflammasjon ved AIP utenom anfall målt som økte cytokiner i 
plasma. Siden prøvetakingsbetingelsene påvirker analyseresultatet for cytokiner, så sammenlignet 
vi verdiene av 27 ulike cytokiner i serum og i fire ulike plasmatyper fra friske personer tilsatt 
forskjellige antikoagulantia for å finne optimal prøvebehandling. I tillegg undersøkte vi effekten av 
lagringstemperatur, frysing og tining av prøvene. Vi konkluderte med at cytokiner bør analyseres i 
EDTA plasma lagret på is og sentrifugert innen fire timer. I tillegg etablerte vi et referanseområde 
for cytokiner fra 162 friske personer. Ved bruk av multiplex analyse fant vi signifikant økte 
cytokiner i gruppen med 50 personer med AIP som uttrykk for lavgradig inflammasjon 
sammenlignet med de 50 personene i kontrollgruppen som var matsjet for alder, kjønn og bosted. 
Inflammasjonen kan muligens være med på å forklare den høyere risiko for leverkreft ved AIP. Det 
ble funnet lavere nivå av prealbumin (transtyretin) og lavere nyrefunksjon hos symptomatiske vs. 
asymptomatiske personer med AIP. Fastende C-peptid og Insulin verdier var lavere i gruppen med 
symptomatisk AIP sammenlignet med sine matsjede kontroller. Personer med AIP spiste mindre 
karbohydrat enn det som er anbefalt i retningslinjer, til tross for anbefalinger om et karbohydratrikt 
kosthold da glukose hemmer første steg i hemsyntesen. Forskningsdeltakerne fylte ut 7 dagers 
kostdagbok, fikk gjort antropometriske mål, fylte ut spørreskjema inneholdende bl.a. spørsmål om 
livsstil og ble intervjuet av lege. Blodprøver ble analysert for vitaminer samt markører for 
glukosemetabolismen og fettstoffskiftet, markører for jernmetabolismen, komplementaktiverings-






Acute intermittent porphyria (AIP) is a rare autosomal dominant inherited metabolic disease with 
lowered function of the enzyme, hydroxymethylbilane synthase (HMBS) in the haem synthesis, due 
to mutation in its gene. The resulting excess of the porphyrin precursors, ALA and PBG, can result 
in acute abdominal pain, paresis and fatigue, as well as increased risk of kidney failure and 
hepatocellular carcinoma (HCC). Certain drugs, fasting, infections and stress can trigger AIP 
attacks. Metabolic diseases like diabetes mellitus are associated with inflammation. Therefore, we 
investigated if there also were inflammation in AIP outside attacks measured as elevated levels of 
plasma cytokines. Since the handling of blood samples can affect the cytokine levels, we compared 
the levels of 27 different cytokines in serum and in plasma from healthy controls using four 
different anticoagulants. The effects of storage temperature, freezing and thawing were also 
examined. We concluded that one should analyse cytokines in EDTA plasma samples stored at 4 ºC 
for up to four hours before centrifugation. Also, we established reference ranges for cytokines from 
162 healthy persons. By using a multiplex assay, we found significantly elevated levels of cytokines 
in the 50 AIP cases as a sign of low-grade inflammation as compared with the 50 controls matched 
for age, gender and place of residence. The inflammation may be one of the explanations for the 
higher risk for HCC in AIP. The cases and controls filled out a seven-day diet logbook, had their 
anthropometric measures recorded, filled out a questionnaire on lifestyle factors and were 
interviewed by a physician. The blood was also analysed for vitamins, glucose metabolism 
measures, fats, iron metabolism markers, complement activation markers and immunoglobulins, 
and the urine was analysed for PBG, ALA and catecholamines. We found lower levels of 
prealbumin (transthyretin) and lower kidney function in symptomatic vs. asymptomatic AIP cases. 
The fasting C-peptide and insulin levels were lower in the symptomatic AIP cases as compared with 
their matched controls. Notably, people with AIP had a lower carbohydrate intake than the quantity 
recommended by guidelines; hence, they were recommended a higher carbohydrate intake because 




Acute intermittent porphyria (AIP) is a rare autosomal dominant inherited metabolic disease caused 
by an impaired function of the enzyme, hydroxymethylbilane synthase (HMBS, EC 2.5.1.61), also 
called porphobilinogen deaminase (PBGD). AIP occurs most often due to a heterozygote mutation 
in the gene encoding of HMBS during haem synthesis. AIP has the phenotype Mendelian 
Inheritance in Man (MIM)–number, #176000 (Omim.org, accessed December 2019). The disease 
causes neurovisceral attacks manifesting as acute abdominal pain, nausea, vomiting, obstipation, 
tachycardia, high blood pressure, decreased muscle strength and fatigue. In seriously ill patients, 
paresis and involvement of the respiratory muscles can give rise to the need for respiratory help (2, 
3). Insomnia, depression and anxiety may also occur in association with acute pain during an AIP 
attack (4, 5). Rarely, psychosis and hallucinations may be seen during an AIP attack, but these 
resolve completely on remission (4).The urine can become dark red, particularly if standing in light 
for some hours (6). Although the disease is rare, it is relatively prevalent in the area around 
Nordland Hospital, with Saltdal municipality having a prevalence of 600/100,000 (7). This high 
prevalence gives us a special opportunity and responsibility to study AIP.  
Most persons with AIP remain asymptomatic, while certain others exhibit the afore-
mentioned symptoms of AIP repeatedly (6, 8). To investigate the reason for this difference in 
symptoms, we compared symptomatic cases and asymptomatic cases, and cases with high and low 
PBG. By adding a matched control group, we could also test our hypotheses on health-related 
differences between the cases and controls since we know that the symptomatic AIP cases have 
elevated porphyrin precursor levels. Some AIP cases have elevated porphyrin precursor levels all 
the time, while certain others show elevated levels only sometimes, and this might have several 
consequences other than an AIP attack (9). There is increased risk for hepatocellular carcinoma 
(HCC) and impaired kidney function in AIP (10). This study aimed to examine if there were 
differences in the status of low-degree inflammation, kidney and liver function, glucose metabolism 
in symptomatic cases, asymptomatic cases and matched controls, as inflammation and glucose 
metabolism can affect the AIP disease activity. We also wanted to scrutinize the role of nutritional 
factors, how they differed (if they did) between symptomatic cases, asymptomatic cases and 
matched controls and if these factors affected the AIP disease activity. The purpose was to 
contribute to better general health of patients suffering from AIP by increasing the knowledge on 
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the disease that, in the future, can contribute to better treatment of AIP. It was very important to 
record reliable cytokine measurements, for which we performed a methodological study on how to 
best handle blood samples for cytokine analysis to get a correct answer and to find reference values 
for cytokines in plasma samples of healthy adults.  
1.1.1 History of acute intermittent porphyria  
Hippocrates (460–277 BC) is cited as being the first to recognize porphyria; he described a woman 
from Thasos with abdominal pain and red urine (11, 12). The Dutch physician, B. J. Stokvis, 
described in 1889 a woman with dark urine who died after taking Sulfonal (1, 13). Quantitative 
methods for measuring PBG and ALA in urine were described in 1955 (14). In 1970, it was found 
that AIP was related to a deficiency of HMBS (15). In 1971, hematin was introduced to treat acute 
porphyria (16); it was given to a woman with a serious AIP attack, after she failed to respond to 
other treatments. It resulted in a decline in ALA and PBG, but unfortunately, she died six weeks 
later of CNS failure attributed to AIP and uraemia (16). In 1980, the gene for HMBS on 
chromosome 11 was found (17), and in 1984, cDNA for HMBS mRNA was found (18). Later, 
mutation analyses became available (19, 20).  
1.1.2 Local aspects of AIP history 
In Sweden, there has been extensive research on AIP since J. Waldenström and E. Wahlquist did 
family investigations in northern Sweden. They found 103 cases by testing their urine using para-
dimethylaminobenzaldehyde in HCl diluted with distilled water (Ehrlich’s reagent), and then noting 
the red colour (1, 13) as reported in Waldenströms dissertation in 1937. The disease was called 
Swedish Porphyria (21). In 1935, A. Engel and E. Wahlquist provided evidence of acute 
intermittent porphyria, then called hematoporphyrinuria, as an inherited disease (13, 22). In around 
1830, Swedes from this area migrated and likely brought the W198X AIP mutation to Nordland 
county in northern Norway.  
In 1982, Eldøen and Sandvik published an article on AIP in Saltdal community, Nordland 
county in northern Norway (23). They performed biochemical analysis of urine samples collected 
from 91 persons above 13 years of age in Saltdal and surrounding areas and found 17 persons with 
certain AIP diagnosed with both high PBG and low enzyme activity, among whom eight people 
classified as possible AIP cases based on either high PBG or low enzyme activity. Of the 17 
confirmed cases, only two were known beforehand. A total of 108 persons filled out questionnaires 





Tollåli, Waage Nielsen and Brekke reported in 2002 that after three years of studying families in 
Nordland in cooperation with general practitioners, they found 59 persons with AIP (7). This gave a 
prevalence of 25 per 100 000 in Nordland county, and 600 per 100.000 in Saltdal municipality (7). 
In 1999, The Porphyria Association in Nordland (PIN) was established. The local aspects of AIP 
history, the local high AIP prevalence and the presence of a local AIP patient association made it 
possible and important for us to study AIP to gain knowledge in the interest of patients. 
  
1.1.3 Mutation, prevalence, incidence and penetrance of AIP  
AIP is a disease distributed worldwide (24). The incidence of symptomatic AIP reported in 2013 
was 0.13 new cases per year per million inhabitants in Europe, while Sweden had 0.51 and Norway 
0.14 (25). The high incidence of W198X mutation in northern Sweden and northern Norway is 
possibly explained (partly) by a founder effect that arose in northern Sweden in the 1700s (26, 27). 
The Norwegian Porphyria Centre (NAPOS) reported that the number of registered AIP cases in 
Norway till 2012 were 326 persons, of whom 189 were symptomatic and 137 were predictively 
identified as asymptomatic (27). The data from NAPOS indicates a prevalence ratio of AIP in 
Norway of approximately 4:100,000 of symptomatic AIP cases (40 per million in Norway), and a 
prevalence ratio of 7:100,000 for AIP when predictively identified genetic predisposition were also 
included (27). This number is higher than the 6.3 per million in Norway that was calculated from 
the incidence in a study by Elder et al. (25). Puy et al. reported in 2010 that in European countries, 
1:75,000 are affected by AIP, except northern Sweden which has a higher prevalence (2). 
A study of blood collected from donors in 1997 in France found a high prevalence of 
mutations in the HMBS gene in the ratio of 1:1675 (28). A clinical penetrance of around 1–2% was 
estimated when comparing the prevalence of likely pathogenic HMBS mutations among 
Caucasians, with the prevalence estimate of symptomatic European heterozygotes (6, 28-30). An 
oligogenic model of heredity as the cause of AIP is suggested (31), and the low penetrance suggests 
the importance of environmental modifiers and predisposing or protective genes (30). In families 
with known mutations, the clinical penetrance is higher, hence the percentage of symptomatic 
persons in known AIP families ranging from approximately 10% (32), to 23% (25), and up to 42% 
(33), 44% (34) and 52% (35). These findings possibly point toward other factors that are shared in a 
family, or that these families were very well mapped and diagnosed. This raises the question as to 
why only some of them contract AIP symptoms and some do not, which is reflected in our 
hypotheses. In Norway, more than 30 HMBS mutations have been found (36), and 454 mutations 
have been reported globally so far (29, 30, 37-39). However, the prevalence of pathogenic HMBS 
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mutations and the actual disease penetrance are uncertain (30). Some mutations reported as disease-
causing did not have sufficient supportive evidence for verifications, and has later been classified as 
questionably pathogenic (40). There is recently initiated an International Porphyria Diagnostic 
Collaborative that is working on an evidence-based database of verified pathogenic and benign 
variants for the porphyrias (40). Different mutations could have different pathogenicity (35), and 
there is also variable expression of the clinical phenotype within the same family (5). The 
penetrance of different mutations may also be different (34), and out of W198X, R173W and 
R167W, the last one showed a lower clinical penetrance (26). 
The HMBS enzyme consists of three domains, and HMBS-mutations are found on all three 
domains. Many of these mutations are single base changes (missense), while others form a 
truncated protein (nonsense) (41). The W198X (Trp198Term) mutation is a nonsense mutation, 
which results in a truncated protein where both folding and stability is affected since the mutation 
leads to a premature stop codon (41). In persons showing W198X mutation, a base substitution of G 
to A in exon 10 in the HMBS gene is observed (42). The protein is easily degraded and possibly 
becomes inactive (41). This lower than normal activity of HMBS is often sufficient, but when AIP 
patients encounter a trigger that increases the demand for haem, then the first and rate-limiting step 
in the haem biosynthesis, ALAS1, is induced (43). HMBS becomes rate-limiting (43) and ALA and 
PBG build up, which can induce an AIP attack.  
1.2 Pathophysiology of AIP 
AIP is classified as an acute hepatic porphyria. The symptoms most often manifest as acute attacks 
(43). AIP mutations affect the synthesis of haem, a cofactor for many haemoproteins such as 
haemoglobin, myoglobin, cytochrome p450 (CYP), mitochondrial cytochrome, catalase and 
peroxidase (6). The formation of haem is a process involving several steps and eight different 
enzymes (6). The mutation which is required for an AIP diagnosis, decreases approximately 50% of 
the functioning capability of the third enzyme involved in the haem synthesis, HMBS or PBG 
deaminase, potentially resulting in a build-up of ALA and PBG upfront (43, 44). In humans, 75–
80% of the haem is synthesized by erythroblasts in the bone marrow, while 15–20% is formed in 
the liver (6). The haem biosynthesis in the liver is of main importance in AIP, as this is where ALA, 
PBG and porphyrins build up (43). The ALAS enzyme has two isoforms: ALAS1 and ALAS2. The 
ubiquitous housekeeping form called ALAS1 is present in virtually all cells, including hepatocytes, 
while ALAS2 is an erythroid form, which is the main form for developing erythrocytes. ALAS1 is 
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the enzyme of interest for AIP, especially in the hepatocytes (43). The ALAS enzyme in the 
mitochondria catalyses the condensation of glycine and succinyl-CoA and forms ALA, which then 
enters the cytosol. By the actions of the enzyme, δ–aminolevulinic acid dehydratase (ALAD), two 
ALA molecules join and form PBG. After that, HMBS polymerizes four PBG molecules to form 
the linear tetrapyrrole hydroxymethylbilane (HMB). Then, HMB readily cyclizes to form 
uroporphyrinogen I, but little of it is made because of the activity of the uroporphyrinogen III 
synthase (43). Uroporphyrinogens are then subjected to decarboxylation by uroporphyrinogen 
decarboxylase that resides in the cytoplasm (43). This forms coproporphyrinogen. The latter 
converts into protoporphyrinogen because of the activity of coproporphyrinogen oxidase (43). 
Then, protoporphyrin oxidase in the cytosol carries out sequential decarboxylation reactions to form 
protoporphyrin (43). Finally, ferrochelatase catalyses the insertion of ferrous iron in protoporphyrin 
to produce haem (43). 
1.2.1 Regulation of haem biosynthesis and haem catabolism 
Haem-mediated feedback inhibition regulates ALAS1 activity in the hepatocytes (45). Glucose 
downregulates ALAS1 activity through peroxisome proliferator-activated receptor-γ coactivator 1α 
(PGC-1α) (43). Drugs and chemicals stimulate transcription of ALAS1 through pregnane X 
receptor (PXR) (43). In hepatic cells, there are two forms of ALAS1: major and minor. Haem 
regulates the major form through increased breakdown of mRNA, while the minor form is resistant 
(43). Also, haem decreases the transportation of preALAS1 into mitochondria (43). To sum up, 
deficiency of glucose, deficiency of haem or presence of porphyrinogenic medications can 
upregulate ALAS1 – probably mainly in the liver (46). Stress, infections and porphyrinogenic drugs 
metabolizing through CYP can increase haem consumption, thereby indirectly triggering ALAS1 
(47). It is not clearly known how the menstrual cycle and female hormones affect ALAS1 activity 
(47). Nevertheless, it is known that progesterone is an inducer of ALAS1, and it was reported that 
persons with AIP that was given ethinyl estradiol, got higher levels of ALA and PBG (48, 49). 
The spleen and the liver degrade haem, resulting in the formation of biliverdin, iron and 
carbon monoxide (CO). The breakdown of haem is regulated by haem oxygenase (HO), which is 
the first and rate-controlling enzyme in haem degradation (43). Haem oxygenase-1 (HO-1) is 
inducible by factors causing physical and chemical stress, e.g. reactive oxygen species, heat shock, 
transition metals and by it´s substrate haem (43). Notably, haem oxygenase-2 (HO-2) is almost non-
inducible (43). Small non-coding RNAs that regulate gene expression, miRNAs, also play a role in 






1.2.2 Predisposition and initiation of AIP attack 
In addition to the pathogenic mutation, there are possibly other genetic or environmental modifiers 
that predispose some to AIP attack and protect others. Moreover, even diet affects ALAS1 and AIP 
disease activity (50, 51) (Fig. 1). Alcohol, smoking and marijuana could trigger an AIP attack due 
to their known induction of hepatic ALAS1 (6, 52, 53). Psychological, emotional and physical 
stress can be triggers for AIP attacks as well (6). 
 
 
Fig. 1. Regulation of haem biosynthesis in the liver and haem proteins. 
The illustration shows potential targets for ALAS1 induction causing acute attacks in AIP. 
Abbreviations: CO = carbon monoxide, HO = haem oxygenase, NO = nitric oxide, PGC-1α = 
Peroxisome proliferator-activated receptor-γ coactivator 1α, TRP = tryptophan. Reprint of Fig. from 
Clinics and Research in Hepatology and Gastroenterology (2015) 29, Karim et al., Porphyrias: A 
2015 Update, pages 412–425 (54) with permission from Elsevier.  
 
The level of PBG has been shown to be associated with emotional stress (55). The functioning of 
the liver CYP is affected by the central and peripheral nervous systems and neurotransmitters (56). 
A study on AIP carriers suggested that CYP2D6 genotype could be a susceptibility factor that 
modified the penetrance (35). Metabolic stress caused by infections, acute inflammation or other 
diseases are possible triggers of AIP attacks, and appropriate vaccines should be administered to 
AIP patients (6). The nuclear receptor, constitutively active receptor (CAR), is associated with 
control of the ALAS1-transcription. The expression of CAR is increased by xenobiotics and 
steroid-hormones such as cortisol, which is generated during different forms of stress, infections 
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and fasting (57). Many of the hypothalamic-pituitary-adrenal-axis stressors are clinically recognized 
as porphyrinogenic (57). Hormones play a crucial part in the fluctuation of AIP activity, and the 
second part of the menstrual cycle, the luteal phase, during which the progesterone is elevated, is 
especially prone to attacks (48, 58). Pregnancy is most often tolerated well, but some can get more 
frequent attacks during pregnancy (6). Medications that may trigger AIP disease activity include 
oestrogens (49), progestogens, barbiturates, sulfonamides and others that induce CYP and ALAS1 
(6, 59). The porphyrogenicity of the drug is partly related to the effect on the CYP system, which 
increases the hepatic turnover of haem and gives feedback to ALAS1 to speed up the haem 
synthesis (59) (Fig. 2). If drugs have side effects that patients with AIP are vulnerable to, such as 
nausea or decreased appetite, it can possibly also trigger an AIP attack. ALA and PBG may enter 
neural cells and induce porphyrin accumulation that may lead to transient reversible protein-
porphyrin aggregates, which could contribute to acute porphyria attacks (60). 
Fig. 2. Precipitating factors and pathogenesis of an acute attack in AIP. 
The illustration shows several exogenic and endogenic factors that induce haem biosynthesis via 
direct or indirect activation of ALA synthase. Reprint of Fig. from: The Application of Clinical 
Genetics 2015:8. An update of clinical management of acute intermittent porphyria, Pischik E., 
Kauppinen R., pages 201–214, 2015 (47), with permission from Dove Medical Press, a part of 
Taylor & Francis Group.  
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1.2.3 Porphyrin precursor toxicity causing symptoms in AIP  
The first compound in the porphyrin synthesis pathway is ALA, and it is produced by ALAS1 from 
glycine and succinyl CoA, through the reaction called the Shemin pathway (61). PBG is a pyrrole-
containing intermediate in the biosynthesis of porphyrins, and it is generated from ALA by enzyme 
ALA dehydratase (61). Under certain conditions, it can act as a neurotoxin that causes damage to 
nerve cells and tissue, and also as a metabotoxin, which is an endogenously produced metabolite 
that causes adverse health effects at chronically high levels (61). There have been different 
hypotheses on what causes the symptoms of AIP. The pathophysiological mechanisms causing pain 
and other clinical manifestations of AIP are not completely understood (54).  
In AIP, the autonomic neuropathy and autonomic dysfunction are thought to be responsible 
for most of the symptoms (62). The peripheral nervous system can be affected in AIP, and signs of 
central nervous system involvement have also been seen (47, 63). The AIP attack is reported to be a 
neurovisceral crisis including acute abdominal pain; acute peripheral neuropathy and 
encephalopathy may develop in severe AIP attacks (62). The probable cause of the neuropathic 
symptoms and pain in acute porphyria has been attributed to either direct toxic effect of PBG, 
especially ALA (62, 64-66), possibly in combination with depletion of the “free” haem pool, or 
because of neural haem deficiency (62, 66).  
In homozygous dominant AIP, MRI suggested selective cerebral oligodendrocyte postnatal 
involvement, whereas most structures that developed prenatally were intact (67). Symptomatic AIP 
cases that had high ALA and PBG and got a liver transplant became asymptomatic, with 
normalized ALA and PBG levels, supporting the toxic effect of ALA and PBG (65, 67, 68). The 
neuropathy is suggested to be linked to impaired Na+/K+ pump function (69). Lead poisoning and 
hereditary tyrosinemia, which also show perturbed haem synthesis and high ALA, present with a 
similar pain syndrome (65). There are several different hypotheses of how excess ALA could cause 
pain, including direct toxicity. There is also the possibility of demyelination secondary to the 
formation of free radicals, and that excess ALA could cause vasospasm (70). Bylesjø et al. did not 
find evidence to support for the theory of demyelination from investigations of cerebrospinal fluid 
of eight symptomatic and eight asymptomatic AIP cases, finding no oligoclonal immunoglobulin 
bands, although they were checked outside AIP attacks. However, four of the 16 AIP cases had 
multiple white matter lesions in the brain seen on magnetic resonance imaging (63). On the 
contrary, the report by Marsden et al. did not support the idea of ALA as a neurotoxin that might be 
responsible for many of the AIP symptoms, unless it is proposed that the body adapts fairly quickly 
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to elevated urine ALA, and it is the rapid changes in ALA concentrations which cause 
complications (71). The reason for their dismissal of the idea of ALA being a neurotoxin is that AIP 
symptoms often resolve in few weeks, while the marked biochemical abnormalities persist for more 
than 10 years (71). The long-standing elevated porphyrin precursor levels do not fit well with the 
model of acute induction of ALAS and toxic porphyrin precursors explaining the complications of 
AIP, according to Marsden et al. (71). Interestingly, in line with this assumption, recombinant 
human HMBS that successfully decreased the level of PBG did not relieve symptoms (72). 
A study of an explanted liver from an AIP patient supports the hypothesis that the 
neurovisceral symptoms of AIP are not associated with generalized hepatic haem deficiency, rather 
they are related to a depletion of hepatic haem confined to the “free” haem pool, leading to 
induction of hepatic ALAS1 and accumulation of neurotoxic ALA and/or PBG (68). ALA and 
especially PBG concentrations were high in the explanted liver, but microsomal haem content was 
sufficient, and representative CYP activities were essentially normal (68). In the perineural fluid, 
the ALA concentration is approximately 30% of that in serum; this is because of a blood-nerve-
barrier (62). Even so, this amount is sufficient to cause both axonal degeneration and 
polyneuropathy in AIP patients (62). An unaffected blood-brain barrier results in only 1% of ALA 
entering the brain, but there is possibly a lower barrier protection in the limbic area, which perhaps 
could explain mild mental changes like anxiety and insomnia during the initial part of an AIP attack 
(62). Autonomic nerves do not have this barrier, and this could be the reason for dysautonomia 
during AIP attacks (62). ALA is structurally similar to gamma-aminobutyric acid (GABA), a major 
inhibitory neurotransmitter in the central nervous system (73). ALA interacts with GABA receptors 
and can inhibit the potassium induced release of GABA (73). Regarding the potential lack of haem 
proteins, there has been evidence of decreased function of some haem proteins, particularly hepatic 
tryptophan dioxygenase, and of hepatic cytochromes, P450, while the question of neuronal haem 
deficiency was unsettled (66). Pischik et al. suggested that a combination of overproduction of ALA 
via direct neurotoxicity, oxidative damage and modification of glutamatergic release may initiate 
the neuronal damage (62). 
1.2.4 Impact of AIP on mitochondrial energetic metabolism  
It has been seen that the treatment of rats with ALA caused fatigue (74). Homedan et al. performed 
a study on 34 mice, of which 16 were controls and the rest were HMBS-/- (75). They suggested a 
cataplerosis of the tricarboxylic acid cycle (TCA cycle), in this case induced by phenobarbital (75), 
and that the bioenergetic failure is part of the reason for muscular dysfunction (76) (Fig. 3). The 
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reason for the cataplerosis is that succinyl-CoA is withdrawn by ALAS induction. In this way, the 
TCA cycle cannot supply the respiratory chain with the reduced cofactors (75). A pilot study was 
performed on cellular bioenergetics measuring oxygen consumption rate in monocytes and 
neutrophils in peripheral blood in humans with different kinds of porphyria, including AIP (77). 
They suggest an existence of mitochondrial abnormalities in porphyria during active disease and 
less so during remission (77). Recently, a depression-like behaviour and mitochondrial dysfunction 
was found in a mouse model of homozygous AIP, which suggested a mechanistic role for the 
disrupted mitochondrial energy production in the pathogenesis of the behavioural consequences of 
severe HMBS deficiency (78). Urinary metabolomics profiling of asymptomatic AIP has shown 
higher concentrations of acetate, citrate and pyruvate as compared with PCT patients (79). In 
asymptomatic AIP patients, these results suggest metabolic reprogramming “and supports the 
relationship that occur between haem synthesis and mitochondrial energetic metabolism” (79). 
Fig. 3. Interconnections between haem synthesis, the respiratory chain and tricarboxylic acid cycle 
during phenobarbital exposure and the treatment with haem arginate and glucose. 
Abbreviations: α-CG = α-ketoglutarate, αKGDH = alpha-ketoglutarate dehydrogenase, ACdH = 
acyl-CoA dehydrogenase, ADP = adenosine diphosphate, ALA = 5-aminolevulinic acid, ALAS = 
ALA synthase, ANT = adenine nucleotide translocator, ATP = adenosine triphosphate, CoASH = 
coenzyme A, CS = citrate synthase; Cx1 = complex I or NADH ubiquinone reductase, Cx II = 
 24 
complex II or succinate ubiquinone reductase, Cx III = complex III or ubiquinone-cytochrome c 
reductase, Cx IV = complex IV or cytochrome-c-oxydase, CPT1 = carnitine palmitoyl transferases, 
FADH2 = flavin adenine dinucleotide (hydroquinone form), HAD = 3-hydroxyl-CoA 
dehydrogenase, ICDH = isocitrate dehydrogenase, IMM = inner mitochondrial membrane, MCAD 
= medium-chain acyl-coenzyme A dehydrogenase, NADH = nicotinamide adenine dinucleotide – 
hydrogen (reduced form), OA = oxaloacetate, OMM = outer mitochondrial membrane, OXPHOS = 
oxidative phosphorylation; PDH = pyruvate dehydrogenase, SDH = succinate dehydrogenase. 
Figure reprinted from The International Journal of Biochemistry & Cell Biology, 2014, June; 51, 
Homedan et al., Acute intermittent porphyria causes hepatic mitochondrial energetic failure in a 
mouse model, pages 93-101, copyright (75), with permission from Elsevier.  
1.2.5 Ischemia and vascular reactivity 
It has been suggested that the abdominal pain could be partly due to intestinal angina, as 
exemplified by an AIP patient whose autopsy showed intestinal gangrene (80). Vasospasm has been 
suggested as the cause of transient cortical blindness in a few AIP cases (81, 82). It was reported an 
increased maximal contraction in the arteries of AIP mice during an induced attack as a response to 
phenylephrine (PE), and the AIP arteries in female mice had increased sensitivity to PE (83). The 
AIP mice model had ~30% of normal PBGD activity (83). Hemin induced greater relaxation in 
arteries in AIP mice than in wild type mice (83). 
1.3 Diagnosing AIP 
There is no definite consensus on what an AIP attack is, according to an oral statement made by 
Sverre Sandberg, the President of the European Porphyria Network, at the International Conference 
on Porphyrins and Porphyrias (ICPP) 2019. To diagnose an acute porphyria attack, there are 
different pieces of a puzzle that should be put together, without all being necessary present: 1) 
Positive anamnesis of triggering factors such as drugs, starvation, stress, infection; 2) Known AIP 
history in the family, being a known carrier; 3) Presence of AIP symptoms; 4) Presence of 
hyponatremia; 5) Positive urinary PBG and ALA quantitative test; 6) Levels of urine ALA, PBG 
above the limit; and 7) normal stool porphyrins and 8) New biomarkers (84). According to a study 
on the biological variation of urine ALA and PBG, a rise of 50% of PBG is considered significant 
to diagnose an AIP attack in a known carrier of an HMBS mutation (9).  
1.3.1 ALA, PBG and porphyrins analysis and genetic testing 
Biochemical methods are applied to monitor disease activity of AIP, by studying the levels of PBG 
especially, along with ALA and porphyrins (85-87). Gene analysis is used for carrier detection of 
HMBS mutations (85-87). There is increased PBG also in variegate porphyria (VP) and hereditary 
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coproporphyria (HCP). Plasma fluorescence scanning separate VP from AIP and HCP and faecal 
porphyrin fractionation of coproporphyrin III and I show greatly elevated coproporphyrin isomer III 
levels in HCP (88). The urine porphyrins are usually increased in AIP and other acute porphyrias, 
mainly because of in vitro polymerization of PBG to uroporphyrin. Urine porphyrins consist of uro-
porhyrins I/III, hepta-carboxyl-porphyrin I, hexa-carboxyl-porphyrin I, penta-carboxyl-porphyrin I, 
copro-porphyrin I/III and very little or no proto-porphyrin IX. Urine porphyrins can be elevated in 
conditions such as hepatobiliary disease, infections and alcohol abuse (84). PBG, ALA and the 
porphyrins generate a pattern that points to different porphyrias. Normal urine PBG and ALA 
excretion in an adult person excludes an AIP attack with high probability, given that that the sample 
is taken during or in the days right after typical symptoms. Receiver operating characteristic (ROC) 
curve analysis for PBG helps to find the optimal cut-off for PBG and gives the associated 
sensitivity and specificity (85). During the follow up of an AIP patient, if an AIP attack is 
suspected, the current PBG/mmol creatinine is compared to PBG outside-attacks.  
In accordance with the regulations in Norway, predictive testing for first-degree relatives 
involves genetic testing for the mutation of interest in persons above 18 years of age, but it is done 
only if they consent after genetic counselling (6, 89). If the presymptomatic genetic testing is 
performed in children below 16 years of age, the parents must first provide a written informed 
consent and attend genetic counselling. In Norway, genetic testing of adults with symptomatic AIP 
does not require genetic counselling, but it is mandatory to make a note of the symptoms and signs 
of AIP and get an oral consent from the patient. There is no convincing genotype-phenotype 
correlation in AIP since the mutation analysis does not predict the disease severity; moreover, most 
carriers of HMBS mutations are asymptomatic.  
1.4 Symptoms and signs 
AIP is called the ‘little imitator’ due to its variety of symptoms and the possibility to imitate or be 
confused with other diseases (90). The signs and symptoms of AIP attacks can mimic a range of 
conditions (84). There is no pathognomonic symptom for AIP (46). Symptoms can arise at all ages 
and sexes, but women tend to have more AIP disease activity than men, and the symptoms often 
arise during the reproductive years in women and at old age in men (48). This is possibly linked to 
menstruation in fertile women and changes in hormones in elderly men. The symptoms in AIP can 
manifest recurrently in some patients, but only as one or a few acute AIP attacks in most 
symptomatic cases. No official scaling system of AIP patients is available. However, the AIP cases 
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are characterized as asymptomatic when they have no symptoms and no history of attacks (Table 
1). Symptomatic cases have had at least one porphyric attack. Symptomatic AIP cases with more 
than four AIP attacks per year was classified as recurrent AIP by Neeleman et al. (91), while many 
classify recurrent AIP as four or more AIP attacks per year (25, 92-94). Severe AIP is characterized 
as recurrent AIP if more than 24 attacks per year occur. 
Table 1. Clinical characteristics of patients with acute intermittent porphyria 
Asymptomatic AIP Symptomatic AIP Recurrent AIP 
HMBS mutation Yes Yes Yes 
At least one proven 
AIP attack during life 
No Yes Yes 
Four or more AIP 
attacks per year 
No No Yes 
1.4.1 Abdominal pain, nausea and vomiting 
The key symptoms indicating AIP, if no other cause is evident, are acute attacks with abdominal 
pain without peritoneal signs, nausea, vomiting, hypertensive crisis and polyneuropathies (47, 54). 
Abdominal pain is especially AIP-like if it is associated with nausea, vomiting, constipation, 
tachycardia and hypertension as a sign of dysautonomia (3). The abdominal pain is severe and 
poorly localized, and the pain can also affect legs, back and other sites (4).  
1.4.2 Autonomic neuropathy and peripheral neuropathy  
Abdominal pain, constipation, decreased gastric motility, tachycardia and hypertension could all 
possibly be related to autonomic neuropathy (64), and e.g. hypertension and tachycardia being 
caused by sympathetic hyperactivity (46). Arrhythmia also occurs during AIP attacks (95). In a 
study of 30 AIP patients, 83.3% had cardiac dysautonomia (96). It has been suggested that a 
parasympathetic dysfunction in AIP could be linked to arrhythmias (97). Porphyric neuropathy 
presents typically as a motor neuropathy of axonal type (64). The peripheral motor neuropathy may 
progress to difficulties in swallowing, flaccid paralysis and the need for support by a ventilator due 
to respiratory insufficiency (4, 64). Also, the peripheral motor neuropathy has been linked to the 
development of urinary retention or incontinence in some AIP cases (4). 
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1.4.3 Seizures, encephalopathy, hyponatremia and fatigue 
Insomnia, agitation, confusion, psychosis with hallucinations (4, 98), acute encephalopathy, 
epileptic seizures and rhabdomyolysis can occur in relation to an AIP attack (47, 54, 99). The 
encephalopathy could be explained by posterior reversible encephalopathy syndrome, and it could 
include both mental symptoms, seizures and too much ADH in the syndrome of inappropriate anti-
diuretic hormone secretion (SIADH) (62). Fatigue, irritability and confusion are common symptoms 
in patients with recurrent AIP (100). Convulsions (95) and acute encephalopathy (47, 101) in an 
AIP attack is often associated with hyponatremia (95), and it could be drug-resistant and 
premenstrual (47, 101). The hyponatremia could be caused by vomiting, diarrhoea or poor oral 
intake of sodium and could potentially be dangerous. Another possible cause of hyponatremia is the 
presence of SIADH, which is related to the hypothalamus, but could also be an adverse effect of 
prolonged treatment with glucose intravenously if sodium is not added to the glucose (102, 103). It 
is hypothesized that in AIP, the SIADH sometimes rather could be renal salt wasting (RSW), 
according to an oral statement by professor R. Hift at ICPP 2019. SIADH and RSW have similar 
characteristics including e.g. hyponatremia and concentrated urine, while differing e.g. in that 
SIADH have normal to high extra-cellular fluid volume, while it is decreased in RSW(104).  
1.4.4 Red urine 
Red urine without blood can lead to a suspicion of AIP. High PBG concentrations in the urine of 
AIP patients may develop a red colour, either when the urine is fresh, or typically after some hours 
of storage, exposing it to air and light (Fig. 4). The red-purple-brown colour is due to formation of 
porphobilin, oxidized porphyrins and other compounds produced by condensation of the urine PBG 
(3, 43, 105). 
Fig. 4. Urine from an AIP patient at intervals of 0 hours, 2 hours, 4 hours and > 24 hours after urine 
void developing the characteristic dark red-purple colour after 4 hours of storage. 
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1.4.5 Recurrent attacks and chronic symptoms 
Recurrent attacks are defined as more than or similar to four attacks per year (94). In France, where 
patients with recurrent attacks were rare, it was reported that recurrent attacks had increased as they 
found that this percentage in later years was 7.6% of the symptomatic AIP cases (< 10%), and this 
had happened during the same time period as treatment with haem arginate was introduced (2, 94). 
The estimated percentage of AIP patients that would develop recurrent attacks was 3–5% (25, 106). 
In a Spanish study it was reported that 23% of 35 symptomatic AIP patients had recurrent attacks 
that required hemin infusions and were without long-term biochemical remission (107). 
Approximately 20% of the persons with AIP who have recurrent symptoms develop chronic and 
ongoing pain and other symptoms (6) such as fatigue and nausea (108) and incomplete recovery of 
paresis (109). Frequency of symptoms was a predictor of fatigue score in a model from a study of 
patients, which reported outcome measurement information system scales in AIP (110). In Sweden, 
chronic impairment in 18% of 149 symptomatic cases was reported, including moderate abdominal 
pain, muscle pain or paraesthesia, muscle weakness, fatigue and mild psychiatric symptoms. Also, 
one patient developed chronic paresis (33).  
1.5 Complications and associated diseases 
Complications associated with AIP are chronic peripheral neuropathy, hypertension, renal 
impairment and hepatocellular carcinoma (HCC) (10). These complications are further discussed in 
relation to inflammation in sections 1.7.8 and 1.7.9. 
1.5.1 Hypertension 
Hypertension is more prevalent in persons with symptomatic AIP than in the general population 
(47). Of 108 persons with acute porphyria, of whom 90 had AIP, it was found that 41% had 
systemic arterial hypertension as compared with 23% of the controls (5). In a study from Sweden, 
where the vast majority had the W198X mutation, 40% of the persons with symptomatic AIP had 
hypertension as compared with 10% of the asymptomatic AIP carriers (33). The risk of renal failure 
may be correlated with the occurrence of hypertension during AIP attacks, although vasospasm 
during attacks and nephrotoxicity of ALA are also possible contributors (10). The underlying 
pathogenesis of hypertension in AIP is poorly understood, although recent experiments in a mouse 
model of AIP showed an increased local vasoconstrictor response, a lower sensitivity to 
vasodilatation in vessels from female mice and significant vasodilatation to hemin (83). Also, 
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hypertension and tachycardia have been shown to be related to increased levels of circulating 
catecholamines, assumed to be due to stimulation of the sympathetic nervous system (111). It is 
also suggested that elevated circulating catecholamine levels during acute attacks of porphyria are 
caused at least partially by blockade of re-uptake into the sympathetic neurons (112).  
1.6 Treatment 
Removing triggering factors and increasing glucose intake is the first line of treatment of AIP 
symptoms. In the initial phases of an AIP attack, the patient should try to increase the oral intake of 
carbohydrates, especially the sugar intake. Removing any triggering factors such as alcohol, 
smoking, prolonged fasting and getting treated for known triggers such as ongoing infections is 
important. If feasible, any porphyrinogenic medications should be removed or replaced with safer 
options (3).  
1.6.1 Standard treatment in hospital 
Intravenous glucose and haem arginate are part of the recommended treatment modality for acute 
AIP attacks in the hospitals from both the Norwegian and Swedish competence centres. The glucose 
should be given intravenously with the addition of fast-acting insulin (3, 6, 113). Addition of 
sodium is also recommended because there has been an example where this was not done and 
profound hyponatremia led to death (105). A combination of anti-nausea medication and pain 
medication, often intravenous morphine, are often needed during AIP attacks (114). Regular meals 
with a high carbohydrate content are recommended, although vomiting, nausea and pain may 
perturb regular meals. Pain, poor appetite, changes in taste and early satiety has been reported as 
predictors for malnutrition in a study of patients with chronic liver disease (115). 
1.6.2 Haem preparations 
The haem preparations used for treatment of acute attacks of AIP are haem arginate (Normosang®
Recordati Rare Diseases, SARL, Puteaux, France) and lyophilized hematin (Panhematin® Ovation 
Pharmaceuticals Inc., Deerfield, IL, USA). Haem arginate and hemin act by replenishing the 
hepatocyte haem pool and downregulating ALAS1, thereby decreasing the production of ALA and 
PBG and bettering the clinical condition (116). A severe AIP attack or moderate attacks where 
glucose infusion is not efficient should be treated with haem preparations, possibly promptly (6, 47, 
117). Hemin is clinically more effective than glucose (118), and has possibly reduced the mortality 
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rate of AIP attacks (1), as it was 50-60% around hundred years ago, while seldom lethal now (13). 
Anyhow, the improved prognosis is also likely due to avoidance of known precipitating factors like 
e.g. barbiturates (13). Causes of death in AIP attacks can e.g. be paralysis of the breathing
musculature because of neurological dysfunction orheart rhythm disturbances (13) while also
complications such as kidney failure or hepatocellular carcinoma can add on to morbidity and
mortality (13). In a review from 2017, Stein et al. stated that “Clinical experience gathered in many
different countries over the past 25 years suggests that patients treated with hemin at an early stage
in their attack have faster resolution of symptoms, shorter hospital stays and a lower incidence of
complications, including neuropathy and seizures, than those who did not receive hemin” (4).
However, Stein et al. and the European Porphyria Network (porphyria.eu) suggest that carbohydrate
loading and intravenous glucose have been replaced by haem preparations as the treatment of 
choice for an acute attack of AIP (114, 119). 
In an open-label study on hemin, the treatment was found to be successful in all the cases of 
acute attacks in 73% of the patients (120). A study of 108 Americans with acute porphyria, of 
whom 90 had AIP, showed that 74% felt that hematin was very effective as a treatment of their 
attacks of acute porphyria (5). On the other hand, in a double-blind study comparing placebo and 
haem arginate in 12 patients with AIP, it was found that it effectively reduced ALA and PBG, but 
that this reduction was not accompanied with striking resolution of the clinical manifestations of the 
attack (121). However, several previous reports had suggested that the treatment was associated 
with clinical improvement (122, 123). 
The use of haem preparations not only for an acute AIP attack but also as prophylaxis of 
AIP attack has propelled its use and is recommended for AIP patients with recurrent attacks (106, 
120). However, only AIP attacks, and not long-term treatment with haem, has been an indication 
from the pharmaceutical companies such as Recordati (124). Whether AIP patients with chronic 
symptoms or recurrent AIP attacks should get prophylactic haem therapy is debatable, as some 
recommend it to be restricted to those with severe neurovisceral crisis (94). 
1.6.3 Treatment of pain, nausea, tachycardia, hypertension and electrolyte imbalances 
Opiates are most often necessary to treat the pain during acute AIP attacks (4). Decisions about the 
type of analgesics and anti-emetics must be individualized and always checked against the drug-
database for acute porphyria. Balwani et al. recently stated: “The cardinal symptom of acute hepatic 
porphyria, neuropathic pain, is often refractory to treatment and requires complex analgesic 
regimens” (125). Seizures would warrant anticonvulsive medication, and if relevant, careful 
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correction of hyponatremia and hypomagnesemia must be done (113). If tachycardia and systemic 
arterial hypertension arise during an AIP attack, and if treatment with drugs such as beta-adrenergic 
blockers is needed, this should be performed with caution, taking into account the possibility of 
hypovolemia and a compensatory catecholamine secretion (113). 
1.6.4 Removing triggering factors and long-term management 
A cornerstone in the treatment of AIP attack is to remove present triggering factors, such as treating 
an ongoing bacterial infection (113). Also, since stress is a very common trigger of AIP attacks 
(95), unnecessary stress should be avoided by the patient (6, 95). Removing or replacing 
porphyrinogenic medications is important. Persons with symptomatic AIP should get yearly check-
up of biomarkers of kidney and liver function, plasma sodium and magnesium, cell blood count and 
measurement of urine PBG and ALA. Persons with AIP should be monitored for the potential 
development of long-term complications (6), especially those with frequent attacks, and patients 
with complications require close follow up and referral to subspecialists when needed (106). 
Persons with AIP should get a physical examination including measurement of blood pressure and 
assessment of kidney function, and they should be asked about the quality of life. Further, persons 
with AIP above 50 years of age should get a liver ultrasound done twice every year due to the high 
risk of HCC (106). Those with asymptomatic AIP in Norway are recommended to get a regular 
check-up at their G.P. every third year. A dialogue with a medical doctor, where medication use is 
checked against a relevant database, is warranted. Also, a discussion of how a precipitating factor 
such as stress should be handled is important. If relevant, a talk on how to avoid alcohol, drugs and 
smoking must also be performed. The patients should be informed about the importance of sharing 
information about AIP with their relatives, giving them the opportunity to decide if they want to get 
tested for AIP. AIP in pregnancy should be closely monitored, as excess risk of perinatal death in 
first-time mothers with active acute porphyria have been observed (126). A previous report 
suggested that in AIP, pregnancy can be  associated with an increased rate of hypertension, 
spontaneous abortion, infants with low birth weight and increased mortality (127).  
1.6.5 Givosiran, liver transplantation or gonadotropin-releasing hormone analogue 
Givosiran, which is available in the market in the US and EU, is an option to be considered in 
patients aged 12 years and older, especially in patients with recurrent attacks, as it is shown to 
reduce the AIP attack rate (92) and porphyrin precursor levels (128). Givosiran is an RNAi, that is, 
RNA interference or silencing RNA that targets the hepatic ALAS1 mRNA. It has been tested in 
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mice, where it prevented and treated AIP attacks (129, 130). A phase I study on humans showed 
that once-monthly injections of givosiran in AIP patients with recurrent AIP attacks nearly 
normalized ALA and PBG and gave a lower AIP attack rate than in patients treated with placebo 
(131). In November 2019, the Food and Drug Administration (FDA) approved givosiran in USA 
under the name, GIVLAARI®, for adults with acute hepatic porphyria (92, 93). GIVLAARI® was 
recently approved by the EU. The efficacy and safety was reported in ENVISION, a randomized-
double-blind placebo-controlled, multinational phase 3 trial enrolling 94 patients with acute hepatic 
porphyria (93, 125). They found a mean annualized attack rate of 3.2 in the givosiran group and 
12.5 in the placebo group, hence a 74% lower rate in the group receiving givosiran (125).  
Further, it should be evaluated when the criteria for a liver transplant is met for patients. If 
there are serious and prolonged symptoms, high biochemical disease activity and organs such as the 
kidneys start to get affected. A liver transplantation could be indicated in such situations (132, 133). 
Others have stated that when neurological symptoms progress despite ovulatory suppression and/or 
prophylactic hemin, then liver transplant should become a consideration (8). A liver transplant in 
AIP gives the patient a liver without the genetic AIP mutations, thereby normalising the level of 
HMBS and subsequent normalization of ALA, PBG and resolution of symptoms (134). Liver 
transplant for AIP cured a patient in 2002 (133), and combined liver and kidney transplants in AIP 
have also been performed (135). By now, several liver transplantations have been performed on 
AIP patients with good results (68). In total, 34 patients who had acute porphyria and got a liver 
transplant have been included in the European Liver Transplant Registry (ELTR) according to an 
oral presentation by Lissing M. (ICPP conference, Milano 2019). A disease-specific complication 
after liver transplantation in AIP is possibly hepatic artery thrombosis (136). Another medication 
used in the treatment of AIP are gonadotropin-releasing hormone (GnRH)–analogues given to 
prevent cyclical attacks of AIP in women (137, 138).  
1.7 Inflammation 
1.7.1 Could inflammation be a trigger, part of symptoms and a consequence of AIP? 
The clinical symptoms of inflammation were defined during the 1st century AD as heat (calor), pain 
(dolor), redness (rubor) and pain (dolor) and thereafter with the addition of loss of function (functio 
laesa). A controlled inflammatory response is beneficial to fight back certain triggers, but becomes 
damaging if dysregulated. Inflammation is a host response to various stimuli, and it is now 
 33 
considered as complex immune processes and having complex consequences (139). Inflammation 
affects haem synthesis, and infections and/or inflammation are known to trigger AIP attacks (47). 
Surgery and infections can induce HMBS indirectly by inducing HO (Fig. 2), which is an enzyme 
that catabolizes haem and causes and increased demand (2). A possible mechanism for developing 
porphyria symptoms is that the inflammation activates the transcription factor NF-κB. This, in turn, 
influences various CYP enzymes in liver (140), which affects haem synthesis (141). CYP are also 
involved in the initiation of pain by directly activating sensory neurons and cytokines (142). AIP 
has many known trigger factors, but some AIP patients may suffer acute attacks without any 
identifiable trigger other than physical and mental stress (100). In the liver cells, acute phase 
proteins and Interleukin-(IL)-6 may increase ALAS1 activity (143). Also, inflammation may 
possibly affect the haem synthesis, perhaps, through hepcidin, a key regulator of the entry of iron 
into the circulation (144). One could, therefore, speculate that inflammation could be a part of a 
possible vicious cycle in AIP, and that inflammation is partly responsible for the symptoms in AIP. 
Inflammation increases ALAS1 activity and can trigger increased AIP biochemical activity and 
symptoms, and this might again trigger and enhance inflammation due to organ damage induced by 
ALA, PBG or porphyrins. In addition, other metabolic diseases such as diabetes are associated with 
inflammation (139, 145, 146). This urged us to investigate the role of inflammation in AIP. 
1.7.2 Haem preparations as a possible trigger of inflammation 
Free Normosang solution is mildly caustic and hypertonic, which can cause painful inflammation, 
venous thrombosis and thrombophlebitis in the small peripheral veins (65). A study of a human 
hepatoma cell line to which haem was added concluded that haem exerts a variety of effects on 
mRNA and miRNA profiling, including effect on oxidative/stress response (147). From a study of 
livers in a HMBS-/- mouse model and five human explanted livers from recurrent AIP patients, it 
was reported that frequent hemin infusions generated a chronic inflammatory hepatic disease, and 
that this inflammation induced HO-1 remotely to the hemin treatment (94). The induced HO-1 
maintains a high ALAS1 level that could be responsible for recurrent attacks, which has, according 
to Schmitt et al., increased 4.4-fold after hemin was introduced as a treatment option (94). This 
increase could have many explanations, including both induction of HO-1 and improved survival by 
heme therapy (94, 148). Further, inflammation and liver deposits of iron in the explanted liver of 
patients who received intravenous haem have been reported (106, 149). Based on these findings 
(94, 106, 149), a restrictive use has been called upon regarding long-term treatment with 





found that the administration of intravenous haem for valid cause and reasons [treatment of acute 
attacks and prevention of recurrent attacks of acute hepatic porphyrias] leads to any increased 
incidence of recurrent attacks” (150). Yarra et al. further stated that: “Their suggestion [Schmitt et 
al.] seems rather unlikely a priori because only patients with pre-existent recurrent and frequent 
symptoms will be those who will be treated with repeated haem infusions”, and Yarra et al. noted 
that in the key figure of Schmitt et al. the apparent frequency of recurrent attacks in France already 
was increased before the institution of prophylactic haem arginate therapy (150). Anyway, in our 
study, none were on prophylactic or long-term Normosang treatment, and none were treated with 
Normosang at the time of study (151). Hence, we would look at the other possible causes of 
inflammation. 
 
1.7.3 Metaflammation, low-grade inflammation, sterile inflammation 
Metaflammation, meaning chronic metabolic inflammation, is a term that has emerged in recent 
years in relation to metabolic diseases (152). Both tissue homeostasis and metabolic diseases’ 
pathogenesis are determined partly by inflammatory cells’ actions and interactions with stromal 
components in metabolic organs such as the liver, brain, pancreas and adipose tissue (152). 
Elevated levels of cytokines has been shown to be associated with increased risk for type 2 diabetes 
(T2D) (145). Increased expression of tumour necrosis factor (TNF) in human adipose tissue and in 
persons with obesity is seen (153). T2D is related to lifestyle and genetic factors (154). The disease 
is caused by insufficient insulin production from beta cells in the setting of IR, but not all persons 
with IR get T2D since an impairment of insulin secretion from dysfunctional pancreatic beta cells is 
required (154). Then, hyperglycaemia follows, and eventually T2D develops. Contributing factors 
to the pancreatic islet dysfunction may be deposits of amyloid polypeptide (154, 155), branched 
chain amino acids associated with the microbiome in the gut (156), metaflammation and obesity 
(157). The root cause of this error in stimulus-secretion coupling is not totally understood (158).   
Sterile inflammation is inflammation that occurs typically in the absence of any 
microorganisms. It can be the result of trauma, ischemia-reperfusion injury, atherosclerosis, gout, 
chemically induced injury and certain metabolic diseases (159). It can lead to recruitment of 
neutrophils and macrophages, and production of cytokines, chemokines and induction of T 
cell-mediated adaptive immune responses (159). Sterile inflammation can be a result of damage-
associated molecular patterns (DAMPs) released into the extracellular environment during necrotic 
cell death (159). A part of the rationale for one of our hypothesis is that AIP is a metabolic disease, 
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and many metabolic diseases in the later years have been linked to low-grade sterile inflammation, 
including atherosclerosis and T2D (139, 146).  
Although others have talked about the possibility of inflammation in AIP and the increased 
risk for HCC indicating a possibility for chronic low-grade inflammation, there were no studies 
where this was investigated in AIP. Inflammation could possibly also be associated with kidney 
failure in AIP. Further, infections and/or acute inflammation are known to cause AIP attacks (54). 
Part of the rationale for investigating inflammation in AIP is that symptomatic AIP cases, perhaps, 
could exhibit a chronic inflammation that could explain why some have symptoms while others do 
not. Furthermore, we hypothesized that the inflammation could affect haem synthesis in the liver, 
thereby increasing the biochemical disease activity and symptoms.  
Potential information regarding inflammation and its effects could give new insight into 
pathogenesis of AIP and its symptoms and complications. We found it quite interesting to test the 
hypothesis regarding the role of low-grade inflammation in AIP and whether they had higher 
number of inflammatory diseases as compared with the controls. 
1.7.4 Cytokines and long-pentraxin 3 (PTX3) 
Cytokines are small signal proteins that include interleukins, chemokines, lymphokines and 
interferons (160). Cytokines can be excreted from different cells such as macrophages, mast cells, 
fibroblasts and leucocytes (160-162). They can affect cells all over the body, and they also have 
autocrine and paracrine effects. Cytokines can act pro-inflammatory or anti-inflammatory. They 
regulate a variety of immune responses through binding to receptors on different cells (160). A part 
of the rationale for measuring cytokines in AIP is that T2D, which also is a metabolic disease, has 
been shown to be associated with elevated cytokines levels (145, 163). The cytokine concentrations 
have also been shown to be elevated acutely after induced hyperglycaemia (164). Another rationale 
for measuring cytokines was that AIP is linked to increased prevalence of kidney damage (165), 
and kidney damage has earlier been shown to be linked to inflammation in other diseases (166). IL-
17 is a proinflammatory cytokine derived from Th17 helper T cells and natural killer cells and is 
involved in the Th17 response in many chronic inflammatory conditions (167). Long-pentraxin 3 is 
a soluble pattern-recognition molecule that is present in the blood and body fluids and is a part of 
the innate immunity (168). It has the ability to recognise pathogens and promote their disposal 
(168). PTX3 is produced locally in a number of tissues, mostly in macrophages and neutrophils. 
Further, pentraxins interact with components of the complement system, and thereby has 
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implications for host defence and regulation of inflammation (168). We, therefore, aimed to 
measure cytokines in AIP patients and controls. 
1.7.5 Damage-associated molecular patterns (DAMPs)  
There are many potential sources of inflammation in AIP, enhanced concentrations of ALA and 
PBG in plasma being one possibility (129, 169). If ALA and PBG act as DAMPs, they could be one 
of the causes of inflammation in AIP, since it is known that circulating DAMPs cause inflammatory 
response to injury (170, 171). However, this has not been extensively investigated, although 
incubation with ALA increased lipid peroxidation in a cancer cell line (172). On the other hand, 
ALA decreased the LPS-induced cytokines in a macrophage cell line in vitro, indicating that ALA 
may have anti-inflammatory effects on some cell types (173). It has been reported that ALA 
treatment of a normal gastric cell line enhanced reactive oxygen species generation and induced 
apoptosis associated with p53, whereas cancer-like mutant cells were unaffected (174). Porphyrins 
have been reported to activate the complement system (175), and one could speculate that 
porphyrins act as DAMPs.  
The term DAMPs is used for self-molecules that can initiate inflammatory response without 
any pathogens or other external antigen (176). DAMPs remain unrecognized by the immune system 
under normal physiological conditions, but during cellular stress or tissue injury, these molecules 
are exposed (170). There are a growing number of known DAMPs such as uric acid crystals, 
nuclear DNA, histones, mitochondrial DNA, high-mobility group protein B1, heat shock protein 
(176), RNA, ATP and others (177). We cannot totally rule out that ALA and PBG can act as 
DAMPs directly. However, ALA has several anti-inflammatory effects, indicating that it may be 
unlikely that ALA acts as DAMP in AIP (173, 178). We speculate that the damage in tissues, 
possibly caused by ALA and PBG giving free radicals and oxidative stress (179, 180) and related 
inflammation could release DAMPs, , which have been shown to stimulate immune cells and 
inflammation in many diseases (170, 181, 182). In sterile inflammatory liver diseases such as non-
alcoholic steatohepatitis (NASH) or hepatic ischemia-reperfusion injury (I/R), first line and second 
line DAMPs have been reported (183). The immune system does not only discriminate between self 
and non-self but also between self-safe and self-dangerous entities (183). 
1.7.6 Complement 
Some DAMPs, including histones, heat-shock proteins and biglycane, have been shown to activate 
the complement cascade during reperfusion after ischemia (184). Uric acid might also activate the 
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complement pathway to induce inflammatory response (185). Complement plays an important role 
in the innate immunological recognition of DAMPs. The complement system is a part of the human 
innate immunity system, protecting the body from invading microbes and other threats; it also takes 
part in immune surveillance and housekeeping tasks (186). Normally, specialized pattern 
recognition receptors detect DAMPs and initiate enzymatic cascades, activating one of three main 
initiation routes that are called the classical (CP), lectin (LP) and alternative pathways (AP) (186). 
CP is activated by pentraxins and surfaces covered with antibodies. LP is activated by ficolins, 
mannose binding lectin (MBL) or collectins that are bound to carbohydrates. Foreign and damaged 
cells activate AP. Importantly, C3b that comes from initial activation of CP and LP also initiates the 
AP, in which C3 activation is amplified by formation of a C3 convertase (186, 187). In the 
complement cascade, the next step is the production of C3 convertases. Then, C3 is cleaved to form 
the anaphylatoxin C3a and C3b, which further activate the cascade (187). Then C5 convertase is 
formed, which is cleaved to form the anaphylatoxin C5a and C5b (188). The component C5b 
together with one unit of C6, C7, C8, and several C9 molecules, form the membrane attack complex 
(MAC) or a soluble form sC5b9 (189). When the balance between complement activation and 
regulation is disturbed, it plays a role in many clinical disorders (186). The complement system is 
involved in many diseases including paroxysmal nocturnal haemoglobinuria (PNH), atypical 
haemolytic uremic syndrome (aHUS), ischemia-reperfusion injuries, cardiac infarction, trauma and 
stroke (186, 187, 190). Haem and porphyrins, although not officially listed as DAMPs, have been 
reported to activate the alternative complement pathway (175, 191, 192). This added to the rationale 
for investigating levels of complement markers in AIP and controls. This is since it is known that 
porphyrin precursors ALA and PBG build-up in AIP, that these components and porphyrins are 
elevated in the urine, and that part of the treatment for AIP is giving haem-containing products. 
Dietary supplementation with ALA has been shown to induce T-cell responses in chickens through 
oxidative stress (193). On the other hand, ALA has antioxidant properties; 5-aminolevulinic acid–
sodium ferrous citrate (5-ALA-SFC) has been reported to activate electron transport chain in 
mitochondria and further induce haem oxygenase-1, resulting in prevention of ROS production and 
elimination of ROS (194). Also, ALA is studied for possible use in diabetes management (195). 
1.7.7 Pattern recognition receptors and the inflammasome 
The pattern recognition receptors can be localized on the cellular membrane surface, such as on the 
Toll-like receptors (TLR) recognizing pathogen-associated molecular patterns (PAMPS) (196) or 
DAMPs (177). Furthermore, there are similar receptors on the cellular inside, such as the Nod-like 
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receptors (NLRs) recognizing DAMPs (197). Both infection-associated PAMPs and host-derived 
DAMPs can impact several metabolic diseases that are associated with inflammation (198). A 
subgroup of NLRs is called NOD-like receptor protein 3 (NLRP3), and this is one of the proteins 
that is able to assemble to a structure called inflammasome, a multimolecular protein (199, 200). 
The NLRP3 inflammasome recognizes PAMPs and DAMPs and other inflammation-inducing 
stimuli, and then activates the caspace-1 cascade, leading to the production of proinflammatory 
cytokines, especially IL-1β and IL-18 (200). The inflammasome can be activated by a wide 
spectrum of danger signals coming not only from microorganisms but also from metabolic 
dysregulation (199). Gout-associated uric acid crystals can activate the NLRP3 inflammasome 
(201). The NLRP3 inflammasome has been shown to sense obesity-associated signals and 
contribute to obesity-induced inflammation and IR (202). Further, the NLRP3 inflammasome is 
also activated by cholesterol crystals and required for atherogenesis (203). Further, the NLRP3 
inflammasome can be regulated by dietary metabolites, and this adds to our rationale for looking 
into both diet and inflammation in AIP (204).  
1.7.8 Hepatocellular carcinoma and inflammation  
There is high prevalence of hepatocellular carcinoma (HCC) in AIP (205-208), especially without 
preceding cirrhosis (209). HCC was found in 3% of symptomatic AIP and in 1% of latent AIP in a 
study from Sweden (33). Although in some AIP patients whose liver could be examined, a 
concomitant existence of portal cirrhosis was found in 5 of 11 AIP patients with HCC (206). The 
annual incidence rates range from 0.16 to 0.35% and are higher in Sweden and Norway (210). In 
the global incidence of HCC, there is male dominance, but in AIP, it is the opposite. High levels of 
ALA and PBG seem to be more common in the AIP cases that gets cancer, although porphyria 
specific risk factors are still unclear (208, 209, 211). The risk of HCC is higher among persons with 
AIP as compared with the average population, especially after the age of 50 (10, 211, 212). In 
France, a 36-fold increased risk was found (213), and in Norway, eight persons had primary liver 
cancer out of the 91 persons with symptomatic acute hepatic porphyria, which was relatively higher 
than in the reference population (212). Non-resolving inflammation increases the risk for HCC 
(214). An intrinsic pathway where genetic events lead to activation of transcription factors such as 
NF-κB and an extrinsic pathway where PAMPs and DAMPs also lead to activation of transcription 
factors can lead to cytokine production (214). In AIP, the mechanism(s) of carcinogenesis leading 
to HCC are unknown. However, many growth factors such as fibroblast growth factor (FGF), 
platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) may act as 
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possible pro-angiogenic factors secreted by stromal cells after chronic liver injury, and IL-17 may 
be involved in tumour progression (215). ALA may also be a carcinogenic factor in AIP (10). It was 
found that the mRNA expression of proinflammatory cytokines, IL-1β, IL-6 and TNF, were 
elevated in the liver of AIP patients as compared with the mean control levels (68). Possible 
pathophysiology of HCC in AIP could be either a direct toxic effect of the haem precursors on the 
liver, expecially ALA, compound heterozygosity for genes that possibly are involved in haem 
biosynthesis, or maybe a relative lack of haem could cause loss of oxidative stress homeostasis 
(210). Liver injury that leads to cell death, inflammation and compensatory regeneration of 
hepatocytes is a charachteristic lesion underlying hepatic carcinogenesis. This takes place in the 
context of oxidative stress, providing a mutagenic environment, thereby increasing the risk for HCC 
(210). A histological study of an explanted liver from an AIP patient showed that most portal areas 
had mild nonspecific lymphocytic inflammation and mild ductular reaction but no cirrhosis (68), 
and there was expression of HO-1. Haem accumulation, inflammatory cytokines, hypoxia and 
oxidative stress can induce HO-1 (216). 
1.7.9 Impaired kidney function and inflammation 
Chronic kidney disease is seen in up to 59% of the symptomatic AIP patients (165, 217), with a 
decline in the glomerular filtration rate by ~ 1 mL/min per 1.73 m2 annually (165). In a study of 108 
cases with acute porphyria, 29% had chronic kidney disease as against 1% of the controls (5). 
Histopathologically, two types of lesions characterized porphyria associated kidney disease 
(PAKD) (165). According to Pallet et al. these were: “A chronic tubulointerstitial nephropathy, 
which is often associated with mild and nonspecific arteriosclerosis, and a chronic fibrous intimal 
hyperplasia associated with focal cortical atrophy” (165). It is suggested that in proximal tubular 
cells, ALA and PBG can promote endoplasmic reticulum stress, apoptosis and changes in epithelial 
phenotype (165). Tubulointerstitial nephritis was described in a case of AIP (218). While apoptosis 
is well tolerated by the immune system, other types of cell deaths cause DAMP release and 







Fig. 5. Complement–coagulation reciprocal interactions.  
Zymogens are marked in light green, and active components are shown in red.  
Black arrows illustrate the interactions of complement with coagulation, increasing the propensity 
of blood to clot. The amplification of complement activation exerted through the components of the 
coagulation system is shown as red arrows. Abbreviations: HMWK = high molecular weight 
kininogen, MBL = mannose binding lectin, P = P-selectin, PAI = plasminogen activator inhibitor, 
TF = Tissue factor. Fig. reprinted from Trends in Immunology, 2007, Markiewski et al., 
Complement and coagulation: strangers or partners in crime? 28: pages 184-192, copyright 
(2007)(220) with permission from Elsevier. 
 
1.7.10 Thromboinflammation and prothrombin fragment 1.2 (PTF1.2) 
Thromboinflammation is the result of activation of the cascade systems in the blood (190), 
including the complement, contact, coagulation and fibrinolytic systems (Fig. 5). Together, these 
systems lead to activation of polymorphonuclear cells, platelets, monocytes and endothelial cells 
that line the blood vessels (190). Some of the AIP patients receiving Normosang encounter 
thrombophlebitis in the peripheral vein where Normosang is given. AIP patients who have 
received a liver transplant might have increased risk of thrombus in the hepatic arteries and are, 
therefore, advised to use acetyl salicylic acid (136). PTF1.2 is a marker for hypercoagulable state 
and may reflect an increased risk for thrombosis, and it is cleaved from the end of human 
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prothrombin when activated by FXa to yield thrombin (221). Since we suspected inflammation in 
AIP, it gave us the rationale for also measuring a marker of coagulation, PTF1.2 .  
1.8 Diet and glucose metabolism 
The low penetrance of AIP points to a critical role of modifying factors, either genetic or 
environmental (30). Since glucose already is a part of treatment for acute attacks (3, 6, 113), we 
surmised that studying diet and hormones related to glucose metabolism in AIP could possibly give 
new insights into the disease activity and its treatment modalities.  
1.8.1 Glucose, sugar, carbohydrates 
During an AIP attack, nausea and vomiting often contribute to the lack of nutrition. Glucose 
reduces the AIP disease activity by downregulating ALAS1, the first and rate-limiting step in the 
haem synthesis (222), through effects on PGC-1α (223-225). A high carbohydrate diet might, 
therefore, contribute to the decrease in the level of AIP disease activity through the inhibiting effect 
of glucose on haem synthesis (224). The American Porphyria Foundation states on their internet 
pages that, “If an acute attack is severe or prolonged, sufficient glucose can be given by vein to 
meet the total energy requirements of a patient. This is accomplished best by using a catheter that is 
inserted into a large central vein. Additional nutrients, including vitamins, minerals, amino acids 
and fat can also be given to maintain all dietary requirements. Provision of total nutritional needs in 
this manner by vein is commonly called total parenteral nutrition (TPN). Oral feedings can be 
introduced gradually as recovery from an attack begins, and when there are signs that functions of 
the stomach and intestines are improving.” Balwani et al. were in line with this regarding 
recommendation of a balanced diet, avoiding prolonged fasting or crash dieting, and recommending 
carbohydrate loading for early stages of an acute attack, but somewhat to the contrary they also 
stated that: “Moreover, a sustained adherence to a high‐carbohydrate diet does not prevent attacks 
and is not recommended (106).” Anyhow, the Nordic nutrition recommendations state that for the 
general population, 45–60% of the total energy intake (E%) from carbohydrates is recommended 
(226). Studies of seven AIP patients who did not have symptoms at the outset of the study, but five 
of them previously had experienced symptoms, suggest that increased carbohydrate content in the 
diet reduced ALA and PBG excretion (51). Glucose given, mainly intravenously, reduced the 
excretion of ALA and PBG in 15 AIP patients after 3–5 days of treatment (227). Glucose also 
reduced the induction of ALAS1 because of the barbiturate meprobamate in avian liver cells (227). 
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In four patients in an acute AIP attack and one in remission who was treated with laevulose 
(fructose) intravenously the treatment was associated with a fall in urinary PBG and ALA (228). 
The AIP symptoms also decreased in a woman who got total parenteral nutrition with 62% 
carbohydrate (223). In Sweden, sixteen persons with symptomatic AIP who later developed type 2 
diabetes (T2D) no longer had porphyria symptoms (229). Taken together, this gave us a rationale 
for our hypotheses regarding possible differences in the diet, glucose intake and carbohydrate intake 
in AIP cases as compared with controls and in the symptomatic as compared with asymptomatic 
AIP cases. 
1.8.2 Fat and protein 
Generally, the amount of saturated fat intake in the Norwegian population is excessive (226). In 
AIP patients, this might be of particular importance because a high-fat diet has fewer carbohydrates, 
which could provide less glucose effect on the haem synthesis, which is not good for AIP patients 
(51). The typical AIP trigger factor, low glucose level in hepatocytes, gives us a rationale to also 
look into the amount of fat as not only a competitive nutrient to carbohydrates but also as an 
energy-dense nutrient which might result in obesity. Chronic elevated fatty acids are linked to 
inflammation and insulin resistance (IR), and saturated fatty acids (SFA) can activate the NLRP3 
inflammasome (204). IL-1β inhibits the signalling of insulin in both hepatocytes, pancreatic cells 
and adipocytes (204). These complicated fat-inflammation-insulin connections add to the rationale 
for investigating all these markers in AIP, where the patients are better off without fasting and 
experience fewer AIP attacks if they develop T2D (229). Protein should provide 10–20% of the 
total energy intake in the general population and 15–20% for the elderly (226), and persons with 
gout should reduce intake of purine-rich food (230). 
1.8.3 Insulin and C-peptide 
Insulin is an endocrine peptide hormone that is secreted by the β-cells of the pancreatic islets of 
Langerhans. The half-life of insulin is 3–5 min. Wilcox stated that insulin “maintains normal blood 
glucose levels by facilitating cellular glucose uptake, regulating carbohydrate, lipid and protein 
metabolism and promoting cell division through its mitogenic effects” (231). Insulin “binds plasma 
membrane-bound receptors in target cells to orchestrate an integrated anabolic response to nutrient 
availability” (232). Insulin regulates the metabolism of carbohydrates and also of lipids and proteins 
(233). IR means impaired signal transduction and biological actions as a response to insulin 
stimulation (233), and when the secretion of insulin no longer can compensate for the IR, a person 
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can develop T2D (233). There is a complex interplay of multiple metabolic pathways on insulin; 
lipids, amino acids and bile acids also have roles in modulation of the insulin sensitivity (233). C-
peptide, a 31-amino-acid peptide with a half-life of 20–30 min, is a part of proinsulin, and it is 
cleaved before co-secretion with insulin from pancreatic beta cells (234). Plasma C-peptide is a 
measure of insulin secretion and pancreatic beta-cell function (234). 
1.8.4 Visfatin, Resistin, Ghrelin, Leptin and Gastric inhibitory polypeptide 
Visfatin is a protein of 52-kDa and is synthesized in visceral adipose tissue (235) and secreted by 
macrophages. Also, the bone marrow, liver and muscles have high expression of visfatin (235). Its 
functions are regulation of adipogenesis, angiogenesis, insulin sensitivity and glucose metabolism. 
Further, it upregulates the gene expression of both pro- and anti-inflammatory cytokines (235). 
Visfatin is identical to nicotinamide phosphoribosyl transferase, and it is found upregulated in 
diabetes and atherosclerosis (236). 
Resistin got its name because of its ability to resist or interfere with insulin action (237). 
Human resistin is a peptide of 12.5 kDa. In humans, it is primarily produced by peripheral blood 
mononuclear cells, macrophages and bone marrow cells but also by hepatocytes (237). Its 
physiological functions have been reported to be regulation of glucose metabolism, insulin 
sensitivity, adipogenesis and angiogenesis (235). Positive correlations have been reported between 
IR and obesity and serum resistin (237). Further, resistin is an adipokine and as such has been found 
to induce cytokine expression in chondrocytes in humans (237). Resistin is involved in the 
increased release of cytokines, as it can activate TLR4 on macrophages (238). Thus, since resistin is 
linked to insulin, dietary factors and inflammation, and since we suspected that there could be 
differences in diet, insulin and inflammation among the asymptomatic AIP cases and symptomatic 
AIP cases and the controls, it gave us the rationale to investigate both resistin and the hormones and 
biomarkers related to diabetes. 
Ghrelin is a peptide of 28 amino acids and is a gut-derived hormone (239). It is derived from 
preproghrelin that is produced by cells within the gastric oxyntic glands of the stomach (239). 
Ghrelin has a variety of functions: it impacts glucose metabolism, both during fasting and fed 
states; influences to the effect of stress as; affects the energy expenditure, appetite and nutrient 
intake (240). This gave us a rationale for analysing this marker in AIP. It was initially known to be 
a growth hormone releasing peptide; however, later it was found to increase body weight through 
its action on the hypothalamic melanocortinergic system and by stimulation of lipogenesis (239). 
Leptin is an adipocytokine-like hormone, and it increases the secretion of proinflammatory 
cytokines and chemokines (235). It is a 16 kDa protein (235). In humans, it is produced mainly by 
adipocytes but also by T cells, basophils and mast cells (235). Its physiological functions are 
regulation of food intake, energy expenditure, body weight, angiogenesis, blood pressure, 
reproduction and haematopoiesis (235).  
Gastric inhibitory polypeptide (GIP), also called gastroinhibitory peptide or glucose-
dependent insulinotropic peptide, is a hormone belonging to the secretin family (241). It is a 
stimulator of insulin secretion and a weak inhibitor of gastric acid secretion. It is an incretin. 
Another incretin is glucagon-like peptide-1 (GLP-1). GIP and GLP-1 are accountable for the 
“incretin -effect”, meaning a greater stimulation of insulin release after peroral intake of glucose as 
compared with intravenous glucose intake (241). 
1.8.5 Vitamins and micronutrients 
The overall health can be influenced by low levels of vitamins and micronutrients (226, 242, 243), 
as can also the haem biosynthesis (43). It has been suggested that the cobalamin-folate system has a 
role in the acute porphyric process (244). Thunell et al. found higher levels of vitamin B12 in 
persons with symptomatic acute intermittent porphyria than in the controls (244). It is also known 
that the key enzyme ALAS1 has pyridoxal phosphate, i.e. the active form of vitamin B6 as 
prostethic group suggesting a possible role of vitamin B6 in AIP (245). Lack of vitamin D is 
associated with increased inflammation since vitamin D can inhibit monocyte/macrophage cytokine 
production (246).  
1.9 Iron metabolism and biomarkers of liver and kidney function 
AIP attacks can be provoked by factors that induce the haem biosynthesis (45). Haem consists of 
iron and protoporphyrin IX; therefore, it might be possible that iron supplements taken because of 
iron deficiency can induce increased haem synthesis, thereby triggering or aggravating AIP 
symptoms (144, 247). Of interest in this aspect is that the first step in haem synthesis has two 
different possible isoenzymes, ALAS1 and ALAS2, one expressed in erythroid cells in the bone 
marrow, and one liver form of the enzyme ALAS1 expressed ubiquitously, suggesting a nonspecific 
form (248). 
AIP is a liver disease with possible kidney complications (217), whose mechanisms are not 
fully understood. We hypothesized differences between liver and kidney parameters in the AIP 






studying the hepatic markers insulin-like growth factor 1 and prealbumin (transthyretin) in AIP 
(249) would be of help, and we analysed prealbumin. In addition, we measured regular liver 
damage markers such as ALT, AST and ferritin, and liver failure related biomarkers such as 
bilirubin and platelets. Gamma–glutamyl transferase (GT) and alkaline phosphatase (ALP) activity 
are related to cholestatic liver disease. In addition, kidney function and kidney damage biomarkers 
such as Cystatin C and creatinine and calculated eGFR were included.  
 
1.10 Effect of anticoagulant, storage time and temperature of blood samples on 
cytokine concentrations, and reference range for plasma cytokine 
 
1.10.1 Sampling and processing of cytokines 
Cytokines are extensively used for research purposes as biomarkers of inflammation (250-252), but 
the sampling and processing techniques are not standardized. Under suboptimal circumstances, 
these sampling and processing techniques could potentially affect the results since cytokines can be 
released from blood leucocytes even after sampling. Furthermore, coagulation and thrombin can 
probably elicit the release of cytokines from peripheral blood mononuclear cells (253). Sepsis with 
bacteria is still a serious condition with substantial mortality, and there are partly uncertain 
diagnostic methods (254, 255). Modern research on sepsis and a long row of other studies on 
inflammation measure many biomarkers, including cytokines, chemokines and growth factors made 
by leukocytes and other cells in the blood. Several of these cytokines and growth factors are 
potential new markers for inflammatory diseases such as sepsis in humans, and interleukin-6 and 
interleukin-1β and TNF are considered markers for neonatal sepsis (256). The effect of different 
anticoagulants that are added to the blood during sampling and the appropriate storage conditions 
for the blood sample after sampling (time, temperature) were not investigated sufficiently 
previously. We aimed to study the effect of different anticoagulants and sampling conditions on 
venous blood sampling for analysis of a host of cytokines, chemokines and growth factors in 
humans. The research group has a whole blood model of inflammation in humans using the 
anticoagulant lepirudin that does not affect the complement system (257). The complement system 
has a great impact on the activation of leucocytes and cytokine release (258). Also, there is 
interaction between the complement system and coagulation (190). Surfaces such as plastic, PVC 
and the tube wall in glass tubes and blood sampling tubes and the surface of alginate microcapsules 
(259) can activate complement and contribute to cytokine synthesis. Coagulation-activation due to 
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upregulation and activation of tissue factor (TF) can also be increased because of complement 
activation and increased cytokine synthesis (260). TF mRNA is upregulated spontaneously when 
the whole blood is incubated in vitro in plastic sampling tubes (260). We investigated the impact of 
the sampling conditions and different anticoagulants on cytokine levels in fresh human venous 
blood samples (Paper III). 
1.10.2 Reference ranges for plasma cytokines  
There were no specific reference ranges for plasma cytokines in a large number of healthy controls, 
with what we found as the most reasonable sampling conditions, including choice of anticoagulant, 
time and temperature (Paper III). Reference intervals are the most common decision support tool 
used for the interpretation of numerical reports from medical biochemistry (261). We aimed to 
calculate the reference ranges for 27 different cytokines based on venous blood samples collected 
from 162 healthy Norwegians. The different tubes with anticoagulants that were tested to find the 
optimal sampling conditions for cytokines were lepirudin-containing tubes, to which EDTA was 
added to stop complement activation immediately before centrifugation, heparin tubes, citrate tubes 
and EDTA tubes. The mechanism by which these anticoagulants work is that both sodium citrate 
and EDTA bind to calcium. In comparison, lepirudin is a direct and specific thrombin inhibitor, 
which has the effect that the coagulation cascade is functional upstream of thrombin. Lepirudin is a 
hirudin analog, and it has no effect on complement activation (257). Lithium–heparin accelerates 
the effect of antithrombin III, which neutralizes thrombin, thereby preventing the formation of 
fibrin from fibrinogen. 
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1.11 Hypotheses 
1.11.1 Inflammation, glucose metabolism and diet 
H0-1: There is similarity in the content of energy, protein, carbohydrates, sugar, alcohol, folate, thiamin 
and iron between the diet of the symptomatic AIP and the asymptomatic AIP and the control groups. 
Ha-1: There is a difference in the content of energy, protein, carbohydrates, sugar, alcohol, folate, thiamin 
and iron between the diet of the symptomatic AIP, the asymptomatic AIP and the control groups. 
H0-2: There is similarity in the body mass index (BMI) and waist–hip ratio between the symptomatic 
AIP, the asymptomatic AIP and the control groups. 
Ha-2: There is a difference in the BMI and waist/hip-ratio between the symptomatic AIP, the 
asymptomatic AIP and the control groups. 
H0-3: The biomarkers in the blood/serum/plasma related to inflammation, iron metabolism and glucose 
metabolism, vitamins and stress (see variables) show the same levels in the symptomatic AIP, the 
asymptomatic AIP and the control groups. 
Ha-3: The biomarkers in the blood/serum/plasma related to inflammation, iron metabolism and glucose 
metabolism, vitamins and stress (see variables) show difference in their levels in the symptomatic AIP, 
the asymptomatic AIP, and the control groups. 
H0-4: The number of persons in the symptomatic AIP group with gout or other chronic inflammatory 
conditions are not more than those in the asymptomatic AIP group or the control group.  
Ha-4: The number of persons in the symptomatic group AIP with gout or other chronic inflammatory 
conditions are more than those in the asymptomatic AIP or the control group. 
H0-5: The number of persons in the symptomatic AIP group with possible complications such as high 
blood pressure and reduced kidney function are not more than those in the asymptomatic AIP group or the 
control group. 
Ha-5: The number of people in the symptomatic AIP group with possible complications such as 
high blood pressure and reduced kidney are more than those in the asymptomatic AIP group or the 
control group. 
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H0-6: There are no significant correlations between markers of biochemical AIP disease activity and 
dietary intake, biomarkers of glucose metabolism, stress, inflammation, kidney failure or liver function 
markers. 
Ha-6: There are significant correlations between markers of biochemical AIP disease activity and dietary 
intake, biomarkers of glucose metabolism, stress, inflammation, kidney failure or liver function markers. 
Further, we wanted to map the use of porphyrinogenic medications and herbal remedies, and then 
register which medications were used by the AIP cases and controls. We wanted to measure urine 
ALA and PBG in both the cases and controls, map the percentage of symptomatic AIP cases with 
different AIP symptoms and different triggers of the AIP symptoms. 
1.11.2 Cytokine measurements and reference ranges 
H0-7: Time and storage temperature between sampling and centrifugation have no effect on plasma 
cytokine values in venous blood samples. 
Ha-7 Time and storage temperatures between sampling and centrifugation will affect plasma cytokine 
values in venous blood samples. 
H0-8: Plasma obtained using different anticoagulants give similar levels of cytokine values in venous 
blood samples. 






1.12 Aim of thesis  
The overarching aim was to investigate inflammation, diet and related biomarkers to try to find 
differences between symptomatic AIP cases and asymptomatic AIP cases, along with the possible 
differences between the AIP cases and the controls. To achieve this aim, we had to ensure we had 
the best way to handle the cytokine analyses, and sampling conditions and the reference ranges of 
several cytokines were examined. Thus, specifically we intended to do the following: 
 
• Paper I: Study inflammation and glucose metabolism in AIP and correlations between 
inflammatory markers, including cytokines, and AIP disease activity measured in terms of 
PBG. 
• Paper II: Examine the role of diet, particularly carbohydrates and sugar, in the AIP cases and 
correlations between nutritional markers and AIP disease activity measured in terms of PBG 
and inflammatory markers, including cytokines. 
• Paper III: Find the optimal conditions for sampling, handling and storage for cytokine 






2  Materials and methods 
2.1 Study participants and design of papers 
In total, 50 AIP cases and 50 controls matched for age, gender and place of residence participated in 
the study (Paper I). Exclusion criteria were age below 18 years and lacking consent competence. 
The dietary intake was registered using a standardized seven-day diet logbook by 46 of the total 50 
pairs of AIP cases and controls matched for age, gender and place of residence (Paper II). Of 
interest were the intake of sugar, carbohydrates, fat, protein and iron, constituents that could impact 
haem synthesis. Asymptomatic AIP was defined as a condition with an AIP mutation but not 
exhibiting symptoms of AIP ever. Symptomatic AIP was defined as a condition with an AIP 
mutation and exhibiting typical AIP symptoms at least once. Blood samples from 10 healthy blood 
donors, five women and five men, were collected to investigate the optimal conditions for sampling, 
handling and storage of the analysis of 27 cytokines (Paper III). Blood samples from a total of 162 
healthy persons in the range of 18–65 years of age, of whom 107 were women and 55 men were 
used for calculating the reference interval for cytokines. This included 49 healthy blood donors 
from the Blood Bank of Nordland Hospital Trust Norway, 42 healthy controls in a clinical 
epidemiological study performed in Nordland county Norway (262) and 71 healthy persons from a 
study on health care workers in Nordland county (263).  
 For papers I and II, the study participants with AIP were sent invitation letters. One matched 
control for each AIP participant were randomly picked from the same population by Evry.com 
based on gender, age and postal code of cases. Some persons of the first draw declined to 
participate in the study, so we asked Evry.com to do one additional draw. The controls also got an 
invitation letter and signed consent forms. Three of the consenting matched controls did not show 
up, so they were replaced by other persons who matched by age, gender and postal code. One of the 
possible AIP patients and her control were excluded since she neither had a positive genetic test nor 
high biochemical disease activity. The reason for postal code being matched was that matching for 
place of residence is a common design of epidemiological studies since health issues might be 
affected by the place of residence. One could also assume that dietary habits are similar among 





2.2 Questionnaires, structured interview and diet logbook 
The participants filled out a questionnaire at home (Appendix I and II). Another questionnaire in 
Appendix III, IV and V was a modification of a previously used patient-filled questionnaire made 
by NAPOS for use in the national registry (27), and in this research project, the MD filled it out 
during the interview. There were two different versions of the patient questionnaire, one for AIP 
(Appendix I) and one for the matched controls (Appendix II) and three different versions of the 
questionnaire filled out by the MD: one for manifest or symptomatic AIP (Appendix III), one for 
latent or asymptomatic AIP (Appendix IV) and one for the matched controls (Appendix V). 
Symptomatic AIP cases were asked about the time of AIP diagnosis, AIP symptoms, number and 
duration of attacks, triggering and relieving factors related to attacks. All the participants were 
questioned about information on symptoms, regular medication, nutritional supplements, lifestyle 
factors, present and chronic diseases, any surgeries prior to the interview, smoking and alcohol 
habits, physical activity and emotional stress. 
A clinical nutritionist gave the same instructions to all the participants beforehand, both in 
writing (Appendix VI), by pictures (Appendix VII) and orally, on how to fill in the seven-day diet 
logbook (Appendix VIII) to make sure all the participants filled out the logbook correctly. 
Appendix VII contains only some examples of the pictures given to the participants. She was 
available on telephone for follow-up questions through the week they filled out their diet logbook. 
The logbook was, afterwards, scanned using the Teleform program, version 6.0. Daily intakes of 
energy and nutrients were computed using a food database and software system developed at the 
Department of Nutrition, University of Oslo. Sugar intake was regarded as intake of “added sugar” 
and did not include naturally occurring sugars. Vitamin A intake was calculated as the sum of 
retinol and 1/12 beta-carotene. 
 
2.3 Clinical examinations, blood and urine samples  
 
2.3.1 Blood pressure and anthropometric measures 
Serial systolic and diastolic blood pressure was automatically measured over a 20–30 min period, 
after every second minute, using a CAS 740 monitor (CAS Medical Systems Inc., Branford, CT, 
USA). Nurses at the hospital measured and registered the bodyweight, length and waist/hip-ratio for 
each participant, according to the Norwegian written summary of the WHO recommendations 
(Appendix IX). 
2.3.2 Energy intake, resting metabolic rate and physical activity level factor 
The total energy intake was calculated as (g carbohydrate x 17 kJ/g) + (g protein x 17 kJ/g) + (g fat 
x 27 kJ/g) + (g fibre x 8 kJ/g). Resting metabolic rate (RMR) was calculated by employing 
Mifflin’s formula; for women: RMR (kcal) = 10 x weight (kg) + 6.25 x height (cm) - 5 x age 
(years) – 161; for men: RMR (kcal) = 10 x weight (kg) + 6.25 x height (cm) - 5 x age (years). 
Energy requirement was calculated by multiplying RMR with a physical activity level factor (PAL) 
(226). Energy requirement was converted from kcal to kJ by multiplying with 4.184. The physical 
activity level (PAL) factors for the participants were set by individual evaluation of the description 
of their work and leisure physical activity.  
2.3.3 Analysis of aminolevulinic acid, porphobilinogen and porphyrins in urine 
The participants delivered fresh urine samples collected from the morning urine void, in light 
protected containers; light protection was used to avoid a decrease in urinary porphyrin 
concentrations (264). We used the cut-off for PBG/creatinine < 1.5 µmol/mmol creatinine (44, 264-
266). PBG and ALA were analysed using a kit from BioRad Laboratories (Munich, Germany) and 
Ehrlich’s reagent, a column test, (Paper I and II); such tests are widely used for analysis of ALA 
and PBG (267, 268). The PBG ratio (µmol porphobilinogen/mmol creatinine) was calculated. The 
analytic method chosen was column chromatography, which is read spectrophotometrically. The 
urine is separated using mini chromatographic columns. Carbamide is removed, and ALA and PBG 
are separated. Then, ALA is eluated and spectrophotometrically measured, and the same was 
followed for PBG. The addition of Ehrlich’s reagent gives a red colour, and the amount of coloured 
product and ALA and PBG standards are detected spectrophotometrically (14). According to the 
EPNET, the preferred method for measurement of PBG is quantification of the red product formed 
because of its reaction with Ehrlich’s reagent after removal of urobilinogen and other interfering 
substances by anion exchange chromatography. Urine total porphyrins were analysed 
spectrophotometrically after extraction on a BioRad column containing anion exchange resin 
(269).The determination of fractionated urine porphyrins by HPLC was performed using HPLC 
columns and reagents obtained from Recipé GmbH (München, Germany), as previously described 
(270). All the participants with AIP had their genetic analyses for AIP performed prior to inclusion 
in the study using routine laboratory methods. 
All the blood samples were obtained using venipuncture between 8 and 9 a.m. after an overnight 
fast. Vacuette citrate, EDTA and serum tubes were used for collecting the samples. 
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2.3.4 Complement and coagulation analyses 
Total complement activation measured as the soluble terminal complement complex (TCC) was 
analysed by enzyme-linked immunosorbent assay (ELISA) (271). C3bc was analysed as previously 
described with ELISA (271). BN Prospec® nephelometer was used to measure the complement 
components, C3 and C4. The Enzygnost F1 + 2 (monoclonal) kit (Dade Behring, Marburg GmbH, 
Germany) was used to analyse prothrombin fragment 1 + 2 (PTF1.2) in EDTA plasma. The optical 
density was measured on an MRX microplate reader (Dynex Technologies, Denkendorf, Germany). 
Long-pentraxin 3 (PTX3) was analysed with enzyme-linked immunosorbent assay (ELISA) kit 
from R&D Systems Inc. (Minneapolis, MN, USA). C3bc and sC5-b9 (TCC) were analysed using 
ELISA (271). These are both assays based on monoclonal antibodies to neoepitopes exposed in the 
activation products and is not present in the native components. Further, our measurements of anti-
transglutaminase, anti-endomysium, anti-nuclear antibody screen, rheumatoid factor and anti-CCP 
was performed using ELISA kits (262). Anti-cardiolipin was analysed using indirect EIA. 
2.3.5 Analysis of cytokines using multiplex technology 
The cytokines were analysed in EDTA plasma using a Bio-Plex Human Cytokine 27-plex kit from 
BioRad Laboratories Inc. (Hercules, CA, USA). The EDTA blood was immediately cooled on 
crushed ice, immediately centrifuged and stored at -80 °C (Paper I and, II) as recommended (272). 
The multiplex technology consists of bead-based analyses, measuring all the 27 cytokines 
(antigens) at the same time. The beads are distinguished from each other by colour. An antibody 
that emits phycoerythrin targets the antigen of interest and is conjugated to the surface of the beads. 
Flow cytometric technology is used to determine the type of bead and the fluorescence intensity. 
For testing of cytokine stability, the impact of storage, temperature and how different anti-
coagulants could affect the cytokine results in venous blood samples were examined (Paper III). 
We, in addition, measured cytokines also from the following: (1) lepirudin-containing tubes, to 
which EDTA (10 mM final concentration) was added immediately before centrifugation to prevent 
further complement activation, (2) citrate tubes (3.2% sodium citrate) and (3) EDTA tubes (4.43 
mM final concentration) and (4) heparin tubes. Further, for testing of cytokine stability, lepirudin-
anticoagulated whole blood samples were incubated with E. coli (1 x 107/mL) in Nunc™ cryotubes. 
The Nunc tubes were incubated for two hours at 37 °C before centrifugation (Paper III). Control 
samples were obtained by immediate centrifugation (T0). To examine the stability of cytokines in 
the plasma samples, the samples were stored in Nunc tubes in the dark at either room temperature 
(RT) or at +4 °C for two, four and 24 hours. The E. coli strain LE392 (ATCC 33572) was obtained 
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from the American Type Culture Collection (Manassas, VA, U.S.A.). E. coli was grown overnight 
on a lactose dish, after which 5–10 colonies were transferred to LB-medium [1% tryptone, 0.5% 
(w/v) yeast extract, 1% (v/v) NaCl] purchased from Becton Dickinson (Sparks, MD) and grown 
overnight. The bacteria were harvested and washed once with Dulbecco’s PBS without Ca2+ and 
Mg2+ by centrifugation at 3220xg for 10 min at +4 °C. The bacteria were aliquoted, heat inactivated 
for one hour at 60 °C and stored at -80 °C. A frozen ampoule was thawed at ambient temperature, 
and the cells were washed six times with PBS by centrifugation at 3220xg for 10 min at +4 °C. 
2.3.6 Diabetogenic hormones analysed by multiplex technology, and other immunoassays 
Plasma (P)-insulin, visfatin, resistin, ghrelin and leptin and C-peptide in EDTA plasma were 
measured on a Bio-Plex 200 system from BioRad using a pro human diabetes 10-plex kit from Bio-
Rad Laboratories Inc. (Hercules, CA, USA). The EDTA tubes for analysing diabetogenic hormones 
in plasma were immediately placed on crushed ice, centrifuged at 1500xg for 15 min at +4 °C, and 
the plasma was stored at -80 °C until analysis. Multiplex also has a sandwich format: capture 
antibody, sample addition and detection antibody, and then a chemiluminescent/fluorescent reporter 
system. Chemiluminescence means the emission of light as the result of a chemical reaction that 
could be mediated by, for instance, luminol or acridinium esters. For the specific Bio-Plex 
multiplex immunoassays used in our study for cytokines, chemokines and growth factors, and for 
T2D-related markers and obesity markers, biotin labelled detection antibodies are specific for the 
epitopes on each target, and a fluorescent labelled streptavidin reporter binds to the biotin-labelled 
detection antibodies. There is a dual detection flow cytometer that in one channel is used to sort the 
different assays by bead colour; a bead is a fluorescently dyed microsphere with a distinct colour 
code or spectral address. In another channel, the analyte concentration is determined by measuring 
the reporter dye fluorescence (bead region). Phycoerythrin is the fluorescent reporter. The principle 
is similar to sandwich ELISA. In general, immunoassays have a sandwich format: capture antibody, 
sample addition and detection antibody, addition of colorimetric enzymatic substrates. 
Immunoassays compare the immunogenicity of the analyte that you want to measure, with a 
particular defined standard. Enzyme immunoassay (EIA) and enzyme-linked immunosorbent assay 
(273, 274), singleplex, are methods using the immunoassay principle with an enzyme attached to 
the antigen or antibody, as per the reporter label (275).  
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2.3.7 Biochemical analyses  
Serum ferritin, folate and vitamin B12 and anti-thyroid peroxidase antibodies (anti-TPO) were 
analysed by immunoassays on an ADVIA Centaur® XP system (Siemens Healthineers). 
Haematology tests were performed using a Siemens ADVIA 2120i Hematology Systems (Siemens 
Healthineers). The ADVIA 2120i system has flow cytometry based analysis using light scatter, 
differential white blood cell (WBC) lysis and myeloperoxidase and oxazine 750 staining to provide 
a complete blood count, a WBC differential and reticulocyte count (276). Electrolytes such as (S)-
Na+, K+, Mg2+, immunoglobulins and albumin, liver parameters and kidney parameters such as S-
creatinine and urine creatinine, S-iron and other routine clinical chemistry parameters were 
analysed on an ADVIA®1800 system (Siemens Healthineers, Siemens Medical Solutions 
Diagnostics, Japan) using reagents from Siemens Healthcare Diagnostics Ltd.  
B-HbA1c (% or mmol/L) was analysed on a Tosoh G8 high-performance liquid 
chromatography (Tosoh Bioscience, Inc., San Fran, CA, US). For total 25-OH-vitamin-D (25-
hydroxy vitamin-D), a Thermo HPLC system with a liquid chromatography-mass spectrometry 
(LC-MS/MS) detector was used, which can detect analytes that are able to ionize based on the 
relationship between mass and charge. Total vitamin D kits from Chromsystems and an Ultimate 
3000 HPLC system (Thermo Scientific, Waltham, MA, USA) equipped with a TSQ Quantum 
Access MAX triple quadrupole mass spectrometry detector were used. Chromatography is based on 
two phases that cannot merge, one mobile and one stationary. A sample is injected in the mobile 
phase and then transported through a column along the stationary phase. The different analytes 
distribute between or interact with the two phases to a different degree, thereby getting separated. 
Liquid chromatography has liquid during the mobile phase. In liquid chromatography (LC), the 
difference in the size of the particles is used in the separation column. At the end of the separation 
column, there is a detector that gives an electrical signal when different analytes eluate from the 
column. This gives a concentration profile, a chromatogram along a time frame. High performance 
LC (HPLC) has particles of 3.5 to 10 µm used in the separation column.  
Catecholamines such as epinephrine and norepinephrine and vanillylmandelic acid (VMA) 
in random morning urine samples were analysed by HPLC using kits from Chromsystems 
Instruments & Chemicals GmbH (Munich, Germany). The analytical principle is that an 
electrochemical detector is used that can detect components that are able to oxidize or reduce.  
A BN ProSpec® nephelometer (Siemens Healthcare Diagnostics Ltd.) was used to measure S-
prealbumin, alpha-1 antitrypsin, complement components C3 and C4 and S-CDT% (percentage of 
carbohydrate-deficient transferrin). The nephelometry principle is measurement of the scattered 
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light intensity from a fixed angle (for BN ProSpec of 13–24 degrees) for quantitative measurement 
of the analytes. Depending on how muddy/turbid the fluid (serum) is, the light will spread in 
different ways, and this is measured. The “muddiness” depends on the size of the particles, the 
shape of the particles and the number of them. A nephelometer measures the “muddiness” of the 
fluid sample, where the light is spread and a photometer measures its intensity. If you measure the 
intensity of light that is let directly through the sample, the instrument is then called a turbidimeter. 
2.4 Statistical analyses 
A few normally distributed data were presented as mean and standard deviation. Nonparametric 
data were presented as median and interquartile range (IQR). Categorical data were presented in 
terms of percentage. Statistical significance was considered at p < 0.05. Most of the statistical 
analysis was performed using Prism version 6.0 from GraphPad Software Inc. (CA, USA). The 
Spearman’s rank correlation coefficient was calculated, giving r and two-tailed p. for the AIP cases 
since the data were not distributed normally. The Mann-Whitney U-test was used on non-matched 
data and nonparametric data, that is, on symptomatic and asymptomatic cases. The Fischer’s exact 
test was used on categorical variables. Multiple linear regression analyses were performed on data 
from the AIP cases using IBM SPSS Statistics for Macintosh version 23 (Armonk, NY, USA).  
In the hierarchical cluster analysis, the data were imported into R version 3.1.3, Bug in Your Hair. 
The matrix results were then transformed using natural logarithm. The Bioconductor (version 3.3) 
library complex heatmap (version1.10.2) was used to cluster and distance the cytoplex matrix for 
both row and columns with the following parameters: cluster = complete linkage, distance = 
Euclidian (277).  
2.5 Ethical aspects of paper I–III 
Paper I–II 
The Regional Ethics Committee of South East approved the study before inclusion of the study 
participants (2011/2197/REK sør-øst D). The participants signed a written, informed consent. The 
study followed the World Medical Association Declaration of Helsinki ethical principles on 
medical research involving human subjects. All procedures in this trial were in accordance with 
these ethical standards. The bio-bank was created and treated according to the chapter 6 in the 
Health Research Act of 2008 (278). The samples were de-identified. This study is registered with 
the ClinicalTrials.gov number NCT01617642. A possible benefit for the individual research 





have been detected. The benefit of this could be debatable, as unnecessary findings and time-
consuming follow-up by a general practitioner could be a result (GP). The fact that there are 
relatively many people with AIP in our hospitals area gives us a special responsibility to advance 
the knowledge about AIP. Enhanced knowledge about AIP is of major importance, both for the 
patients and the health service.  
 
Paper III 
The blood donors provided written informed consent. The regional ethics committee of the 
Northern Health Region of Norway approved the study (PREK Nord 32/2004), and the biobank was 
approved by the Department of Health in Norway. The study by Barene et al. was approved by The 
Regional Ethics Committee of the Northern Health Region of Norway (PREK Nord 2010/2385-8).  
  
3  Summary of results  
3.1 Paper I 
In this study of 50 AIP cases – 35 symptomatic and 15 asymptomatic – and 50 matched controls, 
the levels of 27 cytokines, chemokines and growth factors were significantly increased in the cases 
with AIP as compared with the matched controls. The complement activation markers, including 
plasma C3bc and C3bc/C3 ratio, were also increased in the AIP cases as compared with the 
controls. ALT, IgG level and blood monocyte count were significantly higher. The levels of 27 
cytokines, chemokines and growth factors and the C3bc/C3 ratio were also significantly enhanced in 
the symptomatic AIP cases versus their matched controls. The levels of 23 of the 27 cytokines were 
significantly enhanced in the asymptomatic AIP cases as compared with matched controls. 
Hierarchical cluster analyses of cytokines of AIP cases and matched controls divided them into two 
main clusters: (a) and (b). Cluster (b) had high levels of many cytokines and included 30 AIP cases 
and five controls. The five controls in cluster (b) had inflammatory diseases. The 30 AIP cases in 
cluster (b) had significantly higher cytokine and visfatin levels than the 20 AIP cases in cluster (a).  
PBG levels in the 50 AIP cases correlated positively with the inflammatory biomarkers, 
PTX3, IL-9, IL-7, S-Cystatin C, CCL4 and with the biomarkers of complement activation, C3bc/C3 
ratio and TCC levels. PBG correlated negatively with prealbumin levels. PTX3 was independently 
associated with PBG in the AIP cases after adjusting for potential confounders in a multiple linear 
regression analysis. Kidney function expressed as relative estimated glomerular filtration rate 
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(eGFR) Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) based on cystatin C 
levels was a significant predictor of the biochemical disease marker PBG in the multiple linear 
regression analysis. Serum prealbumin levels and kidney function (eGFR) were both significantly 
lower in the symptomatic than in the asymptomatic AIP cases. C-peptide and insulin levels after an 
overnight fast were significantly lower in the symptomatic AIP cases than in the matched controls, 
while plasma visfatin levels were significantly increased in the symptomatic AIP cases as compared 
with the matched controls. The results indicated that AIP cases had significantly elevated plasma 
cytokine levels as compared with the controls, and that the PBG levels were associated with the PTX3 
levels and eGFR based on Cystatin C levels. 
3.2 Paper II 
The dietary intake of carbohydrates was lower than recommended in NNR12 in 91% of the controls 
and 78% of the AIP cases, while the intake of added sugar was higher than recommended in 37% of 
the cases and in 26% of the controls (226). The intake of carbohydrates and added sugar were 
different neither between the case and control groups nor between AIP cases with high and low 
PBG levels, and the intake of sugar/candies and carbohydrates was not significantly different 
between the symptomatic and asymptomatic AIP cases. The intake of sugar/candies in g/day was 
significantly higher in the AIP cases with low ALA levels, and ALA correlated significantly and 
negatively with the sugar/candy intake. The intake of fibre was lower than recommended in both 
the cases and the controls. The intake of total fat and SFA were similar in both the groups but 
higher than recommended. In comparison, the serum total cholesterol, LDL cholesterol and 
triglyceride levels were significantly higher in the AIP cases than in the controls. The intake of 
polyunsaturated fatty acids (PUFA) was significantly lower in the cases than in the controls. The 
intake of vitamin D and folate was below the recommended quantity in more than half of both the 
cases and the controls. The PBG levels correlated significantly and positively with total cholesterol 
levels and significantly and negatively with total energy intake and PUFA intake.  
The creatinine and homocysteine levels were significantly higher in the AIP cases with high 
PBG levels than in those with low PBG levels. The homocysteine levels were significantly higher 
in the symptomatic AIP cases as compared with their matched controls. Kidney function, measured 
as eGFR CKD-EPI with the creatinine equation, was significantly lower in the symptomatic than in 
the asymptomatic AIP cases. The PBG levels correlated significantly and positively with P-
homocysteine, S-creatinine and PTX3. Stress was the most prevalent trigger factor for AIP attacks. 
ALA correlated significantly and positively with serum cortisol levels and with smoking, depending 
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on the number of cigarettes smoked/day. Both urine PBG and ALA correlated with P-PTF1.2 
levels. P-leptin, P-ghrelin and P-resistin correlated positively and significantly with PTF1.2 levels. 
The median plasma insulin level was significantly higher, and the glucose/insulin-ratio was 
significantly lower in the AIP cases with low PBG levels than those with high PBG levels. The P-
resistin level was significantly higher in the symptomatic than in the asymptomatic AIP cases. ALA 
and PBG correlated significantly and negatively with S-prealbumin. The results indicated that diet 
and energy intake affect the AIP disease activity. Smoking and the levels of some hormones were 
associated with enhanced AIP disease activity.  
3.3 Paper III 
In this paper, we investigated the effect of storage time, temperature and different anticoagulants, 
including EDTA, heparin, citrate and lepirudin, on the level of multiplex assayed cytokines in 
human venous blood samples. Most serum samples showed significantly higher cytokine levels than 
plasma samples consistent with in vitro release during coagulation. CCL2 and CCL4 were 
significantly increased in heparin plasma. 
Storing plasma at RT for one hour increased most cytokines as compared with the baseline 
T0 sample. Stable cytokine levels were observed in whole blood anticoagulated with EDTA, citrate 
and lepirudin when the samples were stored at 4 °C for one hour, but when stored at RT, a 
significant increase in some of the cytokine levels was observed after one hour, and even more so 
after four hours. There was no significant change in the cytokine levels in plasma samples frozen 
and thawed up to three times. 
We defined the reference ranges for the cytokines in EDTA plasma obtained from 162 healthy 
blood donors. Both the 2.5–97.5th percentile and the < 95th percentile levels of the cytokines were 
calculated. In conclusion, cytokines should be analysed in EDTA (or citrated blood) samples, 
immediately cooled and rapidly centrifuged (within four hours) to obtain EDTA (or citrated plasma) 
to be stored at -80 °C. 
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4 Discussion 
4.1 General discussion 
The studies in this thesis examined the presence of and possible interactions between inflammation, 
lifestyle factors including diet, biomarkers and AIP disease activity in acute intermittent porphyria. 
In addition, the sampling conditions for analysing plasma cytokines in venous blood samples were 
examined. The most common symptoms and signs during AIP attacks were abdominal pain (91%), 
dark urine (80%), tiredness (71%), muscle ache and muscle weakness (both 60%) (Paper II), and 
this was in line with other reports on AIP attacks (33, 279). We found, as hypothesized, elevated 
ALA and PBG in the AIP cases and discussed if these could be associated with tissue damage and 
the measured elevated cytokines and inflammation, and if glucose metabolism is disturbed. 
4.1.1 Cytokines, complement, kidney damage and possible DAMPs in AIP  
AIP was associated with a low-grade systemic inflammation, and some inflammatory markers and 
markers of complement activation correlated positively with AIP biochemical disease activity 
(Paper I). PTX3 and relative eGFR based on Cystatin C levels were associated independently with 
disease activity measured as PBG in multiple linear regression analysis (Paper I). The cytokine 
levels were elevated in the AIP cases, and biomarkers of complement activation were slightly 
activated in these AIP cases. This could possibly contribute to the understanding of the 
pathophysiology of AIP and its complications and symptoms. We speculate that a part of the 
cytokine elevation seen in AIP cases is a result of the neurotoxic porphyrin precursors ALA and 
PBG inducing organ damage in the liver and kidney or other tissues. The inflammation could 
possibly be due to DAMPs (159, 170). The toxicity of ALA causing symptoms such as pain (65) 
and possible organ damage in AIP (210) is supported by many but not all studies (71), while the 
possibility of organ damage/complications in AIP is described widely (10, 62, 165, 210, 211). 
Further, prealbumin and kidney function were decreased in the symptomatic AIP cases but not in 
the asymptomatic cases, suggesting inflammation in the liver and organ damage in the kidneys 
(Paper I). C-peptide and insulin were lower in the symptomatic cases as compared with the matched 
controls (Paper I), and insulin was lower in those with high PBG levels (Paper II). From these 
results, we suggest that AIP is associated with a systemic low-grade inflammation, possibly due to 
organ damage by the porphyrin precursors or other molecules, and most likely the lower prealbumin 





or starved (Paper II). Although systemic low-degree inflammation has not previously been found in 
AIP, our results are partly in line with a suggestion that decreased prealbumin levels in AIP cases 
could be due to under-nutrition or hepatic inflammation due to sustained accumulation of porphyrin 
precursors (249). Another study reported that chronic inflammation in the liver of some AIP 
patients may be due to iron overload after repeated haem infusions (94). However, none of the AIP 
cases in our study had received repeated haem injections in the last six months before blood 
sampling.  
Relevant DAMP candidates in symptomatic AIP cases could be ALA, PBG, porphyrins, 
also uric acid crystals due to kidney failure, although the difference in the number of persons with 
gout in AIP cases as compared to the controls was not statistically significant (Paper I). DAMPs can 
stimulate immune competent cells directly by receptor binding (139, 159, 170) or by damaging the 
organs, thereby activating complement and activation of immune cells (175, 191). Our finding 
could fit with the speculation that ALA is the primary causal factor of the AIP, and that ALA 
induces inflammation, oxidative stress, vascular damage and cell death in multiple cell types (65, 
280). However, others have reported that ALA has anti-inflammatory effects (178). The cause of 
elevated cytokine levels in AIP thus remains to be investigated.  
 Although the AIP cases had higher cytokine levels than their controls, there was no 
increase in other inflammatory diseases in AIP, such as rheumatoid arthritis (Paper I). There was 
neither any significant difference in number of persons with inflammatory diseases between 
symptomatic vs. asymptomatic AIP cases (not shown). We chose to compare the cytokine levels in 
AIP cases with the 50 controls since these were matched for age, gender and place of residence. If 
we instead had compared the cytokine levels in the AIP cases with the cytokine values of the 162 
healthy controls (Paper III), we would have seen that the median of eight – IL-1β, IL-4, IL-5, IL-7, 
IL-12, CCL4, CXCL8 and VEGF – of the 27 cytokines in AIP cases were above the 95 percentile 
of the cytokine levels in the 162 healthy controls, perhaps pointing toward the extra importance of 
these in AIP (comparing Paper I and Paper III). When comparing the cytokine levels of the 162 
healthy controls (Paper III) with the 50 AIP cases using the Mann Whitney U-test, we found that 25 
of the 27 cytokines were significantly higher in the AIP cases (p < 0.0001). The exceptions were 
CCL5 and PDGF-BB, which did not reach significance.  
In the symptomatic AIP cases, eGFR was reduced, possibly due to kidney damage (Paper I, 
II). The median eGFR was similar between the AIP cases and controls, as AIP is only one of the 
many causes of kidney failure in the general population. The prevalence of CKD in the general 





linked to the improved treatment of hypertension and hypercholesterolemia and higher physical 
activity (281). Persons with AIP, in addition to having per se increased risk of CKD due to AIP, 
may also have increased risk associated with the hypertension that often accompanies AIP attacks 
(10). The diastolic blood pressure was higher in the symptomatic than in the asymptomatic cases 
(Paper II). The increased PTH levels (Paper II) could be due to reduced kidney function or 
insufficient 1,25-dihydroxy vitamin D levels; however, the latter was not analysed in this study. We 
speculate that the PTH elevation observed in AIP patients with CKD in this study is most likely due 
to the CKD because the number of persons with vitamin D deficiency were not different between 
the AIP cases and controls (Paper II). Low vitamin D levels may also be associated with enhanced 
inflammation (246). We speculate that the end-organ effects of AIP, such as CKD and liver 
damage, may be a better indicator of AIP disease activity over time as compared with single 
measurements of urine ALA and PBG, since the levels of porphyrin precursors tend to vary around 
the same levels in each patient (9).  
Further, our results suggest that in a cluster of AIP cases, the inflammatory cytokine 
response is dominated by a Th17 response. Other inflammatory diseases such as rheumatoid 
arthritis (RA) also have a Th17 response, and a cluster of AIP cases with high cytokine levels were 
clustered together with controls with RA and ankylosing spondylitis (Paper I). Further, IL-1β, IL-6 
and TNF that were elevated in the AIP cases, are known to be involved in the development of Th17 
cells (167).The link between organ damage and inflammation in AIP has not been thoroughly 
elucidated, although a possible association of inflammation in the liver in AIP cases was reported 
after repeated use of haem arginate treatment (94). We hypothesize that other pathways are 
involved in the cytokine release in AIP cases, including DAMPs from the cells damaged by ALA, 
PBG or porphyrins. Release of DAMPs from damaged cells, including uric acid crystals in gout due 
to reduced kidney function, has been shown to directly or indirectly activate immune cells to release 
cytokines, interleukins and growth factors (159). Whether enhanced levels of ALA, PBG and 
porphyrins may act as DAMP themselves remains to be elucidated. Interestingly, different types of 
cell death affect the immune system differently; necroptosis and necrosis gives inflammation (282, 
283), while apoptosis can give anti-inflammation from metabolites (284).  
However, the idea of liver-derived PBG and ALA being toxic and causing symptoms is 
supported by the observations of patients who got liver transplant from donors with AIP, and then 
developed AIP symptoms (285). Interestingly, a woman with AIP who got a liver transplant from 
her brother with unknown asymptomatic AIP, got symptoms of AIP after a few years, showing the 
need for modifying factors (286). Further, it has been shown that dietary supplements with ALA 
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produce an inflammatory response in broiler chickens (193). The low-grade inflammation per se 
could also add on to the symptoms of AIP. One possible mechanism could be that inflammation and 
cytokines activate NF-κB, which again affects different CYP enzymes in the liver that speeds up the 
haem synthesis in the liver (140). Repeated hemin infusions can create iron overload, and excess 
iron in the liver can also generate inflammation in the liver, which induces HO and can maintain a 
high ALAS1 level that could be responsible for recurrent attacks (94). In comparison, in our study, 
only 21% of the symptomatic AIP cases had ever received Normosang, and of these only 3% got 
Normosang more than three times, and none received Normosang during the study period. The half-
life, t ½, of elimination for haemarginate is 10.8 ± 1.6 hour, which increases to 18.1 hours after the 
4th infusion (124, 287), suggesting that previous use of Normosang cannot be the whole reason for, 
if any, increase in the cytokines in our study. The iron levels in the AIP cases were not higher than 
the reference level, and we found equal serum levels of ferritin, iron and soluble transferrin receptor 
in the cases and controls, ruling out iron overload. However, a tendency to higher S-TIBC levels in 
the cases than in the controls, and a significantly higher S-iron level in the cases with high PBG 
compared to those with low PBG may suggest that iron status may play a role in the disease 
activity. S-soluble transferrin receptor, which is more reliable marker under current inflammation, 
and % hypochromic RBCs (long-term parameter) and reticulocyte haemoglobin (short-term 
parameter), which are helpful for the diagnosis of functional iron deficiency in patients with kidney 
failure, were not different between cases and controls. Notably, a link between inflammation and 
iron metabolism is hepcidin. Hepcidin – we will analyse in the future – is produced by hepatocytes 
and is an iron regulatory hormone that increases in persons with inflammation, especially because 
of IL-6 (288). The iron homeostasis is important for haem synthesis, implying that it possibly 
influences the biochemical AIP disease activity, too. Since the AIP cases with high PBG levels had 
higher S-iron, this could mean a speedy haem synthesis. In line with this, a previous study reported 
a higher level of leukocyte iron in persons with AIP than in the controls (244). 
Non-resolving inflammation increases the risk for HCC (214). In AIP, the mechanism(s) of 
carcinogenesis of HCC is unknown. In general, the driver for HCC could be both an intrinsic 
pathway, where genetic events leads to activation of transcription factors such as NF-κB and 
cytokine release, and an extrinsic pathway, where PAMPs and DAMPs also lead to activation of 
transcription factors and cytokine release (214). Our findings of low-grade inflammation in AIP 
could possibly support the suggestion of inflammation as being one of the contributors for HCC in 
AIP (210). 
 64 
4.1.2 Complement, coagulation and metabolic disease  
Organ damage may activate complement, which is measured as increased levels of TCC and C5a 
(187). In turn, complement may activate cells to release cytokines (187, 188). There is possible 
organ damage in AIP, both in the kidneys (165) and liver (94, 101). In line with Cystatin C, TCC 
and C3bc/C3-ratio, the latter two markers for complement activation, all correlated with PBG 
(Paper I). On the other hand, the elevation in C3bc and ALT in AIP when compared with matched 
controls was slight, so there are probably other mechanisms involved, too. In general, the 
complement system has many roles in health and disease, one of them being participating in the 
clearance of damaged cells and tissues, and another being prevention and development of chronic 
inflammation and cancer (289). We speculate that both the roles are relevant for damaged cells and 
inflamed tissues in patients with AIP. Further, complement prevents spread of infection to other 
cells and tissues (289). Many tissues such as those in the liver, kidneys and the nervous system and 
other organs can be affected and damaged in AIP. In AIP, complement activation is sparsely 
reported in the literature, but in porphyria cutanea tarda, photodynamic action of uroporphyrin on 
the complement system has been seen (175).We found low-degree complement activation and 
correlations between PBG and plasma TCC levels in AIP (Paper I). There is communication 
between the complement system, the pattern recognition receptors TLR and haemostasis (290). 
Since the complement system is slightly activated, cytokines are elevated in AIP and ALA and PBG 
correlate positively with PTF 1.2 (Paper II), we speculate that there could be a slightly increased 
risk of thrombosis in AIP. In line with this, a possible increased risk for hepatic artery thrombosis in 
liver is found in recipients with AIP as compared with non-AIP liver recipients (136). In T2D, 
elevated cytokines were possible facilitators of hypercoagulation and abnormal clot formation 
(291). It is reported that diabetes likely enhanced the capacity of platelets to mediate microvascular 
thrombosis and inflammation during ischemia-reperfusion injury (292).	Also, in a study of acute 
ischemic stroke in rats it was reported that hyperglycemia primed the thromboinflammataory 
cascade, amplifying middle cerebral artery occlusion –induced downstream microvascular 
thromboinflammation (293). Interestingly, a high glucose level may itself increase cytokine release 
through an oxidative mechanism and epigenetic changes (164, 294), which are different kind of 
modifications of the DNA, such as DNA methylation, caused by environmental factors (295). The 
epigenome is the compound layer which surrounds the DNA, that in response to different 
environmental signals, has the capacity to alter the gene expression within the genome, without 
changing the DNA sequence (295), thereby impacting the disease risk (296). However, in AIP cases 
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with T2D, the beneficial effect of slightly higher levels of glucose on the AIP disease activity 
dominates the clinical picture (229). 
Fig. 6. Possible pathways from increased ALA, PBG, and porphyrins to increased cytokines. 
Abbreviations: AIP = acute intermittent porphyria, ALA = 5-aminolevulinic acid, DAMPs = 
damage‐associated molecular pattern, eGFR = estimated glomerular filtration rate, PBG = 
porphobilinogen, TCC = terminal complement complex. Fig. reprinted from Clinical & 
Experimental Immunology, 2016, Storjord et al., Systemic inflammation in acute intermittent 
porphyria: a case control study,187: pages 466–479, copyright (2016) (262) with permission from 
John Wiley and Son. 
4.1.3 Inflammation, organ damage, lifestyle and glucose metabolism  
Lifestyle factors such as smoking, alcohol and dietary factors may activate cells to release cytokines 
(297, 298). Smoking causes cellular damage, oxidative stress, cell death, DAMP release and 
inflammation (299), and it may contribute partly to inflammation in AIP (Fig. 6), as smoking 
correlated positively with some cytokines (results not shown). The number of cigarettes per day and 
the ALA level were significantly correlated (Paper II). This finding is in line with earlier reports 
where smoking was reported to be a triggering factor of AIP attacks (33, 300), although AIP cases 
did not smoke more than the controls (Paper II). A recent study concluded that self-efficacy among 
Norwegian HMBS mutation carriers is high, and that they try to avoid possible triggers and 
implement recommended eating habits after diagnosis and information (301). Total cholesterol and 
triglyceride were higher in AIP cases than in controls (Paper II). This is in line with the study by 
Stein and Tschudy, who found elevated cholesterol levels in many of the symptomatic and 
asymptomatic AIP cases (101). In comparison, in a study of asymptomatic acute porphyria, only 
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HDL was found to be elevated in AIP (302). Further, the insulin and C-peptide levels were lower in 
the symptomatic cases than in the matched controls (Paper I). We speculate that the pancreas could 
be affected by DAMPs in AIP, and that symptomatic AIP is associated with disturbed glucose 
metabolism and possibly reduced uptake of glucose into cells due to decreased insulin levels. This 
is most likely in line with the study by Stein and Tschudy, who found elevated glucose levels two 
hours after oral glucose tolerance test in many symptomatic AIP cases (101). In a study of a mother 
with compensated AIP compared to a daughter with decompensated AIP and high ALA and PBG, it 
was found hyperinsulinemia during a glucose tolerance test only in the daughter, from which Sixel-
Dietrich et al. suggested a cellular insulin resistance and altered hormonal homeostasis (303). 
Anyhow, T2D is also a metabolic disease with low-grade inflammation and decreased insulin 
secretion (146, 163, 295). It is alleged that components of nutrition, such as glucose and fatty acids, 
can act as DAMPs, and by-products of metabolites such as cholesterol, ceramide and uric acid are 
DAMPs (204). Total cholesterol correlated positively with PBG (Paper II). DAMPs generate 
chronic inflammation that can be involved in development and progression of IR, T2D and kidney 
failure (146). Also, chronic consumption of a Western diet, typically described as high in terms of 
calories and rich in sugars, trans and saturated fats, salt and food additives, but low in complex 
carbohydrates, fibres, vitamins and minerals, along with a sedentary behaviour can cause 
metaflammation (157). The intake of saturated fatty acids was excessive in both cases and controls 
(Paper II), and the intake of SFA can, therefore, not explain the difference in cholesterol levels and 
cytokine levels between the cases and controls. The energy requirement calculated from RMR and 
PAL was also the same in the cases and controls (Paper II). We found reduced fasting insulin levels 
in symptomatic cases and slightly enhanced HbA1c and triglyceride levels in AIP cases, which 
could suggest that DAMPs such as glucose and lipids may play a role in AIP. 
4.1.4 Disturbed glucose metabolism 
There are a variety of signals and receptors that are involved in different physiological aspects of 
glucose metabolism, regulation of glucose and insulin level, such as glucose transporters, glucose 
receptors, insulin receptors, a host of diabetogenic hormones, diet and lifestyle (304-307). 
4.1.5 Insulin, C–peptide and factors affecting level of glucose  
The participants had fasted overnight (Paper I, II). In the fasting state, the insulin and C-peptide 
levels are naturally lower than after a meal (234). Insulin regulates gluconeogenesis, and the control 
of gluconeogenesis depends on the availability of substrates, allostery from metabolites and 
transcriptional mechanisms such as PGC-1α and cellular redox state (308). It is alleged that already 
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after 3 hours of fasting you get a fasting blood glucose level (309). During fasting, the glucagon-
effects prevent hypoglycaemia by stimulating glycogenolysis and gluconeogenesis and by initiating 
hepatic glucose release (310). Gluconeogenesis contributes approximately half of the total hepatic 
glucose production after an overnight fast (308). Most of gluconeogenesis occurs in the liver (310). 
The kidneys can also make new glucose (311). The liver, which is the culprit organ in AIP and the 
“gluco-stat” of the body, is exposed to insulin concentrations two- to three-fold higher than in the 
general circulation (232). The symptomatic AIP cases evidence reduced fasting insulin release 
when compared with the matched controls (Paper I); which may indicate that decreased glucose 
uptake into cells may explain the accelerated haem synthesis in at least the symptomatic AIP cases. 
In addition to this, C-peptide was also lower in the symptomatic AIP cases as compared with their 
matched controls (Paper I). This could suggest a reduced beta cell function in the symptomatic 
cases, and that reduced insulin release is associated with enhanced disease activity. On the other 
hand, we found no significant difference between plasma insulin and plasma C-peptide levels 
between symptomatic and asymptomatic AIP cases (Paper I), although C-peptide has a large intra-
individual biological variation. The level of plasma insulin was lower and glucose/insulin ratio was 
higher in those with high PBG levels as compared with those with low PBG levels (Paper II), 
suggesting that hormones regulating glucose uptake may be disturbed in the AIP cases with 
increased PBG excretion, and that pancreas function might be affected. We speculate that the 
reduced insulin and C-peptide secretion from the pancreas in the symptomatic cases (Paper I, II) 
may be due to organ damage, reduced hormone secretion or disturbed regulation. It is suggested 
that fasting, which reduces the insulin levels, gives higher PGC-1 α, which gives higher ALAS1, 
thereby resulting in higher PBG (224, 303, 312). PGC-1α-induced ALAS1 transcript levels are 
reduced by insulin (224). Further, hepatic PGC-1α is a major determinant of the severity of acute 
porphyric attacks in a mouse model (224). An increase in fatty-acid β-oxidation and elevation of 
hepatic gluconeogenesis are both controlled by PGC-1α, and PGC-1α has a key role in liver energy 
homeostasis and targets haem proteins (224). Interestingly, Andersson et al. suggested that T2D 
could reduce symptoms in AIP, showing an example of reduced PBG and ALA in an AIP patient 
who had T2D, and reporting about 16 AIP patients who had T2D and no longer had AIP symptoms 
(229). Although there is no known increase of T2D in AIP, we speculate that the diabetogenic 
hormones are disturbed in symptomatic AIP cases. This shows that the lower insulin levels in those 
with an increased AIP disease activity (Paper I, II) is in line with the findings that low insulin level 
affects PGC-1α (308), thereby affecting ALAS1 (224). The combination of glucose and insulin is 
more potent in inhibiting fasting-mediated induction of PGC-1α and ALAS1 (224). Glucose loading 
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reduces ALAS1 transcript levels 30 min after injection (224). Our findings (Paper I, II) may support 
the addition of insulin to the glucose given to AIP patients during a porphyric attack. This is also in 
line with the findings in diabetic mice with decreased insulin levels that got an insulin-mimetic, and 
then got reversed ALAS1 induction and reduction of PGC-1α (313). Further, altered glucose 
homeostasis and hepatic carbohydrate metabolism has been observed during fasting in HMBS-
deficient mice (314). After 14 hours of fasting, HMBS-deficient mice have shown activated 
gluconeogenesis and ketogenesis due to inability to use stored glycogen (314). However, in studies 
on fasting HMBS-deficient mice (314) and in a rat model of acute porphyria, elevated levels of 
insulin were seen (315). The insulin sensitivity can also be associated with lipids and related 
metabolites (233). We speculate that ALA can induce liver and kidney damage and, perhaps, even 
pancreas damage, secondary elevated cytokines and perhaps a disturbance in diabetogenic 
hormones, both contributing to disease activity and complications. The use of different medications 
(Paper I and II) adds to the complexity of interpreting the insulin result.  
Further, we speculate if potentially different diet and eating patterns over time could have 
impacted the levels of glucose, insulin and C-peptide, as long-term metabolic effects of the diet 
could lead to metabolic changes. A long-term Western diet and sedentary lifestyle can create 
metaflammation that is “memorized” by innate immune cells through long-lasting metabolic and 
epigenetic cellular reprogramming (157), and metaflammation is known to be associated with 
insulin resistance (152). The sensitivity of glucose – how sensitive the body’s cells are in response 
to insulin – can be affected by, for instance, the physical activity level in the last 72 hours (316). 
According to Homedan et al. (Fig. 3), giving glucose is a way of helping the TCA, through pyruvate 
and then acetyl CoA, which gives extra substrate to the depleted TCA cycle (75). An affected 
respiratory chain perhaps fits with being tired or fatigued as some of the symptomatic cases were 
(Paper II). Chronic inflammation in the liver causes insulin resistance, leading to increased hepatic 
glucose production (317). Further, the gut microbiota, which we did not measure, can also impact 
on the liver glucose and lipid metabolism (317).  
The sympathetic nervous system and the parasympathetic nervous system can also affect 
glucose levels, although we found similarity in terms of epinephrine and norepinephrine in cases 
and controls in our study (Paper II). In comparison, the breakdown product of catecholamines, 
urinary vanillylmandelic acid, was lower in cases than in controls, and stress was a common 
triggering factor of AIP attacks (Paper II). Cortisol levels, which are generally higher in the 
morning, affect glucose metabolism. We drew the blood samples in the morning and found no 
significant difference in serum cortisol levels between cases and controls (Paper II), but we did not 
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measure urine cortisol. Stress could have affected cortisol, thereby affecting the glucose output. 
Pozo et al. found lower urine cortisol levels in AIP cases (318), speculating that this could be a 
physiological compensation mechanism due to long lasting ALAS1 induction in the liver (318). 
In AIP, the level of glucose particularly inside the hepatocyte is of importance for the AIP 
disease activity. Glucose is hydrophilic, so transport of glucose across the plasma membrane and 
into the cells depends on the carrier proteins expressed in the plasma membrane since the lipid 
bilayer of plasma membrane is impermeable for glucose (311, 319). Glucose transporter 2 
(GLUT2), which is present in the liver, is insulin-independent and constitutively present at the 
plasma membrane; it maintains an equilibrium between intracellular and extracellular glucose 
(310). Thus, insulin is not needed for the glucose to enter the hepatocyte; hence, the influx of 
glucose into the hepatocyte in AIP may, therefore, not be directly affected by the low insulin levels 
found in some AIP cases. However, insulin has important functions for the metabolism in the liver 
and other organs. Insulin promotes glucose uptake and protein synthesis in muscles. Also, insulin 
promotes glucose and fatty acid uptake and inhibits lipolysis in adipose tissue. In the liver, insulin 
promotes glucose utilization, suppresses glucose production and promotes triglyceride synthesis 
(320). Levels of HbA1c, cholesterol and triglycerides were slightly higher in the AIP cases vs. 
control (Paper I). We speculate that the lower levels of insulin in the symptomatic cases gives a 
lower level of lipoprotein lipase, which again gives a higher level of triglycerides, as found in AIP 
cases (Paper I, II), and from that, perhaps, an increased risk of nephrosclerosis or coronary disease 
emerges. In a muscle cell, the binding of insulin to the insulin receptor is needed for GLUT4 to be 
translocated to the surface, and then for the glucose uptake to take place (232). We, therefore, 
speculate that the influx of glucose could be lower in some cells in symptomatic AIP cases, such as 
in muscles, adipose tissue and heart, since they depend on GLUT4, and this again could affect the 
glucose metabolism.  
There is a range of possible implications of a potentially disturbed insulin level in AIP, as 
insulin targets many tissues, the major being muscle, adipose tissue, liver and neurons (320). 
Further, the kidneys also have GLUTs and SGLTs, and contributes to the glucose homeostasis, by 
renal gluconeogenesis that prevents hypoglycaemia (311). Interestingly, it is suggested that a brain-
centred glucoregulatory system can also lower blood glucose levels via both insulin-dependent and 
-independent mechanisms, also having interactions with pancreatic islets (321). Further, the brain
has an emerging role in the homeostatic regulation and glucose metabolism due to insulin, leptin
and ghrelin acting on the hypothalamic arcuate nucleus (322). Also, insulin receptor substrate
proteins are involved in metabolic homeostasis and are important transducers of the insulin signal in
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the liver (320). Immune cell activation in the liver, muscle, pancreas and brain can impair the local 
insulin signalling and lead to metabolic dysfunction (323). It is suggested that fibroblast growth 
factor (FGF)-21 participates in regulation of glucose metabolism in liver (324), from which we 
could speculate that the low grade inflammation in AIP could cause metabolic dysfunction, or that 
the lower insulin in the symptomatic cases is a form of complex adaption to the circumstances that 
has not yet been understood. In neurons, insulin promotes anorexigenic/appetite-suppressant and 
locomotor signals (320). The insulin receptor signalling is of great importance in T2D, obesity and 
insulin resistance, and perhaps in AIP, too. In addition to the direct effects of insulin on signalling 
kinases and metabolic enzymes, it also affects insulin-regulated gene transcription (320). Hence, we 
speculate that the slightly lower insulin may be a sign of a slightly damaged pancreas, maybe as a 
consequence of increased ALA, PBG or inflammation in AIP, or that the low level of insulin is due 
to perturbed signalling of the other hormones affecting insulin levels, which again can be associated 
with inflammation related to AIP (Table 2). 







AIP or cluster 
with AIP  
C-peptide F N é é ê 
P é é é 
Insufficient 
ND 
Insulin F N é ê or (é) 
Insufficient 
ê 
P é é ê ND 
Resistin F  N é é é 
P é ND 
Visfatin F N é é é 
P ND 
IR = insulin resistance, N = Normal, F = Fasting, P = postprandial (carbohydrate intake), é= 
increased/high, ê= Decreased/low, ND = not determined in our study. 
4.1.6 Visfatin 
We surmise a role of the adipose tissue in the inflammation observed in some of the AIP cases, as 
there was an increased visfatin level seen in the AIP cases in cluster (b) with high cytokine levels 
(Paper I). Visfatin is known to act on insulin sensitivity and glucose metabolism, and it is 
upregulated in humans with T2D (235). In line with this, insulin correlated positively with the 
 71 
levels of plasma visfatin and leptin (Paper II). It is suggested that hepatocyte-secreted dipeptidyl 
peptidase 4 in obesity promotes adipose inflammation and IR (325). Although the BMI, waist- and 
hip-circumference were not different between the AIP cases and controls (Paper I, II), both the 
groups had a high percentage of persons with overweight where one could speculate that the 
adipose tissue adds to the low-grade inflammation.  
4.1.7 Resistin 
Resistin was higher in symptomatic than in asymptomatic AIP cases after an overnight fast, and 
there was a positive correlation between resistin and leptin (Paper II). This may suggest that the 
effect of inflammation on AIP (Paper I), and that adipokines and hormones affecting insulin 
resistance or a disturbed glucose metabolism may be involved in a high AIP disease activity (101, 
237). Lee et al. showed that resistin levels did not significantly change even after 48 hours of 
fasting (326), and Gruendel et al. showed that serum resistin levels increased postprandially (327). 
We speculate that the elevated fasting resistin levels found in the AIP cases could be an effect of the 
AIP disease itself since it was observed during periods between AIP attacks and outside acute 
inflammation, and since there were not any difference in number of persons that had inflammatory 
diseases in AIP cases compared to controls (Paper I). This is in line with the claim that resistin 
activates TLR4 on macrophages and increases cytokine release (238). The higher resistin levels in 
the symptomatic as compared with asymptomatic AIP cases may also imply that hormones 
regulating the glucose uptake may be disturbed in the symptomatic AIP cases (Paper I and II). The 
higher resistin levels in the symptomatic than in the asymptomatic cases (Paper II) and the higher 
cytokine levels in AIP cases than in the controls (Paper I) might indirectly impact the glucose 
metabolism, for instance, IL-6 is known to suppress gluconeogenesis in the liver by activating a 
transcription factor (317). In the symptomatic AIP cases, the higher resistin production was not 
followed by higher insulin release as it is in persons with IR and excess body weight (Table 2). 
Resistin exerts its glucoregulatory effects by stimulating hepatic glucose production (305). 
Furthermore, resistin has an anorexic effect, decreasing body mass and increasing lipogenic 
enzymes and inflammatory cytokines in the liver (305). This is partly in line with our findings 
regarding increased resistin in the symptomatic AIP cases, although the cytokines were increased in 
both asymptomatic and symptomatic AIP cases (Paper I, II). Further, it is stated that resistin can 
directly activate the complement system, and this is justified by the slightly elevated markers of 
complement in AIP cases who also have elevated resistin (Paper I, II). The slightly lower 
prealbumin levels in the symptomatic AIP cases as compared with the asymptomatic cases may 
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indicate liver inflammation in the symptomatic AIP cases, and this may be a partial cause of the 
elevated cytokines (Paper I). A study on Hispanic non-porphyric persons reported that higher 
resistin levels were associated with low insulin sensitivity and higher adiposity (328). Elevated 
levels of resistin have been shown to be related to increased risk for T2D, but the potential effect of 
resistin on risk for T2D decreases after adjustment for overweight and inflammation (329). Others 
have found that serum resistin levels increased in patients with T2D, but they did not find any link 
to markers of IR or adiposity (330). There was no significant difference in the number of persons 
with T2D between AIP cases and controls (Paper I). Interestingly, weakening of porphyria 
symptoms has been reported in AIP patients having T2D (229). The role of resistin in AIP thus 
needs further investigation.  
4.1.8 Diet and lifestyle  
We speculate that a low energy intake and a low carbohydrate intake is detrimental in AIP since we 
found that carbohydrate intake of the AIP cases was lower than recommended, and that a low 
energy intake was correlated with higher biochemical disease activity (Paper II). This fits with the 
beneficial effect of glucose in AIP due to the glucose and insulin’s effects on PGC-1α (224); it also 
fits with the rise in ALA and PBG when the caloric intake was decreased and a decline in ALA and 
PBG when carbohydrate and energy intake was increased in a study of seven persons with AIP who 
received meticulous attention in a hospital metabolic unit (51). In a recent review, Wang et al. 
stated that extreme dieting and starvation should be avoided in AIP (6). Furthermore, persons with 
AIP should be offered a consultation with a dietitian “to promote and maintain a well-balanced diet 
somewhat high in carbohydrates (60–70% of total calorie intake)” (6). Actually, charcoaled food, 
cabbage and Brussel sprouts contain chemical substances that could upregulate ALAS1, but the 
amount needed to do so would probably be far above what is normally consumed 
(porphyriafoundation.org, accessed November 2019). The dietary intake of most dietary variables 
were not different between the cases and controls, which fits with what was found in a group of 20 
persons with AIP and 20 controls in northern Sweden; however, the latter was based on a 
retrospective interview filling in a standardized questionnaire (244), whereas our study used a 
prospective diet logbook (Paper II). A higher intake of marmalade and jam in the symptomatic 
cases was found (244). The cases showed a mild but not significant tendency to consume more 
added sugar as compared with the controls (Paper II). This possibly reflects that the AIP patients 
followed the advice of eating carbohydrate-rich food, perhaps incorrectly interpreted by them as 
added sugar. Also, the campaigns against consumption of excess sugar might have lead some of 
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them to incorrectly assume that carbohydrates are not good for the health, while actually most 
persons do not reach the recommended 45–60 E% of the diet from carbohydrates (226). Both too 
high and too low percentages of carbohydrates have been associated with increased mortality, with 
a minimal risk observed at 50–55% carbohydrate intake (226). What one eats instead of the 
recommended carbohydrates affects mortality (331). Eating more of the healthy carbohydrates in 
general and restricting the increased added sugar intake to periods when there is a risk of an attack 
would be in line with the recommendations. However, since we found a significantly higher intake 
of sugar/candies in AIP cases with low urine ALA (Paper II), we speculate that this otherwise 
considered unhealthy dietary habit is, in some ways, beneficial in AIP not only during attacks, but 
increasing the healthy carbohydrates would perhaps be better. Clinical improvement by glucose, 
although given intravenously, was shown in a study on eight patients with attacks of acute 
porphyrias and three in remission (222). It has been postulated that high glucose exposure may play 
a role in the etiology of metabolic diseases, the background being studies on human adipose tissue 
stromal cells, where high levels of extracellular glucose sensitized an inflammatory response gene 
expression program and exposure to high glucose altered histone methylation in inflammation 
response genes (332). Further, our findings of elevated cytokines (Paper I) and possibly disturbed 
hormones (Paper II) fit with the idea of AIP being a chronic disorder in at least the symptomatic 
patients, meaning that a person with AIP is not a completely healthy person, even though they 
experience only a few days of attack a couple of times during their lifespan. An analogy would be 
addressing T2D as acute intermittent ketoacidosis, which would not be a good idea. 
The AIP cases and controls had the common task of consuming little fibre and a lot of 
saturated fat (Paper II), even if the contrary is advised in general (226). We found a lower intake of 
PUFA in cases when compared with controls, and that the intake of PUFA correlated negatively 
with PBG (Paper II). This fits with the suggestion given by a case-control diet study on 16 AIP 
patients, which said that the intake of PUFA, complex carbohydrates, MUFA and folic acid must be 
increased in AIP, and the intake of protein, lipid and SFA should be decreased (333). Also, 
nutrients are used as substrates in metabolic pathways and can also directly regulate the cell’s fate 
through different mechanisms, and these activities can cause the response to inflammatory insults 
(204). As AIP patients are prone to hypertension and the risk of chronic kidney disease, for some of 
them, it could be important that the dietary recommendations also include their vulnerability, which 
should be manageable since a diet emphasizing vegetables, fruits and low-fat dairy foods and 
moderate amounts of whole grains, fish, poultry and nuts are beneficial for patients with CKD or 
hypertension (334). In recent years, carbohydrates has been discredited by some, and the a “low-
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carb, high-fat” diet has spread (335) even though there is lack of data supporting its long-term 
efficacy, safety and health benefits (336). The American Porphyria Foundation 
(porphyriafoundation.org, accessed November 2019) stated that when the Atkins Diet – high fat, 
high protein, low carbohydrate-diet – became popular, many persons with AIP who adhered to this 
diet became ill, (337); moreover, the trending ketogenic diet has porphyria as a contraindication 
(338). We speculate that intermittent fasting diets could also trigger AIP attacks (339).The intake of 
polyunsaturated fatty acids (PUFA) was significantly lower in the cases than in the controls (Paper 
II), which we speculate could be unfortunate since PUFAs are mainly anti-inflammatory (233). In 
animal studies; PUFAs have been associated with improved insulin sensitivity, albeit this effect is 
controversial in humans (233). Also, the PBG levels correlated negatively with the total PUFA 
intake. SFAs are found to be worsening the insulin sensitivity in animal studies, but in humans, the 
role of SFAs on IR is conflicting (233). 
Low-grade inflammation in AIP and the recommended increased carbohydrate intake give 
rise to the question on how to eat both to reduce inflammation and the AIP disease activity. It is 
reported that anti-inflammatory diets, which also stabilize insulin levels, should be rich in colourful, 
non-starchy vegetables, as they consist of polyphenols that could inhibit the nuclear factor, NF-κB 
(298). This would hold true if our speculation that chronic low-degree inflammation in AIP is more 
of a burden in the long run than a harmless accommodation due to the enhanced levels of toxic 
porphyrin precursors. In the case of smoking-induced inflammation, exercise produces increased 
anti-oxidative defence and decreased expression of inflammatory cytokines (299). Hence, AIP 
patients must also be encouraged to exercise. Stress has been found to be a frequent triggering 
factor of AIP attacks (Paper II) (100), and it may increase proinflammatory cytokines, which, in 
turn, could give rise to depression and fatigue (340). Hence, we speculate that avoiding or 
combating stress is important. Also, PTX3 worked as a significant predictor of PBG after 
adjustment of confounders in the regression analysis (Paper I). Also, elevated inflammation 
biomarkers were found in serum of persons who dealt with multiple stressors as compared with a 
group without as many stressors (341). Even so, counselling AIP patients on how to avoid or handle 
stress is not widely practiced; but they are informed that stress is a potential triggering factor. In my 
opinion, this should be addressed in the future. There is no risk calculator/risk chart to use with 
suggested interventions for persons with AIP outside AIP attacks, such as those existing for 
coronary heart disease and T2D. Due to the rarity of the disease, there are no large studies to use as 
a background for advice to persons with AIP, such as the Framingham study used for coronary 
disease risk stratification; nevertheless, a multinational natural history study including 112 patients 
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of whom 104 have recurrent AIP attacks has been described (279). Lifestyle factors, including 
psychological stress, have been shown to be associated with shortening of telomere length (342). 
Even though previous studies on clinical and biochemical characteristics of AIP attacks have not 
reported cytokine measurements, we speculate that some of the physical signs and symptoms during 
an AIP attack, such as pain and a reduced functioning level and fatigue could perhaps also be 
associated with sterile inflammation. We speculate that the cytokine levels are even higher during 
many AIP attacks than in “remission”, but this remains to be examined.  
4.1.9 Micronutrients, vitamins and herbal remedies  
We did not find a significant difference regarding intake of either vitamin B12 and folate or S-B12 
or S-folate levels between the case and control group, although there was a higher median for both 
in the cases (Paper II), whereas Thunell et al. had found higher levels of vitamin B12 in persons 
with symptomatic acute intermittent porphyria when compared with the controls (244). Vitamin B6, 
also called pyridoxine, is a water-soluble vitamin (343). It is important for the normal functioning 
of many organs (343). It is metabolized to pyridoxal 5-phospate, an active molecule that serves as a 
co-enzyme for many metabolic enzymatic reactions, and it is directly involved in the first step of 
haem synthesis as a co-factor of ALAS1. ALA and PBG levels declined during vitamin B6 
deficiency in a study of one asymptomatic AIP patient and increased following the administration 
of vitamin B6 (343). This impairment of ALA and PBG was not found in starved animals with 
severe vitamin B6 deficiency (343). We do not have the results of the effect of vitamin B6 levels 
from our study available yet. The level of vitamin D – which functions as a nutrient, a hormone and 
an immuno-modulator (344) – was insufficient in many cases and controls (Paper II). This could 
perhaps contribute to the inflammation, but can not explain the enhanced inflammation in the AIP 
cases. Use of complementary and alternative medicine is common in patients with inborn defects of 
metabolism (345), as some of them are not satisfied with conventional therapy (321). Use of 
vitamin supplements, fish oil and herbal remedies was relatively common in AIP cases (Paper II), 
and should be discussed between them and their doctor.  
4.1.10 Link between different factors 
There occurs constant communication between the complement system, the PRRs, haemostasis, 
haem synthesis, diabetogenic hormones and the nervous system. This creates a mesh of signals, but 
also gives rise to a wide range of possible treatment modalities, for instance, from preventing stress 
or consuming carbohydrates to giving haem arginate or using small interfering RNA. Irrespective of 
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their lifestyle and dietary routine, people with AIP are just as much prone to stress and infections as 
others. We must acknowledge the unpredictability and probability of this disease attacking people. 
Availability of treatment modalities and knowledge is important to help people experiencing an AIP 
attack. This project has tried, in addition to gaining knowledge, to spread knowledge regarding AIP 
to relevant persons in the local health care and to AIP patients. We found stress to be a common 
triggering factor, and suggest the presence of an increased inflammation and a disturbed glucose 
metabolism in AIP cases. Based on this, we speculate that it is beneficial in people suffering from 
AIP to get enough sleep, adopt a healthy diet with lots of carbohydrates of high quality (e.g. 
vegetables, berries, whole grains, etc.) which maintain a steady insulin level, find ways of coping 
with stress and the right amount and type of physical activity. Anyhow, a recent study highlights the 
need for individualized advice, as they observed large inter-individual variability in postprandial 
responses of blood triglyceride, glucose and insulin following identical meals (346). Berry et al. 
report that person-specific factors, like the gut microbiome, had a greater influence than did meal 
macronutrients for postprandial lipemia, but not for postprandial glycemia, while genetic variants 
had a modest impact on predictions (346). Further, the oral health should also be recognized as a 
possible contributor to the general health, inflammation and the “blurred nexus” regarding IR (347), 
with a potential to affect the haem synthesis.  
Although AIP is a chronic enzyme deficiency increasing the risk of HCC and possible 
inflammation in the body, most persons today are not using any long-term medication for AIP. It is 
thought-provoking that the AIP cases have low-grade inflammations outside attacks, perhaps 
because of the elevated ALA and PBG levels that cause organ damage. This upholds the need for 
devising treatment plans for dormant AIP, such as in the case of diabetic patients. Having high 
ALA and PBG without obvious symptoms should also be taken seriously in AIP, such as elevated 
blood sugar levels in diabetes. For those who show symptoms, there are many possible 
interventions and precautionary measures, which give most of persons with AIP the hope to lead a 
normal life. One should acknowledge the suffering of patients with recurrent and chronic AIP 
symptoms; they need treatment now as they did a hundred years ago (see quote, Dr Einar Wallquist, 
page 3). 
4.1.11 Sampling conditions and reference values of cytokines 
Correct sampling conditions for cytokines in venous blood samples are important in good clinical 
and research practice. Our recommendation for cytokine analyses obtained from this study are 
EDTA or citrated blood immediately cooled on crushed ice, and immediately centrifuged and 
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plasma stored at -80°C (Paper III). EDTA blood is preferred since it can be stored for up to four 
hours at 4 °C before centrifugation. Cytokine levels were lowest in the EDTA tubes as compared 
with all the other tubes when the blood samples were centrifuged at T0 (Paper III). Further, we 
think that complement activation cannot explain the difference in cytokine concentration between 
serum and plasma because TCC was only elevated in the serum tube with gel and clot activator 
while the cytokine levels were increased in both the serum tubes; this shows that the cytokine level 
were elevated with or without the presence of clot activator (Paper III). Regarding storage of 
samples, we found that cytokine concentrations in anti-coagulated whole blood increased 
significantly after one hour at room temperature. We, therefore, suggest storing samples at +4 °C 
for up to four hours since it had little or no effect on cytokine levels (Paper III). The increase of 
cytokines at room temperature could be due to in vitro synthesis or release of pre-synthesized 
cytokines by blood leukocytes (348). Cytokine levels measured in EDTA and citrate plasma stayed 
stable despite several rounds of thawing and freezing; hence, we suggest that it is acceptable to 
thaw and freeze the sample maximally three times. In our opinion, the sampling conditions may 
influence the results substantially. If future studies analysing cytokines follow these advices, it 
would ensure better comparability and validity of the results. For optimal use of cytokine analysis 
in clinical practice as a biomarker of conditions such as sepsis or post-traumatic complications, 
further research is needed. The cytokine concentrations in serum were significantly higher than in 
plasma. This is in line with several previous reports (349). This may implicate that the cytokines are 
synthesized or released from blood cells during coagulation activation in vitro. We postulated that 
the coagulation process and thrombin activation enhance cytokine release, which also fits with 
previous findings (350, 351). Coagulation itself may induce cytokine release from whole blood 
leukocytes, which is consistent with earlier findings showing that thrombin activates leukocytes and 
cytokine release through activation of protease-activated receptors PAR-1 and PAR-4 (253). Use of 
serum for cytokine analyses should, therefore, be avoided. Another finding in paper III in addition 
to the recommended guidelines for cytokine analysis was the estimation of reference ranges for 
cytokines in humans. We consider the upper 95th percentile values to be the best estimate of the 
reference ranges, and they are common for women and men (Paper III). Whether the reference 
ranges should be separate for women and men could be argued, but for practical reasons, and since 
the differences were small and only existed on a minority of the 27 cytokines, we chose common 
reference values for both the sexes. Since the 2.5 percentile was not measurable in some of the 
participants, and since an increase in cytokines is more logically related to the disease than a low 
value, we chose the upper 95th percentile as the value of choice. In healthy individuals, the 
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concentration of many cytokines were either immeasurable or very low. These reference ranges for 
plasma cytokines were not previously described in the literature in a large number of healthy 
individuals. However, the sampling conditions, handling and storage of samples may vary among 
the studies, which may explain at least some of the different results obtained from different studies 
(352). To interpret the results of cytokine analyses, one must also take into account the large 
biological variation (160), which could cause the need for repeated measurements. In addition, the 
levels of cytokines can be affected by many environmental factors such as age, gender, smoking, 
depression, medication, the microbiome, time of year, time of day and genetic factors (353, 354). 
4.1.12 Strengths 
The study’s strength is that it has analysed a relatively large group of AIP patients considering the fact 
that it is a rare disease. Also, it has measured many relevant inflammatory biomarkers on which the local 
research laboratories have expertise. The standardized sampling conditions and preparations improve the 
strength of the study; for instance, the cytokine analyses and other analyses on fasting patients were all 
performed at the same time in the morning by skilled technicians at the same laboratory and during the 
same time of the year. The set up with controls matched for age, gender and place of residence is also a 
great advantage since the afore-mentioned factors are no longer the reason for differences between cases 
and controls. 
4.1.13 Limitations of the study 
Doing several different group stratifications and multiple hypotheses testing on a relatively small 
number of participants may be a weakness. Performing many correlations between many 
biomarkers from the results of an analysis on a relatively low number of participants is a weakness 
and could lead to false-positive results. Hence, one should acknowledge the preliminary nature of 
some of the results and understand that there is a possibility that we may have over-interpreted 
some of the data. Also, in the interview-setting, there was no blinding, indicating that we knew who 
had AIP and who did not, and this could have perhaps led to bias in our questions and their 
answering. When comparing asymptomatic and symptomatic patients, the age and sex distribution 
was no longer matched between the groups. A weakness is the cross-sectional way of the study, 
only giving an instant picture of how the biomarkers and clinical measurements were at one point of 
time instead of over a significant period of time. However, the participants provided information 
through questionnaires and interviews on previous diseases and AIP attacks. Also, even if this study 
analysed the urine ALA and PBG levels only at one point, which could be a weakness, another 
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study investigating biological variation in AIP suggests that AIP patients vary around their own 
typical porphyrin precursor level, making this less of a problem (9). Since this study was not 
undertaken on AIP cases during the attacks, it is not possible for us to elucidate how the cytokine 
levels and other biomarkers and clinical measurements would be during an porphyric attack. 
Regarding our grouping of AIP cases based on high and low biochemical disease activity (ALA and 
PBG), and then comparing different dietary markers and other markers in these groups with those in 
others, it is to be noted that a high PBG or ALA level does not necessarily correlate to AIP 
symptoms.  
The lack of international consensus on precisely what an AIP attack is proves to be a 
limitation regarding the correct classification of persons with AIP as asymptomatic or symptomatic. 
The low power can reduce the chance of detecting a true effect. Also, it reduces the likelihood that a 
statistically significant result would reflect a true effect. Although no official scaling system is 
available for AIP, there are four major subgroups of acute porphyria patients: symptomatic patients 
with sporadic attacks (< four attacks/year) or symptomatic cases with recurrent acute attacks ( ≥ 
four attacks/year), asymptomatic high porphyrin precursor excretors and asymptomatic latent 
patients without symptoms or porphyrin precursor elevations (106). We grouped the AIP cases 
based on whether they had a history of AIP attack (symptomatic) or not (asymptomatic). Further, 
we also compared the AIP cases with high and low PBG levels.  
To classify a case as symptomatic, we relied on previous routine genetic and biochemical 
testing and previous clinical symptoms and diagnosis perceived as AIP attacks. In addition to this, 
many of the symptomatic AIP cases and some of the asymptomatic AIP cases also had present 
verified elevated PBG levels. Given the continuum between total asymptomatic and substantially 
symptomatic, the classification of the cases becomes troublesome. However, when a patient 
presents with a history of previous attack with high PBG levels, typical symptoms and positive 
genetic testing, there is very little doubt about its classification. Anyhow, the distinction against the
matched controls was clear. 
4.2 Methodological considerations: external and internal validity 
External validity: sampling bias 
Research on rare diseases such as AIP can often be hindered due to small sample sizes (Paper I, II). 
However, this limitation can be overcome by multicentre studies. Almost all, except two 
participants, had the same AIP mutation (Paper I, II), and all the included participants were from 
Norway (Paper I, II, III). This renders the external validity of the study questionable. On the other 
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hand, the same mutation is also prevalent in Sweden, and all the AIP mutations lead to reduced 
function of the same enzyme. Showing many aspects in depth on these particular AIP cases could 
prove to be the strength of the study, but some might regard it as a limitation since it could be 
argued that the possibility to transfer the results to patients with other AIP mutations is less.  
Regarding inclusion, of the persons with AIP, it could be likely that those who thought it 
would be most useful to participate were the ones with symptoms, therefore wanting to participate. 
The sampling bias can thus affect the external validity by lowering the generalizability of the study. 
Also, persons who were very much affected by the AIP could hesitate to participate since the travel 
to the hospital could be too much of a stressor. Thus, 35 symptomatic and 15 asymptomatic people 
were included in the study. When stratifying the asymptomatic and symptomatic AIP cases based 
on clinical history and interview, there were possibilities for misclassifications since there is no 
international consensus on what an AIP attack is. The symptomatic AIP patients had AIP mutation, 
at least one AIP attack with typical symptoms and elevated PBG levels. An advantage of this 
presumably overrepresentation of symptomatic cases is that we got a thorough look at the 
symptoms and related diseases that can arise in symptomatic AIP persons. Regarding the matched 
controls, they were randomly selected based on their age, gender, and place of residence. Some 
persons from the first batch of controls rejected the invitation, so a second random selection was 
necessary to obtain 50 matched controls.  
Internal validity: selection bias and recall bias 
Internal validity can be affected by systematic errors such as selection bias, information bias, 
incorrect statistical methods and confounding factors. Of the AIP cases who got information about 
the study, only three did not want to participate, among whom one was too ill to join, creating a 
healthy user bias or non-respondent bias (355). All persons with AIP who consented to participate 
in the study showed up for the interview and clinical examination. Of the controls, three men did 
not show up for interview and clinical examination, but they were replaced by other men with 
matched age and postal code. 
By doing a matched case control study, we avoided some of the selection bias, producing as 
similar groups as possible for comparison. One person was classified as having AIP on the basis of 
the information they provided, but genetic analyses and urine analyses ruled out the provisional 
diagnosis. This person and the matched control were thereafter removed from the study. The 
response rate for using the diet logbook was high, giving a good impression of the dietary habits in 
the cohort. Our study asked about previous attacks and specific symptoms that the patients may 
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have experienced long time ago, which made the study vulnerable to recall bias (355), as the 
question might lead to overestimation of the symptoms. A prospective study of AIP attacks could 
have given more accurate results. Regarding information bias, all the participants were given the 
same information, but one could assume that AIP cases had more information and awareness on 
dietary factors and general knowledge on AIP beforehand. 
4.3 Considerations regarding statistics and statistical power 
For PBG, a difference of 9 µmol/mmol creatinine was anticipated between the mean value of the healthy 
control group and the AIP cases. A minimum of 20 persons were needed to find a statistical difference 
between the groups with 95% probability (p < 0.05) at previously observed SD for mean value. A 
limitation is the relatively low number of participants, that may render the study vulnerable for random 
error (356), (Papers I and II). The relatively high number of hypotheses leads to carefulness in the 
interpretation of the set threshold for the p-value, since if Bonferroni correction had been used, the p-
value needed for statistical significance would be lower. When multiple hypotheses are tested, the 
likelihood for incorrectly rejecting a null hypothesis increases (Type I error, false positive). The 
advantage of using PBG as a means in the power calculations was that we compared the AIP cases with 
the controls. The power is the probability that the test will correctly identify the difference, if any. It 
might be that, for some comparisons, we were not able to detect a difference, such as between the 
asymptomatic and the symptomatic AIP cases, if any. If so, we would fail to reject the null hypothesis 
(H0), even though H0 is false (Type II error, false negative) (357). To decide the sample size, we also had 
to look to at how many participants could be included, knowing the rarity of the disease, costs and 
workload. A case control study, in itself, generates new hypotheses and points to a direction for new 
research but does not find the causality. It rather pinpoints significant correlations, and from them, one 
could speculate on the causative factor and its outcome, based on the existing knowledge on AIP. 
However, it is important to keep in mind that correlations do not imply causation (358).  
We performed multiple linear regression analyses to describe the relationship between PBG 
and inflammatory molecules. Nevertheless, a pitfall exists; since the dataset included 50 patients 
with latent or symptomatic AIP, the number of observations is too small for running a linear 
regression analyses, and we encountered quite a few obstacles in order to fulfil the underlying 
assumptions for linear regression. The assumption of normal distribution was tested for all 
independent variables using q-q-plots and, to some extent, the Shapiro-Wilk test. Standardized 
residual plots were generated for all the analyses in order to evaluate the underlying assumptions of 
a linear regression analyses, namely normality, homoscedasticity and linearity. When the 
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assumptions were not met, we transformed the variables using natural logarithm, which was 
sufficient to achieve satisfactory residual plots. As a result, most variables were transformed using 
natural logarithm, including the dependent variables PBG. The following factors were hypothesized 
to influence the disease activity in the linear regression analysis and were tested for being potential 
confounders: liver function/damage, kidney function, fasting, mental stress, smoking, alcohol 
consumption, pancreas function, sex hormones, age and gender. Additionally, we tried to test all the 
cytokines in the model, but we encountered problems with multicollinearity. We, therefore, did not 
make a model including all the cytokines and confounders because the dataset included only 50 
patients and we could not present a model including 30 variables. Moreover, several of the 
independent variables were highly correlated. We, therefore, thought that the best way to present 
the results is to present the adjusted p-value of PTX3, pre-albumin and eGFR, instead of producing 
a large table with confusing results that cannot be trusted. Anyhow, the fact that there was an 
unknown confounder that was not considered is not dismissed. To achieve slightly more reliable 
results in the linear regression analysis, we should have recorded more than 110 observations. 
We chose a model in hierarchical clustering analysis that provided information and clustered 
persons in groups which produced a pattern that made sense by using a clustering method described 
before (277). This analysis is a statistical classification technique where cases or biomarkers are 
divided into groups and subgroups (clusters) in a way that the biomarkers (cytokines levels) in a 
cluster resemble each other and are different from the biomarkers (cytokine levels) in other clusters. 
This is a tool for finding associations, patterns and structures within big datasets. We chose an 
agglomerative way of making the hierarchy of clusters, meaning “bottom up”, that every 
observation starts in its own cluster, and that pairs of clusters are put together when going up in the 
hierarchy. Before clustering, the dataset was distanced, for instance, by measuring the distance 
between different cytokines using Euclidian distance – the shortest distance between two points. 
Higher in the hierarchy, the distance between a pair and another sample must be measured, which is 
more complicated. Hence, we chose a method called maximum or complete linkage method, where 
the distance between the coupled pair and the other is set as the maximum of the pair of differences 
in each case. 
4.4 Pros and cons regarding main group of the used methods and analysis 
The laboratory was participating in external quality assessment and is also performing internal 
quality controls, where applicable, which is important to ensure good analysis quality (267). 
Certain interfering substances can affect the binding between analyte and antibody and thereby 
 83 
produce analytical errors in immunoassays (359). Selectivity is only as good as the antibody can 
offer, and the results can possibly be affected by autoantibodies and matrix effects. Another 
problem is that some antibodies do not identify small differences in antigens, such as different 
protein isoforms. The manual processes can lead to relatively high interlaboratory variability and 
intra- and inter-assay variability. Advantages of immunoassays include the fact that because they 
are so widely used, they are often already fully validated and accepted. The microplate format 
makes a relatively high throughput possible because of many samples in parallel; but with 
multiplex, multiple analytes in each sample can also be measured. Immunoassays are relatively 
sensitive when coupled with good signal amplification. With multiplex (ELISA) technology, 
multiple biomarkers are measured at once, minimizing time and sample volume required. It can, in 
total, give biomarker profiles in addition to each single analyte. Notably, multiplexing has the 
possibility for cross-reactivity. The advantage of LC-MS/MS analysis used for measuring serum 
total vitamin D level is its selectivity. It can (a) distinguish between quite similar biomolecules, (b) 
shows sensitivity in detection of very small analytes and (c) the intra- and inter-assay 
reproducibility is high. Flowcytometry gives quick analyses of large cell populations but no 
information on individual cells. Its accuracy depends on how well trained the operators are and 
using the correct reagents and techniques. The presence of extreme lipemia, chylomicrons or 
extremely high bilirubin might interfere with and elevate the haemoglobin levels (according to the 
Advia 2120i Operator´s guide). However, none of the participants in our study had extreme lipemia 
or extremely high bilirubin. Regarding nephelometry analysis of proteins, a limitation could be the 
antigen excess or matrix effects, but this was not a problem in our study. 
Using a seven-day diet logbook has a potential for underreporting (360), and the dietary 
intake is, therefore, probably slightly (17%) underreported. Advantages with our method were that a 
trained clinical nutritionist had conducted an instruction meeting with all the participants 
beforehand, and she also conducted follow-ups along the way when the participants had any 
questions. The nutrition institute in Oslo analysed the diet logbooks using their regular methods and 
gave us systemized data. 
We used the PBG ratio and urine creatinine to correct urine concentration, and we set an 
upper reference limit of PBG at 1.5 µmol/mmol creatinine (44, 264-266). ALA, PBG and total 
porphyrins can remain elevated for many years, and some persons are constant high excretors of 
porphyrins precursors (71). The half-life of PBG is 10.6 years, highlighting the concerns of using 
these analyses for diagnosis of recurrent attacks (71). A two-fold increase in PBG (U-
PBG/creatinine-ratio) in combination with symptoms are suggestive of an AIP attack (9). However, 
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it has previously been suggested that an AIP attack can be confirmed by a PBG concentration (not 
ratio) at least ten times the upper limit of normal (361) within one week of the onset of 
neurovisceral symptoms (31, 265, 362). During an AIP attack, the PBG concentration is typically 
10 mg/L (44.2 µmol/L) (363). None of the AIP cases experienced an AIP attack at the time of the 
study (Paper I, II), but several cases had PBG levels above the cut-off, being high excretors without 
present apparent symptoms, either with or without a history of previous symptoms, as ALA and 
PBG can also be significantly elevated above the upper reference limit in asymptomatic AIP cases. 
A less than 50% change of PBG/creatinine can be due to analytical and biological variation (9). In a 
short-term setting, the reference change value (RCV) of PBG has been approximately 50% and 70% 
in a long-term setting (9). Other causes of increased ALA are lead poisoning and tyrosinemia (65). 
Methenamine hippurate intake can give false-negative PBG results (268). Although rare, AIP 
symptoms can also arise in children (364), but ALA and PBG do not always increase substantially 
(364, 365). In our study, only adults had participated. It is stated regarding children that, “Acute 
porphyrias should be considered in the differential diagnosis of cases with unexplained neurological 
weakness and myalgias, as well as in children with hypertension in association with behavioral 
abnormalities, including irritability and lethargy” (364). Qualitative tests for PBG are rapid and 
cheap, whereas screening tests have low sensitivity and poor specificity and should always be 
confirmed using a specific, quantitative method (95, 265). In our study, we relied on the 
quantitative ALA and PBG tests (Paper I, II). Further, most persons with AIP mutation have a 
lowered enzyme activity of the HMBS in their RBCs, but this is variable and not a reliable test for 
AIP (44), thus was not used in the study. 
4.5 Clinical and other implications 
Paper I and II: One of the current clinical practice recommendations from NAPOS is that insulin 
should be added to the 10% glucose solution when given intravenously to AIP patients to counter 
AIP attacks. During AIP attacks, the transcription of ALAS1 can, to some extent, be downregulated 
by giving glucose and the subsequent increased endogen production of insulin and/or the given 
insulin added to glucose (224, 225). Our finding that fasting insulin was lower in the symptomatic 
cases supports this clinical practice, but more research is needed on glucose metabolism and insulin 
effects during AIP attacks. Insulin is needed for glucose uptake into many cells and for metabolic 
purposes (320), but glucose has to be given at the same time in large enough amounts. Haem 
arginate treatment is assessed as very effective in improving the symptoms of acute AIP attacks (5), 
but the inflammatory potential and the possibility of adding to potential chronicity advocates a more 
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cautious way of using it as a long-term treatment (94). However, haem is still recommended as a 
treatment modality for AIP attacks. The potential effects of low-grade inflammation and lifestyle 
factors, including diet, in AIP have been widely discussed in meetings with the local porphyria 
association and at international conferences. 
Paper III: This paper has contributed to the knowledge regarding optimal sampling methods, 
enhanced in terms of accuracy, for cytokines, chemokines and growth factors in venous human 
blood samples. The project has laid the foundation for future research projects regarding the use of 
cytokines, growth factors and other biomarkers for detecting cytokines in different diseases and 
conditions in humans. Notably, some cytokines are promising biomarker for assessment of neonatal 
sepsis, although conflicting cut-off levels were reported and potential confounders should be 
considered	(255).	
4.6  Way forward 
For some, the burden of AIP is high (279, 366). This highlights the need for novel therapies and 
better knowledge on prevention of AIP attacks and the modifying factors that impact breakthrough 
of symptoms. Research on inflammation and diabetogenic hormones could be extended, such as by 
studying givosiran’s impact. Mapping and changing the diet in AIP patients with chronic symptoms 
and studying PBG and ALA changes after intake of carbohydrates or glucose with and without 
insulin-treatment could be fruitful. Also, of interest are genetic studies, including studies of mRNA 
and other RNA molecules, to examine the role of other related mutations and epigenetic changes. In 
an animal model, one could use CRISPRCas9 gene editing to study the effect of AIP on the HMBS 
enzyme activity, metabolomics and transcriptomics. In a whole blood model, the possible roles of 
PBG, ALA, porphyrins and haem arginate as possible DAMPs on cytokine release and complement 
activation can be studied. To analyse serum concentrations of different environmental pollutants, 
new liver markers, TSH, FT4, plasma hepcidin, adiponectin and faecal microbiome could be 
compared with PBG, ALA and inflammatory markers. It would also be interesting to analyse 
cytokine levels and hepcidin during AIP attacks. Gut microbes have been shown to impact insulin 
sensitivity (156) and affects health and disease (367). We will complete the studies about enhanced 
liver fibrosis test (ELF) in AIP, dental health in AIP, ROC-curves for ALA and PBG in diagnosing 
AIP and the role of different B-vitamins, including B6, in AIP. With interest, I will follow the work 
of research groups focusing on AIP therapy in the form of liver directed gene-therapy (116, 368-
370), hepatocyte transplantation (371), pharmacological chaperones (372), systemic mRNA (373, 
374) and inhibition of β–catenin (375). I will also follow the planned international genome-wide
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associations study and those studying modifiers that could impact AIP disease activity, such as a 
polymorphism in the peptide transporter 2 (PET2T) gene (376). Also, I will follow the search for 
better diagnostic tools for AIP and AIP disease activity, such as cellular bioenergetics (77), Vitamin 
D-binding protein (377) and Protein Induced by Vitamin K absence or Antagonist II (PIVKA-II)
(210). The application of machine learning and knowledge engineering to electronic health records
will also give interesting results (378).
4.7  Conclusions 
The thesis brings to the research area the idea of low-grade inflammation as a part of the 
pathogenesis and consequence of AIP. AIP cases had low-grade inflammation measured as higher 
levels of plasma cytokines. We speculate that the low-grade inflammation could possibly be 
involved in the carcinogenesis of HCC in AIP cases. The lower prealbumin levels in the 
symptomatic AIP cases as compared with the asymptomatic cases may suggest inflammation in the 
liver. PBG correlated positively with PTX3, suggesting a link between AIP disease activity and 
inflammation. However, cytokines were increased in asymptomatic cases also. Prealbumin 
correlated negatively with PBG, pointing towards increased hepatic inflammation at higher PBG 
levels. We suggest porphyrin-precursor-related organ damage in the liver and other organs that may 
drive inflammation. Also, kidney function was decreased in the symptomatic AIP cases, and this 
could contribute to inflammation as well as perhaps being at least partly caused by inflammation. In 
some of the cases and controls who smoked, the habit seemed to influence inflammation.  
We also found that fasting insulin and C-peptide levels were lower in the symptomatic AIP 
cases as compared with the matched controls, and insulin was lower in those with high PBG 
compared to the insulin level in those with low PBG, while P-resistin was higher in the 
symptomatic AIP cases as compared with the asymptomatic cases. Lower insulin levels could lead 
to decreased uptake of glucose into cells and accelerated haem synthesis in some AIP cases. 
Visfatin was higher in a cluster of AIP cases with high cytokines. Dietary challenges were present 
in both the case and control groups; they consumed a lot of saturated fatty acids and quite less fibre. 
The total and LDL cholesterol levels were higher in the AIP cases when compared with matched 
controls. The carbohydrate intake was lower than recommended, and AIP cases could benefit from 
increasing this intake. Moderate alcohol intake was reported among the AIP cases, even though 
they were recommended against it. A high intake of energy, sugar and candies and a higher insulin 
level were associated with a lower biochemical disease activity. The influence of diabetogenic 
hormones along with insulin level and lifestyle factors in relation to AIP disease activity needs 
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further investigation. Cytokines should be analysed in EDTA (or citrate) blood samples, 
immediately cooled and rapidly centrifuged (within four hours) to obtain EDTA (or citrate) plasma 
to be stored at -80 °C. We hope that standardization of sampling conditions and methods to analyse 
cytokines will make it easier to use cytokines as inflammatory biomarkers in the future.  
 88 
5 References 
1. Thunell S, Floderus Y, Henrichson A, Harper P. Porphyria in Sweden. Physiol Res. 2006;55
Suppl 2:S109-18.
2. Puy H, Gouya L, Deybach JC. Porphyrias. Lancet. 2010;375(9718):924-37.
3. Bissell DM, Anderson KE, Bonkovsky HL. Porphyria. N Engl J Med. 2017;377(9):862-72.
4. Stein PE, Badminton MN, Rees DC. Update review of the acute porphyrias. Br J Haematol.
2017;176(4):527-38.
5. Bonkovsky HL, Maddukuri VC, Yazici C, Anderson KE, Bissell DM, Bloomer JR, et al.
Acute porphyrias in the USA: features of 108 subjects from porphyrias consortium. Am J Med.
2014;127(12):1233-41.
6. Wang B, Rudnick S, Cengia B, Bonkovsky HL. Acute Hepatic Porphyrias: Review and
Recent Progress. Hepatol Commun. 2019;3(2):193-206.
7. Tollali G, Nielsen EW, Brekke OL. [Acute intermittent porphyria]. Tidsskr Nor Laegeforen.
2002;122(11):1102-5.
8. Bissell DM, Wang B. Acute Hepatic Porphyria. J Clin Transl Hepatol. 2015;3(1):17-26.
9. Aarsand AK, Petersen PH, Sandberg S. Estimation and application of biological variation of
urinary delta-aminolevulinic acid and porphobilinogen in healthy individuals and in patients with
acute intermittent porphyria. Clin Chem. 2006;52(4):650-6.
10. Stewart MF. Review of hepatocellular cancer, hypertension and renal impairment as late
complications of acute porphyria and recommendations for patient follow-up. J Clin Pathol.
2012;65(11):976-80.
11. Voswinckel P. A constant source of surprises: acute porphyria. Two cases reported by
Hippocrates and Sigmund Freud. Hist Psychiatry. 1990;1(2):159-68.
12. Rimmington C. Was Hippocrates the first to describe a case of acute porphyria? Int J
Biochem. 1993(25):1351-2.
13. Andersson C. Acute intermittent porphyria in northern Sweden, A population-based study
[Medical Dissertation]. Umeå: Umeå University; 1997.
14. Mauzerall DGS. The occurence and determination of γ-aminolevulinic acid and
porphobilinogen in urine. J Biol Chem. 1956;1956(219):435-46.
 89 
15. Strand LJ, Felsher BF, Redeker AG, Marver HS. Heme biosynthesis in intermittent acute 
prophyria: decreased hepatic conversion of porphobilinogen to porphyrins and increased delta 
aminolevulinic acid synthetase activity. Proc Natl Acad Sci U S A. 1970;67(3):1315-20.
16. Bonkowsky HL, Tschudy DP, Collins A, Doherty J, Bossenmaier I, Cardinal R, et al. 
Repression of the overproduction of porphyrin precursors in acute intermittent porphyria by 
intravenous infusions of hematin. Proc Natl Acad Sci U S A. 1971;68(11):2725-9.
17. Meisler M, Wanner L, Eddy RE, Shows TB. The UPS locus encoding uroporphyrinogen I 
synthase is located on human chromosome 11. Biochem Biophys Res Commun. 1980;95(1):170-6.
18. Grandchamp B, Romeo PH, Dubart A, Raich N, Rosa J, Nordmann Y, et al. Molecular 
cloning of a cDNA sequence complementary to porphobilinogen deaminase mRNA from rat. Proc 
Natl Acad Sci U S A. 1984;81(16):5036-40.
19. Grandchamp B, Picat C, Mignotte V, Wilson JH, Te Velde K, Sandkuyl L, et al. Tissue-
specific splicing mutation in acute intermittent porphyria. Proc Natl Acad Sci U S A.
1989;86(2):661-4.
20. Grandchamp B, Picat C, Kauppinen R, Mignotte V, Peltonen L, Mustajoki P, et al. 
Molecular analysis of acute intermittent porphyria in a Finnish family with normal erythrocyte 
porphobilinogen deaminase. Eur J Clin Invest. 1989;19(5):415-8.
21. Waldenstrom J. The porphyrias as inborn errors of metabolism. Am J Med. 
1957;22(5):758-73.
22. Waldenstrom J. Geography and genetics of the porphyrias. Acta dermato-venereologica 
Supplementum. 1982;100:43-6.
23. Eldoen O, Sandvik A. [Acute intermittent porphyria in Saltdal]. Tidsskr Nor Laegeforen. 
1982;102(16):902-6.
24. Anderson KE, Sassa S, Bishop DF, Desnick RJ, Beaudet AL, Vogelstein B, et al. Disorders 
of Heme Biosynthesis: X-Linked Sideroblastic Anemia and the Porphyrias. The Online Metabolic 
and Molecular Bases of Inherited Disease. New York, NY
The McGraw-Hill Companies, Inc.; 2014.
25. Elder G, Harper P, Badminton M, Sandberg S, Deybach JC. The incidence of inherited 
porphyrias in Europe. J Inherit Metab Dis. 2013;36(5):849-57.
26. Floderus Y, Shoolingin-Jordan PM, Harper P. Acute intermittent porphyria in Sweden. 
Molecular, functional and clinical consequences of some new mutations found in the 
porphobilinogen deaminase gene. Clin Genet. 2002;62(4):288-97.
 90 
27. Mykletun M, Aarsand AK, Stole E, Villanger JH, Tollanes MC, Baravelli C, et al. 
Porphyrias in Norway. Tidsskr Nor Laegeforen. 2014;134(8):831-6.
28. Nordmann Y, Puy H, Da Silva V, Simonin S, Robreau AM, Bonaiti C, et al. Acute 
intermittent porphyria: prevalence of mutations in the porphobilinogen deaminase gene in blood 
donors in France. J Intern Med. 1997;242(3):213-7.
29. Chen B, Solis-Villa C, Erwin AL, Balwani M, Nazarenko I, Phillips JD, et al. Identification 
and characterization of 40 novel hydroxymethylbilane synthase mutations that cause acute 
intermittent porphyria. J Inherit Metab Dis. 2019;42(1):186-94.
30. Chen B, Solis-Villa C, Hakenberg J, Qiao W, Srinivasan RR, Yasuda M, et al. Acute 
Intermittent Porphyria: Predicted Pathogenicity of HMBS Variants Indicates Extremely Low 
Penetrance of the Autosomal Dominant Disease. Hum Mutat. 2016;37(11):1215-22.
31. Lenglet H, Schmitt C, Grange T, Manceau H, Karboul N, Bouchet-Crivat F, et al. From a 
dominant to an oligogenic model of inheritance with environmental modifiers in acute intermittent 
porphyria. Hum Mol Genet. 2018;27(7):1164-73.
32. Elder GH, Hift RJ, Meissner PN. The acute porphyrias. Lancet. 1997;349(9065):1613-7.
33. Bylesjo I, Wikberg A, Andersson C. Clinical aspects of acute intermittent porphyria in 
northern Sweden: a population-based study. Scand J Clin Lab Invest. 2009;69(5):612-8.
34. Andersson C, Floderus Y, Wikberg A, Lithner F. The W198X and R173W mutations in the 
porphobilinogen deaminase gene in acute intermittent porphyria have higher clinical penetrance than 
R167W. A population-based study. Scand J Clin Lab Invest. 2000;60(7):643-8.
35. Barreda-Sanchez M, Buendia-Martinez J, Glover-Lopez G, Carazo-Diaz C, Ballesta-
Martinez MJ, Lopez-Gonzalez V, et al. High penetrance of acute intermittent porphyria in a Spanish 
founder mutation population and CYP2D6 genotype as a susceptibility factor. Orphanet J Rare Dis. 
2019;14(1):59.
36. Aarsand AK, Sandberg S. Porfyrisykdommer. Klinisk biokjemi og fysiologi 6ed. Oslo: 
Gyldendal Akademisk; 2019. p. 438-44.
37. Stenson PD, Mort M, Ball EV, Shaw K, Phillips A, Cooper DN. The Human Gene Mutation 
Database: building a comprehensive mutation repository for clinical and molecular genetics, 
diagnostic testing and personalized genomic medicine. Hum Genet. 2014;133(1):1-9.
38. Ramanujam VM, Anderson KE. Porphyria Diagnostics-Part 1: A Brief Overview of the 
Porphyrias. Curr Protoc Hum Genet. 2015;86:17 20 1-6.
39. Stenson PD, Mort M, Ball EV, Evans K, Hayden M, Heywood S, et al. The Human Gene 
Mutation Database: towards a comprehensive repository of inherited mutation data for medical
 91 
research, genetic diagnosis and next-generation sequencing studies. Hum Genet. 2017;136(6):665-
77. 
40. Chen B, Whatley S, Badminton M, Aarsand AK, Anderson KE, Bissell DM, et al.
International Porphyria Molecular Diagnostic Collaborative: an evidence-based database of verified
pathogenic and benign variants for the porphyrias. Genet Med. 2019;21(11):2605-13.
41. Gill R, Kolstoe SE, Mohammed F, Al DBA, Mosely JE, Sarwar M, et al. Structure of
human porphobilinogen deaminase at 2.8 A: the molecular basis of acute intermittent porphyria.
Biochem J. 2009;420(1):17-25.
42. Lee JS, Anvret M. Identification of the most common mutation within the porphobilinogen
deaminase gene in Swedish patients with acute intermittent porphyria. Proc Natl Acad Sci U S A.
1991;88(23):10912-5.
43. Besur S, Hou W, Schmeltzer P, Bonkovsky HL. Clinically important features of porphyrin
and heme metabolism and the porphyrias. Metabolites. 2014;4(4):977-1006.
44. Andersson C, Thunell S, Floderus Y, Forsell C, Lundin G, Anvret M, et al. Diagnosis of
acute intermittent porphyria in northern Sweden: an evaluation of mutation analysis and
biochemical methods. J Intern Med. 1995;237(3):301-8.
45. Phillips JD. Heme biosynthesis and the porphyrias. Mol Genet Metab. 2019;128(3):164-77.
46. Besur S, Schmeltzer P, Bonkovsky HL. Acute Porphyrias. J Emerg Med. 2015;49(3):305-
12.
47. Pischik E, Kauppinen R. An update of clinical management of acute intermittent porphyria.
Appl Clin Genet. 2015;8:201-14.
48. Innala E, Bäckström T, Bixo M, Andersson C. Evaluation of gonadotropin-releasing
hormone agonist treatment for prevention of menstrual-related attacks in acute porphyria. Acta
Obstet Gynecol Scand. 2010;89(1):95-100.
49. Welland FH, Hellman ES, Collins A, Hunter GW, Jr., Tschudy DP. Factors Affecting the
Excretion of Porphyrin Precursors by Patients with Acute Intermittent Porphyria. Ii. The Effect of
Ethinyl Estradiol. Metabolism. 1964;13(3):251-8.
50. Tschudy DP, Welland FH, Collins A, Hunter G, Jr. The Effect of Carbohydrate Feeding on
the Induction of Delta-Aminolevulinic Acid Synthetase. Metabolism. 1964;13:396-406.
51. Welland FH, Hellman ES, Gaddis EM, Collins G, Hunter GW, Jr., Tschudy DP. Factors
Affecting the Excretion of Porphyrin Precursors by Patients with Acute Intermittent Porphyria. I.
The Effect of Diet. Metabolism. 1964;13(3):232-50.
52. Doss M, Baumann H, Sixel F. Alcohol in acute porphyria. Lancet. 1982;1(8284):1307.
 92 
53. Doss MO, Kuhnel A, Gross U. Alcohol and porphyrin metabolism. Alcohol Alcohol.
2000;35(2):109-25.
54. Karim Z, Lyoumi S, Nicolas G, Deybach JC, Gouya L, Puy H. Porphyrias: A 2015 update.
Clin Res Hepatol Gastroenterol. 2015;39(4):412-25.
55. Luby ED, Ware JG, Senf R, Frohman CE. Stress and the precipitation of acute intermittent
porphyria. Psychosom Med. 1959;21(1):34-9.
56. Wojcikowski J, Daniel WA. The role of the nervous system in the regulation of liver
cytochrome p450. Curr Drug Metab. 2011;12(2):124-38.
57. Thunell S. (Far) Outside the box: genomic approach to acute porphyria. Physiol Res.
2006;55 Suppl 2:S43-66.
58. Ahangari A, Backstrom T, Innala E, Andersson C, Turkmen S. Acute intermittent porphyria
symptoms during the menstrual cycle. Intern Med J. 2015;45(7):725-31.
59. Hift RJ, Thunell S, Brun A. Drugs in porphyria: From observation to a modern algorithm-
based system for the prediction of porphyrogenicity. Pharmacol Ther. 2011;132(2):158-69.
60. Maitra D, Bragazzi Cunha J, Elenbaas JS, Bonkovsky HL, Shavit JA, Omary MB.
Porphyrin-Induced Protein Oxidation and Aggregation as a Mechanism of Porphyria-Associated
Cell Injury. Cell Mol Gastroenterol Hepatol. 2019;8(4):535-48.
61. Human Metabolome Database (HMDB) [Internet]. 2019 [cited accessed on Sept. 17, 2019].
Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Porphobilinogen
62. Pischik E, Kauppinen R. Neurological manifestations of acute intermittent porphyria. Cell
Mol Biol (Noisy-le-grand). 2009;55(1):72-83.
63. Bylesjo I, Brekke OL, Prytz J, Skjeflo T, Salvesen R. Brain magnetic resonance imaging
white-matter lesions and cerebrospinal fluid findings in patients with acute intermittent porphyria.
Eur Neurol. 2004;51(1):1-5.
64. Albers JW, Fink JK. Porphyric neuropathy. Muscle & nerve. 2004;30(4):410-22.
65. Bissell DM, Lai JC, Meister RK, Blanc PD. Role of delta-aminolevulinic acid in the
symptoms of acute porphyria. Am J Med. 2015;128(3):313-7.
66. Meyer UA, Schuurmans MM, Lindberg RL. Acute porphyrias: pathogenesis of neurological
manifestations. Semin Liver Dis. 1998;18(1):43-52.
67. Solis C, Martinez-Bermejo A, Naidich TP, Kaufmann WE, Astrin KH, Bishop DF, et al.
Acute intermittent porphyria: studies of the severe homozygous dominant disease provides insights
into the neurologic attacks in acute porphyrias. Arch Neurol. 2004;61(11):1764-70.
 93 
68. Yasuda M, Erwin AL, Liu LU, Balwani M, Chen B, Kadirvel S, et al. Liver Transplantation
for Acute Intermittent Porphyria: Biochemical and Pathologic Studies of the Explanted Liver. Mol
Med. 2015;21(1):487-95.
69. Lin CS, Krishnan AV, Lee MJ, Zagami AS, You HL, Yang CC, et al. Nerve function and
dysfunction in acute intermittent porphyria. Brain : a journal of neurology. 2008;131(Pt 9):2510-9.
70. Cardenas JL, Guerrero C. Acute intermittent porphyria: general aspects with focus on pain.
Curr Med Res Opin. 2018:1-7.
71. Marsden JT, Rees DC. Urinary excretion of porphyrins, porphobilinogen and delta-
aminolaevulinic acid following an attack of acute intermittent porphyria. J Clin Pathol.
2014;67(1):60-5.
72. Sardh E, Rejkjaer L, Andersson DE, Harper P. Safety, pharmacokinetics and
pharmocodynamics of recombinant human porphobilinogen deaminase in healthy subjects and
asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin
precursor excretion. Clin Pharmacokinet. 2007;46(4):335-49.
73. Brennan MJ, Cantrill RC. Delta-aminolaevulinic acid is a potent agonist for GABA
autoreceptors. Nature. 1979;280(5722):514-5.
74. Pereira B, Curi R, Kokubun E, Bechara EJ. 5-aminolevulinic acid-induced alterations of
oxidative metabolism in sedentary and exercise-trained rats. J Appl Physiol. 1992;72(1):226-30.
75. Homedan C, Laafi J, Schmitt C, Gueguen N, Lefebvre T, Karim Z, et al. Acute intermittent
porphyria causes hepatic mitochondrial energetic failure in a mouse model. Int J Biochem Cell Biol.
2014;51:93-101.
76. Homedan C, Schmitt C, Laafi J, Gueguen N, Desquiret-Dumas V, Lenglet H, et al.
Mitochondrial energetic defects in muscle and brain of a Hmbs-/- mouse model of acute
intermittent porphyria. Hum Mol Genet. 2015;24(17):5015-23.
77. Chacko B, Culp ML, Bloomer J, Phillips J, Kuo YF, Darley-Usmar V, et al. Feasibility of
cellular bioenergetics as a biomarker in porphyria patients. Mol Genet Metab Rep. 2019;19:100451.
78. Berger S, Stattmann M, Cicvaric A, Monje FJ, Coiro P, Hotka M, et al. Severe
hydroxymethylbilane synthase deficiency causes depression-like behavior and mitochondrial
dysfunction in a mouse model of homozygous dominant acute intermittent porphyria. Acta
Neuropathol Commun. 2020;8(1):38.
79. Luck M, Schmitt C, Talbi N, Gouya L, Caradeuc C, Puy H, et al. Urinary metabolic
profiling of asymptomatic acute intermittent porphyria using a rule-mining-based algorithm.
Metabolomics. 2018;14(1):10.
 94 
80. Lithner F. Could attacks of abdominal pain in cases of acute intermittent porphyria be due to
intestinal angina? J Intern Med. 2000;247(3):407-9.
81. Flammer J, Pache M, Resink T. Vasospasm, its role in the pathogenesis of diseases with
particular reference to the eye. Prog Retin Eye Res. 2001;20(3):319-49.
82. Kupferschmidt H, Bont A, Schnorf H, Landis T, Walter E, Peter J, et al. Transient cortical
blindness and bioccipital brain lesions in two patients with acute intermittent porphyria. Ann Intern
Med. 1995;123(8):598-600.
83. Pulgar VM, Yasuda M, Gan L, Desnick RJ, Bonkovsky HL. Sex differences in vascular
reactivity in mesenteric arteries from a mouse model of acute intermittent porphyria. Mol Genet
Metab. 2019;128(3):376-81.
84. Ventura P, Cappellini MD, Biolcati G, Guida CC, Rocchi E, Gruppo Italiano P. A
challenging diagnosis for potential fatal diseases: recommendations for diagnosing acute
porphyrias. Eur J Intern Med. 2014;25(6):497-505.
85. Kauppinen R, von und zu Fraunberg M. Molecular and biochemical studies of acute
intermittent porphyria in 196 patients and their families. Clin Chem. 2002;48(11):1891-900.
86. Thunell S, Harper P, Brock A, Petersen NE. Porphyrins, porphyrin metabolism and
porphyrias. II. Diagnosis and monitoring in the acute porphyrias. Scand J Clin Lab Invest.
2000;60(7):541-59.
87. Thunell S. Porphyrins, porphyrin metabolism and porphyrias. I. Update. Scand J Clin Lab
Invest. 2000;60(7):509-40.
88. Whatley SD, Mason NG, Woolf JR, Newcombe RG, Elder GH, Badminton MN. Diagnostic
strategies for autosomal dominant acute porphyrias: retrospective analysis of 467 unrelated patients
referred for mutational analysis of the HMBS, CPOX, or PPOX gene. Clin Chem. 2009;55(7):1406-
14.
89. Lovdata.no, Bioteknologiloven, Kap. 5. Genetiske undersøkelser av fødte m.m. (§§ 5-1 - 5-
9), (2003).
90. Bonkovsky HL. Advances in understanding and treating 'the little imitator,' acute porphyria.
Gastroenterology. 1993;105(2):590-4.
91. Neeleman RA, Wagenmakers M, Koole-Lesuis RH, Mijnhout GS, Wilson JHP, Friesema
ECH, et al. Medical and financial burden of acute intermittent porphyria. J Inherit Metab Dis.
2018;41(5):809-17.
 95 
92. de Paula Brandao PR, Titze-de-Almeida SS, Titze-de-Almeida R. Leading RNA
Interference Therapeutics Part 2: Silencing Delta-Aminolevulinic Acid Synthase 1, with a Focus on
Givosiran. Mol Diagn Ther. 2019;24(1):61-8.
93. Scott LJ. Givosiran: First Approval. Drugs. 2020;80(3):335-9.
94. Schmitt C, Lenglet H, Yu A, Delaby C, Benecke A, Lefebvre T, et al. Recurrent attacks of
acute hepatic porphyria: major role of the chronic inflammatory response in the liver. J Intern Med.
2018;284(1):78-91.
95. Stein P, Badminton M, Barth J, Rees D, Stewart MF, British, et al. Best practice guidelines
on clinical management of acute attacks of porphyria and their complications. Ann Clin Biochem.
2013;50(Pt 3):217-23.
96. Gupta GL, Saksena HC, Gupta BD. Cardiac dysautonomia in acute intermittent porphyria.
Indian J Med Res. 1983;78:253-6.
97. Blom H, Andersson C, Olofsson BO, Bjerle P, Wiklund U, Lithner F. Assessment of
autonomic nerve function in acute intermittent porphyria; a study based on spectral analysis of heart
rate variability. J Intern Med. 1996;240(2):73-9.
98. Duque-Serrano L, Patarroyo-Rodriguez L, Gotlib D, Molano-Eslava JC. Psychiatric Aspects
of Acute Porphyria: a Comprehensive Review. Current psychiatry reports. 2018;20(1):5.
99. Yrjonen A, Pischik E, Mehtala S, Kauppinen R. A novel 19-bp deletion of exon 15 in the
HMBS gene causing acute intermittent porphyria associating with rhabdomyolysis during an acute
attack. Clin Genet. 2008;74(4):396-8.
100. Naik H, Stoecker M, Sanderson SC, Balwani M, Desnick RJ. Experiences and concerns of
patients with recurrent attacks of acute hepatic porphyria: A qualitative study. Mol Genet Metab.
2016;119(3):278-83.
101. Stein JA, Tschudy DP. Acute intermittent porphyria. A clinical and biochemical study of 46
patients. Medicine (Baltimore). 1970;49(1):1-16.
102. Lipschutz DE, Reiter JM. Acute intermittent porphyria with inappropriately elevated ADH
secretion. JAMA : the journal of the American Medical Association. 1974;230(5):716-7.
103. Usalan C, Erdem Y, Altun B, Gursoy M, Celik I, Yasavul U, et al. Severe hyponatremia due
to SIADH provoked by acute intermittent porphyria. Clin Nephrol. 1996;45(6):418.
104. Maesaka JK, Imbriano LJ, Miyawaki N. Determining Fractional Urate Excretion Rates in
Hyponatremic Conditions and Improved Methods to Distinguish Cerebral/Renal Salt Wasting From
the Syndrome of Inappropriate Secretion of Antidiuretic Hormone. Front Med (Lausanne).
2018;5:319.
 96 
105. Stein PE, Badminton MN, Barth JH, Rees DC, Sarkany R, Stewart MF, et al. Acute
intermittent porphyria: fatal complications of treatment. Clin Med (Lond). 2012;12(3):293-4.
106. Balwani M, Wang B, Anderson KE, Bloomer JR, Bissell DM, Bonkovsky HL, et al. Acute
hepatic porphyrias: Recommendations for evaluation and long-term management. Hepatology.
2017;66(4):1314-22.
107. Herrero C, Badenas C, Aguilera P, To-Figueras J. [Acute intermittent porphyria: Long-term
follow up of 35 patients]. Medicina clinica. 2015;145(8):332-7.
108. Simon A, Pompilus F, Querbes W, Wei A, Strzok S, Penz C, et al. Patient Perspective on
Acute Intermittent Porphyria with Frequent Attacks: A Disease with Intermittent and Chronic
Manifestations. Patient. 2018;11(5):527-37.
109. Andersson C, Nilsson A, Backstrom T. Atypical attack of acute intermittent porphyria--
paresis but no abdominal pain. J Intern Med. 2002;252(3):265-70.
110. Naik H, Overbey JR, Montgomery GH, Winkel G, Balwani M, Anderson KE, et al.
Evaluating the Patient-Reported Outcomes Measurement Information System scales in acute
intermittent porphyria. Genet Med. 2020;22(3):590-7.
111. Schley G, Bock KD, Hocevar V, Merguet P, Rausch-Stroomann JG, Schroder E, et al.
[Hypertension and tachycardia in acute intermittent porphyria]. Klin Wochenschr. 1970;48(1):36-
42.
112. Beal MF, Atuk NO, Westfall TC, Turner SM. Catecholamine uptake, accumulation, and
release in acute porphyria. J Clin Invest. 1977;60(5):1141-8.
113. Anderson KE, Bloomer JR, Bonkovsky HL, Kushner JP, Pierach CA, Pimstone NR, et al.
Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med.
2005;142(6):439-50.
114. Balwani M, Desnick RJ. The porphyrias: advances in diagnosis and treatment. Hematology
Am Soc Hematol Educ Program. 2012;2012:19-27.
115. Lindqvist C, Slinde F, Majeed A, Bottai M, Wahlin S. Nutrition impact symptoms are
related to malnutrition and quality of life - A cross-sectional study of patients with chronic liver
disease. Clin Nutr. 2020;39(6):1840-8.
116. Fontanellas A, Avila MA, Berraondo P. Emerging therapies for acute intermittent porphyria.
Expert Rev Mol Med. 2016;18:e17.
117. Mustajoki P, Nordmann Y. Early administration of heme arginate for acute porphyric
attacks. Arch Intern Med. 1993;153(17):2004-8.
 97 
118. Harper P, Wahlin S. Treatment options in acute porphyria, porphyria cutanea tarda, and
erythropoietic protoporphyria. Current treatment options in gastroenterology. 2007;10(6):444-55.
119. Deybach JC, Badminton M, Puy H, Sandberg S, Frank J, Harper P, et al. European
porphyria initiative (EPI): a platform to develop a common approach to the management of
porphyrias and to promote research in the field. Physiol Res. 2006;55 Suppl 2:S67-73.
120. Anderson KE, Collins S. Open-label study of hemin for acute porphyria: clinical practice
implications. Am J Med. 2006;119(9):801 e19-24.
121. Herrick AL, McColl KE, Moore MR, Cook A, Goldberg A. Controlled trial of haem
arginate in acute hepatic porphyria. Lancet. 1989;1(8650):1295-7.
122. Mustajoki P, Tenhunen R, Tokola O, Gothoni G. Haem arginate in the treatment of acute
hepatic porphyrias. Br Med J (Clin Res Ed). 1986;293(6546):538-9.
123. Bissell DM. Treatment of acute hepatic porphyria with hematin. J Hepatol. 1988;6(1):1-7.
124. Recordati. Summary of product characteristics, labelling and package leaflet, Normosang.
In: Recordati, editor. revised in 06/06/2017 ed. recordatirarediseases.com2017.
125. Balwani M, Sardh E, Ventura P, Peiro PA, Rees DC, Stolzel U, et al. Phase 3 Trial of RNAi
Therapeutic Givosiran for Acute Intermittent Porphyria. N Engl J Med. 2020;382(24):2289-301.
126. Tollanes MC, Aarsand AK, Sandberg S. Excess risk of adverse pregnancy outcomes in
women with porphyria: a population-based cohort study. J Inherit Metab Dis. 2011;34(1):217-23.
127. Farfaras A, Zagouri F, Zografos G, Kostopoulou A, Sergentanis TN, Antoniou S. Acute
intermittent porphyria in pregnancy: a common misdiagnosis. Clin Exp Obstet Gynecol.
2010;37(4):256-60.
128. Agarwal S, Simon AR, Goel V, Habtemariam BA, Clausen VA, Kim JB, et al.
Pharmacokinetics and Pharmacodynamics of the Small Interfering Ribonucleic Acid, Givosiran, in
Patients With Acute Hepatic Porphyria. Clin Pharmacol Ther. 2020;108(1):63-72.
129. Yasuda M, Gan L, Chen B, Kadirvel S, Yu C, Phillips JD, et al. RNAi-mediated silencing of
hepatic Alas1 effectively prevents and treats the induced acute attacks in acute intermittent
porphyria mice. Proc Natl Acad Sci U S A. 2014;111(21):7777-82.
130. Chan A, Liebow A, Yasuda M, Gan L, Racie T, Maier M, et al. Preclinical Development of
a Subcutaneous ALAS1 RNAi Therapeutic for Treatment of Hepatic Porphyrias Using Circulating
RNA Quantification. Mol Ther Nucleic Acids. 2015;4(e263):1-9.
131. Sardh E, Harper P, Balwani M, Stein P, Rees D, Bissell DM, et al. Phase 1 Trial of an RNA
Interference Therapy for Acute Intermittent Porphyria. N Engl J Med. 2019;380(6):549-58.
 98 
132. Seth AK, Badminton MN, Mirza D, Russell S, Elias E. Liver transplantation for porphyria:
who, when, and how? Liver Transpl. 2007;13(9):1219-27.
133. Soonawalla ZF, Orug T, Badminton MN, Elder GH, Rhodes JM, Bramhall SR, et al. Liver
transplantation as a cure for acute intermittent porphyria. Lancet. 2004;363(9410):705-6.
134. Singal AK, Parker C, Bowden C, Thapar M, Liu L, McGuire BM. Liver transplantation in
the management of porphyria. Hepatology. 2014;60(3):1082-9.
135. Wahlin S, Harper P, Sardh E, Andersson C, Andersson DE, Ericzon BG. Combined liver
and kidney transplantation in acute intermittent porphyria. Transpl Int. 2010;23(6):e18-21.
136. Dowman JK, Gunson BK, Mirza DF, Bramhall SR, Badminton MN, Newsome PN, et al.
Liver transplantation for acute intermittent porphyria is complicated by a high rate of hepatic artery
thrombosis. Liver Transpl. 2012;18(2):195-200.
137. Anderson KE, Spitz IM, Sassa S, Bardin CW, Kappas A. Prevention of cyclical attacks of
acute intermittent porphyria with a long-acting agonist of luteinizing hormone-releasing hormone.
N Engl J Med. 1984;311(10):643-5.
138. Anderson KE, Spitz IM, Bardin CW, Kappas A. A gonadotropin releasing hormone
analogue prevents cyclical attacks of porphyria. Arch Intern Med. 1990;150(7):1469-74.
139. Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008;454(7203):428-
35.
140. Morgan MJ, Liu ZG. Crosstalk of reactive oxygen species and NF-kappaB signaling. Cell
Res. 2011;21(1):103-15.
141. Correia MA, Sinclair PR, De Matteis F. Cytochrome P450 regulation: the interplay between
its heme and apoprotein moieties in synthesis, assembly, repair, and disposal. Drug Metab Rev.
2011;43(1):1-26.
142. Stavropoulou E, Pircalabioru GG, Bezirtzoglou E. The Role of Cytochromes P450 in
Infection. Front Immunol. 2018;9(89):1-7.
143. Iwasa F, Sassa S, Kappas A. The effects of acute-phase inducers and dimethyl sulphoxide
on delta-aminolaevulinate synthase activity in human HepG2 hepatoma cells. Biochem J.
1989;259(2):605-7.
144. Weiss G. Iron metabolism in the anemia of chronic disease. Biochim Biophys Acta.
2009;1790(7):682-93.
145. Wang X, Bao W, Liu J, Ouyang YY, Wang D, Rong S, et al. Inflammatory markers and risk
of type 2 diabetes: a systematic review and meta-analysis. Diabetes care. 2013;36(1):166-75.
 99 
146. Wada J, Makino H. Innate immunity in diabetes and diabetic nephropathy. Nat Rev
Nephrol. 2016;12(1):13-26.
147. Bonkovsky HL, Hou W, Steuerwald N, Tian Q, Li T, Parsons J, et al. Heme status affects
human hepatic messenger RNA and microRNA expression. World J Gastroenterol.
2013;19(10):1593-601.
148. Stolzel U, Doss MO, Schuppan D. Clinical Guide and Update on Porphyrias.
Gastroenterology. 2019;157(2):365-81 e4.
149. Willandt B, Langendonk JG, Biermann K, Meersseman W, D'Heygere F, George C, et al.
Liver Fibrosis Associated with Iron Accumulation Due to Long-Term Heme-Arginate Treatment in
Acute Intermittent Porphyria: A Case Series. JIMD reports. 2016;25:77-81.
150. Yarra P, Faust D, Bennett M, Rudnick S, Bonkovsky HL. Benefits of prophylactic heme
therapy in severe acute intermittent porphyria. Mol Genet Metab Rep. 2019;19(100450):1-5.
151. Storjord E, Dahl JA, Landsem A, Ludviksen JK, Karlsen MB, Karlsen BO, et al. Lifestyle
factors including diet and biochemical biomarkers in acute intermittent porphyria: Results from a
case-control study in northern Norway. Mol Genet Metab. 2018;128(3):254-70.
152. Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. Nature.
2017;542(7640):177-85.
153. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue
expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest.
1995;95(5):2409-15.
154. Hu F, Qiu X, Bu S. Pancreatic islet dysfunction in type 2 diabetes mellitus. Arch Physiol
Biochem. 2020;126(3):235-41.
155. Hoppener JW, Ahren B, Lips CJ. Islet amyloid and type 2 diabetes mellitus. N Engl J Med.
2000;343(6):411-9.
156. Pedersen HK, Gudmundsdottir V, Nielsen HB, Hyotylainen T, Nielsen T, Jensen BA, et al.
Human gut microbes impact host serum metabolome and insulin sensitivity. Nature.
2016;535(7612):376-81.
157. Christ A, Latz E. The Western lifestyle has lasting effects on metaflammation. Nat Rev
Immunol. 2019;19(5):267-8.
158. Cantley J, Ashcroft FM. Q&A: insulin secretion and type 2 diabetes: why do beta-cells fail?
BMC Biol. 2015;13(33):1-7.
159. Chen GY, Nunez G. Sterile inflammation: sensing and reacting to damage. Nat Rev
Immunol. 2010;10(12):826-37.
 100 
160. Stenken JA, Poschenrieder AJ. Bioanalytical chemistry of cytokines--a review. Anal Chim
Acta. 2015;853:95-115.
161. Mukai K, Tsai M, Saito H, Galli SJ. Mast cells as sources of cytokines, chemokines, and
growth factors. Immunol Rev. 2018;282(1):121-50.
162. Kendall RT, Feghali-Bostwick CA. Fibroblasts in fibrosis: novel roles and mediators. Front
Pharmacol. 2014;5(123):1-13.
163. Liu C, Feng X, Li Q, Wang Y, Li Q, Hua M. Adiponectin, TNF-alpha and inflammatory
cytokines and risk of type 2 diabetes: A systematic review and meta-analysis. Cytokine.
2016;86:100-9.
164. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, et al. Inflammatory
cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress.
Circulation. 2002;106(16):2067-72.
165. Pallet N, Mami I, Schmitt C, Karim Z, Francois A, Rabant M, et al. High prevalence of and
potential mechanisms for chronic kidney disease in patients with acute intermittent porphyria.
Kidney Int. 2015;88(2):386-95.
166. Holdsworth SR, Gan PY. Cytokines: Names and Numbers You Should Care About. Clin J
Am Soc Nephrol. 2015;10(12):2243-54.
167. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med.
2009;361(9):888-98.
168. Inforzato A, Doni A, Barajon I, Leone R, Garlanda C, Bottazzi B, et al. PTX3 as a paradigm
for the interaction of pentraxins with the complement system. Semin Immunol. 2013;25(1):79-85.
169. Sardh E, Harper P, Andersson DE, Floderus Y. Plasma porphobilinogen as a sensitive
biomarker to monitor the clinical and therapeutic course of acute intermittent porphyria attacks. Eur
J Intern Med. 2009;20(2):201-7.
170. Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, et al. Circulating mitochondrial
DAMPs cause inflammatory responses to injury. Nature. 2010;464(7285):104-7.
171. Newton K, Dixit VM. Signaling in innate immunity and inflammation. Cold Spring Harb
Perspect Biol. 2012;4(3):1-19.
172. Gederaas OA, Lagerberg JW, Brekke O, Berg K, Dubbelman TM. 5-aminolevulinic acid
induced lipid peroxidation after light exposure on human colon carcinoma cells and effects of
alpha-tocopherol treatment. Cancer Lett. 2000;159(1):23-32.
 101 
173. Sugiyama Y, Hiraiwa Y, Hagiya Y, Nakajima M, Tanaka T, Ogura SI. 5-Aminolevulinic
acid regulates the immune response in LPS-stimulated RAW 264.7 macrophages. BMC Immunol.
2018;19(1):41.
174. Ito H, Tamura M, Matsui H, Majima HJ, Indo HP, Hyodo I. Reactive oxygen species
involved cancer cellular specific 5-aminolevulinic acid uptake in gastric epithelial cells. J Clin
Biochem Nutr. 2014;54(2):81-5.
175. Meurer M, Schulte C, Weiler A, Goerz G. Photodynamic action of uroporphyrin on the
complement system in porphyria cutanea tarda. Arch Dermatol Res. 1985;277(4):293-8.
176. Garcia-Martinez I, Shaker ME, Mehal WZ. Therapeutic Opportunities in Damage-
Associated Molecular Pattern-Driven Metabolic Diseases. Antioxid Redox Signal.
2015;23(17):1305-15.
177. Rider P, Voronov E, Dinarello CA, Apte RN, Cohen I. Alarmins: Feel the Stress. J
Immunol. 2017;198(4):1395-402.
178. Fujino M, Nishio Y, Ito H, Tanaka T, Li XK. 5-Aminolevulinic acid regulates the
inflammatory response and alloimmune reaction. Int Immunopharmacol. 2016;37:71-8.
179. Goncalves TL, Benvegnu DM, Bonfanti G, Frediani AV, Rocha JB. Delta-ALA-D activity
is a reliable marker for oxidative stress in bone marrow transplant patients. BMC cancer.
2009;9:138.
180. Ito S, Miyoshi N, Degraff WG, Nagashima K, Kirschenbaum LJ, Riesz P. Enhancement of
5-Aminolevulinic acid-induced oxidative stress on two cancer cell lines by gold nanoparticles. Free
radical research. 2009;43(12):1214-24.
181. Roh JS, Sohn DH. Damage-Associated Molecular Patterns in Inflammatory Diseases.
Immune Netw. 2018;18(4):e27.
182. Furman D, Campisi J, Verdin E, Carrera-Bastos P, Targ S, Franceschi C, et al. Chronic
inflammation in the etiology of disease across the life span. Nat Med. 2019;25(12):1822-32.
183. Mihm S. Danger-Associated Molecular Patterns (DAMPs): Molecular Triggers for Sterile
Inflammation in the Liver. Int J Mol Sci. 2018;19(10):1-18.
184. Ricklin D, Reis ES, Lambris JD. Complement in disease: a defence system turning
offensive. Nat Rev Nephrol. 2016;12(7):383-401.
185. Rock KL, Kataoka H, Lai JJ. Uric acid as a danger signal in gout and its comorbidities. Nat
Rev Rheumatol. 2013;9(1):13-23.
186. Ricklin D, Barratt-Due A, Mollnes TE. Complement in clinical medicine: Clinical trials,
case reports and therapy monitoring. Mol Immunol. 2017;89:10-21.
 102 
187. Thorgersen EB, Barratt-Due A, Haugaa H, Harboe M, Pischke SE, Nilsson PH, et al. The
Role of Complement in Liver Injury, Regeneration, and Transplantation. Hepatology.
2019;70(2):725-36.
188. Ricklin D, Lambris JD. Complement in immune and inflammatory disorders:
pathophysiological mechanisms. J Immunol. 2013;190(8):3831-8.
189. Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement System Part I -
Molecular Mechanisms of Activation and Regulation. Front Immunol. 2015;6(262):1-30.
190. Ekdahl KN, Teramura Y, Hamad OA, Asif S, Duehrkop C, Fromell K, et al. Dangerous
liaisons: complement, coagulation, and kallikrein/kinin cross-talk act as a linchpin in the events
leading to thromboinflammation. Immunol Rev. 2016;274(1):245-69.
191. Frimat M, Tabarin F, Dimitrov JD, Poitou C, Halbwachs-Mecarelli L, Fremeaux-Bacchi V,
et al. Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome.
Blood. 2013;122(2):282-92.
192. Thomas AM, Gerogianni A, McAdam MB, Floisand Y, Lau C, Espevik T, et al.
Complement Component C5 and TLR Molecule CD14 Mediate Heme-Induced
Thromboinflammation in Human Blood. J Immunol. 2019;203(6):1571-8.
193. Sato K, Matsushita K, Takahashi K, Aoki M, Fuziwara J, Miyanari S, et al. Dietary
supplementation with 5-aminolevulinic acid modulates growth performance and inflammatory
responses in broiler chickens. Poult Sci. 2012;91(7):1582-9.
194. Al-Saber F, Aldosari W, Alselaiti M, Khalfan H, Kaladari A, Khan G, et al. The Safety and
Tolerability of 5-Aminolevulinic Acid Phosphate with Sodium Ferrous Citrate in Patients with
Type 2 Diabetes Mellitus in Bahrain. J Diabetes Res. 2016;2016(Article ID 8294805):1-10.
195. Rehani PR, Iftikhar H, Nakajima M, Tanaka T, Jabbar Z, Rehani RN. Safety and Mode of
Action of Diabetes Medications in comparison with 5-Aminolevulinic Acid (5-ALA). J Diabetes
Res. 2019;2019:4267357.
196. Janeway CA, Jr. Approaching the asymptote? Evolution and revolution in immunology.
Cold Spring Harb Symp Quant Biol. 1989;54 Pt 1:1-13.
197. Barra NG, Henriksbo BD, Anhe FF, Schertzer JD. The NLRP3 inflammasome regulates
adipose tissue metabolism. Biochem J. 2020;477(6):1089-107.
198. Wallet SM, Puri V, Gibson FC. Linkage of Infection to Adverse Systemic Complications:
Periodontal Disease, Toll-Like Receptors, and Other Pattern Recognition Systems. Vaccines
(Basel). 2018;6(2):1-27.
 103 
199. Tschopp J, Schroder K. NLRP3 inflammasome activation: The convergence of multiple
signalling pathways on ROS production? Nat Rev Immunol. 2010;10(3):210-5.
200. Strowig T, Henao-Mejia J, Elinav E, Flavell R. Inflammasomes in health and disease.
Nature. 2012;481(7381):278-86.
201. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals
activate the NALP3 inflammasome. Nature. 2006;440(7081):237-41.
202. Vandanmagsar B, Youm YH, Ravussin A, Galgani JE, Stadler K, Mynatt RL, et al. The
NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med.
2011;17(2):179-88.
203. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, et al. NLRP3
inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature.
2010;464(7293):1357-61.
204. Camell C, Goldberg E, Dixit VD. Regulation of Nlrp3 inflammasome by dietary
metabolites. Semin Immunol. 2015;27(5):334-42.
205. Hardell L, Bengtsson NO, Jonsson U, Eriksson S, Larsson LG. Aetiological aspects on
primary liver cancer with special regard to alcohol, organic solvents and acute intermittent
porphyria--an epidemiological investigation. Br J Cancer. 1984;50(3):389-97.
206. Lithner F, Wetterberg L. Hepatocellular carcinoma in patients with acute intermittent
porphyria. Acta Med Scand. 1984;215(3):271-4.
207. Lang E, Schafer M, Schwender H, Neumann NJ, Frank J. Occurrence of Malignant
Tumours in the Acute Hepatic Porphyrias. JIMD reports. 2015;22:17-22.
208. Sardh E, Wahlin S, Bjornstedt M, Harper P, Andersson DE. High risk of primary liver
cancer in a cohort of 179 patients with Acute Hepatic Porphyria. J Inherit Metab Dis.
2013;36(6):1063-71.
209. Deybach JC, Puy H. Hepatocellular carcinoma without cirrhosis: think acute hepatic
porphyrias and vice versa. J Intern Med. 2011;269(5):521-4.
210. Peoc'h K, Manceau H, Karim Z, Wahlin S, Gouya L, Puy H, et al. Hepatocellular carcinoma
in acute hepatic porphyrias: A Damocles Sword. Mol Genet Metab. 2018;128(3):236-41.
211. Innala E, Andersson C. Screening for hepatocellular carcinoma in acute intermittent
porphyria: a 15-year follow-up in northern Sweden. J Intern Med. 2011;269(5):538-45.
212. Baravelli CM, Sandberg S, Aarsand AK, Nilsen RM, Tollanes MC. Acute hepatic porphyria
and cancer risk: a nationwide cohort study. J Intern Med. 2017;282(3):229-40.
 104 
213. Andant C, Puy H, Bogard C, Faivre J, Soule JC, Nordmann Y, et al. Hepatocellular
carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors. J
Hepatol. 2000;32(6):933-9.
214. Yu LX, Ling Y, Wang HY. Role of nonresolving inflammation in hepatocellular carcinoma
development and progression. NPJ Precis Oncol. 2018;2(1):6.
215. Hernandez-Gea V, Toffanin S, Friedman SL, Llovet JM. Role of the microenvironment in
the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology. 2013;144(3):512-27.
216. Srisook K, Kim C, Cha YN. Molecular mechanisms involved in enhancing HO-1
expression: de-repression by heme and activation by Nrf2, the "one-two" punch. Antioxid Redox
Signal. 2005;7(11-12):1674-87.
217. Andersson C, Wikberg A, Stegmayr B, Lithner F. Renal symptomatology in patients with
acute intermittent porphyria. A population-based study. J Intern Med. 2000;248(4):319-25.
218. Onozato ML, Tojo A, Kamijo A, Taniguchi S, Kimura K, Goto A, et al. Tubulointerstitial
nephritis associated with acute intermittent porphyria. Clin Nephrol. 2001;55(2):171-4.
219. Sarhan M, von Massenhausen A, Hugo C, Oberbauer R, Linkermann A. Immunological
consequences of kidney cell death. Cell Death Dis. 2018;9(2):114.
220. Markiewski MM, Nilsson B, Ekdahl KN, Mollnes TE, Lambris JD. Complement and
coagulation: strangers or partners in crime? Trends Immunol. 2007;28(4):184-92.
221. Ota S, Wada H, Abe Y, Yamada E, Sakaguchi A, Nishioka J, et al. Elevated levels of
prothrombin fragment 1 + 2 indicate high risk of thrombosis. Clin Appl Thromb Hemost.
2008;14(3):279-85.
222. Doss M, Verspohl F. The "glucose effect" in acute hepatic porphyrias and in experimental
porphyria. Klin Wochenschr. 1981;59(13):727-35.
223. Robert TL, Varella L, Meguid MM. Nutrition management of acute intermittent porphyria.
Nutrition. 1994;10(6):551-5; quiz 6-7.
224. Handschin C, Lin J, Rhee J, Peyer AK, Chin S, Wu PH, et al. Nutritional regulation of
hepatic heme biosynthesis and porphyria through PGC-1alpha. Cell. 2005;122(4):505-15.
225. Phillips JD, Kushner JP. Fast track to the porphyrias. Nat Med. 2005;11(10):1049-50.
226. Nordic Nutrition Recommendations 2012 -Integrating nutrition and physical activity. Nord
2014-002, Nordic Council of Ministers, Copenhagen 2014 Nord 2014-002.
227. Doss M, Sixel-Dietrich F, Verspohl F. "Glucose effect" and rate limiting function of
uroporphyrinogen synthase on porphyrin metabolism in hepatocyte culture: relationship with
human acute hepatic porphyrias. J Clin Chem Clin Biochem. 1985;23(9):505-13.
 105 
228. Brodie MJ, Moore MR, Thompson GG, Goldberg A. The treatment of acute intermittent
porphyria with laevulose. Clinical science and molecular medicine. 1977;53(4):365-71.
229. Andersson C, Bylesjo I, Lithner F. Effects of diabetes mellitus on patients with acute
intermittent porphyria. J Intern Med. 1999;245(2):193-7.
230. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, dairy and
protein intake, and the risk of gout in men. N Engl J Med. 2004;350(11):1093-103.
231. Wilcox G. Insulin and insulin resistance. Clin Biochem Rev. 2005;26(2):19-39.
232. Petersen MC, Shulman GI. Mechanisms of Insulin Action and Insulin Resistance. Physiol
Rev. 2018;98(4):2133-223.
233. Yang Q, Vijayakumar A, Kahn BB. Metabolites as regulators of insulin sensitivity and
metabolism. Nat Rev Mol Cell Biol. 2018;19(10):654-72.
234. Leighton E, Sainsbury CA, Jones GC. A Practical Review of C-Peptide Testing in Diabetes.
Diabetes Ther. 2017;8(3):475-87.
235. Zelechowska P, Kozlowska E, Pastwinska J, Agier J, Brzezinska-Blaszczyk E.
Adipocytokine Involvement in Innate Immune Mechanisms. J Interferon Cytokine Res.
2018;38(12):527-38.
236. Romacho T, Valencia I, Ramos-Gonzalez M, Vallejo S, Lopez-Esteban M, Lorenzo O, et al.
Visfatin/eNampt induces endothelial dysfunction in vivo: a role for Toll-Like Receptor 4 and
NLRP3 inflammasome. Sci Rep. 2020;10(1):5386.
237. Jamaluddin MS, Weakley SM, Yao Q, Chen C. Resistin: functional roles and therapeutic
considerations for cardiovascular disease. Br J Pharmacol. 2012;165(3):622-32.
238. Zuniga MC, Raghuraman G, Hitchner E, Weyand C, Robinson W, Zhou W. PKC-epsilon
and TLR4 synergistically regulate resistin-mediated inflammation in human macrophages.
Atherosclerosis. 2017;259:51-9.
239. Poher AL, Tschop MH, Muller TD. Ghrelin regulation of glucose metabolism. Peptides.
2018;100:236-42.
240. Gray SM, Page LC, Tong J. Ghrelin Regulation of Glucose Metabolism. J Neuroendocrinol.
2019(e12705):1-11.
241. Pederson RA, McIntosh CH. Discovery of gastric inhibitory polypeptide and its subsequent
fate: Personal reflections. J Diabetes Investig. 2016;7 Suppl 1:4-7.
242. Dietary Guidelines for Americans. 8th Edition  2015-2020. January 2016 US Department of
Health and Human Services and US Department of Agriculture,
Health.gov/DietaryGuidelines/2015/guidelines
 106 
243. Norwegian guidelines on diet, nutrition and physical activity (Norwegian: Anbefalinger om
kosthold, ernæring og fysisk aktivitet). The Norwegian Directorate of Health2014.
244. Thunell S, Andersson C, Carlmark B, Floderus Y, Gronqvist SO, Harper P, et al. Markers
for vulnerability in acute porphyria. A hypothesis paper. Eur J Clin Chem Clin Biochem.
1995;33(4):179-94.
245. Hunter GA, Ferreira GC. Molecular enzymology of 5-aminolevulinate synthase, the
gatekeeper of heme biosynthesis. Biochim Biophys Acta. 2011;1814(11):1467-73.
246. Zhang Y, Leung DY, Richers BN, Liu Y, Remigio LK, Riches DW, et al. Vitamin D
inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK
phosphatase-1. J Immunol. 2012;188(5):2127-35.
247. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011-23.
248. Riddle RD, Yamamoto M, Engel JD. Expression of delta-aminolevulinate synthase in avian
cells: separate genes encode erythroid-specific and nonspecific isozymes. Proc Natl Acad Sci U S
A. 1989;86(3):792-6.
249. Delaby C, To-Figueras J, Deybach JC, Casamitjana R, Puy H, Herrero C. Role of two
nutritional hepatic markers (insulin-like growth factor 1 and transthyretin) in the clinical assessment
and follow-up of acute intermittent porphyria patients. J Intern Med. 2009;266(3):277-85.
250. Maier B, Lefering R, Lehnert M, Laurer HL, Steudel WI, Neugebauer EA, et al. Early
versus late onset of multiple organ failure is associated with differing patterns of plasma cytokine
biomarker expression and outcome after severe trauma. Shock. 2007;28(6):668-74.
251. Kunz M, Ibrahim SM. Cytokines and cytokine profiles in human autoimmune diseases and
animal models of autoimmunity. Mediators Inflamm. 2009;2009(979258):1-20.
252. Hytonen J, Kortela E, Waris M, Puustinen J, Salo J, Oksi J. CXCL13 and neopterin
concentrations in cerebrospinal fluid of patients with Lyme neuroborreliosis and other diseases that
cause neuroinflammation. J Neuroinflammation. 2014;11:103.
253. Nieuwenhuizen L, Falkenburg WJ, Schutgens RE, Roosendaal G, van Veghel K, Biesma
DH, et al. Stimulation of naive monocytes and PBMCs with coagulation proteases results in
thrombin-mediated and PAR-1-dependent cytokine release and cell proliferation in PBMCs only.
Scand J Immunol. 2013;77(5):339-49.
254. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving
Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Crit
Care Med. 2017;45(3):486-552.
 107 
255. Herzum I, Renz H. Inflammatory markers in SIRS, sepsis and septic shock. Curr Med
Chem. 2008;15(6):581-7.
256. Shane AL, Sanchez PJ, Stoll BJ. Neonatal sepsis. Lancet. 2017;390(10104):1770-80.
257. Mollnes TE, Brekke OL, Fung M, Fure H, Christiansen D, Bergseth G, et al. Essential role
of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel
lepirudin-based human whole blood model of inflammation. Blood. 2002;100(5):1869-77.
258. Brekke OL, Christiansen D, Fure H, Pharo A, Fung M, Riesenfeld J, et al. Combined
inhibition of complement and CD14 abolish E. coli-induced cytokine-, chemokine- and growth
factor-synthesis in human whole blood. Mol Immunol. 2008;45(14):3804-13.
259. Rokstad AM, Brekke OL, Steinkjer B, Ryan L, Kollarikova G, Strand BL, et al. The
induction of cytokines by polycation containing microspheres by a complement dependent
mechanism. Biomaterials. 2013;34(3):621-30.
260. Brekke OL, Waage C, Christiansen D, Fure H, Qu H, Lambris JD, et al. The effects of
selective complement and CD14 inhibition on the E. coli-induced tissue factor mRNA upregulation,
monocyte tissue factor expression, and tissue factor functional activity in human whole blood. Adv
Exp Med Biol. 2013;735:123-36.
261. Jones G, Barker A. Reference intervals. Clin Biochem Rev. 2008;29 Suppl 1:S93-7.
262. Storjord E, Dahl JA, Landsem A, Fure H, Ludviksen JK, Goldbeck-Wood S, et al. Systemic
inflammation in acute intermittent porphyria: a case-control study. Clin Exp Immunol.
2017;187(3):466-79.
263. Barene S, Krustrup P, Brekke OL, Holtermann A. Soccer and Zumba as health-promoting
activities among female hospital employees: a 40-weeks cluster randomised intervention study. J
Sports Sci. 2014;32(16):1539-49.
264. Deacon AC, Elder GH. ACP Best Practice No 165: front line tests for the investigation of
suspected porphyria. J Clin Pathol. 2001;54(7):500-7.
265. Europen Porphyria Network (EPNET) [Internet]. 2019 [cited 2019 november 30th].
Available from: https://porphyria.eu/.
266. Woolf J, Marsden JT, Degg T, Whatley S, Reed P, Brazil N, et al. Best practice guidelines
on first-line laboratory testing for porphyria. Ann Clin Biochem. 2017;54(2):188-98.
267. Aarsand AK, Villanger JH, Stole E, Deybach JC, Marsden J, To-Figueras J, et al. European
specialist porphyria laboratories: diagnostic strategies, analytical quality, clinical interpretation, and
reporting as assessed by an external quality assurance program. Clin Chem. 2011;57(11):1514-23.
 108 
268. Webber PR, Aarsand AK, Sandvik AK, Skadberg O, Lindberg M, Sandberg S. Acute
porphyrias may be overlooked in patients taking methenamine hippurate. Clin Chem Lab Med.
2010;48(9):1355-7.
269. Doss M, Schmidt A. Rapid determination of urinary total porphyrins by ion exchange
chromatography. Zeitschrift fur klinische Chemie und klinische Biochemie. 1971;9(5):415-8.
270. Storjord E, Brekke OL, Nielsen EW. Safe usage of isotretinoin in a woman with latent acute
intermittent porphyria. Acta dermato-venereologica. 2007;87(3):267-8.
271. Bergseth G, Ludviksen JK, Kirschfink M, Giclas PC, Nilsson B, Mollnes TE. An
international serum standard for application in assays to detect human complement activation
products. Mol Immunol. 2013;56(3):232-9.
272. Henno LT, Storjord E, Christiansen D, Bergseth G, Ludviksen JK, Fure H, et al. Effect of
the anticoagulant, storage time and temperature of blood samples on the concentrations of 27
multiplex assayed cytokines - Consequences for defining reference values in healthy humans.
Cytokine. 2017;97:86-95.
273. Engvall E, Perlmann P. Enzyme-linked immunosorbent assay (ELISA). Quantitative assay
of immunoglobulin G. Immunochemistry. 1971;8(9):871-4.
274. Van Weemen BK, Schuurs AH. Immunoassay using antigen-enzyme conjugates. FEBS
Lett. 1971;15(3):232-6.
275. Lequin RM. Enzyme immunoassay (EIA)/enzyme-linked immunosorbent assay (ELISA).
Clin Chem. 2005;51(12):2415-8.
276. Harris N, Kunicka J, Kratz A. The ADVIA 2120 hematology system: flow cytometry-based
analysis of blood and body fluids in the routine hematology laboratory. Lab Hematol.
2005;11(1):47-61.
277. Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in
multidimensional genomic data. Bioinformatics. 2016;32(18):2847-9.
278. Lovdata.no, Helseforskningsloven, Kap. 6. Forskningsbiobanker og forskning som
involverer humant biologisk materiale (§§ 25-31), (2008).
279. Gouya L, Ventura P, Balwani M, Bissell DM, Rees DC, Stolzel U, et al. EXPLORE: A
Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with
Recurrent Attacks. Hepatology. 2020;71(5):1546-58.
280. Monteiro HP, Abdalla DS, Faljoni-Alario A, Bechara EJ. Generation of active oxygen
species during coupled autoxidation of oxyhemoglobin and delta-aminolevulinic acid. Biochim
Biophys Acta. 1986;881(1):100-6.
 109 
281. Hallan SI, Ovrehus MA, Romundstad S, Rifkin D, Langhammer A, Stevens PE, et al. Long-
term trends in the prevalence of chronic kidney disease and the influence of cardiovascular risk
factors in Norway. Kidney Int. 2016;90(3):665-73.
282. Chan FK, Luz NF, Moriwaki K. Programmed necrosis in the cross talk of cell death and
inflammation. Annu Rev Immunol. 2015;33:79-106.
283. Pasparakis M, Vandenabeele P. Necroptosis and its role in inflammation. Nature.
2015;517(7534):311-20.
284. Medina CB, Mehrotra P, Arandjelovic S, Perry JSA, Guo Y, Morioka S, et al. Metabolites
released from apoptotic cells act as tissue messengers. Nature. 2020;580(7801):130-5.
285. Dowman JK, Gunson BK, Bramhall S, Badminton MN, Newsome PN. Liver transplantation
from donors with acute intermittent porphyria. Ann Intern Med. 2011;154(8):571-2.
286. Al-Samkari H, Patel AA, Schiano TD, Kuter DJ. Recurrence of Acute Intermittent
Porphyria After Liver Transplantation. Ann Intern Med. 2019;170(12):904-5.
287. Felleskatalogen. Normosang Felleskatalogen.no: Felleskatalogen AS 2020 [updated May 26.
Available from: https://www.felleskatalogen.no/medisin/normosang-recordati-rare-diseases-
562095.
288. Ganz T. Anemia of Inflammation. N Engl J Med. 2019;381(12):1148-57.
289. Cedzynski M, Thielens NM, Mollnes TE, Vorup-Jensen T. Editorial: The Role of
Complement in Health and Disease. Front Immunol. 2019;10:1869.
290. Skjeflo EW, Christiansen D, Fure H, Ludviksen JK, Woodruff TM, Espevik T, et al.
Staphylococcus aureus-induced complement activation promotes tissue factor-mediated
coagulation. J Thromb Haemost. 2018;16(5):905-18.
291. Randeria SN, Thomson GJA, Nell TA, Roberts T, Pretorius E. Inflammatory cytokines in
type 2 diabetes mellitus as facilitators of hypercoagulation and abnormal clot formation. Cardiovasc
Diabetol. 2019;18(1):72.
292. Maiocchi S, Alwis I, Wu MCL, Yuan Y, Jackson SP. Thromboinflammatory Functions of
Platelets in Ischemia-Reperfusion Injury and Its Dysregulation in Diabetes. Semin Thromb Hemost.
2018;44(2):102-13.
293. Desilles JP, Syvannarath V, Ollivier V, Journe C, Delbosc S, Ducroux C, et al. Exacerbation
of Thromboinflammation by Hyperglycemia Precipitates Cerebral Infarct Growth and Hemorrhagic
Transformation. Stroke; a journal of cerebral circulation. 2017;48(7):1932-40.
294. Yun JM, Jialal I, Devaraj S. Epigenetic regulation of high glucose-induced proinflammatory





295. Naidoo V, Naidoo M, Ghai M. Cell- and tissue-specific epigenetic changes associated with 
chronic inflammation in insulin resistance and type 2 diabetes mellitus. Scand J Immunol. 
2018;88(6):e12723. 
296. Feinberg AP. The Key Role of Epigenetics in Human Disease Prevention and Mitigation. N 
Engl J Med. 2018;378(14):1323-34. 
297. Wang HJ, Zakhari S, Jung MK. Alcohol, inflammation, and gut-liver-brain interactions in 
tissue damage and disease development. World J Gastroenterol. 2010;16(11):1304-13. 
298. Sears B. Anti-inflammatory Diets. J Am Coll Nutr. 2015;34 Suppl 1:14-21. 
299. Madani A, Alack K, Richter MJ, Kruger K. Immune-regulating effects of exercise on 
cigarette smoke-induced inflammation. J Inflamm Res. 2018;11:155-67. 
300. Lip GY, McColl KE, Goldberg A, Moore MR. Smoking and recurrent attacks of acute 
intermittent porphyria. Bmj. 1991;302(6775):507. 
301. Hammersland MH, Aarsand AK, Sandberg S, Andersen J. Self-efficacy and self-
management strategies in acute intermittent porphyria. BMC Health Serv Res. 2019;19(1):444. 
302. Mustajoki P, Nikkila EA. Serum lipoproteins in asymptomatic acute porphyria: no evidence 
for hyperbetalipoproteinemia. Metabolism. 1984;33(3):266-9. 
303. Sixel-Dietrich F, Verspohl F, Doss M. Hyperinsulinemia in acute intermittent porphyria. 
Horm Metab Res. 1985;17(7):375-6. 
304. Han HS, Kang G, Kim JS, Choi BH, Koo SH. Regulation of glucose metabolism from a 
liver-centric perspective. Exp Mol Med. 2016;48:e218. 
305. Acquarone E, Monacelli F, Borghi R, Nencioni A, Odetti P. Resistin: A reappraisal. Mech 
Ageing Dev. 2019;178:46-63. 
306. Tokarz VL, MacDonald PE, Klip A. The cell biology of systemic insulin function. The 
Journal of cell biology. 2018;217(7):2273-89. 
307. Martin AM, Sun EW, Keating DJ. Mechanisms controlling hormone secretion in human gut 
and its relevance to metabolism. The Journal of endocrinology. 2019;244(1):R1-R15. 
308. Petersen MC, Vatner DF, Shulman GI. Regulation of hepatic glucose metabolism in health 
and disease. Nat Rev Endocrinol. 2017;13(10):572-87. 
309. Moebus S, Gores L, Losch C, Jockel KH. Impact of time since last caloric intake on blood 
glucose levels. Eur J Epidemiol. 2011;26(9):719-28. 
310. Klover PJ, Mooney RA. Hepatocytes: critical for glucose homeostasis. Int J Biochem Cell 
Biol. 2004;36(5):753-8. 
 111 
311. Szablewski L. Distribution of glucose transporters in renal diseases. J Biomed Sci.
2017;24(1):64.
312. Li D. PGC-1alpha: looking behind the sweet treat for porphyria. Cell. 2005;122(4):487-9.
313. Oliveri LM, Davio C, Batlle AM, Gerez EN. ALAS1 gene expression is down-regulated by
Akt-mediated phosphorylation and nuclear exclusion of FOXO1 by vanadate in diabetic mice.
Biochem J. 2012;442(2):303-10.
314. Collantes M, Serrano-Mendioroz I, Benito M, Molinet-Dronda F, Delgado M, Vinaixa M, et
al. Glucose metabolism during fasting is altered in experimental porphobilinogen deaminase
deficiency. Hum Mol Genet. 2016;25(7):1318-27.
315. Matkovic LB, D'Andrea F, Fornes D, San Martin de Viale LC, Mazzetti MB. How
porphyrinogenic drugs modeling acute porphyria impair the hormonal status that regulates glucose
metabolism. Their relevance in the onset of this disease. Toxicology. 2011;290(1):22-30.
316. Bird SR, Hawley JA. Update on the effects of physical activity on insulin sensitivity in
humans. BMJ Open Sport Exerc Med. 2016;2(1):e000143.
317. Rui L. Energy metabolism in the liver. Compr Physiol. 2014;4(1):177-97.
318. Pozo OJ, Marcos J, Fabregat A, Ventura R, Casals G, Aguilera P, et al. Adrenal hormonal
imbalance in acute intermittent porphyria patients: results of a case control study. Orphanet J Rare
Dis. 2014;9:54.
319. Szablewski L. Expression of glucose transporters in cancers. Biochim Biophys Acta.
2013;1835(2):164-9.
320. Haeusler RA, McGraw TE, Accili D. Biochemical and cellular properties of insulin receptor
signalling. Nat Rev Mol Cell Biol. 2018;19(1):31-44.
321. Schwartz MW, Seeley RJ, Tschop MH, Woods SC, Morton GJ, Myers MG, et al.
Cooperation between brain and islet in glucose homeostasis and diabetes. Nature.
2013;503(7474):59-66.
322. Roh E, Song DK, Kim MS. Emerging role of the brain in the homeostatic regulation of
energy and glucose metabolism. Exp Mol Med. 2016;48:e216.
323. Osborn O, Olefsky JM. The cellular and signaling networks linking the immune system and
metabolism in disease. Nat Med. 2012;18(3):363-74.
324. Liu M, Cao H, Hou Y, Sun G, Li D, Wang W. Liver Plays a Major Role in FGF-21





325. Ghorpade DS, Ozcan L, Zheng Z, Nicoloro SM, Shen Y, Chen E, et al. Hepatocyte-secreted 
DPP4 in obesity promotes adipose inflammation and insulin resistance. Nature. 
2018;555(7698):673-7. 
326. Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Estrada E, Seip R, et al. Circulating 
resistin levels are not associated with obesity or insulin resistance in humans and are not regulated 
by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-
resistant, and diabetic subjects. J Clin Endocrinol Metab. 2003;88(10):4848-56. 
327. Gruendel S, Weickert MO, Garcia AL, Wagner K, Pfeiffer AF, Harsch I, et al. Serum 
resistin increases in a postprandial state during liquid meal challenge test in healthy human subjects. 
J Endocrinol Invest. 2006;29(10):RC27-30. 
328. Nieva-Vazquez A, Perez-Fuentes R, Torres-Rasgado E, Lopez-Lopez JG, Romero JR. 
Serum resistin levels are associated with adiposity and insulin sensitivity in obese Hispanic 
subjects. Metab Syndr Relat Disord. 2014;12(2):143-8. 
329. Chen BH, Song Y, Ding EL, Roberts CK, Manson JE, Rifai N, et al. Circulating levels of 
resistin and risk of type 2 diabetes in men and women: results from two prospective cohorts. 
Diabetes care. 2009;32(2):329-34. 
330. Hasegawa G, Ohta M, Ichida Y, Obayashi H, Shigeta M, Yamasaki M, et al. Increased 
serum resistin levels in patients with type 2 diabetes are not linked with markers of insulin 
resistance and adiposity. Acta Diabetol. 2005;42(2):104-9. 
331. Seidelmann SB, Claggett B, Cheng S, Henglin M, Shah A, Steffen LM, et al. Dietary 
carbohydrate intake and mortality: a prospective cohort study and meta-analysis. Lancet Public 
Health. 2018;3(9):e419-e28. 
332. Ronningen T, Shah A, Reiner AH, Collas P, Moskaug JO. Epigenetic priming of 
inflammatory response genes by high glucose in adipose progenitor cells. Biochem Biophys Res 
Commun. 2015;467(4):979-86. 
333. Garcia-Diz L, Murcia MA, Gris JL, Pons A, Monteagudo C, Martinez-Tome M, et al. 
Assessing nutritional status of acute intermittent porphyria patients. Eur J Clin Invest. 
2012;42(9):943-52. 
334. Mozaffari H, Ajabshir S, Alizadeh S. Dietary Approaches to Stop Hypertension and risk of 
chronic kidney disease: A systematic review and meta-analysis of observational studies. Clin Nutr. 
2019;39(7):2035-44. 
335. Fredriksson E, Brekke HK, Ellegard L. Dietary intake in Swedish medical students during 
2007-2012. Scand J Public Health. 2016;44(1):77-83. 
 113 
336. Brouns F. Overweight and diabetes prevention: is a low-carbohydrate-high-fat diet
recommendable? Eur J Nutr. 2018;57(4):1301-12.
337. Foundation AP. The Glucose Effect in Acute Porphyrias [Internet] 2020 [cited 2020 04
April]. Available from: https://porphyriafoundation.org/for-patients/diet-and-nutrition/the-glucose-
effect-in-acute-porphyrias/.
338. Masood W, Uppaluri KR. Ketogenic Diet. Treasure Island (FL): StatPearls2019.
339. Patterson RE, Sears DD. Metabolic Effects of Intermittent Fasting. Annu Rev Nutr.
2017;37:371-93.
340. Slavich GM, Irwin MR. From stress to inflammation and major depressive disorder: a social
signal transduction theory of depression. Psychol Bull. 2014;140(3):774-815.
341. Gouin JP, Glaser R, Malarkey WB, Beversdorf D, Kiecolt-Glaser J. Chronic stress, daily
stressors, and circulating inflammatory markers. Health Psychol. 2012;31(2):264-8.
342. Blackburn EH, Epel ES, Lin J. Human telomere biology: A contributory and interactive
factor in aging, disease risks, and protection. Science. 2015;350(6265):1193-8.
343. Di Pierro E, Granata F. Nutrients and Porphyria: An Intriguing Crosstalk. Int J Mol Sci.
2020;21(10):3462.
344. Sassi F, Tamone C, D'Amelio P. Vitamin D: Nutrient, Hormone, and Immunomodulator.
Nutrients. 2018;10(11).
345. Tao J, Rupar CA, Miller MR, Ratko S, Prasad C. Use of complementary and alternative
medicine in patients with inborn errors of metabolism: A single-center study. JIMD reports.
2020;51(1):105-12.
346. Berry SE, Valdes AM, Drew DA, Asnicar F, Mazidi M, Wolf J, et al. Human postprandial
responses to food and potential for precision nutrition. Nat Med. 2020;26(6):964-73.
347. Gurav AN. Periodontitis and insulin resistance: casual or causal relationship? Diabetes
Metab J. 2012;36(6):404-11.
348. Nilsson PH, Ekdahl KN, Magnusson PU, Qu H, Iwata H, Ricklin D, et al. Autoregulation of
thromboinflammation on biomaterial surfaces by a multicomponent therapeutic coating.
Biomaterials. 2013;34(4):985-94.
349. Tvedt TH, Rye KP, Reikvam H, Brenner AK, Bruserud O. The importance of sample
collection when using single cytokine levels and systemic cytokine profiles as biomarkers--a
comparative study of serum versus plasma samples. J Immunol Methods. 2015;418:19-28.
 114 
350. Biancotto A, Feng X, Langweiler M, Young NS, McCoy JP. Effect of anticoagulants on
multiplexed measurement of cytokine/chemokines in healthy subjects. Cytokine. 2012;60(2):438-
46.
351. Rosenberg-Hasson Y, Hansmann L, Liedtke M, Herschmann I, Maecker HT. Effects of
serum and plasma matrices on multiplex immunoassays. Immunol Res. 2014;58(2-3):224-33.
352. Flower L, Ahuja RH, Humphries SE, Mohamed-Ali V. Effects of sample handling on the
stability of interleukin 6, tumour necrosis factor-alpha and leptin. Cytokine. 2000;12(11):1712-6.
353. Ter Horst R, Jaeger M, Smeekens SP, Oosting M, Swertz MA, Li Y, et al. Host and
Environmental Factors Influencing Individual Human Cytokine Responses. Cell.
2016;167(4):1111-24 e13.
354. Li Y, Oosting M, Smeekens SP, Jaeger M, Aguirre-Gamboa R, Le KTT, et al. A Functional
Genomics Approach to Understand Variation in Cytokine Production in Humans. Cell.
2016;167(4):1099-110 e14.
355. Sackett DL. Bias in analytic research. J Chronic Dis. 1979;32(1-2):51-63.
356. Thiese MS, Ronna B, Ott U. P value interpretations and considerations. J Thorac Dis.
2016;8(9):E928-E31.
357. Faber J, Fonseca LM. How sample size influences research outcomes. Dental Press J
Orthod. 2014;19(4):27-9.
358. Aggarwal R, Ranganathan P. Common pitfalls in statistical analysis: The use of correlation
techniques. Perspect Clin Res. 2016;7(4):187-90.
359. Sturgeon CM, Viljoen A. Analytical error and interference in immunoassay: minimizing
risk. Ann Clin Biochem. 2011;48(Pt 5):418-32.
360. Johansen AMW, Myhre JB, Hjartaker A, Andersen LF. Validation of energy intake
recorded by a 7-day pre-coded food diary against measured energy expenditure in a group of
Norwegian adults. PLoS One. 2019;14(4):e0215638.
361. Sandberg S, Elder GH. Diagnosing acute porphyrias. Clin Chem. 2004;50(5):803-5.
362. Tollanes MC, Aarsand AK, Villanger JH, Stole E, Deybach JC, Marsden J, et al.
Establishing a network of specialist Porphyria centres - effects on diagnostic activities and services.
Orphanet J Rare Dis. 2012;7:93.
363. Lamon J, With TK, Redeker AG. The Hoesch test: bedside screening for urinary
porphobilinogen in patients with suspected porphyria. Clin Chem. 1974;20(11):1438-40.
 115 
364. Balwani M, Singh P, Seth A, Debnath EM, Naik H, Doheny D, et al. Acute Intermittent
Porphyria in children: A case report and review of the literature. Mol Genet Metab.
2016;119(4):295-9.
365. Hultdin J, Schmauch A, Wikberg A, Dahlquist G, Andersson C. Acute intermittent
porphyria in childhood: a population-based study. Acta Paediatr. 2003;92(5):562-8.
366. Baravelli CM, Aarsand AK, Sandberg S, Tollanes MC. Sick leave, disability, and mortality
in acute hepatic porphyria: a nationwide cohort study. Orphanet J Rare Dis. 2020;15(1):56.
367. Lynch SV, Pedersen O. The Human Intestinal Microbiome in Health and Disease. N Engl J
Med. 2016;375(24):2369-79.
368. Brunetti-Pierri N, Newsome PN. AAV-mediated liver-directed gene therapy for Acute
Intermittent Porphyria: It is safe but is it effective? J Hepatol. 2016;65(4):666-7.
369. D'Avola D, Lopez-Franco E, Sangro B, Paneda A, Grossios N, Gil-Farina I, et al. Phase I
open label liver-directed gene therapy clinical trial for acute intermittent porphyria. J Hepatol.
2016;65(4):776-83.
370. Serrano-Mendioroz I, Sampedro A, Serna N, Salamanca RE, Sanz-Parra A, Corrales F, et al.
Bioengineered PBGD variant improves the therapeutic index of gene therapy vectors for acute
intermittent porphyria. Hum Mol Genet. 2018;27(21):3688-96.
371. Yin Z, Wahlin S, Ellis EC, Harper P, Ericzon BG, Nowak G. Hepatocyte transplantation
ameliorates the metabolic abnormality in a mouse model of acute intermittent porphyria. Cell
transplantation. 2014;23(9):1153-62.
372. Bustad HJ, Toska K, Schmitt C, Vorland M, Skjaerven L, Kallio JP, et al. A
Pharmacological Chaperone Therapy for Acute Intermittent Porphyria. Mol Ther. 2020;28(2):677-
89.
373. Jiang L, Berraondo P, Jerico D, Guey LT, Sampedro A, Frassetto A, et al. Systemic
messenger RNA as an etiological treatment for acute intermittent porphyria. Nat Med.
2018;24(12):1899-909.
374. Puy H, Deybach JC, Gouya L. Systemic Administered mRNA as Therapy for Metabolic
Diseases. Trends Mol Med. 2019;25(1):3-5.
375. Saggi H, Maitra D, Jiang A, Zhang R, Wang P, Cornuet P, et al. Loss of hepatocyte beta-
catenin protects mice from experimental porphyria-associated liver injury. J Hepatol.
2019;70(1):108-17.
 116 
376. Yasuda M, Chen B, Desnick RJ. Recent advances on porphyria genetics: Inheritance,
penetrance & molecular heterogeneity, including new modifying/causative genes. Mol Genet
Metab. 2019;128(3):320-31.
377. Serrano-Mendioroz I, Sampedro A, Mora MI, Mauleon I, Segura V, Enriquez de Salamanca
R, et al. Vitamin D-binding protein as a biomarker of active disease in acute intermittent porphyria.
J Proteomics. 2015;127(Pt B):377-85.
378. Cohen AM, Chamberlin S, Deloughery T, Nguyen M, Bedrick S, Meninger S, et al.
Detecting rare diseases in electronic health records using machine learning and knowledge






Published paper II: Fig. legend to Fig. 9: “P-gastrointestinal peptide (GIP)”, should have been 
written “P-gastric inhibitory polypeptide (GIP)”. 
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Summary
This study aimed to examine whether acute intermittent porphyria (AIP) is
associated with systemic inflammation and whether the inflammation
correlates with disease activity. A case–control study with 50 AIP cases and
age-, sex- and place of residence-matched controls was performed. Plasma
cytokines, insulin and C-peptide were analysed after an overnight fast using
multiplex assay. Long pentraxin-3 (PTX3) and complement activation
products (C3bc and TCC) were analysed using enzyme-linked
immunosorbent assay (ELISA). Urine porphobilinogen ratio (U-PBG, mmol/
mmol creatinine), haematological and biochemical tests were performed
using routine methods. Questionnaires were used to register AIP symptoms,
medication and other diseases. All 27 cytokines, chemokines and growth
factors investigated were increased significantly in symptomatic AIP cases
compared with controls (P < 00004). Hierarchical cluster analyses revealed
a cluster with high visfatin levels and several highly expressed cytokines
including interleukin (IL)-17, suggesting a T helper type 17 (Th17)
inflammatory response in a group of AIP cases. C3bc (P 5 0002) and
serum immunoglobulin (Ig)G levels (P 5 003) were increased significantly
in cases with AIP. The U-PBG ratio correlated positively with PTX3
(r 5 038, P 5 0006), and with terminal complement complex (TCC) levels
(r 5 033, P 5 002). PTX3 was a significant predictor of the biochemical
disease activity marker U-PBG in AIP cases after adjustment for potential
confounders in multiple linear regression analyses (P 5 0032). Prealbumin,
C-peptide, insulin and kidney function were all decreased in the
symptomatic AIP cases, but not in the asymptomatic cases. These results
indicate that AIP is associated with systemic inflammation. Decreased C-
peptide levels in symptomatic AIP cases indicate that reduced insulin release
is associated with enhanced disease activity and reduced kidney function.
Keywords: chemokines, complement, cytokines, human, inflammation
Introduction
Acute intermittent porphyria (AIP) is an autosomal domi-
nant metabolic disorder caused by a mutation in the
hydroxymethylbilane synthase gene, which encodes an
enzyme involved in haem synthesis [1]. A rare condition
worldwide, with a prevalence in European populations of
only 1/75 000 to 10–20/100 000 [2,3], AIP is prevalent in
Nordland county in Norway, with a prevalence as high as
600/100 000 in one municipality [4]. Many patients have
only one porphyria attack over a lifetime, and few suffer
chronic AIP symptoms. Individuals carrying the AIP gene
mutation are classified as symptomatic (15–20%) or
asymptomatic (80–85%) [1]. Symptomatic AIP presents
typically with acute, severe abdominal pain, nausea, vomit-
ing, constipation, dark red urine and muscle weakness [1].
Most attacks last from a few days up to 2 weeks. Bulbar or
phrenic nerve paresis may ensue occasionally and lead to
life-threatening respiratory failure [1,5]. A high prevalence
of hypertension and kidney impairment has been docu-
mented [3]. Some mutations, including the W198X
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mutation, carry an increased risk of hepatocellular carci-
noma (HCC), which is found in approximately one-third
of patients with this mutation [3,6].
Established triggers for AIP attack include infections,
alcohol, smoking, hormonal factors, physical or mental
stress and medications affecting haem synthesis [1,2]. In
terms of the mechanisms whereby these triggers cause ill-
ness, fasting, fever and stress are known to induce haem
oxygenase-1 activity, leading to a reduction in the free
haem pool and induction of 5-aminolevulinic synthase-1
(ALAS1) [1]. Acute phase proteins and interleukin (IL)-6
may also increase ALAS1 synthetase activity in liver cells
[7]. ALAS1 is increased in the liver in AIP patients, due
probably to intracellular haem deficiency [8]. Some
patients with AIP, however, may suffer severe forms of the
disease without any known triggers. Treatment for this
group is demanding, and requires the avoidance or treat-
ment of triggering factors, a high oral sugar intake, glucose
and insulin infusion or infusion of haem. In these patients,
ALAS1 mRNA in the liver is decreased by insulin through
the peroxisome proliferator-activated receptor co-activator
1a [9]. The fact that liver transplantation is an efficient
cure for AIP strengthens the evidence that the role of liver
metabolism in AIP pathogenesis is central [10]. In addi-
tion, inflammation may possibly affect haem synthesis
through hepcidin [11].
Low-grade inflammation has been reported to play a
role in several systemic diseases, such as atherosclerosis and
type II diabetes [12,13]. AIP could therefore be associated
with low-grade inflammation. The accumulation of certain
damage-associated molecular patterns (DAMPs) has been
shown to stimulate the immune cells and inflammation in
various diseases [14]. Haem and porphyrins have been
reported to activate the complement system [15,16]. Sato
et al. showed that dietary supplementation with 5-
aminolevulinic acid (ALA) induced T cell responses in
chickens through oxidative stress [17]. Delaby et al.
reported lower prealbumin levels in patients with sympto-
matic AIP, probably as a result of malnutrition or hepatic
inflammation [18].
Although there is evidence for a possible role of inflam-
mation in AIP, it has not been determined whether patients
with AIP have increased systemic inflammation. The aims of
this study were to examine systemic inflammation in AIP by
plasma biomarkers and biochemical disease activity in the
form of urine porphyrin precursor levels, and to determine
whether inflammatory markers are associated with biochem-
ical disease activity, insulin release and kidney function.
Materials and methods
Study design and participants
A case–control study was conducted in 50 individuals with
AIP, 15 asymptomatic and 35 symptomatic carriers of the
AIP gene mutation and 50 controls matched for age, sex
and place of residence (Table 1). Of the 50 AIP patients, 48
had the W198X mutation. The patients and matched con-
trols were recruited from the Norwegian counties of Nord-
land, Troms, Trøndelag and Oslo. The 42 healthy controls
consisted of 22 men and 20 women, with a mean age of
48.8 years, without inflammatory diseases. The single-draw
blood samples were obtained in a period outside AIP
attacks. Only one patient had chronic AIP symptoms.
Ethics, consent and permission
The Regional Committee for Medical and Health Research
Ethics approved the study. Written informed consent was
obtained from all participants. All procedures followed
were in accordance with the ethical standards of the
responsible committee on human experimentation (insti-
tutional and national) and with the Helsinki Declaration.
This trial is registered with ClinicalTrials.gov number
NCT01617642.
Medical evaluation
A physician completed a questionnaire for each participant
during the interview on the same day that the blood sam-
ples were taken. Individuals with the AIP gene mutation
were questioned about the presence or absence of AIP
symptoms, time of diagnosis, number and durations of
attacks and suspected triggering and relieving factors. They
were asked specifically about abdominal pain, vomiting,
constipation, muscle ache, muscle weakness, decreased sen-
sitivity, paresis, headache, tiredness, epilepsy, palpitations,
dark or red urine and psychiatric symptoms. Participants
were also asked about their smoking and alcohol habits,
physical activity and emotional stress. All participants gave
a past medical history, history of current illness and drug
history before the interview. Dietary intake was registered
using a 7-day food diary. Trained nurses measured height
and weight and calculated body mass index (BMI).
Blood sampling and laboratory methods
Blood samples were obtained by venepuncture between 8
a.m. and 9 a.m. after an overnight fast using Vacuette
citrate and ethylenediamine tetraacetic acid (EDTA) serum
tubes (Greiner Bio-one GmbH, Frickenhausen, Germany).
The EDTA tubes for plasma cytokine and complement
analysis were placed immediately onto crushed ice and cen-
trifuged at 1500 g for 15 min at 148C, and the plasma was
stored at 2808C until analysis.
Multiplex technology
The cytokines were analysed in EDTA plasma using a Bio-
Plex Human Cytokine 27-plex kit (Bio-Rad Laboratories
Inc., Hercules, CA, USA). The following cytokines, chemo-
kines and growth factors were analysed: interleukin (IL)-
1b, IL-1RA (IL-1 receptor antagonist), IL-2, IL-4, IL-5, IL-
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6, IL-7, chemokine (C-X-C) motif 8 (CXCL8), IL-9, IL-10,
IL-12 (p70), IL-13, IL-15, IL-17, chemokine (C-C motif)
ligand 5 (CCL5), chemokine ligand 11 (CCL11), basic
fibroblast growth factor (FGF), granulocyte colony-
stimulating factor (G-CSF), granulocyte–macrophage
colony-stimulating factor (GM-CSF), interferon (IFN)-g,
CXCL10, CCL2, CCL3, CCL4, platelet-derived growth
factor-BB (PDGF-BB), tumour necrosis factor (TNF) and
vascular endothelial growth factor (VEGF). Insulin, visfatin
and C-peptide were analysed using the human Bio-plex
Pro human diabetes immunoassay kit from Bio-Rad. The
analysis was performed using the Bio-Plex 200 system
(Bio-Rad).
Enzyme immunoassay
Long-pentraxin 3 (PTX3) was analysed in EDTA plasma
using an enzyme-linked immunosorbent assay (ELISA) kit
(R&D Systems Inc., Minneapolis, MN, USA). The comple-
ment activation products C3bc and soluble C5b-9 (sC5b-9)
Table 1. Baseline patient demographic characteristics of the study population
Controls aAIP cases OR (CI) P
Demographic features
Age, years (s.d.) 504 (186) 506 (184) 038
Height, cm (s.d.) 1716 (95) 1721 (97) 084
Weight, kg (s.d.) 802 (140) 810 (157) 060
Body mass index, kg/m2 (s.d.) 272 (39) 272 (39) 092
Woman, n (%) 21 (42%) 21 (42%)
Men, n (%) 29 (58%) 29 (58%)
Symptomatic aAIP, n (%) 35 (70%)
Asymptomatic aAIP, n (%) 15 (30%)
Inflammatory diseases
Gout, n (%) 2 (4%) 8 (16%) 457 009
Inflammation in the musculoskeletal system, n (%) 6 (12%) 3 (6%) 047 049
Rheumatoid arthritis, n (%) 1 (2%) 1 (2%) 100 100
Ankylosing spondylitis, n (%) 2 (4%) 1 (2%) 049 100
Gastrointestinal inflammatory disease, n (%) 3 (6%) 3 (6%) 100 100
Bacterial infection recently, n (%) 1 (2%) 1 (2%) 100 100
Viral infection recently, n (%) 1 (2%) 0 (0%) 033 100
Diabetes mellitus, n (%) 3 (6%) 4 (8%) 136 100
Anti-inflammatory drugs and allopurinol, current use
Allopurinol, n (%) 1 (2%) 4 (8%) 426 036
NSAIDs, n (%) 5 (10%) 3 (6%) 057 072
Immunosuppressants, n (%) 3 (6%) 1 (2%) 032 062
Prednisolone, n (%) 2 (4%) 1 (2%) 049 100
Penicillin V, n (%) 1 (2%) 0 (0%) 033 100
Autoantibodies and biomarkers
Sc-Rheumatoid factor  6 U/l, n (%) 7 (14%) 4 (8%) 053 053
Sc-Anti-nuclear abb> 20 U/l, n (%) 8 (16%) 10 (20%) 131 (047–366) 080
Sc-Anti-thyroid peroxidase abb > 60 kU/l, n (%) 2 (4%) 6 (12%) 327 027
Sc-Anti-citrullinated peptide abb > 20 U/l, n (%) 2 (4%) 0 (0%) 019 050
Sc-Anti-cardiolipin, U/l, n (%) 1 (2%) 0 (0%) 033 100
Sc-Urate > 400 lmol/l, n (%) 12 (24%) 15 (30%) 135 (056–330) 065
Sc-Cystatin C, mg/l (IQR) 097 (085–103) 098 (086–111) 043
Relative eGFRd CKD-EPI, ml/min/173 m2 (IQR) 87 (69–99) 83 (63–100) 054
Ethanol intake and smoking
Ethanol intake, g per day (IQR) 63 (0–147) 32 (0–119) 028
Never smokers, n (%) 19 (38%) 19 (38%)
Former smokers, n (%) 25 (50%) 21 (42%) 084 (035–199) 083
Current smokers, n (%) 6 (12%) 10 (20%) 167 (050–551) 055
The data represent the mean values (s.d.), n (%) or median values and interquartile range (IQR). Wilcoxon’s matched-pairs signed-rank test
was used for the demographic features; Fisher’s exact test was used for all other variables. OR 5 odds ratio; CI 5 confidence interval; n 5 50
matched pairs, except for daily alcohol intake n 5 46 matched pairs. OR for smoking was calculated by comparing former smokers against never
smokers in cases versus controls and current smokers against never smokers in cases versus controls. aAIP 5 acute intermittent porphyria;
bab 5 antibodies; cS 5 serum; drelative estimated glomerular filtration rate (eGFR) Chronic Kidney Disease Epidemiology Collaboration (CKD-
EPI) based on cystatin C levels; NSAIDs 5 non-steroidal anti-inflammatory drugs; s.d. 5 standard deviation.
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were analysed in EDTA plasma using enzyme-linked
immunosorbent assays (ELISAs), as described previously
[19]. Both assays are based on monoclonal antibodies to
neoepitopes exposed in the activation products and not
present in the native components. Optical density was
measured using an MRX microplate reader (Dynex
Technologies, Denkendorf, Germany) [20]. Anti-
transglutaminase and anti-endomysium were analysed
using Quanta LiteTM h-tTG immunoglobulin (Ig)A ELISA
kits (Inova Diagnostics, Inc., San Diego, CA, USA). Anti-
nuclear antibody (ANA) screen, rheumatoid factor and
anti-CCP were analysed in serum using Quanta LiteTM
ANA, rheumatoid factor (RF) IgM and CCP3 IgG ELISA
kits, respectively (Inova Diagnostics, Inc.). Anti-cardiolipin
was analysed using the indirect enzyme immunoassay
(EIA) test RELISA
VR
cardiolipin IgG and IgM (Immuno-
Concepts N.A. Ltd., Sacramento, CA, USA).
Routine biochemistry tests
Routine haematology parameters were analysed using a
Siemens ADVIA 2120 Hematology System (Siemens
Healthcare Diagnostics Ltd, Camberley, UK). HbA1c was
analysed using a Tosoh G8 high-performance liquid chro-
matography (HPLC) system. Serum levels of urate, IgA,
IgG and IgM, urine creatinine and other clinical chemistry
parameters in urine and serum were measured using an
Advia
VR
1800 system (Siemens Medical Solutions Diagnos-
tics, Tokyo, Japan) and reagents from Siemens Healthcare
Diagnostics Ltd. Anti-thyroid peroxidase antibodies (anti-
TPO) levels were analysed using an Advia Centaur
VR
system
(Siemens). Levels of C3, C4 and high-sensitivity C-reactive
protein (CRP) in serum were analysed using a BN ProS-
pec
VR
nephelometer (Siemens Healthcare Diagnostics Ltd).
Urine porphobilinogen (U-PBG) levels were analysed using
a kit from BioRad Laboratories (M€unchen, Germany) and
Ehrlich reagent, and urine porphyrins were analysed as
described previously [21]. The U-PBG ratio (mmol porpho-
bilinogen/mmol creatinine) was subsequently calculated.
Statistical analyses
The Wilcoxon matched-pairs signed-rank test was used on
the matched case–control data. The non-detectable cyto-
kine values were set to zero. The Mann–Whitney U-test
was used on the non-matched case data. Spearman’s rank
correlation coefficient was used for the cases with AIP and
in the calculations of the r- and two-tailed P-values because
the data were not distributed normally. P< 005 was con-
sidered to be statistically significant. The statistical analysis
was performed using Prism version 6.0 from GraphPad
Software Inc. (San Diego, CA, USA). Multiple linear regres-
sion analyses were performed on data from the AIP cases
using IBM SPSS Statistics for Macintosh version 23
(Armonk, NY, USA). In the hierarchical cluster analysis,
the cytokine levels in each AIP case and matched controls
were divided on the median levels of each cytokine in the
50 matched controls. Individuals with undetectable cyto-
kine values were replaced with a random number below
the lowest detection limit of each assay. The data were then
imported into R version 3.1.3, Bug in Your Hair. The matrix
results were then transformed using natural logarithm. The
Bioconductor (version 3.3) library complex heatmap (ver-
sion 1.10.2) was used to cluster and distance the cytoplex
matrix for both row and columns with the following
parameters: cluster 5 complete linkage, distance 5 Eucli-
dian [22].
Results
Baseline characteristics and demographic features
The demographic features and baseline characteristics were
similar in AIP patients and matched controls (Table 1). Of
the 50 patients, 35 had symptomatic AIP and 48 had the
W198X mutation. There was no difference in the preva-
lence of inflammatory diseases and the use of anti-
inflammatory medication between AIP cases and controls
(Table 1). Finally, the levels of autoantibodies, biomarkers
related to inflammatory diseases and the kidney function
did not differ between the matched controls and AIP cases
(Table 1).
Plasma levels of cytokines, chemokines, growth
factors and other biomarkers in cases with acute
intermittent porphyria compared with controls
The levels of all 27 cytokines, chemokines and growth fac-
tors were increased significantly (P < 00004) in the cases
with AIP compared with the matched controls (Table 2).
Median concentrations of proinflammatory cytokines,
including TNF, IL-1b, CXCL8, CCL2 and IL-6, were
increased significantly (P < 00001 for all) by 41-, 18-,
16-, 15- and 25-fold, respectively, in the cases with AIP
compared with the matched controls (Table 2). Further-
more, median levels of IL-7, IL-12 (p70), IL-17 and IFN-g
(Table 2) were increased significantly (P < 00001 for all)
by 23-, 38-, 246- and 77-fold, respectively. The IL-15
level (Table 2) was increased in cases with AIP, but with
undefined fold-change because the median concentration
in the matched controls was undetectable.
Median levels of the anti-inflammatory cytokines,
including IL-1RA and IL-10, were also increased signifi-
cantly (P< 00001 for both) by 23- and 101-fold, respec-
tively, in AIP cases compared with matched controls (Table
2). The levels of several chemokines, including CCL3 and
CCL4, CCL5, CXCL10 and CCL11 (Table 2), were all
increased significantly (P < 0001 for all) in AIP cases
compared with matched controls. Median levels of the
growth factors FGF basic, VEGF, G-CSF, GM-CSF and
PDGF-BB were also increased significantly (P < 00001 for
Systemic inflammation in AIP
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all) by 26-, 83-, 42-, 35- and 95-fold, respectively, in
AIP cases compared with matched controls (Table 2). IL-2,
IL-4, IL-5, IL-9 and IL-13 were increased significantly (P <
00001 for all) in cases with AIP (Table 2). The levels of
most cytokines were also increased in the AIP cases com-
pared to the median level and the reference ranges in the 42
healthy controls (Table 2). The P-values remained on the
same level when we compared the cytokine levels with the
42 healthy controls instead of the 50 matched controls,
except that the P-values for CCL5 and FGF basic against
the 42 healthy controls were P < 0001 instead of
P< 00001.
Serum ALT, IgG level and blood monocyte count were
slightly, but significantly higher (P < 005) in AIP cases
than matched controls (Table 2). Complement activation
markers, including plasma C3bc and C3bc/C3 ratio, were
higher (P < 001) in cases than matched controls (Table 2).
Serum cholesterol and triglyceride levels were also signifi-
cantly higher in cases than matched controls (Table 2). The
biomarkers of AIP disease activity U-PBG and total
Table 2. Biomarker levels in acute intermittent porphyria cases and controls





Ub-PBGc (lmol/mmol creatinine) 04 (03–05) 26 (09–85)*** 65
Ub-total porphyrins (nmol/mmol creatinine) 67 (44–106) 257 (85–83)*** 38
Sd-ALT (IU/l)e 245 (188–34) 310 (23–45)# 13
Pf-IL-1bg(pg/ml) 09 (065–12) 16 (09–33)*** 18 09 (04–20)
Pf- IL-1RAg (pg/ml) 280 (13–50) 640 (23–197)*** 23 21 (0–117)
Pf-IL-2g (pg/ml) 10 (00–20) 60 (10–16)*** 60 003 (00–79)
Pf-IL-4g(pg/ml) 10 (02–10) 20 (10–40)*** 20 10 (00–20)
Pf-IL-5g (pg/ml) 11 (07–14) 17 (13–40)*** 16 10 (05–39)
Pf-IL-6g (pg/ml) 20 (06–30) 50 (20–93)*** 25 20 (002–69)
Pf-IL-7g (pg/ml) 30 (14–50) 70 (50–14)*** 23 30 (00–11)
Pf-CXCL8g (pg/ml) 50 (30–70) 80 (60–14)*** 16 45 (08–19)
Pf-IL-9g (pg/ml) 55 (40–83) 140 (88–22)*** 26 55 (20–32)
Pf-IL-10g (pg/ml) 014 (00–053) 14 (02–60)*** 101 01 (00–95)
Pf-IL-12(p70)g (pg/ml) 20 (02–53) 135 (68–25)*** 68 18 (00–32)
Pf-IL-13g (pg/ml) 22 (17–40) 50 (22–83)*** 23 21 (09–14)
Pf-IL-15g (pg/ml) 00 (0–012) 125 (00–50)*** jND 00 (00–20)
Pf-IL-17g (pg/ml) 065 (00–93) 160 (35–55)*** 246 05 (00–54)
Pf-CCL2h (pg/ml) 110 (80–140) 165 (130–22)*** 15 100 (30–28)
Pf-CCL3h (pg/ml) 10 (015–30) 30 (20–60)*** 30 10 (00–11)
Pf-CCL4h (pg/ml) 350 (29–46) 575 (45–69)*** 16 340 (21–157)
Pf-CCL5h (ng/ml) 022 (011–052) 113 (017–107)*** 51 021 (002–40)
Pf-CCL11h (pg/ml) 430 (20–67) 790 (59–105)*** 18 355 (05–153)
Pf-FGF basic (pg/ml) 120 (40–235) 310 (10–70)*** 26 120 (00–71)
Pf-G-CSF (pg/ml) 70 (15–150) 295 (48–68)*** 42 70 (00–60)
Pf-GM-CSF (pg/ml) 40 (014–63) 140 (50–31)*** 35 30 (00–15)
Pf-IFN-g (pg/ml) 135 (0–53) 104 (135–264)*** 77 135 (00–117)
Pf-CXCL10 (pg/ml) 601 (402–914) 963 (711–1162)** 16 597 (205–2238)
Pf-TNF (pg/ml) 80 (46–21) 33 (12–84)*** 41 80 (002–54)
Pf-VEGF (pg/ml) 20 (042–50) 165 (68–29)*** 83 18 (00–17)
Pf-PDGF-BB (pg/ml) 20 (027–113) 190 (35 2155)*** 95 15 (0–117)
Pf-C3bc (CAUi/ml) 57 (48–76) 78 (64–91)* 14
Pf-C3bc/C3 ratio (CAUi/ml/g/l) 54 (45–72) 70 (57–80)* 13
S-Immunoglobulin G (g/l) 100 (85–11) 109 (10–12)# 11
B-HbA1c (%) 53 (50–56) 55 (53–57)* 11
Sd-Triglyceride 10 (07–14) 12 (10–19)# 12
Sd-Total cholesterol 51 (46–57) 57 (51–64)* 11
The data represent the median values and interquartile range (IQR). The data were analysed using the Wilcoxon matched-pairs signed-rank
test on AIP cases (n 5 50) versus matched controls. The P-values are exact, two-tailed. #P< 005; *P <001; **P< 0001; ***P< 00001 on AIP
cases (n 5 50) versus matched controls. All P-values< 0001 when comparing the cytokines in the AIP cases with the 42 healthy controls. §Fold
increase, AIP cases median value (n 5 50)/controls median values (n 5 50), $cytokine values, median and 25–975 percentiles in the 42 healthy
controls. aAIP 5 acute intermittent porphyria; bU 5 urine; cPBG 5 porphobilinogen; dS 5 serum; eIL 5 interleukin; fP 5 ethylenediamine tet-
raacetic acid (EDTA) plasma; gIU/l 5 international units per litre; hCCL 5 chemokine ligand; iCAU/ml 5 complement arbitrary units per milli-
litre; jn.d. 5 not determined; kB 5 EDTA blood.
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porphyrins were, as expected, significantly higher (P <
00001 for both) in cases than controls (Table 2). High-
sensitivity CRP, PTX3, serum IgA and IgM levels, total leu-
cocyte count, platelet count and haemoglobin levels were
not significantly different between the AIP cases and the
matched controls (data not shown).
Cytokine levels in asymptomatic and symptomatic
acute intermittent porphyria cases
We next examined whether cytokine levels were increased
both in asymptomatic and symptomatic AIP cases. The lev-
els of all 27 cytokines, chemokines and growth factors were
increased significantly in cases with symptomatic AIP com-
pared with matched controls, and eight of these are shown
(Fig. 1). Furthermore, the levels of 23 of these 27 analytes
were increased significantly in cases with asymptomatic AIP
compared with matched controls, and seven of these are
shown (Fig. 1). However, G-CSF, CCL3, FGF-basic and
CXCL8 were not increased in asymptomatic AIP cases. The
levels of cytokines and growth factors were also increased in
many AIP cases compared to their respective reference
ranges in 42 healthy controls (Fig. 1). The C3bc/C3 ratio
was enhanced significantly by 13-fold (P< 0005) in the
symptomatic AIP cases versus their matched controls.
However, the levels of the complement activation markers
terminal complement complex (TCC), C3bc/C3 ratio, C3
and C4 levels were not significantly different between the
symptomatic and asymptomatic AIP cases (data not shown).
Hierarchical cluster analyses of cytokines
The hierarchical cluster analyses of cytokines in each AIP
case and 50 matched controls divided the AIP cases and
matched controls into two main clusters, (a) and (b) (Fig.
2). Cluster (b) featured high levels (red) of many cytokines
and included five controls and 30 AIP cases, 21 of which
were symptomatic AIP cases and nine were asymptomatic
(Fig. 2). All five controls in cluster (b) with high cytokine
levels had inflammatory diseases, such as undiagnosed
rheumatoid arthritis and ankylosing spondylitis. Cluster
(b2-2) contains one control with undiagnosed, untreated
rheumatoid arthritis and AIP cases. Many AIP cases in
cluster (b2-2) with high cytokine levels also had elevated
U-PBG and U-ALA levels. The 30 AIP cases in cluster (b)
had significantly higher cytokine and visfatin levels than
the 20 AIP cases in cluster (a) (Supporting information,
Table S1). However, the PBG ratio and kidney function
were not significantly different in the AIP cases in cluster
(b). The cytokines clustered in three groups, and the cluster
1 cytokines most elevated in the AIP cases were IL-17,
PDGF-BB, IL-10 and IL-15. Finally, the AIP cases with the
R167W mutation had similar cytokine levels to those with
the W198X mutation (Fig. 2).
Correlations between disease activity, inflammatory
markers and kidney function in cases with acute
intermittent porphyria
Biochemical disease activity in AIP was measured by U-
PBG ratio. U-PBG levels correlated positively with the
inflammatory biomarker PTX3 (r 5 038, P 5 001) (Fig.
3). U-PBG levels also correlated positively with IL-9
(r 5 031, P 5 003) and IL-7 levels (r 5 030, P 5 003)
(Fig. 3). U-PBG levels correlated positively with CCL4 lev-
els (r 5 030, P 5 003, Fig. 3) and negatively with pre-
albumin levels (r 5 2031, P 5 003) (data not shown).
The U-PBG level also correlated positively with the bio-
markers of complement activation, including the C3bc/C3
ratio (r 5 035, P 5 001) and TCC levels (r 5 033, P 5
002) (Fig. 3). Examining the relationship between AIP dis-
ease activity and kidney function, we found that U-PBG
levels correlated positively with the levels of S-cystatin C, a
biomarker that is increased in the presence of impaired
kidney function (r 5 041, P 5 0003) (Fig. 3).
Multiple regression analyses of inflammatory markers
and potential confounding parameters that were
associated independently with the biochemical disease
activity
Multiple linear regression analyses were performed to
describe further the relationship between the biochemical
disease activity measured as the U-PBG ratio and inflam-
matory markers in the AIP cases. PTX3 was associated
independently with the disease activity in the AIP cases
after adjusting for potential confounders and other inflam-
matory markers (Table 3). We tested several regression
models, including various individual or pairs of cytokines,
and the coefficient estimates of PTX3 remained unchanged.
In addition, kidney function expressed as relative estimated
glomerular filtration rate (eGFR) Chronic Kidney Disease
Fig. 1. Increased levels of cytokines and growth factors in asymptomatic (Asympt.) and symptomatic (Sympt.) acute intermittent porphyria
(AIP) cases compared with matched controls (Ctrl). (a) Increased levels of tumour necrosis factor (TNF), (b) interleukin (IL)-1b and (c) IL-17,
(d) interferon (IFN)-g and the growth factors (e) basic fibroblast growth factor (FGF basic), and (f) vascular endothelial growth factor (VEGF),
(g) granulocyte–macrophage colony-stimulating factor (GM-CSF) and (h) platelet-derived growth factor (PDGF)-BB in asymptomatic and
symptomatic AIP cases compared with their respective matched controls (Ctrl). The concentration of cytokines and chemokines were measured
using a multiplex cytokine assay. The results are expressed as pg/ml. The results from the age- and sex-matched controls (n 5 50, including 35
controls for the symptomatic cases) and the cases with AIP (n 5 50, 35 symptomatic) are shown as scatter-plots with the median. The horizontal
dotted gridline indicate each cytokine’s upper reference value (975 percentile) in 42 healthy controls. The data were analysed using the Wilcoxon
matched-pairs signed-rank test.
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Epidemiology Collaboration (CKD-EPI) based on cystatin
C was a significant predictor in the multiple linear regres-
sion analysis (Table 3). The confounders tested including
prealbumin, the ratio between energy consumption and
energy requirements, catecholamines in urine, smoking
pack-years, percentage of alcohol of total energy consump-
tion, fasting C-peptide levels, glucose insulin ratio, age and
gender were not significant themselves and altered neither
the coefficient estimates nor the P-values significantly (data
not shown). We did not test drugs as a confounder, as only
one AIP case received a porphyrinogenic drug.
Prealbumin, kidney function, C-peptide, insulin and
porphyrin precursor levels in symptomatic and
asymptomatic cases with acute intermittent porphyria
Serum prealbumin levels (Fig. 4a) and kidney function meas-
ured as eGFR (Fig. 4b) were both significantly lower in symp-
tomatic compared to asymptomatic AIP cases. C-peptide (Fig.
4c) and insulin levels (Fig. 4d) after an overnight fast were sig-
nificantly lower in the symptomatic AIP cases compared to
their matched controls. The glucose/insulin ratio (Fig. 4e) and
plasma visfatin levels (Fig. 4f) were increased significantly in
symptomatic AIP cases compared to matched controls. In
comparison, plasma glucagon levels were decreased in both
asymptomatic and symptomatic AIP cases compared to their
controls (data not shown). Levels of U-ALA and U-PBG were,
as expected, increased significantly in both symptomatic and
asymptomatic AIP cases (Fig. 4g,h). The number of symptoms
in AIP correlated negatively with kidney function and pre-
albumin levels, but were not correlated significantly with the
inflammatory markers (data not shown).
Discussion
This study found evidence of higher levels of systemic
inflammation in AIP cases than in controls matched for
Asymptomatic AIP (AAIP)
Symptomatic AIP (SAIP)
No symbol = Controls (CTRL)
AIP mutation R167W
Rheumatoid arthritis
Fig. 2. Hierarchical cluster analysis of cytokines in acute intermittent porphyria (AIP) cases and matched controls. The cytokine levels in each
AIP case and matched controls were divided on the median levels of each cytokine in the 50 matched controls. The matrix results were then
transformed using natural logarithm. The ln expression levels of individual cytokines are represented by a colour scale, with high values in red,
intermediate levels in white and low cytokine levels in blue. The cluster analysis was performed using R with Euclidian distance and complete
clustering. The main clusters of AIP cases and controls are named (a) and (b), and the subclusters are named (a1), (a2), (b1) and (b2) on the
dendrogram. The cytokines clustered into three clusters named 1, 2 and 3. The mean ln expressions of all the cytokines levels are given as box-
plots below the dendrogram. The age in years, gender, U-porphobilinogen (U-PBG) and U-ALA ratio expressed as mmol/mmol creatinine, pre-
albumin (g/l) and the relative estimated glomerular filtration rate (eGFR) Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) (ml/
min/173 m2) based on cystatin C levels, are shown as a bar graphs below the heatmap for each AIP case and control. Asymptomatic (open
circles) and symptomatic (filled circles) AIP cases are indicated below the heatmap, those with the R167W mutation are indicated with
underscored symbols.
Systemic inflammation in AIP
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age, sex and place of residence. Virtually all inflammatory
markers, including cytokines, chemokines and growth fac-
tors, were elevated significantly in individuals with AIP
compared with the matched controls. Many AIP cases had
cytokine levels above the reference ranges in the 42 healthy
controls. Furthermore, levels of several inflammatory bio-
markers were correlated with the U-PBG ratio, a biomarker
of AIP disease activity. AIP disease activity was associated
with decreased insulin levels.
The association we found between AIP and inflamma-
tion may have several explanations. One probable explana-
tion for the increased levels of the proinflammatory
cytokines such as TNF and IL-1b, the latter reflecting
inflammasome activation [23], may be the accumulation of
DAMPs [14,23]. Possible DAMPs candidates in AIP might
be ALA, PBG and/or various porphyrins, in addition to tis-
sue injury (Fig. 5). As uric acid, and especially uric acid
crystals, are well-known inflammatory stimuli, we cannot
rule out totally that they may play a role as DAMPs in AIP
cases. DAMPs may stimulate immunocompetent cells
either directly by binding to receptors on the immune-
competent cells [12,14,23], or secondarily through proin-
flammatory, organ damage-related complement or
immune cell activation [15,16]. By analogy, diabetes melli-
tus is another metabolic disease in which DAMPs including
glucose, cholesterol and fatty acids are known to be
involved in insulin resistance and kidney failure [13]. The
reduced insulin levels and slightly enhanced HbA1c and tri-
glyceride levels we found in AIP cases may be due to tissue
damage, and indicate that DAMPs play a similar role in
AIP to the role they are known to play in diabetes. Given
the reduced insulin levels we found in symptomatic AIP
cases – accompanied presumably by reduced cellular glu-
cose uptake, reduced negative feedback on ALAS1 and
enhanced haem synthesis and release of ALA and PBG – it
seems reasonable to argue that symptomatic AIP seems to
be associated with disturbed glucose metabolism.
Fig. 3. Correlation matrix of porphyrins and precursors, biomarkers of inflammation and kidney function. The data in the left lower part are
Spearman’s correlation coefficients, r, in the acute intermittent porphyria group (n 5 50), r 028 and r2028 (blue colour). The pairwise
correlation between the different variables is depicted. The corresponding significant P-values (P< 005) are indicated by red colour in the upper
right part. The following variables were included: urine porphobilinogen ratio (PBG); urine 5-aminolevulinic acid ratio (ALA); uroporphyrin
(Urop.); total porphyrins (Total p.); serum cystatin C (Cyst. C); plasma long pentraxin 3 (PTX3); interleukin (IL)-7 and -9; chemokine ligand
(CCL) 3, 4 and 11; serum immunoglobulin A (IgA); blood (B) monocyte count (Monoc.); serum C3bc/C3 ratio (C3bc/C3); the plasma levels of
the terminal complement complex (TCC); complement C3 and C4.
Table 3. Multiple linear regression of *U-PBG (lmol/mmol creati-
nine), model R2 5 0308
‡B 95% CI P-value
*P-long pentraxin-3 0591 0054 to 1129 0032
†Relative eGFR CKD-EPI 20014 20028 to 20001 0036
S-Prealbumin 25085 211357 to 1188 0110
The data are regression coefficients, B, in the acute intermittent
porphyria cases (n 5 50). *Ln-transformed. †Relative estimated glo-
merular filtration rate (eGFR) calculated using the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) cystatin C equation.
‡B 5 regression coefficients; CI 5 confidence interval.
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The hierarchical cluster analysis of cytokines indicated
that many of the AIP cases with the highest levels of several
cytokines, especially IL-17, PDGF-BB, IL-10 and IL-15, also
had high biochemical disease activity measured by U-PBG
and ALA. Gender, age, kidney function and prealbumin
could not explain the distribution of AIP cases into clusters
(a) and (b). The increased visfatin levels in AIP cases in
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adipose tissue in the inflammation observed in these cases.
The AIP cases with the most elevated cytokines clustered
together with controls with inflammatory diseases, e.g.
untreated rheumatoid arthritis and ankylosing spondylitis.
IL-17 was the cytokine with the highest relative fold
increase in the AIP cases and was also identified in the
most highly expressed cytokine cluster in the cluster analy-
sis. IL-17 is a proinflammatory cytokine derived from type
17 helper T cells and natural killer cells and is involved in
the Th17 response in several chronic inflammatory condi-
tions [24]. IL-1b, IL-6 and TNF, which are involved in the
development of Th17 cells, were also elevated significantly
in the AIP cases [24]. IL-2 and IFN-g, which are involved
in Th1 responses, were increased moderately in the AIP
cases and were also identified in cytokine cluster 2. In com-
parison, IL-5 and IL-13, which are involved in Th2
responses were only slightly elevated in the AIP cases and
were located in cytokine cluster 3. The inflammatory cyto-
kine response in a cluster of AIP cases therefore appears to
be dominated by a Th17 response similar to other chronic
inflammatory conditions, such as rheumatoid arthritis and
multiple sclerosis.
Complement plays an essential role in the innate immu-
nological recognition of DAMPs. Frimat et al. showed that
Fig. 4. Prealbumin levels, kidney function, C-peptide, insulin and glucose/insulin ratio, visfatin and porphyrin precursor levels in asymptomatic
(Asympt.) and symptomatic (Sympt.) acute intermittent porphyria (AIP) cases compared with controls (Ctrl). (a) Serum prealbumin levels (g/l),
(b) relative eGFR (estimated glomerular filtration rate) Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) (ml/min/173 m2), (c)
plasma C-peptide (pg/ml), (d) plasma insulin (pg/ml), (e) glucose/insulin ratio (mmol/l/pg/ml), (f) plasma visfatin levels (pg/ml), (g) urine
delta-amino levulinic acid (ALA, mmol/mmol creatinine), (h) urine porphobilinogen (PBG, mmol/mmol creatinine), in asymptomatic (Asympt.)
and symptomatic (Sympt.) acute intermittent porphyria cases compared with their respective matched controls (Ctrl). Prealbumin, cystatin C, C-
peptide, insulin and visfatin were analysed using immunoassays. Glucose, ALA and PBG were analysed using standard biochemical assays. The
results from the age- and sex-matched controls (n 5 50; of these 35 were controls for the symptomatic cases) and the cases with AIP (n 5 50, 35
symptomatic) are shown as scatter-plots with the median. The paired data were analysed using the Wilcoxon’s matched-pairs signed-rank test.
The asymptomatic and symptomatic AIP cases were compared using the Mann–Whitney U-test.
3
Fig. 5. Possible pathways from increased ALA, PBG and porphyrins to increased cytokines. Increased levels of delta-aminolevulinic acid (ALA),
porphobilinogen (PBG) and porphyrins from the liver of acute intermittent porphyria (AIP) patients may cause tissue damage in several tissues,
including the nervous system, the liver itself, pancreas and kidneys. Reduced prealbumin indicates inflammation in the liver, and reduced eGFR
(estimated glomerular filtration rate) is due to kidney damage. Reduced insulin and C-peptide secretion from the pancreas may be due to
reduced hormone secretion or organ damage. Organ damage may activate complement measured as increased levels of the terminal complement
complex (TCC) and C5a, which activates cells to release cytokines, interleukins and growth factors. Another pathway of cytokine release may
possibly be the release of damage-associated molecular patterns (DAMPS) from damaged cells including uric acid crystals in gout due to reduced
kidney function which activate directly or indirectly immune cells to release cytokines, interleukins and growth factors. Whether enhanced levels
of ALA, PBG and porphyrins may act as DAMPS themselves remains to be elucidated. Other inflammatory stimuli due to smoking and dietary
factors, etc. may also activate cells to release cytokines.
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haem, which consists of protoporphyrin IX and iron, acti-
vates the alternative complement pathway in serum and on
endothelial surfaces [15]. It is well known that complement
activation, in particular through the release of C5a, induces
cytokine release in immune-competent cells [25]. We
observed enhanced complement activation consistently in
the AIP cases revealed by increased levels of C3bc and
C3bc/C3 ratio in plasma. Thus, we provide new evidence
that the complement system may also play a hitherto
unrecognized role in the pathophysiology of AIP. The
inflammatory response in AIP may be due partly to dam-
age in the liver, kidney or other organs induced by ALA,
PBG or porphyrins [12]. Organ damage and cell death may
activate complement, leading to immune cell activation
and cytokine release similar to the complement activation
during sterile inflammation, e.g. myocardial infarction
[23,25]. Consistent with this, the AIP disease activity
marker U-PBG was correlated with the kidney function
biomarker cystatin C, TCC levels and the C3bc/C3 ratio;
the last two are indicators of ongoing complement activa-
tion. The negative correlation between C3, C4 and the lev-
els of ALA, coproporphyrin and uroporphyrin in urine
may be due to complement activation with consumption
of C3 and C4 or liver damage with reduced synthesis of C3
and C4. However, the increases in serum ALT reflecting
liver cell damage and plasma C3bc levels reflecting comple-
ment activation were modest in the cases with AIP com-
pared with the controls, suggesting that other additional
mechanisms are probably involved.
The multiple linear regression analyses showed that PTX3
was associated independently with AIP biochemical disease
activity. This association of AIP with smouldering inflamma-
tion might provide pathophysiological insights into the long-
term consequences of AIP, including the enhanced risk of
HCC and chronic kidney disease. PTX3 is produced by
innate immune cells such as granulocytes, macrophages and
dendritic cells and is involved in inflammation, arteriosclero-
sis and tissue repair [26]. PTX3 is a pattern recognition mol-
ecule able to interact with several complement proteins,
including binding to C1q, which leads to activation of the
classical pathway. As PTX3 was correlated with enhanced dis-
ease activity, enhanced complement activation and decreased
kidney function, we speculate that PTX3-induced comple-
ment activation may be involved in the organ damage and/or
tissue repair observed in the AIP cases [26]. Therefore, our
data indicate that PTX3 may play a key role in the low-grade
inflammation observed in the AIP cases. However, as the
data set included 50 AIP patients, the results of the multiple
linear regression analysis must be confirmed in larger studies.
In this study, we held the number of variables in the multiple
regression model low because of the limited number of cases
and because it is highly probable that several of the cytokines
expressions are inter-related. Furthermore, we cannot exclude
an unknown confounder that we have not taken into account
in the multiple linear regression analyses.
Our data indicate that the basal level of inflammation
might be a driving factor in disease development. First,
many AIP cases had cytokine levels above the reference
ranges in the healthy controls. Secondly, the PTX3 level was
associated independently with disease activity in the multi-
ple regression analysis. Thirdly, this study indicates that
low-grade inflammation is associated with enhanced bio-
chemical disease activity in AIP. Furthermore, inflamma-
tion induced by bacterial and viral infections may provoke
acute attacks in AIP. We speculate that this low-grade
inflammation may be involved in the development of organ
damage, HCC, reduced kidney function and enhanced dis-
ease activity in some of the AIP cases. The decreased kidney
function in AIP was shown previously to be associated
with the development of tubulointerstitial nephropathy
and focal cortical atrophy with progressive arteriosclerosis
in the kidney [27]. The prevalence of HCC is high among
AIP patients [3,6], but the mechanism(s) of carcinogenesis
in AIP are unknown. HCC usually arise in a diseased liver
with a dynamic inflammatory microenvironment. Several
growth factors, including FGF, PDGF and VEGF, may act
as possible pro-angiogenetic factors secreted by stromal
cells after chronic liver injury, and IL-17 may be involved
in tumour progression [28]. In this study, we determined
that several of these cytokines and growth factors were ele-
vated outside attacks, also compared with the reference
ranges, and we therefore speculate that they may be
involved in HCC development in AIP patients. However,
other mechanisms may also possibly explain the enhanced
risk of HCC in AIP patients, including the direct or indi-
rect carcinogenicity of ALA [3].
Immune-competent cells in the liver may also contribute
to inflammation in AIP. The innate hepatic immune system
plays a role in defence against infection, liver damage and
repair [29]. Furthermore, prealbumin levels correlated neg-
atively with the number of symptoms (data not shown)
and with several inflammatory variables. In line with this,
prealbumin levels were decreased in symptomatic AIP
cases, due most probably to inflammation in the liver. The
level of prealbumin correlated negatively with levels of the
AIP disease activity biomarker U-PBG, confirming that
hepatic inflammation is important in the pathophysiology
of AIP [18]. It is unlikely that these lower prealbumin levels
relate to impaired nutritional status in AIP cases, as BMI
and nutritional intake (data not shown) were similar in
both groups. Dowman et al.’s finding that two of three liver
graft recipients from a patient with AIP developed AIP
symptoms and increased U-PBG levels suggests that AIP
symptoms are derived only from metabolites from the liver
[30]. The finding that liver transplantation is a cure for
AIP and normalizes the excretion of ALA and PBG con-
firms this hypothesis [10]. Both porphyrins or porphyrin
precursors from the liver may thus induce inflammation
and organ damage and mediate the symptoms in AIP.
However, most inflammatory biomarkers and cytokines
Systemic inflammation in AIP
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were not correlated with ALA, U-PBG or porphyrin levels,
suggesting that the direct activation of immune-competent
cells by porphyrins and porphyrin precursors may only
partially explain our results. It thus remains to be eluci-
dated whether enhanced levels of ALA, PBG and porphyr-
ins may act as DAMPs themselves in AIP.
The inflammation found in AIP patients may also be
due to ALA, PBG and porphyrin-induced free radical
release, and consequent cytokine release [17,31,32]. Free
radicals may stimulate inflammation through direct activa-
tion of the transcription factor nuclear factor kappa B (NF-
jB), leading to the release of IL-6, IL-8 and other cytokines
[23]. The role of free radicals in the AIP-associated inflam-
mation should be examined in future experimental and
clinical studies. Furthermore, the cytokine profile during
AIP attacks and in other AIP mutations should be
addressed in future studies.
Because the activation of adaptive immunity also stimu-
lates cytokine release, we searched for autoimmune diseases
and examined the levels of different autoantibodies in the
AIP cases and controls. No significant differences were
found in the frequency of inflammatory diseases and anti-
inflammatory medications between the controls and cases
with AIP, indicating that autoimmunity and adaptive
immunity responses do not account for the inflammatory
response. However, the prevalence of gout was enhanced
non-significantly in AIP cases. Furthermore, the reduced
baseline kidney function in the symptomatic AIP patients
might have had an impact upon the levels of some cyto-
kines. The accumulation of uric acid and other metabolites
in kidney failure may induce inflammation. Reduced kid-
ney function has been shown to increase haem synthesis
and the excretion of ALA and PBG in porphyric mice [33].
This is in line with our finding that reduced kidney func-
tion was the only confounding factor that predicted the
biochemical disease activity in the AIP cases.
In conclusion, in this first study of its kind, to our
knowledge, we found that numerous inflammatory
markers, including all 27 cytokines measured, were
increased in individuals with AIP compared with matched
controls, and that several of these correlated with the bio-
marker of disease activity U-PBG. Taken together, these
two findings point towards a new pathophysiological
mechanism in AIP. Our results suggest that probable por-
phyrin/precursor-related hepatic damage may drive inflam-
mation in AIP. The fact that symptomatic AIP cases also
had evidence of reduced insulin release may indicate that
decreased glucose uptake into cells may explain accelerated
haem synthesis in at least some AIP cases. This metabolic
similarity between diabetes mellitus and AIP, both of which
show decreased insulin release and low-grade inflamma-
tion, could usefully be studied further. In particular, the
effect of treatment with a high carbohydrate intake and a
small dosage of insulin in symptomatic AIP patients to
lower the disease activity and prevent attacks should be
examined in future studies.
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Supplementary Table 1.  Cytokine levels in the AIP cases in cluster (a) and (b) 
AIP cases 
in cluster (a) 
AIP cases 
in cluster (b) 
P-value §Fold- 
change 
Age (years) 47 (42-57) 56 (30-70)    0.23 1.2 
Ub-PBGc (µmol/mmol creatinine) 2.7 (0.6-7.1) 2.4 (0.9-12.3) 0.43 1.1 
U-ALA (µmol/mmol creatinine) 3.8 (1.9-6.5) 4.0 (2.6-9.0) 0.42 1.1 
S-Prealbumin (g/L) 0.26 (0.22-0.29) 0.26 (0.23-0.31) 0.44 1.0 
Relative eGFRd CKD-EPI,
(ml/min/1.73 m2)
83 (67-105) 85 (58-98) 0.77 1.0 
Pf-Visfatin (pg/ml) 587 (406-666) 1479 (800-2164) 0.0001 2.5 
Pf-IL-1βe (pg/ml) 0.86 (0.81-0.95) 3.0 (1.9-4.3)	 <0.0001 3.5 
Pf- IL-1RAe (pg/ml) 18 (8.4-28) 154 (99-286) <0.0001 8.5 
Pf-IL-2e (pg/ml) 0.72 (0.02-1.8) 14 (6.0-20) <0.0001 19 
Pf-IL-4e(pg/ml) 1.0 (0.2-1.0) 3.0 (2.0-5.0) <0.0001 3.0 
Pf-IL-5e (pg/ml) 1.3 (0.9-1.4) 3.0 (1.7-5.0) <0.0001 2.3 
Pf-IL-6e (pg/ml) 1.6 (0.9-2.8) 9.0 (5.0-14) <0.0001 5.6 
Pf-IL-7e (pg/ml) 4.5 (2.3-6.8) 11.0 (6.8-19) <0.0001 2.4 
Pf-CXCL8g (pg/ml) 5.0 (4.0-6.0) 12. (8.0-18) <0.0001 2.4 
Pf-IL-9e (pg/ml) 7.5 (4.3-10.9) 19 (15-27) <0.0001 2.5 
Pf-IL-10e (pg/ml) 0.13 (0.02-0.73) 4.0 (1.8-9.0) <0.0001 31 
Pf-IL-12(p70)e (pg/ml) 5.5 (1.6-9.0) 22 (14-36) <0.0001 4.0 
Pf-IL-13e (pg/ml) 2.6 (2.0-4.8) 6.0 (4.0-12) 0.0002 2.3 
Pf-IL-15e (pg/ml) 0.009 (0.005-0.1) 4.0 (1.9-8.0) <0.0001 444 
Pf-IL-17e (pg/ml) 2.0 (0.02-5.8) 45.0 (18-80) <0.0001 23 
Pf-CCL2g (pg/ml) 13.5 (10.0-19.0) 19.0 (13.0-23.5) 0.0276 1.4 
Pf-CCL3g (pg/ml) 2.0(0.89-2.0) 5.0 (3.0-7.3) <0.0001 2.5 
Pf-CCL4g (pg/ml) 48.5 (34.0-60.0) 66.0 (51.8-76.2) 0.0044 1.4 
Pf-CCL5g (pg/ml) 142 (103-378) 7504 (1929-14215) <0.0001 53 
Pf-CCL11g (pg/ml) 55 (44-72 92 (77-120) <0.0001 1.7 
Pf-FGF basic (pg/ml) 10 (4.5-13) 64 (35-96) <0.0001 6.4 
Pf-G-CSF (pg/ml) 3.5 (1.4-7.8) 67 (35-108) <0.0001 19 
Pf-GM-CSF (pg/ml) 4.0 (0.1-7.8) 27 (16-40) <0.0001 6.8 
Pf-IFN-γ (pg/ml) 6.8 (2.2-24) 226 (107-359) <0.0001 33 
Pf-CXCL10 (pg/ml) 837 (540-992) 1071 (801-1258) <0.0259 1.3 
Pf-TNF (pg/ml) 7.5 (4.8-16) 70 (41-116) <0.0001 9.3 
Pf-VEGF (pg/ml) 5.5 (2.3-8.0) 26 (18-46) <0.0001 4.7 
Pf- PDGF-BB (pg/ml) 2.0 (0.1-5.0) 113 (26-293) <0.0001 57 
The data represent the median values and IQR. The data were analyzed using the Mann-Whitney U test 
on AIP cases (n= 20) in cluster (a) vs. the AIP cases (n = 30) in cluster (b) in the hierarchical cluster 
analysis. The P values are exact, two-tailed. §Fold-change, median value in cluster (b)/median value in 
cluster (a). aAIP, acute intermittent porphyria; bU, urine; cPBG, porphobilinogen; dS, serum; eIL, 
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A B S T R A C T
Background: Lifestyle factors, including a low intake of carbohydrates, dieting, alcohol consumption, cigarette
smoking and stress are some of the possible triggers of attacks in acute intermittent porphyria (AIP). The in-
fluence of lifestyle factors, including energy intake, diet and alcohol consumption on the biochemical disease
activity in AIP and biochemical nutritional markers were examined.
Methods: A case-control study with 50 AIP cases and 50 controls matched for age, sex and place of residence was
performed. Dietary intake was registered using a food diary in 46 matched pairs. Symptoms, alcohol intake,
stress and other triggering factors of the last AIP attack were recorded on questionnaires. Porphyrin precursors,
liver and kidney function markers, vitamins, diabetogenic hormones and other nutritional biomarkers were
analyzed by routine methods. The Wilcoxon matched-pairs signed rank test was used to compare the cases vs.
controls. The Spearman's rank correlation coefficient was used on the cases.
Results: Increasing total energy intake was negatively correlated with the biochemical disease activity. The
intake of carbohydrates was lower than recommended, i.e., 40 and 39% of total energy intake in the AIP cases
and controls, respectively. The plasma resistin level was significantly higher (p= .03) in the symptomatic than
asymptomatic cases. Plasma insulin was lower in those with high porphobilinogen levels. The intake of sugar and
candies were higher in the AIP cases with low U-delta aminolevulinic acid (ALA) levels (p= .04). Attacks were
triggered by psychological stress (62%), physical strain (38%), food items (24%) and alcohol (32%) in the 34
symptomatic cases. Alcohol was used regularly by 88% of the cases (3.2 g ethanol/day) and 90% of the controls
(6.3 g/day), but the intake was significantly lower in symptomatic than in asymptomatic cases (p= .045).
Conclusion: A high intake of energy, sugar and candies and a higher insulin level were associated with a lower
biochemical disease activity. The resistin level was higher in the symptomatic than the asymptomatic cases. AIP
patients drink alcohol regularly, but the intake was significantly lower in the symptomatic cases.
Trial registration: ClinicalTrials.gov Identifier: NCT01617642.
1. Introduction
Acute intermittent porphyria (AIP) is an autosomal, dominant, in-
herited and rare metabolic disorder. The disease is caused by a muta-
tion in the hydroxymethyl bilan synthase (HMBS) gene, which encodes
an enzyme in the heme biosynthesis [1,2]. The prevalence of hetero-
zygous AIP mutations in the European population is between 1/75,000
to 10–20/100,000 [3,4], and about 600/100.000 in the Saltdal area in
Nordland County, Norway. A recent study has shown a higher pre-
valence of 1/1675 of the HMBS mutation in the general population in
https://doi.org/10.1016/j.ymgme.2018.12.006
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Europe [5]. AIP is typically asymptomatic, and approximately 90% of
those with AIP mutations never experience symptoms [2].
AIP symptoms may be triggered by mental or physical stress, al-
cohol, smoking, certain medications, infections or hormonal factors
[1–3]. Fasting and fever can also induce heme oxygenase activity; the
free heme pool is then reduced, and 5-aminolevulinic acid (ALA) syn-
thase-1 is induced [1]. Common symptoms during the acute neuro-
visceral attacks include abdominal pain, nausea, vomiting, constipa-
tion, dark red urine and muscle weakness [1,6]. Bulbar or phrenic nerve
paresis may occasionally lead to life-threatening respiratory failure
[1,7]. A high prevalence of hypertension and renal impairment has
been documented [4]. A few patients, mainly females, experience re-
current attacks. Patients who have a AIP gene mutation and have ex-
perienced symptoms of AIP are referred to as symptomatic AIP, while
those who never had symptoms are referred to as asymptomatic [1]. A
recent study by Lenglet et al. indicated oligogenic inheritance for AIP,
and this could be the reason why only a few patients are symptomatic
and why some are high and some are low excreters of ALA and PBG [8].
The first line of treatment is to remove any known triggering factor.
In hospital, intravenous infusion of glucose and/or of synthetic heme
can be administered [9]. The inhibiting effect of glucose on the heme
synthesis is probably related to peroxisome proliferator activated co-
factor 1α (PGC-1α) [10]. Liver transplantation cures AIP completely,
indicating that liver metabolism plays an important part in pathogen-
esis [11].
The dietary advice from the American Porphyria Foundation (APF)
to patients with AIP is to avoid prolonged fasting, and to have a car-
bohydrate intake of 55–60% of the total energy intake (E%). Further,
“The carbohydrates should preferably not include large amount of re-
fined sugars, but during less severe attacks intake of 300 g/day of
dextrose or other metabolizable carbohydrate is recommended.” The
Nordic Nutrition recommendations for the general population re-
commends a carbohydrate intake of 45–60 E% [12]. A recent national
diet survey (Norkost 3) showed that the average diet in Norway con-
sisted of 43–44 E% as carbohydrates [13]. Balwani et al. stated that a
“sustained adherence to a high-carbohydrate diet does not prevent at-
tack and is not recommended” [14]. Crash dieting and bariatric surgery
can precipitate porphyric attacks [15].
Ethanol may precipitate porphyric attacks in some, but not all
persons with AIP mutations, and they are advised to avoid alcohol
[16–18]. Smoking has been reported to be associated with a high fre-
quency of AIP attacks [19,20]. Low levels of vitamins and micro-
nutrients can influence overall health [12,21,22], and especially the
heme biosynthesis [23]. Repeated hemin infusions may have adverse
effects in AIP patients, possibly through a high iron load and in-
flammation [24]. Naik et al. reported that stress was a direct con-
tributor to attacks in 56% of the examined 16 AIP cases with recurrent
attacks [25].
Few studies have examined the role of the dietary intake of sugar,
total carbohydrates and other dietary factors on the disease activity in
AIP and simultaneously analyzing biochemical biomarkers. We hy-
pothesized that the total energy intake and intakes of carbohydrates,
sugar, alcohol, iron or diabetogenic hormones could be different in the
asymptomatic vs. the symptomatic AIP cases.
2. Methods
2.1. Participants and study design
A case-control study was conducted, comparing 50 AIP cases with
50 controls matched for age, sex and place of residence. Of these cases,
15 were asymptomatic and 35 were symptomatic. Most cases had the
AIP mutation W198X (n=48), while two patients had the R167W
mutation. The study was approved by the Regional Ethics Committee
for Medical and Health Research. We recruited all the participants from
September to November 2012, and all participants were examined
once. The controls were randomly selected from the registry of re-
sidents from the Norwegian Tax Administration. The exclusion criteria
for both groups were as follows: age under 18 or lacking competence to
provide consent to participate in the study. An additional exclusion
criterion for the AIP cases was absence of the AIP gene mutation, and
one person was excluded for this reason. The exclusion criteria for the
controls were also proven AIP or other porphyria, none were excluded.
Four members of the control group withdrew from the study im-
mediately before the study began and they were replaced by new
matched controls, while all AIP cases agreed to participate.
2.2. Recording of symptoms, triggering factors and diet
The cases with AIP were questioned by a medical doctor regarding
the presence or absence of AIP symptoms, the time of diagnosis, the
number and durations of attacks, and about triggering and relieving
factors during attacks. All participants were asked about their smoking
and alcohol habits, physical activity, emotional stress, medications,
nutritional supplements, present and chronic diseases and any surgeries
prior to the interview. The dietary intake was registered using a 7-day
diet logbook and was obtained from 46 cases and 46 matched controls.
Of the 35 symptomatic AIP cases, 34 filled out a diet log-book. A
clinical nutritionist instructed the participants on how to use the 7-day
diet logbook. The logbook was scanned using the Teleform program,
version 6.0 (Datascan, Oslo, Norway). Daily intakes of energy and nu-
trients were computed using the food database and software system
(KBS, version 7) developed at the Department of Nutrition, University
of Oslo. The food database (AE-10) is based mainly on the official food
composition table. Energy was calculated as (g carbohydrate× 17 kJ/
g)+ (g protein× 17 kJ/g)+ (g fat× 27 kJ/g)+ (g fiber× 8 kJ/g).
Resting metabolic rate (RMR) was calculated by Mifflin's formula, for
women: RMR (kcal)= 10×weight (kg)+ 6.25× height (cm) –
5× age (years) – 161; for men: RMR (kcal)= 10×weight
(kg)+ 6.25×height (cm) – 5× age (years). Energy requirement was
calculated multiplying RMR with a physical activity factor (PAL) [12].
The PAL factors for the participants were set by individual evaluation of
the description of their work and leisure physical activity. Energy re-
quirement was converted from kcal to kJ by ×4.184. Sugar was re-
garded as “added sugar” and did not include naturally occurring sugars.
Vitamin A was calculated as the sum of retinol and 1/12 beta-carotene.
Nutritional supplements were included in the dietary calculations. Se-
rial diastolic blood pressure was automatically measured over a
20–30min period, every second minute using a CAS 740 monitor (CAS
Medical Systems Inc., Branford, CT, USA). The body weight, length and
waist/hip-ratio were measured according to the WHO recommenda-
tions.
2.3. Blood sampling
Blood samples were obtained between 8 and 9 am by venipuncture
after an overnight fast. Vacuette citrate, EDTA and serum tubes were
used (Greiner Bio-one Gmbh, Frickenhausen, Germany). The EDTA
tubes for analyzing diabetogenic hormones in plasma were immediately
placed on crushed ice, centrifuged at 1500g for 15min at +4 °C, and
the plasma was stored at −80 °C until analysis.
2.4. Routine biochemistry tests
Hematology parameters were analyzed on a Siemens ADVIA 2120i
Hematology System (Siemens Healthcare Diagnostics Ltd., Camberly,
UK). Serum (S)-Na+, K+, Mg2+, creatinine, urine creatinine, S-iron and
other routine clinical chemistry parameters were analyzed on a
ADVIA®1800 system (Siemens Medical Solutions Diagnostics, Japan)
using reagents from Siemens Healthcare Diagnostics Ltd. The relative
estimated glomerular filtration rate (eGFR) was calculated using the
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) using
E. Storjord et al. Molecular Genetics and Metabolism 128 (2019) 254–270
255
the creatinine equation and expressed as ml/min/1.73m2 [26]. Serum
ferritin, folate and vitamin B12 were analyzed on a ADVIA Centaur® XP
system (Siemens). A BN ProSpec® nephelometer (Siemens Healthcare
Diagnostics Ltd.) was used to measure S-prealbumin and alpha-1 anti-
trypsin. Urine porphobilinogen (U-PBG) and U-ALA were analyzed
using a kit from Bio-Rad Laboratories (Munich, Germany). Total and
fractionated porphyrins were analyzed by high-performance liquid
chromatography (HPLC) as previously described [27]. Epinephrine,
norepinephrine and vanillylmandelic acid (VMA) in a random morning
urine sample were analyzed by HPLC using kits from Chromsystems
Instruments & Chemicals GmbH (Munich, Germany). Total 25-OH Vi-
tamin D were analyzed using kits from Chromsystems and an Ultimate
3000 HPLC system (Thermo Scientific, Waltham, MA, USA) equipped
with a TSQ Quantum Access MAX triple quadrupole mass spectrometry
detector.
2.5. Enzyme immunoassay
A Bio-Plex pro human diabetes 10-plex kit from Bio-Rad
Laboratories Inc. (Hercules, CA, USA) was used to measure plasma (P)-
insulin, visfatin, resistin and C-peptide in EDTA plasma on a Bio-Plex
200 system from Bio-Rad. The Enzygnost F1+2 (monoclonal) kit
(Dade Behring, Marburg GmbH, Germany) was used to analyze pro-
thrombin fragment 1+ 2 (PTF1.2) in EDTA plasma. Long-pentraxin 3
(PTX3) was analyzed by an enzyme-linked immunosorbent assay
(ELISA) kit from R&D Systems Inc. (Minneapolis, MN, USA). The optical
density was measured on a MRX microplate reader (Dynex
Technologies, Denkendorf, Germany).
2.6. Statistical analyses
The sample consisted initially of 50 cases with AIP and 50 controls
matched for age, sex and residence. The dietary data arise from
(n=46) AIP-cases and their 46 matched controls. When comparing
groups of AIP cases with high (> 1.5) and low (≤1.5 μmol U-PBG/
mmol creatinine) U-PBG levels and high (> 3.9) and low
(≤3.9 μmol U-ALA/mmol creatinine) ALA levels, we used data from all
47 AIP cases that had filled in the dietary logbook. We used the
Wilcoxon matched-pairs signed rank test on the matched case-control
data. The Spearman's rank correlation coefficient was calculated, giving
an r and two-tailed p. The Mann-Whitney U test was used on non-
matched data, i.e., on symptomatic vs. asymptomatic cases. The
Fischer's exact test was used on categorical variables. Statistical sig-
nificance was considered at p < .05. The statistical analysis was per-
formed using Prism version 6.0 from GraphPad Software Inc. (CA,
USA).
3. Results
3.1. Baseline characteristics of cases with acute intermittent porphyria and
matched controls
The baseline characteristics of the study population, which con-
sisted of AIP cases and controls matched for age, sex and place of re-
sidence, are shown in Table 1. Most variables were similar in the two
groups (Table 1). Of the 50 controls and 50 AIP cases, 6 and 10 persons,
respectively, were current smokers (p= .55) [26]. Of the 34 sympto-
matic AIP cases, 15% had experienced one AIP attack ever, and 85%
have had more than one porphyria attack. Some of them have had more
than twenty AIP attacks during their life. Of the 34 symptomatic cases
50% had been treated with glucose intravenously and 21% with Nor-
mosang intravenously, during their AIP attacks. None of the AIP cases
were under an AIP attack, and none were having glucose or Normosang
treatment at the time of study.
Overweight defined as BMI 25–29.9, was found in 52% of the AIP
cases and 38% of the matched controls. Similarly, 24% of the cases and
30% of the controls had obesity (BMI≥ 30). Of the 50 controls and 50
cases, 3 controls and 4 cases had diabetes mellitus. No significant dif-
ferences in the frequency of inflammatory diseases were observed, ex-
cept for a near-significant difference in the number of persons with gout
[26]. Statins were used by 7 AIP cases and 8 of their matched controls.
However, only 5 of 46 (11%) of the AIP cases had an adequate total
energy intake, i.e. 89% had a too low energy intake according to the
dietary logbook. Of the controls, 4 of 46 (9%) had an adequate total
energy intake, while 42 (91%) had a too low energy intake.
3.2. Dietary intake of carbohydrates, sugar, protein, fat and fatty acids in
cases with acute intermittent porphyria and matched controls
The dietary intake of carbohydrates as E% was similar, but lower
than the Nordic 2012 recommendations in 78% of the AIP cases and
91% of the controls (Fig. 1A). The intake of added sugar was similar
between the groups but was higher than the recommendations in 37%
of cases and 26% of the controls (Fig. 1B). The intake of protein
(Fig. 1C), fiber (Fig. 1D), total fat (Fig. 1E), saturated fatty acids (SFA,
Fig. 1F) and monounsaturated fatty acids (MUFA, Fig. 1G) was similar
in the cases and controls. However, the intake of fiber given as g/MJ
(Fig. 1D) was lower and the intakes of total fat and SFA given as E%
(Fig. 1E, F) were higher than recommended. The intake of poly-
unsaturated fatty acids (PUFA) was significantly lower (p= .04) in
cases than in the controls, and 15% of cases and 9% of controls had a
lower intake of PUFA given as E% intake than recommended (Fig. 1H).
3.3. Dietary intakes of vitamin D, calcium, vitamin B12, folate and the
corresponding serum levels in cases with acute intermittent porphyria and
matched controls
The intake of vitamin D was similar in the two groups, but below the
recommended 10 μg/day in 63% of the AIP cases and 54% of the
controls (Fig. 2A). The intake of calcium was insufficient in 65% of
cases and 50% of controls. The total S-calcium levels were within the
normal reference limits in 98% of cases and 96% of the controls. The
vitamin B12 intake was similar and sufficient in both groups (Fig. 1E),
and S-vitamin B12 levels were above the lower reference limit in both
cases and controls (Fig. 1F). One case and one control used vitamin B12
injections (Fig. 1F). In comparison, the intake of folate was lower than
recommended in 82% of cases and 78% of the controls, when con-
sidering men and postmenopausal women (Fig. 2G), and 88% of cases
and 78% of controls, when considering premenopausal women. How-
ever, only 8% of the controls had S-folate levels below the lower re-
ference limit (Fig. 2H).
3.4. Intake of vitamin supplements
Doctor-prescribed regular vitamin B12 injections and vitamin D
medications was used by 2% of cases and 2% of controls (App Table A).
Of the cases, 2% used isotretinoin (vitamin A), and 2% of controls used
magnesium supplements (App. Table A). Iron medication was taken by
6% of cases and 12% of the controls. Over-the-counter vitamin sup-
plements were taken by several cases and controls, including vitamin B,
vitamin D, multi vitamins, vitamin K and herbal remedies (Appendix
Table A).
3.5. Homocysteine levels, kidney function, calcium, albumin, parathyroid
hormone and porphobilinogen levels in asymptomatic and symptomatic cases
and matched controls
The homocysteine levels in plasma were significantly higher in the
symptomatic AIP cases compared to their matched controls, but were
similar in the asymptomatic cases and controls (Fig. 3A). The kidney
function given as eGFR was significantly lower (p= .0008) in the
symptomatic than in the asymptomatic AIP cases (Fig. 3B). Diastolic
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blood pressure was significantly higher in the symptomatic than in the
asymptomatic cases (Fig. 3C), while the U-epinephrine level was lower
(Fig. 3D). S-calcium and albumin were significantly lower (Fig. 3E, F)
and PTH levels in plasma were significantly higher (Fig. 3G) in the
symptomatic cases than in the asymptomatic cases. As expected, U-PBG
levels were significantly higher in the asymptomatic and symptomatic
cases compared with their respective matched controls (Fig. 3H).
Table 1
Baseline characteristics of the study population.
Characteristics Controls Cases p RIa
(Norway)
RDAb, AI (Am.)
25%ile Median 75%ile 25%ile Median 75%ile
Age, years 31.8 52 68 31.8 52 68.3 0.39
Height, cm 163 172 179 164 171 180 0.84
Weight, kg 71.5 80.3 91.4 69.4 81 92.3 0.6
BMI, kg/m2 23.8 26.8 30 25 27 29.8 0.92 20–25c 18.5–24.9c
Hip circumference, cm 93.9 98.8 106 93.9 99.4 107 0.75
Waist circumference, cm 89 94.6 104 89.3 94.8 106 0.84 ≤93/≤79d,e
Waist/Hip –ratio 0.9 0.97 1.01 0.88 0.98 1.02 > 0.99
RMRf Wg, kJ/day 5054 5448 6125 4971 5515 6268 0.67
Energy req.h, Wg kJ/day 9117 9690 10,933 7786 9590 11,343 0.45
Energy intake Wg, kJ/day 5532 7266 9001 5978 7141 7947 0.84
RMRf Mi, kJ/day 6335 7289 7540 6519 7234 7728 0.12
Energy req.h, Mi kJ/day 10,899 11,983 13,539 11,288 13,188 13,866 0.30
Energy intake Mi, kJ/day 7735 8988 11,111 8209 9383 12,058 0.53
RMRf all, kJ/day 5581 6318 7355 5535 6523 7397 0.40
Energy req.h, all, kJ/day 9786 11,016 12,426 9678 11,527 13,334 0.81
Energy intake all, kJ/day 6996 8367 10,621 7099 8162 10,763 0.72
Protein, g/day 65.6 80.6 105 68.8 77.6 98.9 0.92 56/46e
Fat, g/day 72 86.8 112 70 84.5 115 0.76
Saturated fat, g/day 29 36.8 43.9 28.7 36 47.6 0.38
C-MUFAjl, m, g/day 23 29.1 36.9 21.9 28.4 37.1 0.58
C-PUFAk, g/day 12.5 16.7 20.7 10.8 13.8 20.5 0.19
Cholesterol, mg/day 264 356 434 280 383 483 0.56
Carbohydrates, g/day 156 190 211 166 201 248 0.12 130
Sugar, g/day 27.3 36.6 50 30.7 42.8 56 0.18
Vitamin A, μg/day 645 929 1074 707 909 1160 0.25
Retinol, μg/day 515 701 893 568 750 945 0.31 900/700e 900/700e
B-carotene, μg/day 1194 1875 3104 1101 1728 2368 0.69
Tocopherol, mg/day 8.0 14.2 20.8 9.35 12.3 17.3 0.79 10/8e 15
Thiamin, mg/day 1.00 1.31 1.85 1.01 1.32 1.92 0.94 l 1.2/1.1e
Riboflavin, mg/day 1.27 1.55 2.42 1.26 1.66 2.52 0.77 m 1.3/1.1e
Vitamin B6, mg/day 1.03 1.44 2.13 1.12 1.49 2.32 0.67 1.5/1.2n 1.3n
Vitamin C, mg/day 44.8 63.5 145 51 73.5 134 0.72 75 90/75e
Fe, mg/day 7.8 9.4 14.4 7.7 9.8 14.3 0.48 9/15e,o 8/18e,p
Potassium, mg/day 2716 3537 4325 2637 3201 4108 0.49 3500/3100k 4700
Mg, mg/day 283 332 412 258 289 406 0.33 350/280 e 420/320q,e
Zn, mg/day 8.0 10.6 13.3 7.9 10.5 15.8 0.39 9/7e 11/8e
Se, μg/day 34.5 49.5 73.3 37.5 52.5 75.5 0.77 60/50e 55
Cu, mg/day 0.81 1.1 1.34 0.87 1.08 1.61 0.59 0.9 0.9
Phosphorus, mg/day 1147 1457 1733 1156 1392 1799 0.84 600r 700
Sugar, E%s 6.3 7.5 10.6 6.1 9.1 12.4 0.1 <10 <10
Alcohol, E%s 0 2.5 4.8 0 0.95 4.1 0.55 <5
The data represent median values and interquartile ranges; 25%ile and 75%ile. The data were analyzed using the Wilcoxon matched-pairs signed-rank test on the AIP
cases (n=46) versus matched controls on all data except age, height, weight, BMI, hip circumference, waist circumference and Waist/Hip-ratio (n=50) AIP cases
and 50 matched controls. Of the 46 matched pairs 20 are women and 26 are men. The p-values are exact, two-tailed.
a RI=Recommended intake, from Norwegian guidelines on diet, nutrition and physical activity, The Norwegian Directorate of Health, 2014.
b RDA=Recommended Dietary Allowance, AI=Adequate intake, from Dietary Guidelines for Americans. 8th Edition 2015–2020, January 2016, US Department
of Health and Human Services and US Department of Agriculture.
c Normal body mass index, BMI. For persons above 70 years (y): 22–27.
d Indicates low risk level metabolic disease.
e Men/Women.
f RMR, Resting metabolic rate calculated by Mifflin's formula.
g W=women.
h Energy requirement=RMR* PAL.
i M=men.
j C-MUFA=Cis-mono unsaturated fatty acids, kC-PUFA=Cis-poly unsaturated fatty acids.
l Thiamin: M: 1.4 mg/d for 18–30 y 1.3: 31–60 y, 1.2:> 60. W: 1.1 mg/d for 18–60 y, 1.0: > 60 y.
m Riboflavin; M: 1.6 mg/d for 18–30 y, 1.5: 31–60 y, 1.4: 61–74, 1.3:> 75 y, W: 1.3 mg/d for 18–30 y, 1.2 > 30 y.
n Vitamin B6 Nordic rec.: W > 60 y: 1.2, n Vitamin B6 American rec.: W > 51 y: 1.5, M > 51 y: 1.7.
o Iron, Women:> 61 y: 9.
p Iron, Women, American rec.> 51 y: 8.
q Mg: M:19–30: 400W:19–30 y: 310.
r P: 18–20 y: 700.
s E%=% of total energy intake.
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3.6. Intake of sugar/candies, carbohydrates, protein, meat and alcohol and
plasma resistin and alpha-1 antitrypsin levels in asymptomatic and
symptomatic cases and matched controls
The intake of sugar/candies and carbohydrates was not significantly
different between the symptomatic and asymptomatic AIP cases
(Fig. 4A, B). The median intake of protein was close to be significantly
different (p= .052) between the symptomatic and asymptomatic cases
(Fig. 4C). The intake of meat given as g/day was significantly lower in
the symptomatic than in the asymptomatic cases (Fig. 4D). The P-re-
sistin level were significantly higher (p= .03) in the symptomatic than
in the asymptomatic AIP cases and were significantly lower (p= .004)
in the asymptomatic cases than in their matched controls (Fig. 4E).
Interestingly, the intake of alcohol both given as g/day (Fig. 4G) and as
E% (Fig. 4F) was significantly lower in the symptomatic than in the
asymptomatic AIP cases. However, the alcohol intake was not sig-
nificantly different from the matched controls (Fig. 3E, F).
3.7. Alcohol intake, cigarette smoking and intake of carbohydrates, added
sugar and sugar/candies in acute intermittent porphyria cases with low and
high levels of porphyrin precursors
We next examined if lifestyle factors, including alcohol, cigarette
smoking and intake of carbohydrates and sugar/candies in the diet
were different in the AIP cases with low and high biochemical disease
activity. The intake of alcohol given as g/day (Fig. 5A) and E% (Fig. 5B)
was similar in the AIP cases with low and high U-PBG levels. The
number of cigarettes smoked per day (Fig. 5C), fat intake as E%
(Fig. 5D), carbohydrate intake as E% (Fig. 5E) and added sugar intake
as E% (Fig. 5F) were not different in the AIP cases with high and low U-
Fig. 1. The dietary intake of carbohydrates, added
sugar, protein, fiber, total fat, saturated fatty acids
(SFA), monounsaturated fatty acids (MUFA) and
polyunsaturated fatty acids (PUFA) in 46 acute in-
termittent porphyria (AIP) cases (Case) compared
with their matched controls (Control, n= 46). The
dietary intake of (A) carbohydrates, (B) added sugar,
(C) protein, (E) total fat, (F) saturated fatty acids
(SFA), (G) MUFA and (H) PUFA are expressed as % of
total energy intake, except for fiber intake (g/MJ).
The dietary intake was calculated from a seven-day
dietary logbook. The results are shown as scatter-
plots with the median. The two horizontal dotted
gridlines show the recommended intake (RI)-interval
for adults above 18 years for carbohydrate, protein,
fiber, total fat, MUFA and PUFA. The one horizontal
dotted gridline for added sugar and SFA indicates the
upper recommended intake level. All dietary re-
commendations in the figure are from the current
Norwegian guidelines on diet, nutrition and physical
activity. The data were analyzed using the Wilcoxon
matched-pair signed rank test. The p-values are
exact, two-tailed.
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PBG levels. Interestingly, the intake of sugar/candies given as g/day
(Fig. 5G) was significantly higher (p= .04) in the AIP cases with a low
U-ALA levels (Fig. 5G). However, the sugar/candies intake was not
significantly different in the AIP cases with low and high PBG levels
(Fig. 5H).
3.8. Meat intake and serum iron levels, folate intake and folate levels, and
creatinine and homocysteine levels in acute intermittent porphyria cases with
low and high levels of porphyrin precursors
The intake of meat given as g/day (Fig. 6A) and folate given as μg/
day (Fig. 6C) was similar in the AIP cases with low and high U-PBG
levels. The S-iron levels (Fig. 6B) were close to be significantly different
(p= .053) between the AIP cases with low and high U-PBG levels. The
intake of folate (Fig. 6C) and the S-folate levels (Fig. 6D) were similar in
the AIP cases with low and high PBG levels. However, the S-creatinine
(Fig. 6E) and P-homocysteine levels (Fig. 6F) were significantly higher
in the AIP cases with high U-PBG levels than in those with low PBG
levels.
3.9. Serum glucose, plasma insulin, glucose/insulin ratio, pre-albumin and
plasma C-peptide levels in acute intermittent porphyria cases with low and
high levels of porphyrin precursors
The glucose levels were similar in the AIP cases with low and high
U-PBG levels (Fig. 7A). The median plasma insulin level was sig-
nificantly (p= .02) higher (Fig. 7B) and the glucose/insulin-ratio
(Fig. 7C) was significantly lower (p= .02) in the AIP cases with low
compared to those with high U-PBG levels. The pre-albumin levels
(Fig. 6D) and plasma C-peptide levels (Fig. 6E) were similar in the AIP
cases with low and high U-PBG levels. The C-peptide levels were not
significantly different between the cases with low and high U-ALA
Fig. 2. Dietary intake of vitamin D, calcium, vitamin
B12 and folate and the corresponding serum (S) le-
vels in acute intermittent porphyria (AIP) cases and
matched controls. The intake of (A) vitamin D, (C)
calcium, (E) vitamin B12 and (G) folate in AIP cases
(n=46) was compared with their matched controls
(n=46). The dietary intakes were calculated from a
seven-day dietary logbook and expressed as μg/day,
except for the calcium intake (mg/day). The hor-
izontal dotted gridline shows the recommended in-
take (RI) for adults above 18 years for the following:
(A) vitamin D intake: 10 μg/day, but for persons>
75 years, the RI is 20 μg/day; (C) calcium intake:
800mg/day, but for persons 18–20 years, the RI is
900mg/day, and for postmenopausal women, a
supplement of calcium of 500–1000mg/day might
reduce age-related bone loss and (E) Vitamin B12
intake: 2 μg/day, (G) The RI for folate intake is
300 μg/day for postmenopausal women (open cir-
cles) and men (black squares). The upper horizontal
dot-line gridline in panel (G) shows the RI of folate
400 μg/day for women in fertile age (open triangles).
All dietary recommendations are from the current
Norwegian guidelines on diet, nutrition and physical
activity. The serum level of (B) total 25-OH vitamin
D was analyzed by liquid chromatography with
tandem mass spectrometry (LC-MS/MS) and ex-
pressed as nmol/l. The serum levels of (D) total
calcium (mmol/l), (F) S-vitamin B12 (pg/ml) and
(H) S-folate (nmol/l) were analyzed using standard
biochemical methods and expressed as mmol/l, pg/
ml and nmol/l, respectively. “The control and the
AIP case who received regular vitamin B12 injections
are marked as black dots.” The results are shown as
scatter-plots with the median. The horizontal dotted
gridlines indicate the reference limits for: (B) S-25
OH vitamin D total (50 nmol/l), (D) S-calcium
(2.15–2.55mmol/l), (F) S-vitamin B12 (150 pmol/l)
and (H) S-folate (7 nmol/l). The data were analyzed
using the Wilcoxon matched-pair signed rank test.
The p-values are exact, two-tailed.
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levels (Fig. 7F). The AIP cases (n= 2) who received anti-diabetic
medications are indicated with black dots (Fig. 7). When the p values
for the comparison of biomarkers in the AIP cases with low and high U-
PBG were calculated after the exclusion of those who received anti-
diabetic medication, the results were; S-glucose (p= .11) as before, P-
insulin (p= .04) and Glucose/Insulin-ratio (p= .04).
3.10. Porphyrin precursors, serum cholesterol, triglycerides and other
biochemical biomarkers in cases with acute intermittent porphyria and
controls
The levels of all porphyrins and porphyrin precursors were, as ex-
pected, significantly higher in the AIP cases than in the controls
(Table 2). The S-total cholesterol, S-LDL cholesterol, and S-triglyceride
levels were significantly higher in AIP cases than in the controls
(Table 2). The S-phosphate levels were lower in the cases than in the
controls (Table 2). The VMA levels in random urine samples were sig-
nificantly lower in the AIP cases than in the controls, but the levels of U-
norephinephrine and U-ephineprine were similar. All biomarkers of
iron deficiency, including hemoglobin and erythrocyte numbers, were
similar in the AIP cases compared to those of the controls (Table 2). The
S-CDT%, S-electrolytes and cortisol levels were similar in cases and
controls (Table 2).
3.11. Correlations between dietary intake, alcohol, smoking, biochemical
biomarkers of kidney and liver function, and porphyrin precursors in cases
with acute intermittent porphyria
The U-PBG levels correlated significantly and positively with P-
homocysteine, S-creatinine, PTX3, HDL and total cholesterol levels
Fig. 3. Levels of homocysteine, kidney function,
diastolic blood pressure, urine (U)-epinephrine,
serum (S)-calcium, S-albumin, plasma (P)-PTH and
U-porphobilinogen (U-PBG) levels in asymptomatic
(Asympt.) and symptomatic (Sympt.) acute inter-
mittent porphyria (AIP) cases (n=50) and matched
controls (Control, n= 50). The analytes were ana-
lyzed using standard biochemical methods. (A) P-
homocysteine is expressed as μmol/l, (B) relative
eGFR (estimated glomerular filtration rate) chronic
kidney disease (CKD-EPI) as ml/min/1.73m2 with
the creatinine equation, (C) diastolic blood pressure
as mm Hg, (D) U-epinephrine as nmol/mmol creati-
nine, (E) S-calcium as mmol/l, (F) S-albumin as g/l,
(G) P-PTH as pmol/l and (H) U-PBG as μmol PBG/
mmol creatinine. Serial diastolic blood pressure was
automatically measured over a 20–30min period,
every second minute using a CAS 740 blood pressure
monitor. The paired case-control data were analyzed
using the Wilcoxon matched-pair signed rank test.
The asymptomatic and symptomatic AIP cases were
compared using the Mann-Whitney U test.
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(Fig. 8). U-PBG levels correlated significantly and negatively with pre-
albumin, total energy intake and PUFA intake (Fig. 8). In comparison,
U-ALA correlated significantly and negatively with S-pre-albumin and
sugar/candies intake (Fig. 8). U-ALA correlated significantly and posi-
tively with smoking given as cigarettes smoked/day (Fig. 8). Further-
more, the inflammatory marker PTX3 correlated significantly and ne-
gatively with the carbohydrate intake given as g/day, but not with
carbohydrates as E% (Fig. 8). As expected, the alcohol intake correlated
positively and significantly with the CDT% (data not shown).
3.12. Correlations between biomarkers of glucose metabolism, diabetogenic
hormones and biomarkers of disease activity in cases with acute intermittent
porphyria
The porphyrin precursor U-PBG correlated positively and
significantly with U-ALA and S-iron levels (Fig. 9). U-ALA correlated
significantly and positively with S-cortisol levels (Fig. 9). Both U-PBG
and U-ALA correlated with P-PTF1.2 levels. B-reticulocytes, P-leptin, P-
ghrelin and P-resistin also correlated positively and significantly with
PTF1.2 levels (Fig. 9). Furthermore, resistin and U-VMA showed a po-
sitive correlation. Plasma resistin levels in the cases were not correlated
with BMI (data not shown). As expected, S-glucose correlated sig-
nificantly and positively with HbA1c levels (Fig. 9).
3.13. Triggering factors for attacks and symptoms in cases with acute
intermittent porphyria
The most frequent AIP symptoms and signs were abdominal pain
(91%), dark/red urine (80%), tiredness (71%), muscle ache (60%) and
muscle weakness (60%), followed by vomiting, headaches, decreased
Fig. 4. Dietary intake of sugar and candies, carbo-
hydrates, protein, meat, alcohol and urine-porpho-
bilinogen (U-PBG) levels in asymptomatic (Asympt.)
and symptomatic (Sympt.) acute intermittent por-
phyria (AIP) cases and matched controls (Control).
(A) Intake of sugar and candies is given as g/day, (B)
carbohydrate intake as g/day, (C) protein intake as
g/day, (D) meat intake as g/day, (E) P-resistin as pg/
ml, and the AIP cases and controls who received anti-
diabetic medications are indicated by black dots, (F)
S-alpha-1 antitrypsin as g/l, (G) alcohol intake as g/
day and (H) alcohol intake as % of total energy in-
take. The dietary intake was calculated from a seven-
day dietary logbook from 46 matched pairs, i.e., 12
asymptomatic and 34 symptomatic cases and 12 and
34 matched controls. S-alpha-1 antitrypsin was
analyzed using standard biochemical methods and P-
resistin was analyzed using a Diabetes 10-plex assay
in 15 asymptomatic and 35 symptomatic cases and
matched controls. The paired case-control data were
analyzed using the Wilcoxon matched-pair signed
rank test. The asymptomatic and symptomatic AIP
cases were compared using the Mann-Whitney U
test.
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awareness, palpitations, psychological symptoms, constipation, paresis
and epilepsy (Table 3). The most prevalent triggering factors for por-
phyric attack in the AIP cases were psychological stress (62%), followed
by work environment (41%), which was described in most cases as
stress at work or stressful working (Table 3). Physical strain were the
third most prevalent trigger (38%), followed by other diseases in-
cluding infections, sleep deprivation, food items, hunger, alcohol,
dieting and medications. Cigarette smoking was a triggering factor in 6
% of the symptomatic AIP cases. The menstrual cycle was a trigger for
17% of the attacks in female AIP cases. Of the asymptomatic and
symptomatic AIP males, 75% and 69%, respectively, had finished one
year of military service.
4. Discussion
To our knowledge, this is the first report that both analyzes the
dietary intake using a dietary logbook and simultaneously analyzes
biochemical nutritional markers and diabetogenic hormones in blood
samples in AIP cases and matched controls. The results indicate that the
intake of slow-release carbohydrates was lower, and the intakes of
sugar and saturated fatty acids was higher than recommended for the
Nordic countries, both in the AIP cases and controls. Vitamin D defi-
ciency was the most common vitamin deficiency in both the cases and
controls. The intake of alcohol was unexpectedly high in the AIP cases,
but lower in the symptomatic than in the asymptomatic cases. Insulin
was higher in the cases with low U-PBG levels. Plasma resistin levels
were higher in the symptomatic than the asymptomatic cases. These
Fig. 5. Lifestyle factors, including (A, B) alcohol in-
take, (C) cigarette smoking, (D) total fat intake, and
(E) intake of carbohydrates and (F) total sugar in
acute intermittent porphyria (AIP) cases with low
urine (U)-porphobilinogen (PBG) compared with AIP
cases with high U-PBG levels. (G) Intake of sugar and
candies in AIP cases with low (< 3.9) U-delta-ami-
nolevulinic acid (ALA) compared with AIP cases with
high U-ALA (> 3.9 μmol ALA/mmol creatinine), i.e.,
the reference limit for this assay. A low U-PBG level
was defined as values≤ 1.5 μmol PBG/mmol crea-
tinine, i.e., the reference limit for this assay. The
dietary components were calculated from a seven-
day dietary logbook. The results are shown as
scatter-plots with the median. The two horizontal
dotted gridlines on total fat intake (D) and carbo-
hydrate intake (E) indicate the recommended intake
(RI) range, and the horizontal dotted gridline (F) for
added sugar intake indicates the upper RI, as % of
total energy for adults above 18 years. All dietary
recommendations are from the current Norwegian
guidelines on diet, nutrition and physical activity.
The data were analyzed using the Mann-Whitney U
test. The P-values are exact, two-tailed.
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findings may have several explanations and implications.
The energy intake was sufficient in all AIP cases and controls since
the BMI results indicate that half of the AIP cases and about 4 out of 10
of the matched controls in this study were overweight. Similarly, 1 out
of 4 of the cases and 3 out of 10 of the controls had obesity in line with
the high and increasing frequency of obesity in Norway. However,
when the energy intake was calculated from the diet logbook, most
cases and controls had an insufficient energy intake. However, the
dietary intake is probably slightly (17%) underreported according to
unpublished data from a validation study of the 7- day diet log book
among adults (personal communication from A.M. Wetting Johansen,
the Department of Nutrition, Univ. of Oslo). Interestingly, an increasing
energy intake was negatively correlated with the U-PBG levels in the
AIP cases suggesting that the total energy intake affects the biochemical
disease activity also in periods with no dieting.
The intake of carbohydrates in most AIP cases and controls was
lower than the recommended 45–60 E% in Norway and other Nordic
countries [12,22] and in the US [21]. Thus, the AIP cases did not have a
high intake of slow-release carbohydrate foods, in line with a previous
report on 16 Spanish AIP cases [28]. In addition, the intake of added
sugar was higher than the recommended maximum 10% of total energy
intake in many AIP cases and controls, and this may lead to obesity. The
intake of sugar and candies was higher in those with low ALA levels
than in the group with high ALA levels, suggesting an effect of this
dietary factor on the biochemical disease activity. However, no differ-
ence in sugar and candies or carbohydrate intake was found between
the asymptomatic and symptomatic AIP cases. Finally, no significant
correlation was found between the intake of carbohydrates and disease
activity in the AIP cases, although a near significant correlation was
found between carbohydrate intake in g/day and U-PBG. This may be
due to a too low consumption of carbohydrates in the AIP cases, since
the carbohydrate intake in two previous studies were up to 500 g/day
[29,30], compared to a median intake of 201 g carbohydrates/day in
the cases in this report. However, the previous finding that the AIP
cases who acquired type 2 diabetes mellitus did not have symptoms of
AIP supports the protective role of elevated glucose levels [31]. Fur-
thermore, glucose reduced the synthesis of ALA and PBG in a mouse
model of AIP [10]. However, the plasma glucose level is regulated by
multiple hormones, including insulin, resistin, glucagon, cortisol and
catecholamines. A previous study indicated that the S-glucose level was
unchanged, but the fasting levels of insulin were higher and the glu-
cagon was lower in AIP mice than in wild-type mice [32]. We pre-
viously found that the fasting insulin levels were decreased in the
symptomatic AIP cases compared to the matched controls, but no dif-
ference was found between asymptomatic and symptomatic cases [26].
This report suggests that the fasting insulin was lower and the glucose/
insulin ratio was higher in the AIP cases with high compared to the
group with low U-PBG level. This finding, and the report by Handschin
et al. [10] indicating an inhibitory effect of insulin on porphyrin pre-
cursor levels in mice, suggests that glucose should be administered
together with insulin during porphyric attacks.
The higher resistin level in the symptomatic than the asymptomatic
cases, and the positive correlation with leptin levels may indicate that
inflammation [26], adipokines and hormones affecting insulin
Fig. 6. Intake of meat and folate and the serum (S)
levels of iron, folate, plasma (P) homocysteine and
kidney function markers in acute intermittent por-
phyria (AIP) cases with low U-porphobilinogen
(PBG) compared with AIP cases with high U-PBG.
Low U-PBG was defined as ≤1.5 μmol PBG/mmol
creatinine, corresponding to the upper reference
limit. The dietary components were calculated from
a seven-day dietary logbook including intake of (A)
meat and (C) folate. (B) S-iron, (D) S-folate, (E) S-
creatinine and (F) P-homocysteine levels were ana-
lyzed using standard biochemical assays and the re-
sults are shown as scatter-plots with the median. The
two horizontal dotted gridlines in panel B indicates
the reference values for S-iron (9–34 μmol/l) and
black dots indicate AIP cases who received iron
supplements. (C) The RI for folate intake is 300 μg/
day for postmenopausal women (open circles) and
men (black squares). The upper horizontal dot-line
gridline in panel (C) shows the RI of folate 400 μg/
day for women in fertile age (open triangles). All
dietary recommendations in the figure are from the
current Norwegian guidelines on diet, nutrition and
physical activity. The horizontal dotted gridlines in-
dicate the reference value for: (D) S-folate
(> 7 nmol/l), (E) S-creatinine in women (lower line,
90 μmol/l) and for men (upper line, 105 μmol/l), and
(F) P-homocysteine (> 15 μmol/l) and a black dot
indicates the AIP case who received B12 injections.
The data were analyzed using the Mann-Whitney U
test. The P-values are exact, two-tailed.
E. Storjord et al. Molecular Genetics and Metabolism 128 (2019) 254–270
263
resistance may possibly be involved in a high disease activity [33].
However, we have no explanation for these differences, but this
indicate that the role of hormones regulating glucose uptake such re-
quires further investigation. Acute inflammation can trigger AIP attacks
[1], but the inflammation observed as increased resistin levels found in
the AIP cases could be an effect of the AIP disease itself, since it was
observed in periods between attacks and outside acute inflammation.
Resistin activates TLR4 on macrophages and increases the release of
cytokines [34]. Furthermore, increased resistin levels is probably not an
effect of other inflammatory diseases, as we did not find enhanced
frequency in inflammatory diseases that could explain the difference in
cytokines [26]. On the other hand, the slightly higher frequency of
smoking, higher LDL levels and lower prealbumin levels indicating liver
inflammation in the AIP cases, may partly explain the enhanced in-
flammation [26]. Another possible pathway from AIP with increased
ALA, PBG and porphyrins to inflammation could be that ALA, PBG and
porphyrins cause tissue damage that creates elevated cytokines [26].
Additionally, damage associated patterns (DAMPS) such as elevated
uric acid due to reduced kidney function in some AIP cases could lead to
cytokine production [26].
The intake of fat, and especially saturated fatty acids, was higher
than recommended in both the AIP cases and controls and is associated
with enhanced risk of cardiovascular disease [35]. The higher choles-
terol levels in the cases can not be explained by a higher intake of SFA
in the AIP cases, since the intake of SFA was elevated in both groups.
Replacement of dietary saturated fats with PUFA normally reduces
cholesterol levels and the CVD risk [35], and the lower PUFA intake in
the AIP cases, may partly explain the higher total cholesterol and tri-
glyceride levels in the AIP cases than in the controls. The intake of
protein was within the national recommendations both in the AIP cases
and the controls. The fiber intake was similar but was lower than re-
commended in both AIP cases and controls, in line with a previous
report [28]. The intake of meat was lower in the AIP cases than in the
controls. This may have several reasons, but we speculate that this may
be due to the enhanced prevalence of reduced kidney function and
maybe gout [26] in the AIP cases since patients with gout are advised to
reduce the intake of purine-rich foods [36].
The intake of some vitamins, including vitamin D, was insufficient
in many AIP cases and controls, and vitamin D deficiency was common
in both groups. This may partly explain the enhanced PTH levels in
some AIP cases, although reduced kidney function may also increase
PTH levels [37]. Vitamin D deficiency is very common in Norway due
to insufficient dietary sources and a lack of sunlight in northern Norway
[38]. Vitamin D deficiency may have several negative effects, including
increased risk of osteoporosis [37]. S-iron was close to be significantly
higher in the AIP cases with high PBG levels, but iron deficiency was
rare in the AIP cases. The homocysteine levels were increased in the
symptomatic AIP cases compared to their matched controls, but this
was probably not due to a severe deficiency of folate or vitamin B12.
The increased homocysteine levels in the symptomatic cases was most
likely due to reduced kidney function since homocysteine and creati-
nine levels were highly and positively correlated. However, a deficiency
Fig. 7. Glucose, insulin, glucose/insulin ratio, pre-
albumin and C-peptide levels in acute intermittent
porphyria (AIP) cases with low U-porphobilinogen
(PBG) compared with acute intermittent porphyria
(AIP) cases with high U-PBG. (A) serum glucose le-
vels (mmol/l), (B) insulin (pg/ml), (C) glucose/in-
sulin ratio (mmol/l/pg/ml), (D) S-pre-albumin (g/l),
(E) C-peptide levels (pg/ml) in AIP cases with low
(n= 20) and high (n= 30) levels of porphyrin pre-
cursors in urine. The black dots in panels A, B, C, E
and F, indicate AIP cases who received anti-diabetic
medications. A low U-porphobilinogen (PBG) level
was defined as ≤1.5 μmol PBG/mmol creatinine,
i.e., the reference value in urine. (F) C-peptide levels
in AIP cases with low U-delta aminolevulinic acid
(ALA) defined as<3.9 μmol ALA/mmol creatinine
(n= 25). S-glucose and pre-albumin were analyzed
using standard biochemical assays, while the other
markers were analyzed using a Bio-PlexPro Human
Diabetes 10-plex immunoassay from Bio-Rad. The
results are shown as scatter-plots with the median.
The two horizontal dotted gridlines in panel (D) pre-
albumin are the normal reference values for men
(black squares) and for women>50 years (open
circles). For women<50 years (open inversed tri-
angles) the reference values are 0.23–0.39 g/l (dot-
line gridline). The data were analyzed using the
Mann-Whitney U test. The P-values are exact, two-
tailed.
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of vitamin B1 and B6 cannot be excluded since they were not measured.
The diastolic blood pressure and PTH was higher and S-albumin and
calcium were slightly lower in the symptomatic compared to the
asymptomatic AIP cases, probably also due to a reduced kidney func-
tion in the symptomatic AIP cases.
The use of alcohol in the AIP cases was much higher than expected,
and was higher than the generally recommended upper limit of 1 al-
cohol unit (12 g) per day in a few cases. However, the alcohol intake
was significantly lower in the symptomatic AIP cases than in the
asymptomatic cases. Since alcohol had triggered attacks in 32% of the
AIP cases in line with a previous study [18], we speculate that the
symptomatic cases reduced the intake to avoid attacks. No correlation
was found between the alcohol intake and disease activity. The finding
that most AIP cases in this study used moderate amounts of alcohol
regularly may indicate that a regular, but moderate intake of alcohol is
less porphyrinogenic than an acute intake of alcohol [17,39]. However,
the alcohol intake observed in both the AIP cases and controls, may
partially hide the real impact of alcohol in the AIP group. AIP cases are
advised to avoid alcohol. According to a WHO report from 2016, the
mean total alcohol intake per capita in Norwegian adults above
15 years age was 7.5 l pure alcohol per year, compared to 9.8, 9.8, 6.3
and 7.3 in the whole European region, the US, the African and the
Western Pacific Regions, respectively [40]. The mean total alcohol in-
take was 5.7 and 4.3 l per year in the controls for the asymptomatic and
symptomatic AIP cases, respectively, and 6.1 and 3.1 l in the asymp-
tomatic and symptomatic AIP cases, respectively. This indicates that the
alcohol intake in the cases was not high compared to the rest of Norway
and other countries. Furthermore, the alcohol habits vary between
different countries, and different individuals, and this should be kept in
mind when our results from Norway are being evaluated. It is well
known that alcohol is toxic to the liver and is associated with enhanced
risk of hepatocellular carcinoma (HCC) and liver cirrhosis [41].
Table 2
Biomarker levels in acute intermittent porphyria cases and controls.
Controls Cases p
25%ile Median 75%ile 25%ile Median 75%ile
U-ALAa, μmol/mmol creatinine 1.6 1.9 2.3 2.4 3.9 7.0 < 0.0001
U-PBGb, μmol/mmol creatinine 0.3 0.4 0.5 0.9 2.6 8.5 < 0.0001
U-Total porphyrins, nmol/mmol creatinine 4.4 6.8 11 8.5 26 83 <0.0001
U-Uroporphyrins, nmol/mmol creatinine 1 1.25 1.7 1.3 2.8 19.7 < 0.0001
U-Heptaporphyrins, nmol/mmol creatinine 0.2 0.3 0.5 0.3 0.7 1.3 < 0.0001
U-Hexaporphyrins, nmol/mmol creatinine 0.1 0.1 0.3 0.0 0.2 0.7 0.045
U-Pentaporphyrins, nmol/mmol creatinine 0.0 0.1 0.2 0.1 0.4 1.4 < 0.0001
U-Coproporphyrins, nmol/mmol creatinine 3.0 4.5 8.8 6.3 14 44 <0.0001
S-Total Cholesterol, mmol/l 4.6 5.1 5.7 5.1 5.7 6.4 0.002
S-LDLc-Cholesterol, mmol/l 2.3 3.1 3.7 3.0 3.5 3.9 0.02
S-HDLd-Cholesterol, mmol/l 1.3 1.5 1.8 1.1 1.4 1.8 0.50
S-Triglycerides, mmol/l 0.7 1.0 1.4 1.0 1.2 1.85 0.01
S-CDTe, % 1.2 1.4 1.7 1.3 1.5 1.6 0.49
B-Hemoglobin, g/dl 13.7 14.4 15.3 13.6 15.0 15.8 0.19
B-EVFf 0.40 0.42 0.45 0.41 0.43 0.47 0.08
Erc-MCVg, fl 85 87 91 86 89 93 0.18
Erc-MCHh, pg 29 30 31 29 30 32 0.57
B-EPKi, ×1012/l 4.6 4.9 5.1 4.7 5 5.3 0.25
Erc-Reticulocytes, % 0.8 0.9 1.2 0.8 1 1.2 0.47
Rtkc-CHrj, pg 32.6 33.7 34.7 32.7 33.9 35 0.71
Erc-Hypok, % 0.1 0.2 0.3 0.1 0.2 0.4 0.59
B-Platelets, ×109/l 224 266 299 194 243 287 0.05
S-Ferritin, μg/l 49 120 186 57 111 222 0.76
S-Iron, μmol/l 13 19 22 14 17 19 0.81
S-TIBCl, μmol/l 59 62 70 63 67 75 0.06
S-Soluble transferrin receptor, mg/l 1.0 1.2 1.5 1.0 1.23 1.5 0.70
S-Sodium, mmol/l 140 142 143 140 141 142 0.20
S-Potassium, mmol/l 4.1 4.2 4.4 4.2 4.3 4.5 0.11
S-Magnesium, mmol/l 0.85 0.90 0.93 0.88 0.91 0.96 0.31
S-Phosphate, mmol/l 0.99 1.13 1.25 0.87 1.06 1.21 0.03
S-Cortisol, nmol/l 385 460 587 406 549 584 0.45
U-Norepinephrine, nmol/mmol creatinine 12 16 23 9 14 20 0.09
U-Epinephrine, nmol/mmol creatinine 1.75 2.0 3.25 1.0 2.0 3.0 0.37
U-VMAm, μmol/mmol creatinine 1.1 1.6 2.1 0.8 1.3 1.9 0.01
The data represent the median values and interquartile range; 25 percentile (25%-ile) and 75 percentile (75%-ile).
Wilcoxon's matched-pairs signed-rank test was used on all case-control data in this table. N=50 matched pairs.




e S-CDT%=percentage of carbohydrate-deficient transferrin.
f B-EVF=Whole blood erythrocyte volume fraction.
g Erc-MCV=Erythrocyte mean corpuscular volume.
h Erc-MCH=Erythrocyte mean corpuscular hemoglobin.
i B-EPK=Whole blood erythrocyte-particle concentration.
j Rtkc-Chr=Reticulocyte hemoglobin content.
k Erc-Hypo=Percentage of hypochromic red cells.
l S-TIBC=Serum-total iron-binding capacity.
m U-VMA=Urine vanillylmandelic acid.
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However, in the study by Innala et al., none of the AIP cases developing
HCC were abusing alcohol [42]. This indicates that the general re-
commendation of no or a very low alcohol intake in AIP cases should be
continued.
Psychological stress and physical strain was reported as triggers of
attacks in 62% and 38%, respectively, of the symptomatic AIP cases.
This result is in line with the report by Naik et al. who reported that
56% of patients with acute hepatic porphyrias said that stress, mainly
emotional stress or caused by work, was a direct contributing factor to
their acute attacks [25]. Several stress hormones were analyzed in this
study, outside of AIP attacks, but only the levels of VMA were decreased
in the AIP cases compared to the controls. In comparison, the levels of
epinephrine and norepinephrine were similar in the cases and controls.
We have no explanation for these findings, but speculate that the ca-
techolamine release or VMA formation might be slightly decreased in
the AIP cases in periods outside attacks. Stress may also affect the levels
of stress hormones, which in turn affect the metabolism of glucose and
fat. A previous report by Pozo et al. showed reduced levels of urine
adrenal steroid hormones, including cortisol metabolites, in AIP cases
compared to controls [43]. In this report, S-cortisol levels were similar
in the AIP cases and controls, but urine metabolites of cortisol were not
examined.
This report indicates that 2%, 6% and 20% of the AIP cases used
porphyrinogenic, probably porphyrinogenic or possibly porphyrino-
genic medications, respectively. Furthermore, 29% of the symptomatic
cases reported that medications had triggered attacks. This is an un-
expected finding since it is well known that correct medication is im-
portant in AIP cases and that many medications are porphyrinogenic
[44]. The most likely explanation for this is that some medical doctors
still have limited knowledge about AIP despite repeated information
given regarding correct medication.
Current smoking was slightly more common among the AIP cases
than among the controls. However, smoking had triggered attacks in
only 6 % of the symptomatic AIP cases in this report. Among the
asymptomatic and symptomatic cases, one out of five were smoking
tobacco. Furthermore, the number of cigarettes smoked per day was
correlated with the biochemical disease activity of ALA, but not of PBG,
in the AIP cases. This is partially in agreement with Bylesjo et al. who
reported that smoking was associated with a high AIP attack frequency
[20]. In addition, even low cigarette usage is associated with an en-
hanced risk of several diseases, including lung cancer, coronary heart
disease and stroke and should be avoided [45].
The kidney function was lower in the symptomatic AIP cases, which
is in agreement with several previous reports indicating that the por-
phyrin precursors are toxic to the kidney tubuli and endothelial cells
causing a chronic tubulointerstitial nephropathy [5,6]. In line with this,
the S-albumin and P-PTH levels were slightly lower and higher in the
cases than controls, respectively. Furthermore, the pre-albumin levels
were reduced in the AIP cases, indicating reduced liver function, mal-
nutrition or inflammation of the liver [26,46].
This study has several limitations that might have affected the re-
sults. First, most of the AIP cases had the same AIP mutation. Second,
many different parameters were analyzed, implying that the risk of false
positive results in the statistical analysis is high. Third, the number of
AIP cases was limited to 50, mainly due to the rarity of the disease.
However, to our knowledge this is the first report on the role of dietary
factors in AIP cases using a dietary logbook and biochemical analysis in
blood samples for many of the same nutrients and vitamins. The re-
gistration of food intake, however, may have been underreported since
the reported energy intake was lower than the calculated energy
Fig. 8. Correlation matrix of porphyrin precursors, diet, alcohol, cigarette smoking, diet-related biomarkers and PTX3 in the acute intermittent porphyria (AIP) cases
(n=47). The data in the left lower part are Spearman's correlation coefficients, in the AIP cases (n=47), r≥ 0.29 and r≤−0.29 (blue color). The correlation
matrix shows pairwise correlations of the different variables. In the upper right part the corresponding significant p values (p < .05) are indicated by red color. The
variables included are: urine porphobilinogen ratio (U-PBG); urine 5-aminolevulinic acid ratio (ALA); S-creatinine (Creat.); P-homocysteine (Homoc.); S-pre-albumin
(Prealb.); S-total cholesterol (Cholest.); S-high-density lipoprotein (HDL); S-triglycerides (Trigl.); intake of energy kJ/day (Energy KJ); carbohydrates g/day (Carb. g);
Carbohydrates % of total energy (Carb. %); sugar/candy intake g/day (Sug/Cand.); saturated fatty acids (SFA) (g/day); polyunsaturated fatty acids (PUFA) g/day;
alcohol g/day (Alco. g); current smoking of cigarettes per day (Cig.); and pentraxin 3 (PTX3), ng/ml. (For interpretation of the references to color in this figure
legend, the reader is referred to the web version of this article.)
E. Storjord et al. Molecular Genetics and Metabolism 128 (2019) 254–270
266
requirement, and the RMR-factor (energy intake divided by RMR) was
lower than expected from their activity level in some of the cases and
controls [47]. However, the underreporting seems to be similar in both
cases and controls, indicating that the intake in the cases and controls
can still be compared. Another limitation is that the comparison against
the reference energy and nutritional recommendations are for Norway,
Nordic Countries and Americans, and it may, thus, be questioned with
respect to the extent that this issue may limit the generalization of
Fig. 9. Correlation matrix of porphyrin precursor and biomarkers of glucose metabolism- and diet-related biomarkers, prothrombin factor 1+ 2 (PTF1.2) and CDT%.
In the lower left part are Spearman correlation coefficients, r, in the acute intermittent porphyria group (n= 47), r≥ 0.29 and r≤−0.29 (blue color). The
correlation matrix shows pairwise correlations of the different markers. In the upper right part are the corresponding significant p values (p < .05), which are
indicated by red color. The variables included are the following: urine porphobilinogen ratio (PBG); urine 5-aminolevulinic acid ratio (ALA); Erc-Reticulocytes %
(Retic.); S-iron (Iron); S-glucose (glucose); B-HbA1c (HbA1c); S-cortisol (cortisol); urine vanillylmandelic acid (VMA); P-insulin (Insulin); S-glucose/P-insulin ratio
(G/ins-r); P-visfatin (Visfatin); P-leptin (Leptin); P-resistin (Resistin); P-ghrelin (Ghrelin); P-gastrointestinal peptide (GIP); P-prothrombin F1+2 (PTF1.2) and
percentage of carbohydrate deficient transferrin (CDT%). (For interpretation of the references to color in this figure legend, the reader is referred to the web version
of this article.)
Table 3
Symptoms and triggering factors of attacks in acute intermittent porphyria cases.
Symptoms during AIP attacksa % Triggering factors of attacksb % Triggering factors of attacks,womenc % Military service accomplishedd %
Abdominal pain 91 Psychological stress 62 Birth control pills 0 Asymptomatic men 75
Dark/red urine 80 Work environment (mainly stress) 41 Menstrual cycle 17 Symptomatic men 69
Tiredness 71 Physical strain 38 Menstrual cycle, first day 17
Muscle ache 60 Other disease 32 Menstrual cycle, ovulation 0
Muscle weakness 60 Sleep deprivation 32 Menstrual cycle, other 0
Othere 43 Alcohol 32
Vomiting 43 Medication 29
Headaches 43 Food items 24
Decreased sensibility 40 Hunger 24
Palpitations 40 Dieting 9
Psychological symptoms 26 Other (alternative medications) 6
Constipation 23 Smoking 6
Paresis 17
Epilepsy 6
The data were obtained from interviews done by medical doctors and questionnaires.
a % of AIP symptomatic cases, (n=35), 18 women, 17 men.
b % of AIP symptomatic cases, (n=34), one data missing.
c % of (n= 18) symptomatic women, regarding menstrual cycle.
d % of 12 asymptomatic and % of 16 symptomatic men regarding military service (one of 17 symptomatic men had missing data on question on military service).
e e.g: Diarrhea, visual disturbances, fecal incontinence, impaired memory.
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results to other countries, for instance, in Asia and Southern Europe,
etc. However, the dietary recommendations do not vary much between
the Nordic countries, European countries and the US [48], indicating
that the comparison of intakes in the AIP case and control group with
the recommended intake is valid for many countries. Furthermore, the
comparison of the intake in the AIP case and control groups is also
valid, although the actual dietary habits may vary in different coun-
tries. The differences in dietary habits between the Nordic area [12],
the Mediterranean area [49], and other parts of the world should be
kept in mind when our results are generalized to other AIP patients. In
general, the individual dietary pattern should be assessed when in-
dividualized dietary advice are given to AIP patients. Furthermore, the
biomarkers on glucose metabolism were possibly affected by the anti-
diabetic medication used by two AIP cases..
In summary, several lifestyle factors, including total energy intake,
alcohol, stress and medications may affect the disease activity of AIP
cases. The distinction between slow-release carbohydrates and added
sugar is not always precisely explained to the AIP patients, leaving
some of them on a diet high in added sugar which may lead to obesity.
Resistin levels were higher in the symptomatic than asymptomatic AIP
cases, and insulin was higher in the cases with low U-PBG levels sug-
gesting that hormones regulating glucose uptake may be disturbed in
AIP. Several of these lifestyle factors, including diet, alcohol intake and
stress, are known to affect the expression of genes through epigenetic
changes. A recent study suggested oligogenic inheritance in AIP,
pointing to several factors that dictate who manifests symptoms [8].
Future studies should therefore examine the role of other related mu-
tations and other epigenetic changes that could explain why only a few
of those with an AIP mutation have symptoms of the disease, while
most cases are asymptomatic.
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Appendix A. Appendix Table A Porphyrinogenic medications, vitamin supplements, dietary supplements and herbal remedies in acute
intermittent porphyria cases and controls
Controls n (%) Cases n (%) p
Medications
PSPa medications 4 (8) 10 (20) 0.15
PRPb medications 12 (24) 3 (6) 0.02
Pc medications 1 (2) 1 (2) 1.00
Medications containing vitamins, Mg or iron
Vitamin B12 injection 1 (2) 1 (2) 1.00
Etalpha (1α(OH)-vitamin D3) 1 (2) 1 (2) 1.00
Isotretinoin (Vitamin A) 0 (0) 1 (2) 1.00
Magnesium 4 (8) 0 (0) 0.12
Iron 6 (12) 3 (6) 0.27
Supplements
Vitamin B 6 (12) 4 (8) 0.74
Vitamin C 5 (10) 2 (4) 0.44
Vitamin D 4 (8) 5 (10) 1.00
Multi-vitamins 4 (8) 5 (10) 1.00
Calcium 3 (6) 2 (4) 1.00
Vitamin K 0 (0) 1 (2) 1.00
Fish oil 18 (36) 15 (30) 0.67
Persons using herbal remedies 8 (16) 7 (14) 1.00
The data were obtained from questionnaires from all participants, and from the 7-day diet logbook from n=47 cases and 48 controls, and are given as n and
% of AIP cases (n= 50) and of their age-, sex- and place of residence-matched controls (n=50).
The herbal remedies are not counted in the PSP, PRP and P-data. Herbal remedies containing vitamins, calcium, magnesium or iron are also counted in
supplements where applicable. Two-tailed P values were calculated using Fischers exact test.
a PSP=Possibly porphyrinogenic medication.
b PRP=Probably porphyrinogenic medication.
c P=Porphyrinogenic medication.
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Appendix Fig. A. Possible pathways from lifestyle factors to increased porphyrin precursor levels and symptoms in acute intermittent porphyria. The possible role of
lifestyle factors in the biochemical disease activity and symptoms in AIP cases are summarized. An AIP mutation is the prerequisite for AIP disease. To acquire
elevated porphyrin precursor levels often requires several triggering factors at the same time such as stress, physical strain, dieting, alcohol and/or porphyrinogenic
medications (red box), which may partly explain the low manifestation rate of symptoms in the AIP cases. Many factors may contribute to the worsening or
improvement of porphyrin precursor levels and symptoms, such as genetic and epigenetic modifiers (blue box), the intensity of triggers as the level of protective
factors such as a higher sugar intake and relaxation. Other diseases, such as diabetes mellitus, may also protect those with an AIP mutation. High levels of ALA and
PBG affects the nervous system, the liver and kidney and result in abdominal pain, and vomiting etc. during the acute nevrovisceral attacks. Enhanced U-PBG levels
are possibly associated with lower insulin levels. Resistin levels are higher in the symptomatic than the asymptomatic cases, and are associated with inflammation. As
illustrated, most AIP cases tolerate different amounts of single triggering factors and probably have sufficient protective factors (marked in green) to avoid an
increase in the porphyrin precursors and attacks. This conforms to what we have found, for example, with alcohol intake, since there was no difference in the PBG
levels in those who drank more or less alcohol.
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A B S T R A C T
Cytokines are potentially useful biomarkers of sepsis and other inflammatory conditions. Many cytokines can be
released by leukocytes and platelets after sampling. The sampling and processing techniques are consequently
critically important to measure the in vivo levels. We therefore examined the effects of four different antic-
oagulants, EDTA, citrate, lepirudin, heparin compared to serum, on the levels of 27 different cytokines. The
effects of storage temperature, freezing and thawing on the plasma cytokines were examined. Cytokines were
analysed using a multiplex immunoassay. The cytokine levels in serum were significantly higher compared with
plasma, consistent with release of cytokines in vitro during coagulation. In general, the lowest values for all
cytokines were found in EDTA samples, stored on crushed ice, centrifuged within 4 h and thereafter stored at
−80 °C. MCP-1 and MIP-1β levels were highest in heparin plasma and storage of blood for up to 4 h at room
temperature significantly increased the interleukin (IL)-2, IL-6, IL-8, IFN-γ and GM-CSF levels in EDTA plasma,
indicating post-sampling release. In contrast, the IP-10 levels were unaffected by sample storage at both tem-
peratures. Our results indicate that the cytokines were more stable in plasma than in whole blood after sampling.
Thus, cytokines should be analysed in EDTA plasma samples stored on ice and centrifuged within 4 h. Based on
these data, the reference ranges of 27 cytokines in EDTA plasma in 162 healthy human donors were calculated.
1. Introduction
Cytokines, chemokines and growth factors are potential biomarkers
of sepsis and other inflammatory diseases [1–3]. These compounds are
extensively used as biomarkers of inflammation in a number of human
diseases and inflammatory conditions [4–10]. In the case of many
analytes in general, much attention has been focussed on the pre-
analytical sampling conditions [11,11–13]. Although poorly studied,
the sampling and processing techniques used for analysis of the cyto-
kine levels in plasma and/or serum samples might also be important. To
obtain cytokine values representative of the in vivo conditions, the
sampling techniques must prevent cytokines from being released by
blood leukocytes after sampling. The time and the storage temperature
between the sampling and centrifugation steps might therefore be im-
portant.
Human blood leukocytes, including monocyte-macrophages and
neutrophils, synthesize a number of cytokines after stimulation with an
endotoxin or bacteria through Toll-like receptor activation [14]. A
number of other stimuli, including bacterial products [15], complement
fragment C5a [16], immune complexes, complement activation, C5a
[17] and calcium ionophores also stimulate cytokine synthesis [18].
Coagulation activation itself and thrombin can also enhance the release
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of IL-1β, IL-6 and TNF by monocytes through activation of protease-
activated receptors [19]. Thrombin can activate protease-activated re-
ceptor (PAR)-1 and PAR-4, leading to leukocyte activation and cytokine
release [19].
When blood is drawn into plastic tubes, complement and coagula-
tion activation by the plastic surface leads to the activation of immune-
competent cells and platelets, in part due to their recognition of this
foreign surface [20]. This phenomenon of activation by foreign surfaces
is termed bioincompatibility and opposite biocompatibility [20].
Complement is rapidly activated by plastic and other foreign surfaces
and participates in the activation of platelets and leukocytes [21].
Coating plastic tubing with heparin effectively reduces complement
activation and cytokine release [22]. The release of the anaphylatoxin
C5a is involved in cytokine release triggered by several different stimuli
[17,23]. In addition, coagulation activation and thrombin can also
stimulate immune-competent cells, including leukocytes, leading to
cytokine release [24].
Previously, most studies used serum for cytokine measurements
[25]. The manufacturer of many ELISA and immunoassay kits for cy-
tokine analyses also recommends using serum samples for the analyses.
However, several studies indicated that coagulation activation is linked
to inflammation in a process called immunothrombosis [26]. The po-
tential role of thrombin in coagulation activation leading to cytokine
release in human whole blood samples is yet to be examined. Several
anticoagulants, such as EDTA and citrate, bind calcium and thereby
inhibit both coagulation and the activation of the complement system.
However, newer anticoagulants, such as hirudin and its recombinant
analogue lepirudin, which specifically inhibit thrombin, have not been
evaluated as anticoagulants for use in cytokine analyses. In contrast to
heparin and calcium-binding anticoagulants, such as EDTA and citrate,
lepirudin has no adverse effects on complement activation [27]. Le-
pirudin has therefore been considered the preferred anticoagulant for
whole blood when the role of complement activation in vitro is ex-
amined [27]. The levels of 27 different cytokines, interleukins and
growth factors in EDTA, citrate, lepirudin and heparin plasma and
serum obtained from ten healthy blood donors were therefore ex-
amined. The influence of storage time and temperature before and after
centrifugation on cytokine levels were also studied.
2. Materials and methods
2.1. Study population
To examine the effects of temperature and storage time on cytokine
levels, venous blood was collected from ten healthy blood donors (five
females and five males). The donors were without any medication and
did not experience fever or other symptoms of infectious or in-
flammatory illness during the two weeks prior to blood sampling. The
blood donors provided written informed consent. The study was ap-
proved by the regional ethics committee of the northern Health Region
of Norway. To determine the reference ranges, EDTA plasma samples
from the following groups of healthy donors were included: (1) 49
healthy blood donors from the Blood Bank of Nordlandssykehuset Bodø,
(2) 42 healthy controls in a clinical epidemiological study performed in
Nordland County, Norway, and (3) 71 healthy persons from a local
study on health care workers; giving a total of 162 healthy Norwegian
persons (107 females and 55 males, aged range 18–85). The samples
were obtained by venipuncture after an overnight fast, between 8 and 9
a.m. and were immediately placed on ice, centrifuged within 15 min at
+4 °C and stored at −80 °C until analysis.
2.2. Blood sampling and sample tubes
To prevent contamination by tissue thromboplastin during sam-
pling, blood was first drawn into one dry 5-mL Vacutainer® tube
(Becton Dickinson (BD), Plymouth, UK), which was discarded. Winged
blood collection sets (BD Vactuainer® Safety-Lok™, needle gauge 21,
needle length 0.75 inches, tubing length 7 inches, with luer locks
(Franklin Lakes, NJ, U.S.A.) were used to collect the blood. Tubes were
filled in the following order: blood collected in lepirudin-containing
tubes (Refludan®, 50 μg/mL) was added to 4.5-mL Nunc™ poly-
propylene CryoTubes™ (NUNC A/S, Roskilde, Denmark) using lids from
dry 4.5-mL BD Vacutainer® tubes, blood for serum samples was col-
lected in tubes without an additive (Vacuette®, 2 mL), in 3.2% sodium
citrate Vacuette® tubes (2 mL), in lithium heparin tubes (Vacuette®,
4 mL), in K3EDTA tubes (Vacuette®, 2 mL), and in serum sep clot ac-
tivator tubes (Vacuette®, 4 mL). All Vacuette® tubes were purchased
from Greiner Bio-One GmbH (Kremsmünster, Austria). All of the tubes
were held vertically during sampling to prevent contamination by an-
ticoagulants between using the different tubes. All tubes were gently
rotated eight times by hand after sampling.
2.3. Whole blood storage conditions
After the blood samples were collected, one tube (T0) was im-
mediately centrifuged at 3220g for 15 min at 4 °C and stored at −80 °C.
Two tubes were stored at +4 °C and two tubes were stored at room
temperature (RT), one for one hour (T1 h) and one for four h (T4 h). In
the case of the two serum sampling tubes, the same procedure was
initiated after one h of coagulation at room temperature.
2.4. Treatment of plasma samples
Four healthy blood donors were selected and using the same blood
sampling technique. We chose four different plasma collection tubes, as
follows: (1) lepirudin-containing tubes, to which EDTA (10 mM final
concentration) was added immediately before centrifugation to prevent
further complement activation, (2) citrate-containing tubes (3.2% so-
dium citrate), (3) EDTA-containing tubes (4.43 mM final concentration)
To obtain higher levels of cytokines for testing cytokine stability,
some of the lepirudin anticoagulated whole blood samples were in-
cubated with E. coli (1 × 107/mL) in Nunc™ cryotubes. The Nunc tubes
were incubated for 2 h at 37 °C before centrifugation. Control samples
were obtained by immediate centrifugation (T0). To examine the sta-
bility of cytokines in the plasma samples, the samples were stored in
Nunc tubes in the dark at either RT or at +4 °C for two, four and 24 h.
The E. coli strain LE392 (ATCC 33572) was obtained from American
Type Culture Collection (Manassas, VA, U.S.A.). E. coli was grown
overnight on a lactose dish, after which 5–10 colonies were transferred
to LB-medium (1% tryptone, 0.5% (w/v) yeast extract, 1% (v/v) NaCl)
purchased from Becton Dickinson (Sparks, MD) and grown overnight.
The bacteria were harvested and washed once with Dulbecco’s PBS
without Ca2+ and Mg2+ by centrifugation at 3220g for 10 min at 4 °C.
The bacteria were aliquoted, heat inactivated for 1 h at 60 °C and stored
at −80 °C. A frozen ampoule was thawed at ambient temperature and
the cells were washed six times with PBS by centrifugation at 3220g for
10 min at 4 °C.
2.5. Freezing and thawing of plasma
The effect of freezing and thawing on the cytokines was examined
using the T0 plasma samples (sodium citrate, 4.43 mM EDTA samples).
The samples were frozen (−80 °C) and then thawed on ice (0 °C) for
20 min, followed by one h of storage on ice to simulate standard sample
handling. The samples were then maintained in a −80 °C freezer for a
minimum of 2 h to ensure freezing. The samples were then frozen and
thawed 1, 3 and 6 times.
2.6. Cytokine analyses
The cytokines in the plasma and serum samples were analysed using
a Bio-Plex Human Cytokine 27-Plex Panel kit purchased from Bio-Rad
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Laboratories Inc. (Hercules, CA, U.S.A.). The analyses was performed
using high-sensitivity detection according to the manufacturer’s in-
structions. Estimated values below the lowest standard were used. The
following cytokines were analysed: interleukin (IL)-1 beta (IL-1β), IL-1
receptor antagonist (IL-1RA), IL-2, IL-4, IL-5, IL-6, IL-7, IL-8 (C-X-C
motif chemokine ligand 8; CXCL8), IL-9, IL-10, IL-12, IL-13, IL-15, IL-
17, eotaxin-1 (C-C motif chemokine ligand 11; CCL11), basic fibroblast
growth factor (FGF-basic), granulocyte colony stimulating factor (G-
CSF), granulocyte–macrophage colony stimulating factor (GM-CSF),
interferon gamma (IFN-γ), interferon-γ-inducing protein 10 or IP-10
(CXCL10), monocyte chemoattractant protein 1 (MCP-1 or CCL2),
macrophage inflammatory protein-1-alpha (MIP-1α or CCL3), macro-
phage inflammatory protein-1-beta (MIP-1β or CCL4), platelet-derived
growth factor-BB (PDGF-BB), RANTES (CCL5), tumour necrosis factor
(TNF) and vascular endothelial growth factor (VEGF).
2.7. Statistical analyses
GraphPad Prism 5 (GraphPad Software, CA) was used for the sta-
tistical calculations. A non-parametric, one-way repeated measurement
ANOVA with Dunn’s post-test was used to compare the pre-analytical
sampling conditions. To analyse the effects of whole blood incubation,
all of the T0 samples were compared to the T0 tube with the highest
median concentration, which was the control. The dilution of the
plasma due to the volume of citrate added to the citrate-containing
tubes was corrected for and each donor’s haematocrit was corrected
according to the method of Van Beaumont [28]. The data regarding
storage of whole blood and plasma at different temperatures (4 °C and
RT) in each type of sample tube were analysed separately, leaving time
as the only variable, by comparing the T1 h and T4 h samples to the T0
sample in the same series. P < 0.05 was considered to indicate sig-
nificant differences. The Excel program (Microsoft Corp., Redmond,
WA) replaced immeasurable cytokine levels with random numbers
between 0.001 and the lower detection limit (LDL) value. Measurable
cytokine levels that were lower than that of LDL were accepted as valid
numbers. Some of the levels of the cytokine RANTES were greater than
the highest detection limit (HDL). Excel replaced these values with
random numbers between the level of HDL and the highest measured
concentration of RANTES that we measured. The data for the MIP-1β,
IL-1β and IP-10 levels included one extreme outlier that exceeded the
mean value +/−3 SD of the other data, which were therefore excluded
from the T0 figures without affecting the results of the statistical ana-
lyses. The cytokine levels in females and males were compared using
the Mann-Whitney U test after replacing the values below the lowest
measurable values with zero.
3. Results
We first aimed to investigate the optimal conditions for sampling,
handling and storage of samples to be analysed for the 27 cytokines.
Ten blood donors were selected for these experiments.
3.1. Effect of plasma anticoagulants on cytokine levels in immediately
cooled and centrifuged blood samples compared with serum samples
The cytokine levels in EDTA, citrate, lepirudin and heparin-plasma
obtained from immediately cooled and centrifuged blood samples and
compared them with the levels in serum samples were studied. Two
different serum-collection tubes were used, one was a plain tube lacking
a gel and the other contained a gel and a clot activator. Of the 27 cy-
tokines analysed, all were detected above the lower detection limit in
some controls (see Table 4 below for details). Twelve of these were
representative for the group and are presented in detail (Figs. 1 and 2).
In general serum samples showed significantly (P < 0.05) higher le-
vels than plasma samples (Fig. 1), whereas CXCL10 and CCL11 did not
show these major difference between plasma and serum (Fig. 2).
Notably, two of the cytokines, CCL2 and CCL4, were markedly and
significantly increased in heparin plasma (Fig. 2). Two of the cytokines,
RANTES (CCL5) and PDGF-BB, were markedly higher in serum than in
plasma samples (Fig. 1), consistent with in vitro release during coagu-
lation.
Upon correcting for the time during which the serum samples coa-
gulated at RT, reached by comparing the T0 serum with plasma that
had been stored at RT for 1 h, it was found that the differences in all of
the cytokine levels, except for those of IL-5 and CCL3, were significant.
All together, these results indicate that cytokines should be analysed
in EDTA or citrated blood samples, immediately cooled and rapidly
centrifuged to obtain EDTA or citrate plasma to be stored.
3.2. Effect of storage time and the temperature during the storage of whole
blood samples on plasma cytokine levels
The effect of storage time and temperature on the cytokine levels in
EDTA-, citrate- and lepirudin-anticoagulated whole blood was in-
vestigated (Table 1). The here listed 15 cytokines were selected based
on their robust measurable amount in the samples from tubes that were
stored for 1 and 4 h at RT or 4 °C. Stable cytokine levels were observed
in whole blood anticoagulated with EDTA, citrate and lepirudin when
the samples were stored at 4 °C for one h. However, when EDTA-, ci-
trate- or lepirudin-anticoagulated whole blood was stored at RT, a
significant increase in some of cytokine levels were observed after only
one h of storage (Table 1). An even more pronounced increase in the
levels of several cytokines was observed after 4 h of incubation at RT,
indicating an in vitro cytokine release during storage at RT. The cyto-
kine release in heparinized whole blood was not examined.
3.3. Effect of storage temperature on plasma cytokines
We next examined the stability of the cytokines in plasma during
storage. Plasma obtained from E. coli-incubated whole blood contained
high levels of 13 different cytokines (Table 2). The cytokine levels were
stable for up to four h at 4 °C in the lepirudin- and EDTA-plasma, but
after 24 h, the levels of some of the cytokines decreased. Upon in-
cubation at RT, a decrease in some of the cytokine levels was observed
after only 4 h. and the levels of some cytokines even increased with
increasing incubation time. In sodium citrate plasma, the CCL3 (MIP-
1α), and PDGF-BB levels significantly increased after only 2 h of in-
cubation at 4 °C, whereas that of RANTES increased after 24 h of in-
cubation. The highest concentration of EDTA examined (10 mM) did
not influence the stability of any of the cytokines in plasma (data not
shown). The results indicate that EDTA plasma samples can be stored
for up to 4 h at 4 °C after centrifugation and before freezing.
3.4. The effect of freezing and thawing on plasma cytokine levels
The effect of freezing and thawing on cytokine stability were then
examined in EDTA and citrate plasma (Table 3). There was no sig-
nificant change in the cytokine levels in plasma frozen and thawed up
to three times. After freezing and thawing 6 times, a slight but sig-
nificant decrease in the IL-1β level and an increase in the CCL5
(RANTES) level were observed in EDTA plasma, suggesting a maximum
of three freezing and thawing in the recommendations.
We second aimed to define a reference range in a healthy human
population. Based upon the above findings, we decided to test EDTA
plasma, immediately stored cold, centrifuged within one h and stored at
−80 °C.
3.5. Reference ranges of the cytokine levels in EDTA plasma obtained from
162 healthy controls
The reference ranges for the cytokines in EDTA plasma obtained
from 162 healthy blood donors were then established (Table 4). Both


































































































































































Fig. 1. Cytokine levels in serum compared with those in immediately centrifuged and frozen EDTA, citrate, lepirudin and heparin plasma samples. The levels of (a) IL-1β, (b) IL-1RA, (c)
IL-6, (d) IL-8 or C-X-C motif chemokine ligand 8 (CXCL8), (e) TNF, (f) IL-17, (g) C-C motif chemokine ligand 5 (CCL5) and (h) PDGF-BB were analysed using Multiplex technology and
expressed as pg/mL on the Y axis. The data are given as median values with whiskers (10 and 90 percentiles, n = 10). Serum +; serum tubes containing a gel and a clot activator.
*P < 0.05 compared with the tube in which the highest median concentration of cytokine was detected (H). #P < 0.05 compared with that detected in the tube with lowest median
cytokine concentration (L).
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the 2.5–97.5th percentile and the<95th percentile levels of the cyto-
kines are shown. Some of the cytokines were detected in samples ob-
tained from all of the blood donors, implying that both the 2.5–97.5th
percentile values could be calculated. The frequency distribution and
statistical analysis of these cytokines indicated that the upper limits
were similar in females and males (Supplementary Table 1 and sup-
plementary Fig. 1). The frequency distribution and statistical analyses
of these 27 biomarkers indicated that only one of these inflammatory
biomarkers, CXCL8 in males were normally distributed (Fig. 3 and
Supplementary Fig. 1). The percentage of individuals (%) with un-
detectable cytokines (n, number of cytokines) in> 75% of the donors
were: n = 0; 50–75%: n = 5; 25–50%: n = 9 and< 25% undetectable
values: n = 13 different cytokines.
4. Discussion
The findings of this study indicate that the sampling conditions
greatly affect the cytokine levels. In general, serum showed con-
siderably higher levels in samples taken from both types of serum
collection tubes as compared with those in plasma. After centrifugation
and separation the cytokine levels were stable in plasma samples. In
contrast, storage of whole blood samples, particularly when the latter
were stored at room temperature, lead to increase in many of the cy-
tokines, consistent with in vitro release from the cells. EDTA-plasma,
obtained from blood stored on slushed ice< one h, consistently con-
tained the lowest levels of the cytokines and could be recommended as
guidelines for sampling. Thus, the tentative reference ranges for the
cytokines were calculated using EDTA plasma obtained according to
these guidelines from 162 healthy controls.
The higher cytokine levels observed in serum compared with those
in plasma suggest that the coagulation process and thrombin activation
enhances cytokine release. This result is consistent with those of pre-
vious studies [29,30]. The cytokine levels in samples taken from both
types of serum collection tubes after one h of coagulation at RT were
significantly higher than the levels in the baseline anticoagulated
samples (T0) and anticoagulated whole blood that was stored for one h
at RT. When the levels of the soluble terminal complement complex
(sTCC) as a measure of complement activation were analysed using an
ELISA, we found that complement was activated only in the serum
collection tube containing a gel (data not shown). This result indicates
that complement activation is not responsible for the high concentra-
tion of cytokines in serum. Thus, we suggest that coagulation itself
induce cytokine release from whole blood leukocytes. This hypothesis is
in accordance with a previous observation that thrombin activates
leukocytes and cytokine release through the activation of PAR-1 and
PAR-4 [31].
In anticoagulated whole blood, the levels of many cytokines in-
creased when the samples were stored at RT, even in the presence of
EDTA. These results are likely due to the in vitro synthesis or release of
pre-synthesized cytokines by leukocytes [32], a process that is pre-
vented at low temperature. Interestingly, in the lepirudin-antic-
oagulated whole blood in which thrombin activity was specifically in-
hibited, only a small increase in the release of PDGF-BB, IL-6, IL-8 and
IL-13 was observed, indicating that thrombin is involved in the release
of these cytokines. Further studies are needed to explain these findings.
Due to the temperature effect, we recommend that whole blood samples
be placed on ice (0 °C) after collection and be immediately centrifuged.
If centrifugation is delayed, we recommend storage for up to one h and
a maximal storage of 4 h at +4 °C before centrifugation.



































































































Fig. 2. Cytokines elevated in heparin plasma (a, b) and those detected at similar levels in serum and the immediately centrifuged and frozen EDTA, citrate, lepirudin and heparin plasma
samples (c, d). The levels of (a) C-C motif chemokine ligand 2 or CCL2, (b) CCL4, (c), C-X-C motif chemokine ligand 10 or CXCL10, and (d) CCL11 were analysed using Multiplex
technology and expressed as pg/mL. The data are given as median values with whiskers (10 and 90 percentiles, n = 10). Serum +: serum tubes containing a gel and a clot activator.
*P < 0.05 compared with the tube in which the highest median concentration of cytokine was detected (H). #P < 0.05 compared with that detected in the tube with lowest median
cytokine concentration (L).
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several cytokines, in particular CCL4 (MIP-1β) and CCL2 (MCP-1), were
elevated in such samples. While the reason for this phenomenon re-
mains to be elucidated, we speculate that heparin may activate
monocytes and cytokine release in whole blood, as indicated in a pre-
vious report [33]. Furthermore, the anticoagulant that was used sig-
nificantly affected the upregulation of tissue factor and platelet acti-
vation in fresh human whole blood [34]. This result supports the
observation that the anticoagulant used significantly affects coagula-
tion, platelet activation, and the cytokine levels in fresh human whole
blood and it is reasonable to suggest that among the available antic-
oagulants, EDTA is the one to be preferred for cytokine analysis.
However, citrated plasma can be used, but has the disadvantage that
the plasma needs to be immediately separated from the cells.
The levels of cytokines in plasma were more stable than were those
in whole blood. Therefore, EDTA plasma should be separated from the
cellular fraction optimally within one h and maximally four h after
blood sampling. After separation of plasma, the cytokines were rela-
tively stable although time and temperature influenced the levels.
Storage at RT for up to 24 h lead to a decrease in some cytokines and
increase in others. A decrease may be related to the lower level of
stability of some cytokines in plasma, their degradation by proteases or
the binding of the cytokines to their respective soluble cellular re-
ceptors. Changes in this binding over time could also possibly explain
the changes in cytokine levels that occur during sample storage.
Notably, none of the cytokines changed during storage of EDTA plasma
for up to 4 h at 4 °C.
Finally, the reference ranges of the cytokines in 162 healthy controls
were estimated using the upper 95th percentile and the 2.5–97.5th
percentile values from EDTA plasma samples, obtained in the morning
and treated according to the conditions described above. We suggest
the upper 95th percentile values to be the best estimate of the reference
range instead of 2.5th and 97.5th for two reasons. First, from a pa-
thophysiological point of view an increased value of a cytokine would
be more frequent and reflect a disease state than a low value. Second,
for most of the cytokines there were some individuals with undetectable
levels, precluding an exact 2.5th percentile to be calculated. Although
the distribution of cytokine values were statistically different in males
and females for nine of the cytokines, most of them had very similar
upper 95th percentile values. Thus, the significant difference was due to
a different distribution pattern, only slightly influencing the 95th per-
centile. We therefore suggest that common reference range can be used
for males and females.
In conclusion, our data indicate that the cytokine levels in several
plasma samples, including EDTA and citrate plasma samples, are sig-
nificantly lower than those in serum. Previous studies using serum
should be interpreted with some caution. The mechanisms underlying
the greater cytokine levels in serum compared with those in plasma
remain to be elucidated, but this study indicates that thrombin-induced
cytokine release might be involved. Recommended guidelines for cy-
tokine analyses based on our data would be: EDTA or citrate blood
immediately cooled on crushed ice, and immediately centrifuged and
stored at −80 °C. EDTA blood is preferred since it can be stored for up
to 4 h at 4 °C before centrifugation. The plasma samples can be thawed
and frozen up to three times. The role of thrombin-induced cytokine
release should be addressed in future studies.
Table 3
The effect of freezing and thawing on cytokine stability.
Cytokinea EDTAb Citrateb









































































































a The cytokine levels are given as the median fold change (10–90 percentiles) of their
respective T0 values.
b The effect of freezing and thawing on cytokines in 4.43 mM EDTA or citrate plasma.
c Samples were frozen and thawed three or six times before cytokine analyses.
d CXCL10, C-X-C motif chemokine ligand 10.
e CCL5, C-C motif chemokine ligand 5.
* P < 0.05 compared to its respective T0 value (values in bold).
Table 4









IL-1βa 0.7 0.1–2.0 < 1.6 0 0.03
IL-1RA 26 0–352 <147 11 1.2
IL-2 0.03 0–10 <7.2 49 0.03
IL-4 0.5 0–2.0 < 1.5 17 0.02
IL-5 0.7 0–2.2 < 1.6 22 0.02
IL-6 1.5 0–9.3 < 5.4 20 0.02
IL-7 0.5 0–7.6 < 6.0 46 0.06
IL-8 (CXCL8)b 2.8 0–11 <7.9 14 0.01
IL-9 5.1 0–17 <59 21 0.04
IL-10 0 0–6.6 < 3.0 61 0.03
IL-12(p70) 0.2 0–20 <9.4 49 0.2
IL-13 1.3 0–11 <5.9 7.4 0.03
IL-15 0 0–2.9 < 2.2 54 0.01
IL-17 0 0–69 <31 62 0.01
CCL2 (MCP-1)c 13 3.1–31 <27 1.2 0.6
CCL3 (MIP-1α) 0 0–6 <4.2 70 0.2
CCL4 (MIP-1β) 21 0–63 <50 46 0.5
CCL5 (RANTES) 824 20–8030 <5379 0 3.4
CCL11 (Eotaxin-1) 38 0–120 <91 19 0.3
FGF-basic 0 0–51 <40 63 0.5
G-CSF 5.7 0–47 <43 13 0.3
GM-CSF 2.0 0–37 <24 40 0.2
IFN-γ 11 0–121 <115 25 0.9
CXCL10 439 184–1398 <1202 0 0.9
TNF 6.4 0–52 <44 25 0.08
VEGF 0.4 0–12 <6.0 49 0.2
PDGF-BB 17 0–907 <762 28 0.1
a IL, interleukin.
b CXCL, C-X-C motif chemokine ligand.
c CCL, C-C motif chemokine ligand.
d The cytokine reference ranges were calculated in immediately cooled EDTA plasma
samples obtained from 162 healthy individuals. All cytokines and biomarkers are ex-
pressed as pg/mL.
e LDL, Lower detection limit, defined as the lowest measurable concentration of each
cytokine, or the lowest given assay LDL corresponding to the lowest standard in the assay
for CCL2,4,5 and 11, FGF-basic, G-CSF, IFN-γ, CXCL10 and VEGF.
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Fig. 3. Frequency histograms of selected cytokines and biomarkers in 162 healthy individuals. (a) Interleukin (IL)-1β, (b) IL-1RA, (c) C-X-C motif chemokine ligand 8 or CXCL8, (d) IL-13,
(e) C-C motif chemokine ligand 2 (CCL2), (f) CCL5, (g) CXCL10 and (h) G-CSF were measured using a multiplex cytokine assay. The histogram contains grey bar graphs showing the
frequency distribution of the cytokines with fewest zero values. On the x-axis is the value of the cytokine in pg/mL. On the y-axis is the number of persons with these values. The data were
analysed using Prism 6 for Mac OS X.
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Egenrapportskjema for AIP 
Skjemaet tas med til sykehuset undersøkelsesdagen, og leveres til lege under legekonsultasjonen. 
1. Bruk av faste medisiner, helsekostpreparat og vitamin-tilskudd
MEDIKAMENTNAVN TYPE DOSERING 











2. Tidligere påviste kroniske tilstander
(Hvis det ikke er nok plass i feltet for å beskrive nærmere, kan du gi ytterligere kommentarer på
baksiden  av arkene)





Har du eller har du hatt 
urinsyregikt? 
Har du noen kroniske 
betennelser nå? 
Evnt. hvilke? 
Har du nedsatt 
nyrefunksjon? 
Har du vært plaget med 
munntørrhet? 
Har du vanskeligheter med 
å tygge? 
2 
SYKDOMMER OG TIDLIGERE OPERASJONER DIAGNOSEÅR/ 
OPERERT ÅR 











3. Spørsmål vedr. akutt intermitterende porfyri





Går du til regelmessig 
kontroll hos fastlegen 
angående porfyri? 
Hvor ofte  evnt. ? 
Har du tatt regelmessige 
urinprøver til analyse av 
porfyriner? 
Hvor ofte  evnt. ? 
Har du hatt porfyri-anfall? Når? 
Hvilke porfyri-symptomer 
har du hatt? 
Evnt. beskriv? 
Hvis alder > 50 år: Har du 
tatt årlig ultralyd av lever? 
Hvis > 50 år: Ønsker du at 
vi henviser deg til ditt 
lokale sykehus for årlig 
ultralyd-kontroll? 
Ønsker du at vi foreslår et 
kontrollopplegg til din 
fastlege ang. AIP? 
Ønsker du tilsendt et 
egenkontrollskjema for 
oppfølging av AIP 





Egenrapportskjema for kontrollgruppe 
Skjemaet tas med til sykehuset undersøkelsesdagen, og leveres til lege under legekonsultasjonen. 
1. Bruk av faste medisiner, helsekostpreparat og vitamin-tilskudd
MEDIKAMENTNAVN TYPE DOSERING 











2. Tidligere påviste kroniske tilstander
(Hvis det ikke er nok plass i feltet for å beskrive nærmere, kan du gi ytterligere kommentarer på
baksiden  av arkene)





Har du eller har du hatt 
urinsyregikt? 
Har du noen kroniske 
betennelser nå? 
Evnt. hvilke? 
Har du nedsatt 
nyrefunksjon? 
Har du vært plaget med 
munntørrhet? 
Har du vanskeligheter med 
å tygge? 
2 
SYKDOMMER OG TIDLIGERE OPERASJONER DIAGNOSEÅR/ 
OPERERT ÅR 




























UTFYLLINGSSKJEMA LEGEKONSULTASJON, KONTROLLGRUPPE 
NAVN:________________________________ 
FØDSELSDATO:________________________ 
Har du vært i militæret:   Ja eller Nei  (ring rundt riktig) 
Hvis ja, hadde du noen spesielle plager i forbindelse med din militærtjeneste? 
I så fall hvilke:_____________________________________________________ 
Bare kvinner: 
Alder ved første menstruasjon:________ 
Evt alder ved menopause:____________ 
Antall graviditeter:__________________ 
Har du noen gang vært innlagt på sykehus for magesmerter?  
Nei (ring rundt riktig)                   Ja (ring rundt riktig) 
Har du noen gang blitt operert i magen:  Nei   (ring rundt riktig )                     Ja (ring rundt riktig) 
I så fall hvorfor:_________________________________________________________ 
Har du noen gang fått narkose?  Nei (ring rundt riktig)     Ja (ring rundt riktig) 
Hvis ja, har du fått noen reaksjoner i forbindelse med narkose? 
I så fall hvilke reaksjoner: __________________________________________________________________ 
Har du fått noen reaksjoner i forbindelse med medisiner du bruker nå fortiden, fast eller av og til? 
Nei  (ring rundt riktig)                        Ja (ring rundt riktig) 
Hvis ja, hvilken medisin og hvilken reaksjon:_____________________________________________________ 
__________________________________________________________________________________________ 
Har du tidligere brukt medisiner du har reagert på? 
Nei (ring rundt riktig)                          Ja (ring rundt riktig) 
Hvis ja, hvilken medisin og hvilken reaksjon: 
_____________________________________________________________________________________ 
______________________________________________________________________________________ 
Har du vært spesielt utsatt for noen av plagene som er nevnt nedenfor: (det kan settes flere kryss) 
Magesmerter Lammelser     Fatigue/utmattelse 
              Oppkast  Hodepine      Synsfeltutfall
              Forstoppelse  Tretthet       Inkontinens 
Muskelverk   Epilepsi        Psykiske plager, i så fall hvilke 
Muskelsvakhet  Hjertebank        ______________________ 




























Hvor finner jeg matvarene i dagboken?
Side Side
Drikke  2-4 Poteter/ris/pasta  13
Brød  4 Grønnsaker  13-14
Smør/margarin   5 Saus/dressing  14
Pålegg  5-7 Is/dessert  15
Yoghurt  7 Kaker/kjeks  16
Frokostgryn/grøt  8 Frukt/bær  17
Kjøttretter  9-10 Snacks  17
Fiskeretter  11 Godterier  18-19
Andre retter/salater 12 Tran/kosttilskudd  19
Ukedag
Dato
Var denne dagen en vanlig dag? Skriv ja eller nei i rutene.







 Alt du spiser/drikker skal skrives opp
 Sett ikke kryss i dagboken
 Sett bare bokstaver i de orange rutene
 Sett bare tall i de sorte rutene
Skriv 1 hvis gutt/mann,
2 hvis jente/kvinne
1=mandag, 2=tirsdag, 3=onsdag, 4=torsdag,






Lettmelk,  søt/sur glass
(eks. lettmelk, Cultura)
Ekstra  lett  lettmelk glass
Skummet  melk glass
Drikkeyoghurt  glass
Sjokolademelk  av  glass
lettmelk (eks.  Nesquick, Litago)
Sjokolademelk av glass
skummet  melk (eks. O'boy,  Nesquick)
Kakao  av  helmelk kopp
Kakao av lettmelk kopp
Kakao av skummet  melk kopp
Appelsinjuice  glass
Eplejuice/eplemost glass
Nektar  (eks. eple, tropisk glass
frukt, annen frukt)
Brus med sukker glass
(eks. Cola, Solo)
Brus  med sukker 1/2  liter
(eks. Cola, Solo)
2
Litago sjokolademelk 1/2  liter
For størrelsen på glasset du drikker av, se bildeserie 1.
Fyll inn bokstaven i den orange ruten.
    Antall   kl. 6-10   kl. 10-14 kl. 14-18     kl. 18-22  kl. 22-6
Sjokolademelk av glass
helmelk  (eks.  O'boy, Nesquick)
Brus, kunstig søtet  glass
(eks. Cola light, Solo lett)
Brus, kunstig søtet 1/2  liter
(eks. Cola light, Solo lett)
Sjokolademelk av glass
ekstra  lett lettmelk (eks. O'boy)
Kakao av kopp






(eks. Earl  Grey,  solbær)
Fruktte  (eks.  nype,  kamille) kopp
Iste/urtete  glass/pakning
med sukker    (250 ml)
Kaffe, kokt      kopp
(eks. presskanne)
Sukketter / Natrena / stk
Canderel
Sukker til te/ kaffe teskje/
biter
Melk  til  te/kaffe spiseskje
 
kl.  6-10        kl.  10-14       kl.  14-18      kl.  18-22    kl.  22-6
Annet
beskriv best mulig hva, hvor mye og når:
3
Antall
Saft med sukker glass
(eks. husholdning, appelsin, solbær)









Energidrikk        boks






                             (330 ml)
Sterkøl boks/flaske






kl.  6-10      kl.  10-14       kl.  14-18     kl.  18-22         kl.  22-6
Annet
beskriv best mulig hva, hvor mye og når:
Brød  m.m.
Loff /fint  rundstykke skiver
Mellomgrovt  brød, skiver
grovt  rundstykke, kneippbrød
Grovt brød skiver
Baguette / Ciabatta stk
Knekkebrød  lyst, stk
skonrok, kavring





(eks.  Mors  flatbrød,  Ideal)
 






Skriv  antall  skiver  i  sort  rute.  For  tykkelse på brødskiven
se  bildeserie  2  og  fyll  inn bokstaven  i orange  rute.
1 skive  =  1/2  rundstykke
Alkoholfritt øl, vørterøl glass
(eks. Clausthaler, Munkholm)
Lettøl boks/flaske
    (330 ml)
Dansk rugbrød, skiver
Rusbrus boks/flaske
(eks. Cider, Bacardi breezer)     (330 ml)
Pumpernikkel
31963
Smør eller margarin på brød.
Meierismør til  antall  skiver
Bremykt til antall skiver
Brelett til antall skiver
Margarin til antall  skiver
(eks. Soya, Per, Melange)
Annet
beskriv best mulig hva, hvor mye og når:
Pålegg
Du  skal  oppgi  mengde pålegg  i  forhold  til  brødskiver.  Har  du  spist  to  typer  pålegg på  samme  brødskive,
fører du opp  begge (eks. 1  hvitost  helfet  og 1 skinke).  Hvis  du  bare  har  spist  pålegg  og  ikke  brød,  anslå
til  hvor  mange  skiver  du kunne  brukt  dette  pålegget.
Antall   kl. 6-10   kl. 10-14      kl. 14-18     kl. 18-22        kl. 22-6
Kjøttpålegg
Servelat,  vanlig til  antall  skiver
Kokt skinke, til antall skiver
spekeskinke, lett servelat
Salami, til antall  skiver
spekepølse, fårepølse
Leverpostei, vanlig til antall skiver
Leverpostei, mager til antall  skiver
           Antall     kl. 6-10          kl. 10-14        kl. 14-18      kl. 18-22         kl.22-6
  5
Kalkun-/  til antall skiver
kyllingpålegg
1 skive  = 1/2  rundstykke = 1  knekkebrød
= 2 vaffelhjerter = 2  kjeks = 1/2  ciabatta
Hvor mye smurte du på brødet?
Se bildeserie 3  og  skriv  bokstaven for  det  bildet  som  ligger nærmest  opp til den
smør-/margarinmengden  du  brukte  på brødet.  Hvis  du  hadde  forskjellig  mengde  smør/margarin på de
brødskivene du  spiste  innenfor  det  angitte  tidsrommet,  kan  du  anslå  et  gjennomsnitt  for  skivene.
Bildeserie 3
1 skive = 1/2 rundstykke = 1 knekkebrød
= 2 vaffelhjerter = 2 kjeks = 1/2  ciabatta
              kl. 6-10    kl. 10-14           kl. 14-18   kl. 18-22      kl. 22-6
Lettmargarin til antall  skiver
(eks. Soft light)
31963
Ost Antall         kl. 6-10       kl. 10-14      kl. 14-18      kl. 18-22      kl. 22-6
Hvitost helfet 27% fett til antall skiver
(eks. Jarlsberg,  Norvegia)
Hvitost halvfet 16% fett til antall  skiver
(eks. Norvegia  lettere)
Brunost  helfet til antall  skiver
(eks. Geitost,  G35,  Fløtemysost)
Brunost  halvfet,  prim til antall  skiver
Smøreost,  vanlig til antall  skiver
(eks.  Baconost, Snøfrisk)
Smøreost,  mager til antall skiver
(eks. mager skinkeost)
Dessertost til  antall skiver
(eks.  Brie,  Gräddost, Ridderost)
Fiskepålegg
Kaviar til antall skiver
Røkt laks/ ørret  til antall skiver
Makrell i  tomat, til antall skiver
røkt  makrell
Sardiner,  sursild, til antall  skiver
ansjos
Syltetøy/ søtpålegg
Syltetøy vanlig,  gelé, til antall skiver
marmelade
Syltetøy  lett,  frysetøy til antall  skiver
Peanøttsmør til antall skiver
Hapå/Litago pålegg til antall skiver
Honning til antall skiver
6
Sjokolade-/nøttepålegg     til  antall  skiver
 Antall            kl. 6-10       kl. 10-14      kl. 14-18  kl. 18-22       kl. 22-6
 Antall           kl. 6-10        kl. 10-14      kl. 14-18  kl. 18-22        kl. 22-6
Kremost til  antall skiver
(eks. Philadelphia, Gourmetoster)
Annet
beskriv best mulig hva, hvor mye og når:
31963
Antall kl. 6-10       kl. 10-14      kl. 14-18           kl. 18-22        kl. 22-6
Egg, kokt/stekt til antall  skiver
Majonessalat til antall  skiver
(eks.  italiensk  salat,  rekesalat)
Majonessalat,  lett til antall  skiver
(eks.  italiensk salat,  lett)
Tomat  som  pålegg til antall skiver
Banan  som  pålegg til antall skiver
Annet
beskriv best mulig hva, hvor mye og når:
Pynt  på  brødskiver
Antall     kl. 6-10         kl. 10-14       kl. 14-18         kl. 18-22         kl. 22-6
Majones/remulade, til antall  skiver
vanlig
Majones/remulade, til antall  skiver
lett
Agurk til antall  skiver
(frisk/syltet)
Annet
beskriv best mulig hva, hvor mye og når:
Yoghurt     Antall  kl. 6-10            kl.10-14      kl.14-18          kl.18-22        kl.22-6
Yoghurt  med frukt beger (175 ml)
Yoghurt 0,1% fett beger (125 ml)
Litago  yoghurt beger  (125 ml)
Litago  yoghurt beger inkl. müsli
m/müsli




1 skive = 1/2  rundstykke= 1 knekkebrød
=2 vaffelhjerter= 2  kjeks= 1/2 ciabatta
Paprika til antall  skiver
Piano Duo Yoghurt beger  (125 ml)
Yoplait frukt beger  (125 ml)
Rødbeter (syltet)      til antall  skiver
31963
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